activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	1981727	CHEMBL899248	Inhibition of MELK assessed as residual activity at 0.01 uM	B	N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H]1C[C@@H](O)[C@H](n2cnc3c(N)ncnc32)C1)C(N)=O		CHEMBL397521	=	Activity	%	86.0	CHEMBL4578	Homo sapiens	Activity	%	86.0
	1981727	CHEMBL899248	Inhibition of MELK assessed as residual activity at 0.01 uM	B	N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H]1C[C@@H](O)[C@H](n2cnc3c(N)ncnc32)C1)C(N)=O		CHEMBL397521	=	Activity	%	86.0	CHEMBL4578	Homo sapiens	Activity	%	86.0
	1981728	CHEMBL899249	Inhibition of MELK assessed as residual activity at 1 uM	B	N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H]1C[C@@H](O)[C@H](n2cnc3c(N)ncnc32)C1)C(N)=O		CHEMBL397521	=	Activity	%	10.0	CHEMBL4578	Homo sapiens	Activity	%	10.0
	2147307	CHEMBL921992	Activity of human MELK kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	79.0	CHEMBL4578	Homo sapiens	Activity	%	79.0
	2251043	CHEMBL1011918	Inhibition of MELK at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL525385	=	Inhibition	%	84.0	CHEMBL4578	Homo sapiens	INH	%	84.0
Not Active	2302211	CHEMBL945704	Inhibition of human MELK at 10 uM	B	Nc1ncnc2ncn(CC(=O)c3c[nH]c4ccccc34)c12		CHEMBL485246		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
	2470269	CHEMBL987188	Inhibition of MELK at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL4578	Homo sapiens	INH	%	10.0
	2567257	CHEMBL974588	Inhibition of human MELK assessed as residual enzyme activity at 0.1 uM	B	CCN1C(=O)C(C)(C)c2cc3[nH]c4c(c3cc21)CCCc1c(C)n[nH]c1-4		CHEMBL223147	=	Activity	%	53.0	CHEMBL4578	Homo sapiens	Activity	%	53.0
	2596880	CHEMBL1017898	Inhibition of MELK assessed as enzyme activity relative to control	B	C[C@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL457871	=	Activity	%	24.0	CHEMBL4578	Homo sapiens	Activity	%	24.0
	2635888	CHEMBL1003318	Inhibition of MELK at 1 uM relative to control	B	CSc1cc(Oc2ccnc3[nH]c(=O)[nH]c23)ccc1NC(=O)Nc1cccc(C(F)(F)F)c1		CHEMBL496009	=	Residual_activity	%	100.0	CHEMBL4578	Homo sapiens	Residual_activity	%	100.0
	2635956	CHEMBL1003318	Inhibition of MELK at 1 uM relative to control	B	O=C(Nc1cc(C(F)(F)F)ccc1F)Nc1ccc(Oc2ccnc3[nH]c(=O)[nH]c23)c2ccccc12		CHEMBL498112	=	Residual_activity	%	100.0	CHEMBL4578	Homo sapiens	Residual_activity	%	100.0
	2636024	CHEMBL1003318	Inhibition of MELK at 1 uM relative to control	B	CC(C)(C)c1cccc(NC(=O)Nc2ccc(Oc3ccnc4[nH]c(=O)[nH]c34)c3ccccc23)c1		CHEMBL496073	=	Residual_activity	%	75.0	CHEMBL4578	Homo sapiens	Residual_activity	%	75.0
	2894428	CHEMBL1063803	Binding constant for full-length MELK	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894429	CHEMBL1063803	Binding constant for full-length MELK	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894430	CHEMBL1063803	Binding constant for full-length MELK	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	830.0	CHEMBL4578	Homo sapiens	Kd	nM	830.0
	2894431	CHEMBL1063803	Binding constant for full-length MELK	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894432	CHEMBL1063803	Binding constant for full-length MELK	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894433	CHEMBL1063803	Binding constant for full-length MELK	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	Kd	nM	5600.0	CHEMBL4578	Homo sapiens	Kd	nM	5600.0
	2894434	CHEMBL1063803	Binding constant for full-length MELK	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	1600.0	CHEMBL4578	Homo sapiens	Kd	nM	1600.0
	2894435	CHEMBL1063803	Binding constant for full-length MELK	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894436	CHEMBL1063803	Binding constant for full-length MELK	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894437	CHEMBL1063803	Binding constant for full-length MELK	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894438	CHEMBL1063803	Binding constant for full-length MELK	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894439	CHEMBL1063803	Binding constant for full-length MELK	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894440	CHEMBL1063803	Binding constant for full-length MELK	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894441	CHEMBL1063803	Binding constant for full-length MELK	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894442	CHEMBL1063803	Binding constant for full-length MELK	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894443	CHEMBL1063803	Binding constant for full-length MELK	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894444	CHEMBL1063803	Binding constant for full-length MELK	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894445	CHEMBL1063803	Binding constant for full-length MELK	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894446	CHEMBL1063803	Binding constant for full-length MELK	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Kd	nM	1900.0	CHEMBL4578	Homo sapiens	Kd	nM	1900.0
	2894447	CHEMBL1063803	Binding constant for full-length MELK	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894448	CHEMBL1063803	Binding constant for full-length MELK	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894449	CHEMBL1063803	Binding constant for full-length MELK	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894450	CHEMBL1063803	Binding constant for full-length MELK	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894451	CHEMBL1063803	Binding constant for full-length MELK	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894452	CHEMBL1063803	Binding constant for full-length MELK	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894453	CHEMBL1063803	Binding constant for full-length MELK	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	280.0	CHEMBL4578	Homo sapiens	Kd	nM	280.0
	2894454	CHEMBL1063803	Binding constant for full-length MELK	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894455	CHEMBL1063803	Binding constant for full-length MELK	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894456	CHEMBL1063803	Binding constant for full-length MELK	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894457	CHEMBL1063803	Binding constant for full-length MELK	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894458	CHEMBL1063803	Binding constant for full-length MELK	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894459	CHEMBL1063803	Binding constant for full-length MELK	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894460	CHEMBL1063803	Binding constant for full-length MELK	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	33.0	CHEMBL4578	Homo sapiens	Kd	nM	33.0
	2894461	CHEMBL1063803	Binding constant for full-length MELK	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	340.0	CHEMBL4578	Homo sapiens	Kd	nM	340.0
	2894462	CHEMBL1063803	Binding constant for full-length MELK	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	350.0	CHEMBL4578	Homo sapiens	Kd	nM	350.0
	2894463	CHEMBL1063803	Binding constant for full-length MELK	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	240.0	CHEMBL4578	Homo sapiens	Kd	nM	240.0
	2894464	CHEMBL1063803	Binding constant for full-length MELK	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	2894465	CHEMBL1063803	Binding constant for full-length MELK	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
Antagonist	2897316	CHEMBL1051360	Inhibition of MELK in the presence of 50uM ATP	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	IC50	nM	420.0	CHEMBL4578	Homo sapiens	IC50	uM	0.42
	2906800	CHEMBL1060204	Percentage MELK activity remaining in the presence of 0.01uM inhibitor	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Activity	%	95.0	CHEMBL4578	Homo sapiens	Activity	%	95.0
	2906801	CHEMBL1060204	Percentage MELK activity remaining in the presence of 0.01uM inhibitor	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Activity	%	96.0	CHEMBL4578	Homo sapiens	Activity	%	96.0
	2906802	CHEMBL1060204	Percentage MELK activity remaining in the presence of 0.01uM inhibitor	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Activity	%	53.0	CHEMBL4578	Homo sapiens	Activity	%	53.0
Antagonist	2906803	CHEMBL1052103	Percentage MELK activity remaining in the presence of 0.1uM inhibitor	B	CC(C)CCN1c2nc(Nc3cc(F)c(O)c(F)c3)ncc2N(C)C(=O)C1C		CHEMBL573107	=	Activity	%	40.0	CHEMBL4578	Homo sapiens	Activity	%	40.0
Antagonist	2906804	CHEMBL1052103	Percentage MELK activity remaining in the presence of 0.1uM inhibitor	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Activity	%	32.0	CHEMBL4578	Homo sapiens	Activity	%	32.0
	2906805	CHEMBL1052103	Percentage MELK activity remaining in the presence of 0.1uM inhibitor	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Activity	%	63.0	CHEMBL4578	Homo sapiens	Activity	%	63.0
	2906806	CHEMBL1052103	Percentage MELK activity remaining in the presence of 0.1uM inhibitor	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Activity	%	72.0	CHEMBL4578	Homo sapiens	Activity	%	72.0
	2906807	CHEMBL1052103	Percentage MELK activity remaining in the presence of 0.1uM inhibitor	B	Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL6291	=	Activity	%	61.0	CHEMBL4578	Homo sapiens	Activity	%	61.0
Antagonist	2906808	CHEMBL1052103	Percentage MELK activity remaining in the presence of 0.1uM inhibitor	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Activity	%	15.0	CHEMBL4578	Homo sapiens	Activity	%	15.0
	2906809	CHEMBL1052103	Percentage MELK activity remaining in the presence of 0.1uM inhibitor	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Activity	%	65.0	CHEMBL4578	Homo sapiens	Activity	%	65.0
	2906810	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	=	Activity	%	82.0	CHEMBL4578	Homo sapiens	Activity	%	82.0
	2906811	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	=	Activity	%	107.0	CHEMBL4578	Homo sapiens	Activity	%	107.0
	2906812	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Activity	%	75.0	CHEMBL4578	Homo sapiens	Activity	%	75.0
Antagonist	2906813	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br		CHEMBL573108	=	Activity	%	11.0	CHEMBL4578	Homo sapiens	Activity	%	11.0
	2906814	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Activity	%	83.0	CHEMBL4578	Homo sapiens	Activity	%	83.0
	2906815	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	=	Activity	%	79.0	CHEMBL4578	Homo sapiens	Activity	%	79.0
	2906816	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Activity	%	86.0	CHEMBL4578	Homo sapiens	Activity	%	86.0
	2906817	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Activity	%	66.0	CHEMBL4578	Homo sapiens	Activity	%	66.0
	2906818	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	CC(=O)c1c(O)c(C)c(O)c(Cc2c(O)c3c(c(C(=O)/C=C/c4ccccc4)c2O)OC(C)(C)C=C3)c1O		CHEMBL34241	=	Activity	%	70.0	CHEMBL4578	Homo sapiens	Activity	%	70.0
Antagonist	2906819	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	C[C@H]1CNCCN1S(=O)(=O)c1cccc2cnccc12		CHEMBL1233654	=	Activity	%	37.0	CHEMBL4578	Homo sapiens	Activity	%	37.0
	2906820	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1ccc(O)c(Cl)c1		CHEMBL322970	=	Activity	%	72.0	CHEMBL4578	Homo sapiens	Activity	%	72.0
Antagonist	2906821	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	CNCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL148333	=	Activity	%	23.0	CHEMBL4578	Homo sapiens	Activity	%	23.0
Antagonist	2906822	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Activity	%	24.0	CHEMBL4578	Homo sapiens	Activity	%	24.0
	2906823	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Activity	%	65.0	CHEMBL4578	Homo sapiens	Activity	%	65.0
	2906824	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	NC(=O)c1sc(-c2ccsc2)cc1N		CHEMBL193093	=	Activity	%	80.0	CHEMBL4578	Homo sapiens	Activity	%	80.0
Antagonist	2906825	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21		CHEMBL264406	=	Activity	%	28.0	CHEMBL4578	Homo sapiens	Activity	%	28.0
Antagonist	2906826	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Activity	%	24.0	CHEMBL4578	Homo sapiens	Activity	%	24.0
	2906827	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	Cc1ccc(NC(=O)c2cccc(N(C)C)c2)cc1NC(=O)c1ccc(O)cc1		CHEMBL186526	=	Activity	%	82.0	CHEMBL4578	Homo sapiens	Activity	%	82.0
	2906828	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	Activity	%	56.0	CHEMBL4578	Homo sapiens	Activity	%	56.0
	2906829	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H]1OC(C)=O		CHEMBL240954	=	Activity	%	102.0	CHEMBL4578	Homo sapiens	Activity	%	102.0
	2906830	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	O=C(Nc1cc(Cl)cc2c1[nH]c1cnccc12)c1cccnc1		CHEMBL79004	=	Activity	%	70.0	CHEMBL4578	Homo sapiens	Activity	%	70.0
	2906831	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	O=C(NOC[C@@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl.O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL540501	=	Activity	%	73.0	CHEMBL4578	Homo sapiens	Activity	%	73.0
	2906832	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	N#CC(=C(/N)Sc1ccccc1N)/C(C#N)=C(\N)Sc1ccccc1N		CHEMBL34704	=	Activity	%	83.0	CHEMBL4578	Homo sapiens	Activity	%	83.0
	2906833	CHEMBL1063735	Percentage MELK activity remaining in the presence of 10uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	68.0	CHEMBL4578	Homo sapiens	Activity	%	68.0
	2906834	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	Activity	%	61.0	CHEMBL4578	Homo sapiens	Activity	%	61.0
Antagonist	2906835	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	=	Activity	%	45.0	CHEMBL4578	Homo sapiens	Activity	%	45.0
	2906836	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Activity	%	79.0	CHEMBL4578	Homo sapiens	Activity	%	79.0
	2906837	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br		CHEMBL573108	=	Activity	%	57.0	CHEMBL4578	Homo sapiens	Activity	%	57.0
Antagonist	2906838	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Activity	%	20.0	CHEMBL4578	Homo sapiens	Activity	%	20.0
	2906839	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	=	Activity	%	84.0	CHEMBL4578	Homo sapiens	Activity	%	84.0
	2906840	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Activity	%	68.0	CHEMBL4578	Homo sapiens	Activity	%	68.0
	2906841	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Activity	%	83.0	CHEMBL4578	Homo sapiens	Activity	%	83.0
	2906842	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Activity	%	63.0	CHEMBL4578	Homo sapiens	Activity	%	63.0
	2906843	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O		CHEMBL428496	=	Activity	%	61.0	CHEMBL4578	Homo sapiens	Activity	%	61.0
	2906844	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	Activity	%	88.0	CHEMBL4578	Homo sapiens	Activity	%	88.0
	2906845	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Activity	%	54.0	CHEMBL4578	Homo sapiens	Activity	%	54.0
	2906846	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Activity	%	55.0	CHEMBL4578	Homo sapiens	Activity	%	55.0
	2906847	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	CC(=O)O.O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL265470	=	Activity	%	77.0	CHEMBL4578	Homo sapiens	Activity	%	77.0
Antagonist	2906848	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Activity	%	15.0	CHEMBL4578	Homo sapiens	Activity	%	15.0
	2906849	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Activity	%	92.0	CHEMBL4578	Homo sapiens	Activity	%	92.0
Antagonist	2906850	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	COc1ccc2c(c1)[nH]c1c(C)nccc12		CHEMBL269538	=	Activity	%	8.0	CHEMBL4578	Homo sapiens	Activity	%	8.0
	2906851	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	CC1=NCCc2c1[nH]c1cc(O)ccc21		CHEMBL129177	=	Activity	%	77.0	CHEMBL4578	Homo sapiens	Activity	%	77.0
	2906852	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	Cc1nccc2c1[nH]c1ccccc12		CHEMBL12014	=	Activity	%	82.0	CHEMBL4578	Homo sapiens	Activity	%	82.0
	2906853	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	COc1ccc2c3c([nH]c2c1)C(C)=NCC3		CHEMBL340807	=	Activity	%	95.0	CHEMBL4578	Homo sapiens	Activity	%	95.0
	2906854	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	Oc1c(Br)cc(C=C2c3cc(I)ccc3NC2O)cc1Br		CHEMBL1794051	=	Activity	%	78.0	CHEMBL4578	Homo sapiens	Activity	%	78.0
Antagonist	2906855	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	CNCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL148333	=	Activity	%	43.0	CHEMBL4578	Homo sapiens	Activity	%	43.0
Antagonist	2906856	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12		CHEMBL406821	=	Activity	%	34.0	CHEMBL4578	Homo sapiens	Activity	%	34.0
Antagonist	2906857	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Activity	%	5.0	CHEMBL4578	Homo sapiens	Activity	%	5.0
	2906858	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21		CHEMBL264406	=	Activity	%	84.0	CHEMBL4578	Homo sapiens	Activity	%	84.0
	2906859	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	=	Activity	%	57.0	CHEMBL4578	Homo sapiens	Activity	%	57.0
	2906860	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Activity	%	66.0	CHEMBL4578	Homo sapiens	Activity	%	66.0
	2906861	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Activity	%	74.0	CHEMBL4578	Homo sapiens	Activity	%	74.0
	2906862	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Activity	%	73.0	CHEMBL4578	Homo sapiens	Activity	%	73.0
Antagonist	2906863	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	CCCCCCOC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608532	=	Activity	%	17.0	CHEMBL4578	Homo sapiens	Activity	%	17.0
	2906864	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Activity	%	76.0	CHEMBL4578	Homo sapiens	Activity	%	76.0
	2906865	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	80.0	CHEMBL4578	Homo sapiens	Activity	%	80.0
	2906866	CHEMBL1052104	Percentage MELK activity remaining in the presence of 1uM inhibitor	B	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	=	Activity	%	58.0	CHEMBL4578	Homo sapiens	Activity	%	58.0
	2906867	CHEMBL1060145	Percentage MELK activity remaining in the presence of 25uM inhibitor	B	COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1		CHEMBL576349	=	Activity	%	75.0	CHEMBL4578	Homo sapiens	Activity	%	75.0
	2906868	CHEMBL1060145	Percentage MELK activity remaining in the presence of 25uM inhibitor	B	NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12		CHEMBL489157	=	Activity	%	63.0	CHEMBL4578	Homo sapiens	Activity	%	63.0
	2906869	CHEMBL1060146	Percentage MELK activity remaining in the presence of 2uM inhibitor	B	Cn1cc(C2=C(c3ccc(Cl)cc3Cl)C(=O)NC2=O)c2ccccc21		CHEMBL102714	=	Activity	%	78.0	CHEMBL4578	Homo sapiens	Activity	%	78.0
	2906870	CHEMBL1062761	Percentage MELK activity remaining in the presence of 3uM inhibitor	B	Cc1ccc(-c2c(C(=O)CF)n(CCCO)c3ncnc(N)c23)cc1		CHEMBL515414	=	Activity	%	65.0	CHEMBL4578	Homo sapiens	Activity	%	65.0
	2921268	CHEMBL1047448	Inhibition of MELK assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	100.0	CHEMBL4578	Homo sapiens	Activity	%	100.0
	2924841	CHEMBL1056883	Inhibition of MELK assessed as residual enzyme activity at 10 uM relative to untreated control	B	c1ccc2c(c1)[nH]c1c3cc[nH]c3ccc21		CHEMBL567173	=	Activity	%	82.0	CHEMBL4578	Homo sapiens	Activity	%	82.0
	2924842	CHEMBL1056883	Inhibition of MELK assessed as residual enzyme activity at 10 uM relative to untreated control	B	c1ccc2c(c1)[nH]c1c2ccc2cc[nH]c21		CHEMBL584980	=	Activity	%	93.0	CHEMBL4578	Homo sapiens	Activity	%	93.0
	2924843	CHEMBL1056883	Inhibition of MELK assessed as residual enzyme activity at 10 uM relative to untreated control	B	O=Cc1c[nH]c2ccc3c4ccccc4[nH]c3c12		CHEMBL575754	=	Activity	%	89.0	CHEMBL4578	Homo sapiens	Activity	%	89.0
	2924844	CHEMBL1056883	Inhibition of MELK assessed as residual enzyme activity at 10 uM relative to untreated control	B	O=Cc1c[nH]c2c1ccc1c3ccccc3[nH]c12		CHEMBL583972	=	Activity	%	61.0	CHEMBL4578	Homo sapiens	Activity	%	61.0
	2926228	CHEMBL1054468	Inhibition of MELK assessed as remaining enzyme activity at 3 uM relative to DMSO	B	COc1ccccc1-n1c(-c2ccccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL574236	=	Activity	%	89.0	CHEMBL4578	Homo sapiens	Activity	%	89.0
	2928414	CHEMBL1055325	Inhibition of MELK assessed as remaining enzyme activity at 1 uM relative to DMSO	B	COc1ccccc1-n1c(-c2cc(O)ccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL566515	=	Activity	%	80.0	CHEMBL4578	Homo sapiens	Activity	%	80.0
	2999024	CHEMBL1043727	Inhibition of MELK assessed as residual activity at 10 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	CC(C)c1onc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL220227	=	Activity	%	78.0	CHEMBL4578	Homo sapiens	Activity	%	78.0
	2999814	CHEMBL1043727	Inhibition of MELK assessed as residual activity at 10 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	CC(C)c1noc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL375428	=	Activity	%	108.0	CHEMBL4578	Homo sapiens	Activity	%	108.0
	2999887	CHEMBL1049889	Inhibition of MELK assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL569114	=	Activity	%	81.0	CHEMBL4578	Homo sapiens	Activity	%	81.0
	2999963	CHEMBL1049889	Inhibition of MELK assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c([S+](C)[O-])nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL572006	=	Activity	%	92.0	CHEMBL4578	Homo sapiens	Activity	%	92.0
	3052657	CHEMBL1041144	Residual activity of MELK at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	68.0	CHEMBL4578	Homo sapiens	Residual activity	%	68.0
	3053966	CHEMBL1050297	Residual activity of MELK at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	77.0	CHEMBL4578	Homo sapiens	Residual activity	%	77.0
	3054218	CHEMBL1040686	Residual activity of MELK at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	111.0	CHEMBL4578	Homo sapiens	Residual activity	%	111.0
	3055505	CHEMBL1041144	Residual activity of MELK at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	106.0	CHEMBL4578	Homo sapiens	Residual activity	%	106.0
	3056810	CHEMBL1050297	Residual activity of MELK at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	98.0	CHEMBL4578	Homo sapiens	Residual activity	%	98.0
	3057062	CHEMBL1040686	Residual activity of MELK at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	34.0	CHEMBL4578	Homo sapiens	Residual activity	%	34.0
	3058382	CHEMBL1041144	Residual activity of MELK at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	78.0	CHEMBL4578	Homo sapiens	Residual activity	%	78.0
	3058634	CHEMBL1050297	Residual activity of MELK at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	85.0	CHEMBL4578	Homo sapiens	Residual activity	%	85.0
	3072980	CHEMBL1040686	Residual activity of MELK at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	60.0	CHEMBL4578	Homo sapiens	Residual activity	%	60.0
	3213964	CHEMBL1116712	Inhibition of MELK at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	2.0	CHEMBL4578	Homo sapiens	INH	%	2.0
	3219675	CHEMBL1110426	Inhibition of MELK at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccc(-c2ccnc(N)n2)s1)C(N)=O		CHEMBL1077375	=	Inhibition	%	83.0	CHEMBL4578	Homo sapiens	INH	%	83.0
	3224886	CHEMBL1100964	Inhibition of MELK at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	3226265	CHEMBL1100964	Inhibition of MELK at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	3260043	CHEMBL1108064	Inhibition of MELK at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2nccc(Nc3cccc(Br)c3)c2c1		CHEMBL1089524	=	Activity	%	25.0	CHEMBL4578	Homo sapiens	Activity	%	25.0
	3261369	CHEMBL1108064	Inhibition of MELK at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL1088901	=	Activity	%	49.0	CHEMBL4578	Homo sapiens	Activity	%	49.0
	3332026	CHEMBL1166564	Inhibition of MELK at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	3333441	CHEMBL1166564	Inhibition of MELK at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	3334846	CHEMBL1166564	Inhibition of MELK at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	3336266	CHEMBL1166564	Inhibition of MELK at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	3337581	CHEMBL1166564	Inhibition of MELK at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	3338912	CHEMBL1166564	Inhibition of MELK at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	3339165	CHEMBL1166564	Inhibition of MELK at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	3340469	CHEMBL1166564	Inhibition of MELK at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	3341808	CHEMBL1166564	Inhibition of MELK at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	3343255	CHEMBL1166564	Inhibition of MELK at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	3358668	CHEMBL1174910	Inhibition of MELK at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	8.1	CHEMBL4578	Homo sapiens	INH	%	8.1
	3359110	CHEMBL1174910	Inhibition of MELK at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	6.1	CHEMBL4578	Homo sapiens	INH	%	6.1
	3445198	CHEMBL1244510	Binding affinity to MELK	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	26.0	CHEMBL4578	Homo sapiens	Kd	nM	26.0
	3448502	CHEMBL1244510	Binding affinity to MELK	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	3448986	CHEMBL1244510	Binding affinity to MELK	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	280.0	CHEMBL4578	Homo sapiens	Kd	nM	280.0
	3449270	CHEMBL1244510	Binding affinity to MELK	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	350.0	CHEMBL4578	Homo sapiens	Kd	nM	350.0
	3449735	CHEMBL1244510	Binding affinity to MELK	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	3450139	CHEMBL1244510	Binding affinity to MELK	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	3451056	CHEMBL1244510	Binding affinity to MELK	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	uM	10.0
	5089646	CHEMBL1633366	Inhibition of MELK at 10 uM	B	C(#Cc1n[nH]c2ccccc12)c1ccncc1		CHEMBL1631892	>=	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	5120370	CHEMBL1646193	Inhibition of human MELK at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	105.0	CHEMBL4578	Homo sapiens	INH	%	105.0
	5133700	CHEMBL1648712	Inhibition of MELK assessed as residual activity at 10 uM	B	CN(C)C/C=C/C(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641990	=	Activity	%	75.0	CHEMBL4578	Homo sapiens	Activity	%	75.0
	5133795	CHEMBL1648712	Inhibition of MELK assessed as residual activity at 10 uM	B	CN(C)CCCC(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641989	=	Activity	%	80.0	CHEMBL4578	Homo sapiens	Activity	%	80.0
	5133876	CHEMBL1648712	Inhibition of MELK assessed as residual activity at 10 uM	B	CN1CCN(CCC(=O)Nc2ccc3c(C#N)cnc(Nc4cccc(Br)c4)c3c2)CC1		CHEMBL1641992	=	Activity	%	89.0	CHEMBL4578	Homo sapiens	Activity	%	89.0
	5191409	CHEMBL1664061	Inhibition of MELK at 1 uM	B	COc1cc2nc(-c3cc(F)ccc3O)nc(N[C@@H]3CNC[C@H]3C(C)(C)O)c2cc1OC		CHEMBL1236782	=	Inhibition	%	75.0	CHEMBL4578	Homo sapiens	INH	%	75.0
	5191410	CHEMBL1664061	Inhibition of MELK at 1 uM	B	CC(C)(O)[C@@H]1CNC[C@H]1Nc1nc(-c2cc(-c3cc[nH]n3)ccc2O)nc2ccccc12		CHEMBL1650131	=	Inhibition	%	94.0	CHEMBL4578	Homo sapiens	INH	%	94.0
	5250093	CHEMBL1685707	Inhibition of MELK at 1 uM	B	CCOc1cc2nnc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1N1CCN(C)CC1		CHEMBL1683030	=	Inhibition	%	41.0	CHEMBL4578	Homo sapiens	INH	%	41.0
	5250094	CHEMBL1685708	Inhibition of MELK at 0.1 uM	B	CCOc1cc2nnc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1N1CCN(C)CC1		CHEMBL1683030	=	Inhibition	%	15.0	CHEMBL4578	Homo sapiens	INH	%	15.0
	6198097	CHEMBL1776508	Inhibition of MELK assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	B	CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1		CHEMBL1738758	=	IC50	nM	744.0	CHEMBL4578	Homo sapiens	IC50	uM	0.744
	6273815	CHEMBL1806162	Inhibition of MELK assessed as residual enzyme activity at 10 uM	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833	=	Activity	%	88.0	CHEMBL4578	Homo sapiens	Activity	%	88.0
	6339958	CHEMBL1826895	Activity of MELK kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	81.0	CHEMBL4578	Homo sapiens	Activity	%	81.0
	6352237	CHEMBL1825844	Inhibition of MELK assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205	=	Activity	%	46.0	CHEMBL4578	Homo sapiens	Activity	%	46.0
	7567504	CHEMBL1908784	Binding constant for MELK kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7567975	CHEMBL1908784	Binding constant for MELK kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	=	Kd	nM	1600.0	CHEMBL4578	Homo sapiens	Kd	nM	1600.0
	7568443	CHEMBL1908784	Binding constant for MELK kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7568875	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	340.0	CHEMBL4578	Homo sapiens	Kd	nM	340.0
	7569018	CHEMBL1908784	Binding constant for MELK kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7569478	CHEMBL1908784	Binding constant for MELK kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7569950	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Kd	nM	1900.0	CHEMBL4578	Homo sapiens	Kd	nM	1900.0
	7570413	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7570840	CHEMBL1908784	Binding constant for MELK kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	350.0	CHEMBL4578	Homo sapiens	Kd	nM	350.0
	7570994	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7571451	CHEMBL1908784	Binding constant for MELK kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7571927	CHEMBL1908784	Binding constant for MELK kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	2200.0	CHEMBL4578	Homo sapiens	Kd	nM	2200.0
	7572390	CHEMBL1908784	Binding constant for MELK kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7572806	CHEMBL1908784	Binding constant for MELK kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	99.0	CHEMBL4578	Homo sapiens	Kd	nM	99.0
	7572975	CHEMBL1908784	Binding constant for MELK kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7573432	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7573908	CHEMBL1908784	Binding constant for MELK kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	1100.0	CHEMBL4578	Homo sapiens	Kd	nM	1100.0
	7574377	CHEMBL1908784	Binding constant for MELK kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	280.0	CHEMBL4578	Homo sapiens	Kd	nM	280.0
	7574953	CHEMBL1908784	Binding constant for MELK kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	4.9	CHEMBL4578	Homo sapiens	Kd	nM	4.9
	7575414	CHEMBL1908784	Binding constant for MELK kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7575885	CHEMBL1908784	Binding constant for MELK kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7576316	CHEMBL1908784	Binding constant for MELK kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7576927	CHEMBL1908784	Binding constant for MELK kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7577386	CHEMBL1908784	Binding constant for MELK kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	300.0	CHEMBL4578	Homo sapiens	Kd	nM	300.0
	7577892	CHEMBL1908784	Binding constant for MELK kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7578297	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	2600.0	CHEMBL4578	Homo sapiens	Kd	nM	2600.0
	7578935	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	Kd	nM	590.0	CHEMBL4578	Homo sapiens	Kd	nM	590.0
	7579309	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7579759	CHEMBL1908784	Binding constant for MELK kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7579791	CHEMBL1908784	Binding constant for MELK kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	210.0	CHEMBL4578	Homo sapiens	Kd	nM	210.0
	7580260	CHEMBL1908784	Binding constant for MELK kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Kd	nM	170.0	CHEMBL4578	Homo sapiens	Kd	nM	170.0
	7580663	CHEMBL1908784	Binding constant for MELK kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7581293	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7581678	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7582152	CHEMBL1908784	Binding constant for MELK kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7582616	CHEMBL1908784	Binding constant for MELK kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7583016	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	240.0	CHEMBL4578	Homo sapiens	Kd	nM	240.0
	7584039	CHEMBL1908784	Binding constant for MELK kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7584510	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	=	Kd	nM	5600.0	CHEMBL4578	Homo sapiens	Kd	nM	5600.0
	7584972	CHEMBL1908784	Binding constant for MELK kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7585376	CHEMBL1908784	Binding constant for MELK kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7585527	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7585935	CHEMBL1908784	Binding constant for MELK kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	Kd	nM	5600.0	CHEMBL4578	Homo sapiens	Kd	nM	5600.0
	7586381	CHEMBL1908784	Binding constant for MELK kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	=	Kd	nM	5700.0	CHEMBL4578	Homo sapiens	Kd	nM	5700.0
	7586852	CHEMBL1908784	Binding constant for MELK kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7587306	CHEMBL1908784	Binding constant for MELK kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7587488	CHEMBL1908784	Binding constant for MELK kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7587907	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7588360	CHEMBL1908784	Binding constant for MELK kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7588831	CHEMBL1908784	Binding constant for MELK kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7589282	CHEMBL1908784	Binding constant for MELK kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7589453	CHEMBL1908784	Binding constant for MELK kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7589877	CHEMBL1908784	Binding constant for MELK kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	26.0	CHEMBL4578	Homo sapiens	Kd	nM	26.0
	7590344	CHEMBL1908784	Binding constant for MELK kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7590818	CHEMBL1908784	Binding constant for MELK kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7591426	CHEMBL1908784	Binding constant for MELK kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7591848	CHEMBL1908784	Binding constant for MELK kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	1600.0	CHEMBL4578	Homo sapiens	Kd	nM	1600.0
	7592320	CHEMBL1908784	Binding constant for MELK kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7592804	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7593393	CHEMBL1908784	Binding constant for MELK kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	830.0	CHEMBL4578	Homo sapiens	Kd	nM	830.0
	7593828	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7594300	CHEMBL1908784	Binding constant for MELK kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Kd	nM	890.0	CHEMBL4578	Homo sapiens	Kd	nM	890.0
	7594331	CHEMBL1908784	Binding constant for MELK kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7594783	CHEMBL1908784	Binding constant for MELK kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7595361	CHEMBL1908784	Binding constant for MELK kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7595805	CHEMBL1908784	Binding constant for MELK kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7596308	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7596755	CHEMBL1908784	Binding constant for MELK kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7597333	CHEMBL1908784	Binding constant for MELK kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7597817	CHEMBL1908784	Binding constant for MELK kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7598287	CHEMBL1908784	Binding constant for MELK kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL4578	Homo sapiens	Kd	nM	10000.0
	7598729	CHEMBL1908784	Binding constant for MELK kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	33.0	CHEMBL4578	Homo sapiens	Kd	nM	33.0
	7922649	CHEMBL1918999	Inhibition of human recombinant MELK at 0.5 uM by radiometric filter-binding assay	B	Clc1ccccc1Nc1nc2c(-c3nnc[nH]3)cccc2c2cnccc12		CHEMBL1915438	=	Inhibition	%	87.0	CHEMBL4578	Homo sapiens	INH	%	87.0
	7969750	CHEMBL1931449	Inhibition of MELK assessed as residual activity at 10 uM using [33P-ATP] by radiometric filter binding assay	B	Cc1ccc(F)cc1-c1nc2[nH]nc(N)c2c2c1CCCC2		CHEMBL1927262	=	Activity	%	64.0	CHEMBL4578	Homo sapiens	Activity	%	64.0
	8061270	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	0.75	CHEMBL4578	Homo sapiens	Inhibition	%	0.75
	8061447	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	47.12	CHEMBL4578	Homo sapiens	Inhibition	%	47.12
	8061778	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	3.22	CHEMBL4578	Homo sapiens	Inhibition	%	3.22
	8061969	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	4.43	CHEMBL4578	Homo sapiens	Inhibition	%	4.43
	8062193	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	23.5	CHEMBL4578	Homo sapiens	Inhibition	%	23.5
	8062309	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	7.95	CHEMBL4578	Homo sapiens	Inhibition	%	7.95
	8062695	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	6.89	CHEMBL4578	Homo sapiens	Inhibition	%	6.89
	8062793	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	2.39	CHEMBL4578	Homo sapiens	Inhibition	%	2.39
	8063017	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-0.39	CHEMBL4578	Homo sapiens	Inhibition	%	-0.39
	8063149	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	-1.02	CHEMBL4578	Homo sapiens	Inhibition	%	-1.02
	8063316	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.2	CHEMBL4578	Homo sapiens	Inhibition	%	0.2
	8063540	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	4.8	CHEMBL4578	Homo sapiens	Inhibition	%	4.8
	8063648	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	2.76	CHEMBL4578	Homo sapiens	Inhibition	%	2.76
	8064054	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	1.43	CHEMBL4578	Homo sapiens	Inhibition	%	1.43
	8064169	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	22.05	CHEMBL4578	Homo sapiens	Inhibition	%	22.05
	8064603	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	3.35	CHEMBL4578	Homo sapiens	Inhibition	%	3.35
	8064741	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	0.74	CHEMBL4578	Homo sapiens	Inhibition	%	0.74
	8065131	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	-1.74	CHEMBL4578	Homo sapiens	Inhibition	%	-1.74
	8065247	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	2.1	CHEMBL4578	Homo sapiens	Inhibition	%	2.1
	8065471	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	2.93	CHEMBL4578	Homo sapiens	Inhibition	%	2.93
	8065646	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	4.99	CHEMBL4578	Homo sapiens	Inhibition	%	4.99
	8065761	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	8.41	CHEMBL4578	Homo sapiens	Inhibition	%	8.41
	8065985	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	44.25	CHEMBL4578	Homo sapiens	Inhibition	%	44.25
	8066195	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	-0.92	CHEMBL4578	Homo sapiens	Inhibition	%	-0.92
	8066331	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	8.76	CHEMBL4578	Homo sapiens	Inhibition	%	8.76
	8066555	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	7.1	CHEMBL4578	Homo sapiens	Inhibition	%	7.1
	8066721	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	-0.77	CHEMBL4578	Homo sapiens	Inhibition	%	-0.77
	8067069	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	4.7	CHEMBL4578	Homo sapiens	Inhibition	%	4.7
	8067244	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	1.64	CHEMBL4578	Homo sapiens	Inhibition	%	1.64
	8067589	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	3.07	CHEMBL4578	Homo sapiens	Inhibition	%	3.07
	8067799	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	0.69	CHEMBL4578	Homo sapiens	Inhibition	%	0.69
	8068158	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	43.85	CHEMBL4578	Homo sapiens	Inhibition	%	43.85
	8068322	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	-0.12	CHEMBL4578	Homo sapiens	Inhibition	%	-0.12
	8068671	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.18	CHEMBL4578	Homo sapiens	Inhibition	%	0.18
	8068845	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	4.33	CHEMBL4578	Homo sapiens	Inhibition	%	4.33
	8069194	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	6.94	CHEMBL4578	Homo sapiens	Inhibition	%	6.94
	8069489	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	22.4	CHEMBL4578	Homo sapiens	Inhibition	%	22.4
	8069650	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	2.2	CHEMBL4578	Homo sapiens	Inhibition	%	2.2
	8069874	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	0.8	CHEMBL4578	Homo sapiens	Inhibition	%	0.8
	8070000	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	5.26	CHEMBL4578	Homo sapiens	Inhibition	%	5.26
	8070172	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	2.76	CHEMBL4578	Homo sapiens	Inhibition	%	2.76
	8070396	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	6.5	CHEMBL4578	Homo sapiens	Inhibition	%	6.5
	8070521	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	1.44	CHEMBL4578	Homo sapiens	Inhibition	%	1.44
	8070819	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	76.76	CHEMBL4578	Homo sapiens	Inhibition	%	76.76
	8071200	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	0.86	CHEMBL4578	Homo sapiens	Inhibition	%	0.86
	8071326	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	1.01	CHEMBL4578	Homo sapiens	Inhibition	%	1.01
	8071723	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	2.96	CHEMBL4578	Homo sapiens	Inhibition	%	2.96
	8071848	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	3.48	CHEMBL4578	Homo sapiens	Inhibition	%	3.48
	8072072	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	1.63	CHEMBL4578	Homo sapiens	Inhibition	%	1.63
	8072162	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-0.49	CHEMBL4578	Homo sapiens	Inhibition	%	-0.49
	8072386	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	1.36	CHEMBL4578	Homo sapiens	Inhibition	%	1.36
	8072543	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	0.33	CHEMBL4578	Homo sapiens	Inhibition	%	0.33
	8072668	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	4.06	CHEMBL4578	Homo sapiens	Inhibition	%	4.06
	8072892	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	2.15	CHEMBL4578	Homo sapiens	Inhibition	%	2.15
	8073059	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	7.3	CHEMBL4578	Homo sapiens	Inhibition	%	7.3
	8073408	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	3.51	CHEMBL4578	Homo sapiens	Inhibition	%	3.51
	8073527	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-0.41	CHEMBL4578	Homo sapiens	Inhibition	%	-0.41
	8073751	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	6.27	CHEMBL4578	Homo sapiens	Inhibition	%	6.27
	8073984	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	1.68	CHEMBL4578	Homo sapiens	Inhibition	%	1.68
	8074136	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	2.1	CHEMBL4578	Homo sapiens	Inhibition	%	2.1
	8074490	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	1.97	CHEMBL4578	Homo sapiens	Inhibition	%	1.97
	8074647	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.5	CHEMBL4578	Homo sapiens	Inhibition	%	1.5
	8074998	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	-0.58	CHEMBL4578	Homo sapiens	Inhibition	%	-0.58
	8075333	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-0.32	CHEMBL4578	Homo sapiens	Inhibition	%	-0.32
	8075570	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	5.55	CHEMBL4578	Homo sapiens	Inhibition	%	5.55
	8075711	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	-0.69	CHEMBL4578	Homo sapiens	Inhibition	%	-0.69
	8075935	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	3.67	CHEMBL4578	Homo sapiens	Inhibition	%	3.67
	8076077	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.14	CHEMBL4578	Homo sapiens	Inhibition	%	-0.14
	8076225	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	5.18	CHEMBL4578	Homo sapiens	Inhibition	%	5.18
	8076449	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	3.07	CHEMBL4578	Homo sapiens	Inhibition	%	3.07
	8076583	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	3.21	CHEMBL4578	Homo sapiens	Inhibition	%	3.21
	8076909	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-0.03	CHEMBL4578	Homo sapiens	Inhibition	%	-0.03
	8077156	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	42.22	CHEMBL4578	Homo sapiens	Inhibition	%	42.22
	8077508	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	-0.46	CHEMBL4578	Homo sapiens	Inhibition	%	-0.46
	8077659	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	2.51	CHEMBL4578	Homo sapiens	Inhibition	%	2.51
	8078026	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	1.31	CHEMBL4578	Homo sapiens	Inhibition	%	1.31
	8078165	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-5.49	CHEMBL4578	Homo sapiens	Inhibition	%	-5.49
	8078491	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-0.02	CHEMBL4578	Homo sapiens	Inhibition	%	-0.02
	8078741	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	90.41	CHEMBL4578	Homo sapiens	Inhibition	%	90.41
	8079081	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	6.64	CHEMBL4578	Homo sapiens	Inhibition	%	6.64
	8079239	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-2.58	CHEMBL4578	Homo sapiens	Inhibition	%	-2.58
	8079605	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	2.88	CHEMBL4578	Homo sapiens	Inhibition	%	2.88
	8079744	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	39.26	CHEMBL4578	Homo sapiens	Inhibition	%	39.26
	8079968	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	21.69	CHEMBL4578	Homo sapiens	Inhibition	%	21.69
	8080073	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	1.75	CHEMBL4578	Homo sapiens	Inhibition	%	1.75
	8080325	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	50.11	CHEMBL4578	Homo sapiens	Inhibition	%	50.11
	8080549	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	93.19	CHEMBL4578	Homo sapiens	Inhibition	%	93.19
	8080664	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	-0.28	CHEMBL4578	Homo sapiens	Inhibition	%	-0.28
	8080828	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	3.21	CHEMBL4578	Homo sapiens	Inhibition	%	3.21
	8081052	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-3.33	CHEMBL4578	Homo sapiens	Inhibition	%	-3.33
	8081187	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	1.82	CHEMBL4578	Homo sapiens	Inhibition	%	1.82
	8081555	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	78.7	CHEMBL4578	Homo sapiens	Inhibition	%	78.7
	8081658	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	0.77	CHEMBL4578	Homo sapiens	Inhibition	%	0.77
	8081882	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	6.85	CHEMBL4578	Homo sapiens	Inhibition	%	6.85
	8082134	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	10.31	CHEMBL4578	Homo sapiens	Inhibition	%	10.31
	8082247	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	2.03	CHEMBL4578	Homo sapiens	Inhibition	%	2.03
	8082644	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	4.7	CHEMBL4578	Homo sapiens	Inhibition	%	4.7
	8082767	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	3.33	CHEMBL4578	Homo sapiens	Inhibition	%	3.33
	8082991	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.69	CHEMBL4578	Homo sapiens	Inhibition	%	1.69
	8083147	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	6.78	CHEMBL4578	Homo sapiens	Inhibition	%	6.78
	8083470	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	0.93	CHEMBL4578	Homo sapiens	Inhibition	%	0.93
	8083724	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	74.62	CHEMBL4578	Homo sapiens	Inhibition	%	74.62
	8083834	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	2.15	CHEMBL4578	Homo sapiens	Inhibition	%	2.15
	8084058	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	12.95	CHEMBL4578	Homo sapiens	Inhibition	%	12.95
	8084243	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	50.26	CHEMBL4578	Homo sapiens	Inhibition	%	50.26
	8084585	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	2.68	CHEMBL4578	Homo sapiens	Inhibition	%	2.68
	8084746	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	46.89	CHEMBL4578	Homo sapiens	Inhibition	%	46.89
	8085068	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	4.3	CHEMBL4578	Homo sapiens	Inhibition	%	4.3
	8085324	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	13.22	CHEMBL4578	Homo sapiens	Inhibition	%	13.22
	8085656	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	1.63	CHEMBL4578	Homo sapiens	Inhibition	%	1.63
	8085845	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	93.42	CHEMBL4578	Homo sapiens	Inhibition	%	93.42
	8086184	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	2.1	CHEMBL4578	Homo sapiens	Inhibition	%	2.1
	8086346	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	3.6	CHEMBL4578	Homo sapiens	Inhibition	%	3.6
	8086570	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	11.65	CHEMBL4578	Homo sapiens	Inhibition	%	11.65
	8086669	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-0.81	CHEMBL4578	Homo sapiens	Inhibition	%	-0.81
	8086880	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	6.04	CHEMBL4578	Homo sapiens	Inhibition	%	6.04
	8087104	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	14.67	CHEMBL4578	Homo sapiens	Inhibition	%	14.67
	8087262	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	5.17	CHEMBL4578	Homo sapiens	Inhibition	%	5.17
	8087600	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	4.62	CHEMBL4578	Homo sapiens	Inhibition	%	4.62
	8087738	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	6.62	CHEMBL4578	Homo sapiens	Inhibition	%	6.62
	8088104	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	9.51	CHEMBL4578	Homo sapiens	Inhibition	%	9.51
	8088252	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	3.07	CHEMBL4578	Homo sapiens	Inhibition	%	3.07
	8088476	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	7.77	CHEMBL4578	Homo sapiens	Inhibition	%	7.77
	8088604	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	4.41	CHEMBL4578	Homo sapiens	Inhibition	%	4.41
	8088921	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	7.45	CHEMBL4578	Homo sapiens	Inhibition	%	7.45
	8089049	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	1.25	CHEMBL4578	Homo sapiens	Inhibition	%	1.25
	8089273	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	21.23	CHEMBL4578	Homo sapiens	Inhibition	%	21.23
	8089421	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	0.98	CHEMBL4578	Homo sapiens	Inhibition	%	0.98
	8089765	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	-0.46	CHEMBL4578	Homo sapiens	Inhibition	%	-0.46
	8089945	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-0.87	CHEMBL4578	Homo sapiens	Inhibition	%	-0.87
	8090334	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	18.36	CHEMBL4578	Homo sapiens	Inhibition	%	18.36
	8090501	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	1.4	CHEMBL4578	Homo sapiens	Inhibition	%	1.4
	8090864	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	0.77	CHEMBL4578	Homo sapiens	Inhibition	%	0.77
	8091069	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	6.32	CHEMBL4578	Homo sapiens	Inhibition	%	6.32
	8091430	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	10.0	CHEMBL4578	Homo sapiens	Inhibition	%	10.0
	8091585	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	8.13	CHEMBL4578	Homo sapiens	Inhibition	%	8.13
	8091925	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	8.09	CHEMBL4578	Homo sapiens	Inhibition	%	8.09
	8092062	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	3.76	CHEMBL4578	Homo sapiens	Inhibition	%	3.76
	8092286	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	4.43	CHEMBL4578	Homo sapiens	Inhibition	%	4.43
	8092437	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	5.46	CHEMBL4578	Homo sapiens	Inhibition	%	5.46
	8092809	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	2.25	CHEMBL4578	Homo sapiens	Inhibition	%	2.25
	8092938	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	9.71	CHEMBL4578	Homo sapiens	Inhibition	%	9.71
	8093250	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.52	CHEMBL4578	Homo sapiens	Inhibition	%	0.52
	8093614	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	0.84	CHEMBL4578	Homo sapiens	Inhibition	%	0.84
	8093753	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	25.61	CHEMBL4578	Homo sapiens	Inhibition	%	25.61
	8094097	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	3.44	CHEMBL4578	Homo sapiens	Inhibition	%	3.44
	8094277	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	1.3	CHEMBL4578	Homo sapiens	Inhibition	%	1.3
	8094501	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	0.19	CHEMBL4578	Homo sapiens	Inhibition	%	0.19
	8094676	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	18.04	CHEMBL4578	Homo sapiens	Inhibition	%	18.04
	8094832	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	1.29	CHEMBL4578	Homo sapiens	Inhibition	%	1.29
	8095056	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	3.52	CHEMBL4578	Homo sapiens	Inhibition	%	3.52
	8095196	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	-2.07	CHEMBL4578	Homo sapiens	Inhibition	%	-2.07
	8095399	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	3.76	CHEMBL4578	Homo sapiens	Inhibition	%	3.76
	8095764	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	44.68	CHEMBL4578	Homo sapiens	Inhibition	%	44.68
	8095912	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	3.54	CHEMBL4578	Homo sapiens	Inhibition	%	3.54
	8096136	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	8.01	CHEMBL4578	Homo sapiens	Inhibition	%	8.01
	8096253	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	3.33	CHEMBL4578	Homo sapiens	Inhibition	%	3.33
	8096616	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	2.37	CHEMBL4578	Homo sapiens	Inhibition	%	2.37
	8096772	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	10.47	CHEMBL4578	Homo sapiens	Inhibition	%	10.47
	8097143	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	3.16	CHEMBL4578	Homo sapiens	Inhibition	%	3.16
	8097450	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	2.27	CHEMBL4578	Homo sapiens	Inhibition	%	2.27
	8097674	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	0.82	CHEMBL4578	Homo sapiens	Inhibition	%	0.82
	8097824	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	27.53	CHEMBL4578	Homo sapiens	Inhibition	%	27.53
	8097957	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-0.21	CHEMBL4578	Homo sapiens	Inhibition	%	-0.21
	8098181	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	0.37	CHEMBL4578	Homo sapiens	Inhibition	%	0.37
	8098301	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-2.92	CHEMBL4578	Homo sapiens	Inhibition	%	-2.92
	8098705	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.14	CHEMBL4578	Homo sapiens	Inhibition	%	0.14
	8098890	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	78.28	CHEMBL4578	Homo sapiens	Inhibition	%	78.28
	8099258	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	6.96	CHEMBL4578	Homo sapiens	Inhibition	%	6.96
	8099400	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	3.94	CHEMBL4578	Homo sapiens	Inhibition	%	3.94
	8099594	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	-0.07	CHEMBL4578	Homo sapiens	Inhibition	%	-0.07
	8099818	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	-2.83	CHEMBL4578	Homo sapiens	Inhibition	%	-2.83
	8099965	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	5.47	CHEMBL4578	Homo sapiens	Inhibition	%	5.47
	8100335	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	5.8	CHEMBL4578	Homo sapiens	Inhibition	%	5.8
	8100451	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	5.2	CHEMBL4578	Homo sapiens	Inhibition	%	5.2
	8100675	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	6.59	CHEMBL4578	Homo sapiens	Inhibition	%	6.59
	8100815	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	5.78	CHEMBL4578	Homo sapiens	Inhibition	%	5.78
	8100975	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	3.65	CHEMBL4578	Homo sapiens	Inhibition	%	3.65
	8101199	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	8.7	CHEMBL4578	Homo sapiens	Inhibition	%	8.7
	8101341	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	-0.49	CHEMBL4578	Homo sapiens	Inhibition	%	-0.49
	8101526	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	7.14	CHEMBL4578	Homo sapiens	Inhibition	%	7.14
	8101750	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	6.08	CHEMBL4578	Homo sapiens	Inhibition	%	6.08
	8102003	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	4.88	CHEMBL4578	Homo sapiens	Inhibition	%	4.88
	8102158	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	-1.78	CHEMBL4578	Homo sapiens	Inhibition	%	-1.78
	8102513	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	-0.34	CHEMBL4578	Homo sapiens	Inhibition	%	-0.34
	8102633	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-8.42	CHEMBL4578	Homo sapiens	Inhibition	%	-8.42
	8102857	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-3.14	CHEMBL4578	Homo sapiens	Inhibition	%	-3.14
	8103035	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-3.64	CHEMBL4578	Homo sapiens	Inhibition	%	-3.64
	8103231	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	17.72	CHEMBL4578	Homo sapiens	Inhibition	%	17.72
	8103593	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	-2.04	CHEMBL4578	Homo sapiens	Inhibition	%	-2.04
	8103743	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	1.83	CHEMBL4578	Homo sapiens	Inhibition	%	1.83
	8103967	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	2.63	CHEMBL4578	Homo sapiens	Inhibition	%	2.63
	8104152	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	1.24	CHEMBL4578	Homo sapiens	Inhibition	%	1.24
	8104300	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	12.55	CHEMBL4578	Homo sapiens	Inhibition	%	12.55
	8104524	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	7.59	CHEMBL4578	Homo sapiens	Inhibition	%	7.59
	8104670	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	32.9	CHEMBL4578	Homo sapiens	Inhibition	%	32.9
	8105008	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	4.91	CHEMBL4578	Homo sapiens	Inhibition	%	4.91
	8105148	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	2.83	CHEMBL4578	Homo sapiens	Inhibition	%	2.83
	8105538	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	6.66	CHEMBL4578	Homo sapiens	Inhibition	%	6.66
	8105676	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	5.74	CHEMBL4578	Homo sapiens	Inhibition	%	5.74
	8105956	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	1.32	CHEMBL4578	Homo sapiens	Inhibition	%	1.32
	8106345	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	1.14	CHEMBL4578	Homo sapiens	Inhibition	%	1.14
	8106501	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	8.97	CHEMBL4578	Homo sapiens	Inhibition	%	8.97
	8106725	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	-1.84	CHEMBL4578	Homo sapiens	Inhibition	%	-1.84
	8106854	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	7.01	CHEMBL4578	Homo sapiens	Inhibition	%	7.01
	8107199	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-3.15	CHEMBL4578	Homo sapiens	Inhibition	%	-3.15
	8107371	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	4.69	CHEMBL4578	Homo sapiens	Inhibition	%	4.69
	8107572	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	82.11	CHEMBL4578	Homo sapiens	Inhibition	%	82.11
	8107796	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	3.78	CHEMBL4578	Homo sapiens	Inhibition	%	3.78
	8107931	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	2.88	CHEMBL4578	Homo sapiens	Inhibition	%	2.88
	8108313	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	2.0	CHEMBL4578	Homo sapiens	Inhibition	%	2.0
	8108488	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	-2.93	CHEMBL4578	Homo sapiens	Inhibition	%	-2.93
	8108859	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	37.85	CHEMBL4578	Homo sapiens	Inhibition	%	37.85
	8109001	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	3.07	CHEMBL4578	Homo sapiens	Inhibition	%	3.07
	8109339	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	5.07	CHEMBL4578	Homo sapiens	Inhibition	%	5.07
	8109469	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	4.47	CHEMBL4578	Homo sapiens	Inhibition	%	4.47
	8109693	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-0.36	CHEMBL4578	Homo sapiens	Inhibition	%	-0.36
	8109864	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	26.91	CHEMBL4578	Homo sapiens	Inhibition	%	26.91
	8109996	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	4.58	CHEMBL4578	Homo sapiens	Inhibition	%	4.58
	8110220	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	5.97	CHEMBL4578	Homo sapiens	Inhibition	%	5.97
	8110275	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	1.11	CHEMBL4578	Homo sapiens	Inhibition	%	1.11
	8110499	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.92	CHEMBL4578	Homo sapiens	Inhibition	%	1.92
	8110665	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	2.95	CHEMBL4578	Homo sapiens	Inhibition	%	2.95
	8111047	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	15.97	CHEMBL4578	Homo sapiens	Inhibition	%	15.97
	8111170	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-0.95	CHEMBL4578	Homo sapiens	Inhibition	%	-0.95
	8111521	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	1.75	CHEMBL4578	Homo sapiens	Inhibition	%	1.75
	8111687	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.55	CHEMBL4578	Homo sapiens	Inhibition	%	0.55
	8111911	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	18.76	CHEMBL4578	Homo sapiens	Inhibition	%	18.76
	8112116	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	9.64	CHEMBL4578	Homo sapiens	Inhibition	%	9.64
	8112253	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-0.32	CHEMBL4578	Homo sapiens	Inhibition	%	-0.32
	8112645	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	5.13	CHEMBL4578	Homo sapiens	Inhibition	%	5.13
	8112817	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-0.71	CHEMBL4578	Homo sapiens	Inhibition	%	-0.71
	8113193	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	17.48	CHEMBL4578	Homo sapiens	Inhibition	%	17.48
	8113329	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	7.12	CHEMBL4578	Homo sapiens	Inhibition	%	7.12
	8113553	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	2.31	CHEMBL4578	Homo sapiens	Inhibition	%	2.31
	8113677	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	4.62	CHEMBL4578	Homo sapiens	Inhibition	%	4.62
	8114017	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	1.03	CHEMBL4578	Homo sapiens	Inhibition	%	1.03
	8114193	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	3.5	CHEMBL4578	Homo sapiens	Inhibition	%	3.5
	8114549	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	5.07	CHEMBL4578	Homo sapiens	Inhibition	%	5.07
	8114825	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	2.41	CHEMBL4578	Homo sapiens	Inhibition	%	2.41
	8114991	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	-6.51	CHEMBL4578	Homo sapiens	Inhibition	%	-6.51
	8115380	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-2.29	CHEMBL4578	Homo sapiens	Inhibition	%	-2.29
	8115500	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	2.29	CHEMBL4578	Homo sapiens	Inhibition	%	2.29
	8115724	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-1.18	CHEMBL4578	Homo sapiens	Inhibition	%	-1.18
	8115857	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	18.39	CHEMBL4578	Homo sapiens	Inhibition	%	18.39
	8116240	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	72.66	CHEMBL4578	Homo sapiens	Inhibition	%	72.66
	8116443	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	21.23	CHEMBL4578	Homo sapiens	Inhibition	%	21.23
	8116577	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	1.96	CHEMBL4578	Homo sapiens	Inhibition	%	1.96
	8116801	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	0.88	CHEMBL4578	Homo sapiens	Inhibition	%	0.88
	8116973	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	2.9	CHEMBL4578	Homo sapiens	Inhibition	%	2.9
	8117144	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-0.61	CHEMBL4578	Homo sapiens	Inhibition	%	-0.61
	8117368	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	4.76	CHEMBL4578	Homo sapiens	Inhibition	%	4.76
	8117526	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	81.07	CHEMBL4578	Homo sapiens	Inhibition	%	81.07
	8117880	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	3.16	CHEMBL4578	Homo sapiens	Inhibition	%	3.16
	8118018	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	7.73	CHEMBL4578	Homo sapiens	Inhibition	%	7.73
	8118358	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	6.28	CHEMBL4578	Homo sapiens	Inhibition	%	6.28
	8118530	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	11.43	CHEMBL4578	Homo sapiens	Inhibition	%	11.43
	8118754	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	6.14	CHEMBL4578	Homo sapiens	Inhibition	%	6.14
	8118890	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	1.45	CHEMBL4578	Homo sapiens	Inhibition	%	1.45
	8119161	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	2.85	CHEMBL4578	Homo sapiens	Inhibition	%	2.85
	8119320	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12	Outside typical range	CHEMBL588025	=	Inhibition	%	-33.46	CHEMBL4578	Homo sapiens	Inhibition	%	-33.46
	8119544	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	6.74	CHEMBL4578	Homo sapiens	Inhibition	%	6.74
	8119711	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-2.61	CHEMBL4578	Homo sapiens	Inhibition	%	-2.61
	8120054	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	3.48	CHEMBL4578	Homo sapiens	Inhibition	%	3.48
	8120193	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	-1.46	CHEMBL4578	Homo sapiens	Inhibition	%	-1.46
	8120577	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-2.54	CHEMBL4578	Homo sapiens	Inhibition	%	-2.54
	8120778	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	76.43	CHEMBL4578	Homo sapiens	Inhibition	%	76.43
	8121130	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	0.52	CHEMBL4578	Homo sapiens	Inhibition	%	0.52
	8121302	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	0.46	CHEMBL4578	Homo sapiens	Inhibition	%	0.46
	8121693	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	34.72	CHEMBL4578	Homo sapiens	Inhibition	%	34.72
	8121856	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	4.71	CHEMBL4578	Homo sapiens	Inhibition	%	4.71
	8122201	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-4.36	CHEMBL4578	Homo sapiens	Inhibition	%	-4.36
	8122339	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	7.03	CHEMBL4578	Homo sapiens	Inhibition	%	7.03
	8122563	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	38.59	CHEMBL4578	Homo sapiens	Inhibition	%	38.59
	8122683	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	14.58	CHEMBL4578	Homo sapiens	Inhibition	%	14.58
	8123074	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	8.59	CHEMBL4578	Homo sapiens	Inhibition	%	8.59
	8123216	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	5.92	CHEMBL4578	Homo sapiens	Inhibition	%	5.92
	8123494	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	18.13	CHEMBL4578	Homo sapiens	Inhibition	%	18.13
	8123868	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	43.84	CHEMBL4578	Homo sapiens	Inhibition	%	43.84
	8124035	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-1.92	CHEMBL4578	Homo sapiens	Inhibition	%	-1.92
	8124378	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	5.16	CHEMBL4578	Homo sapiens	Inhibition	%	5.16
	8124517	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	0.19	CHEMBL4578	Homo sapiens	Inhibition	%	0.19
	8124741	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	-2.15	CHEMBL4578	Homo sapiens	Inhibition	%	-2.15
	8124906	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-1.35	CHEMBL4578	Homo sapiens	Inhibition	%	-1.35
	8125107	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	6.32	CHEMBL4578	Homo sapiens	Inhibition	%	6.32
	8125331	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	5.64	CHEMBL4578	Homo sapiens	Inhibition	%	5.64
	8125461	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	-0.51	CHEMBL4578	Homo sapiens	Inhibition	%	-0.51
	8125629	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	-1.31	CHEMBL4578	Homo sapiens	Inhibition	%	-1.31
	8125853	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	5.66	CHEMBL4578	Homo sapiens	Inhibition	%	5.66
	8126017	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-1.02	CHEMBL4578	Homo sapiens	Inhibition	%	-1.02
	8126181	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	10.06	CHEMBL4578	Homo sapiens	Inhibition	%	10.06
	8126405	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	12.46	CHEMBL4578	Homo sapiens	Inhibition	%	12.46
	8126520	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12	Outside typical range	CHEMBL247228	=	Inhibition	%	-27.24	CHEMBL4578	Homo sapiens	Inhibition	%	-27.24
	8126880	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	89.47	CHEMBL4578	Homo sapiens	Inhibition	%	89.47
	8127002	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	6.35	CHEMBL4578	Homo sapiens	Inhibition	%	6.35
	8127226	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	11.11	CHEMBL4578	Homo sapiens	Inhibition	%	11.11
	8127393	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	7.0	CHEMBL4578	Homo sapiens	Inhibition	%	7.0
	8127535	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	10.35	CHEMBL4578	Homo sapiens	Inhibition	%	10.35
	8127759	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	3.16	CHEMBL4578	Homo sapiens	Inhibition	%	3.16
	8127823	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	3.48	CHEMBL4578	Homo sapiens	Inhibition	%	3.48
	8128047	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	10.83	CHEMBL4578	Homo sapiens	Inhibition	%	10.83
	8128199	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	3.84	CHEMBL4578	Homo sapiens	Inhibition	%	3.84
	8128366	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-4.7	CHEMBL4578	Homo sapiens	Inhibition	%	-4.7
	8128590	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	0.11	CHEMBL4578	Homo sapiens	Inhibition	%	0.11
	8128709	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	52.31	CHEMBL4578	Homo sapiens	Inhibition	%	52.31
	8129070	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	-3.64	CHEMBL4578	Homo sapiens	Inhibition	%	-3.64
	8129241	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-1.71	CHEMBL4578	Homo sapiens	Inhibition	%	-1.71
	8129654	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	0.8	CHEMBL4578	Homo sapiens	Inhibition	%	0.8
	8129793	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	1.48	CHEMBL4578	Homo sapiens	Inhibition	%	1.48
	8130178	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	27.47	CHEMBL4578	Homo sapiens	Inhibition	%	27.47
	8130350	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-1.79	CHEMBL4578	Homo sapiens	Inhibition	%	-1.79
	8130734	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	55.42	CHEMBL4578	Homo sapiens	Inhibition	%	55.42
	8130850	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	2.75	CHEMBL4578	Homo sapiens	Inhibition	%	2.75
	8131213	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	6.61	CHEMBL4578	Homo sapiens	Inhibition	%	6.61
	8131557	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	7.41	CHEMBL4578	Homo sapiens	Inhibition	%	7.41
	8131724	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	15.36	CHEMBL4578	Homo sapiens	Inhibition	%	15.36
	8132089	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12	Outside typical range	CHEMBL273564	=	Inhibition	%	-13.98	CHEMBL4578	Homo sapiens	Inhibition	%	-13.98
	8132375	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-1.34	CHEMBL4578	Homo sapiens	Inhibition	%	-1.34
	8132522	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	4.23	CHEMBL4578	Homo sapiens	Inhibition	%	4.23
	8132914	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	-3.52	CHEMBL4578	Homo sapiens	Inhibition	%	-3.52
	8133035	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	-0.99	CHEMBL4578	Homo sapiens	Inhibition	%	-0.99
	8133259	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	16.41	CHEMBL4578	Homo sapiens	Inhibition	%	16.41
	8133397	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	3.71	CHEMBL4578	Homo sapiens	Inhibition	%	3.71
	8133569	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-1.71	CHEMBL4578	Homo sapiens	Inhibition	%	-1.71
	8133793	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-3.26	CHEMBL4578	Homo sapiens	Inhibition	%	-3.26
	8133973	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	13.25	CHEMBL4578	Homo sapiens	Inhibition	%	13.25
	8134121	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-3.33	CHEMBL4578	Homo sapiens	Inhibition	%	-3.33
	8134345	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-1.79	CHEMBL4578	Homo sapiens	Inhibition	%	-1.79
	8134505	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	3.06	CHEMBL4578	Homo sapiens	Inhibition	%	3.06
	8134689	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-1.64	CHEMBL4578	Homo sapiens	Inhibition	%	-1.64
	8135073	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	4.28	CHEMBL4578	Homo sapiens	Inhibition	%	4.28
	8135188	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	5.71	CHEMBL4578	Homo sapiens	Inhibition	%	5.71
	8135412	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	2.98	CHEMBL4578	Homo sapiens	Inhibition	%	2.98
	8135553	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	7.7	CHEMBL4578	Homo sapiens	Inhibition	%	7.7
	8135898	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	11.67	CHEMBL4578	Homo sapiens	Inhibition	%	11.67
	8136066	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	3.83	CHEMBL4578	Homo sapiens	Inhibition	%	3.83
	8136434	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	6.04	CHEMBL4578	Homo sapiens	Inhibition	%	6.04
	8136724	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	5.45	CHEMBL4578	Homo sapiens	Inhibition	%	5.45
	8136859	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	-0.28	CHEMBL4578	Homo sapiens	Inhibition	%	-0.28
	8137083	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	5.33	CHEMBL4578	Homo sapiens	Inhibition	%	5.33
	8137246	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	-0.14	CHEMBL4578	Homo sapiens	Inhibition	%	-0.14
	8137590	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-1.92	CHEMBL4578	Homo sapiens	Inhibition	%	-1.92
	8137738	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	2.39	CHEMBL4578	Homo sapiens	Inhibition	%	2.39
	8138128	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-2.77	CHEMBL4578	Homo sapiens	Inhibition	%	-2.77
	8138307	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	0.45	CHEMBL4578	Homo sapiens	Inhibition	%	0.45
	8138679	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-2.85	CHEMBL4578	Homo sapiens	Inhibition	%	-2.85
	8138837	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	-0.33	CHEMBL4578	Homo sapiens	Inhibition	%	-0.33
	8139022	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	20.89	CHEMBL4578	Homo sapiens	Inhibition	%	20.89
	8139246	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	2.86	CHEMBL4578	Homo sapiens	Inhibition	%	2.86
	8139405	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	9.19	CHEMBL4578	Homo sapiens	Inhibition	%	9.19
	8139743	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	2.19	CHEMBL4578	Homo sapiens	Inhibition	%	2.19
	8139884	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	7.16	CHEMBL4578	Homo sapiens	Inhibition	%	7.16
	8140108	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	5.89	CHEMBL4578	Homo sapiens	Inhibition	%	5.89
	8140231	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	4.49	CHEMBL4578	Homo sapiens	Inhibition	%	4.49
	8140390	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	9.57	CHEMBL4578	Homo sapiens	Inhibition	%	9.57
	8140614	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	4.19	CHEMBL4578	Homo sapiens	Inhibition	%	4.19
	8140757	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	6.41	CHEMBL4578	Homo sapiens	Inhibition	%	6.41
	8141059	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.9	CHEMBL4578	Homo sapiens	Inhibition	%	1.9
	8141413	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	2.23	CHEMBL4578	Homo sapiens	Inhibition	%	2.23
	8141573	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	3.93	CHEMBL4578	Homo sapiens	Inhibition	%	3.93
	8141916	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	0.37	CHEMBL4578	Homo sapiens	Inhibition	%	0.37
	8142077	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	-1.54	CHEMBL4578	Homo sapiens	Inhibition	%	-1.54
	8142301	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	2.58	CHEMBL4578	Homo sapiens	Inhibition	%	2.58
	8142469	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	0.09	CHEMBL4578	Homo sapiens	Inhibition	%	0.09
	8142645	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	2.55	CHEMBL4578	Homo sapiens	Inhibition	%	2.55
	8143018	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-2.99	CHEMBL4578	Homo sapiens	Inhibition	%	-2.99
	8143173	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	2.97	CHEMBL4578	Homo sapiens	Inhibition	%	2.97
	8143397	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.48	CHEMBL4578	Homo sapiens	Inhibition	%	1.48
	8143584	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	13.79	CHEMBL4578	Homo sapiens	Inhibition	%	13.79
	8143743	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	5.84	CHEMBL4578	Homo sapiens	Inhibition	%	5.84
	8144081	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	5.3	CHEMBL4578	Homo sapiens	Inhibition	%	5.3
	8144444	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	2.02	CHEMBL4578	Homo sapiens	Inhibition	%	2.02
	8144574	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	11.43	CHEMBL4578	Homo sapiens	Inhibition	%	11.43
	8144951	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	3.17	CHEMBL4578	Homo sapiens	Inhibition	%	3.17
	8145088	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	5.2	CHEMBL4578	Homo sapiens	Inhibition	%	5.2
	8145312	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	3.07	CHEMBL4578	Homo sapiens	Inhibition	%	3.07
	8145401	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	2.27	CHEMBL4578	Homo sapiens	Inhibition	%	2.27
	8145749	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	2.05	CHEMBL4578	Homo sapiens	Inhibition	%	2.05
	8145910	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	3.73	CHEMBL4578	Homo sapiens	Inhibition	%	3.73
	8146134	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	3.32	CHEMBL4578	Homo sapiens	Inhibition	%	3.32
	8146254	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-2.18	CHEMBL4578	Homo sapiens	Inhibition	%	-2.18
	8146638	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	1.24	CHEMBL4578	Homo sapiens	Inhibition	%	1.24
	8146805	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	22.0	CHEMBL4578	Homo sapiens	Inhibition	%	22.0
	8146974	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	2.34	CHEMBL4578	Homo sapiens	Inhibition	%	2.34
	8147198	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	8.84	CHEMBL4578	Homo sapiens	Inhibition	%	8.84
	8147340	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	4.89	CHEMBL4578	Homo sapiens	Inhibition	%	4.89
	8147717	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	2.53	CHEMBL4578	Homo sapiens	Inhibition	%	2.53
	8147904	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	6.21	CHEMBL4578	Homo sapiens	Inhibition	%	6.21
	8148062	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	10.39	CHEMBL4578	Homo sapiens	Inhibition	%	10.39
	8148286	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	5.53	CHEMBL4578	Homo sapiens	Inhibition	%	5.53
	8148400	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	5.37	CHEMBL4578	Homo sapiens	Inhibition	%	5.37
	8148763	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	10.03	CHEMBL4578	Homo sapiens	Inhibition	%	10.03
	8148901	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	7.28	CHEMBL4578	Homo sapiens	Inhibition	%	7.28
	8149125	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	11.64	CHEMBL4578	Homo sapiens	Inhibition	%	11.64
	8149284	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	3.85	CHEMBL4578	Homo sapiens	Inhibition	%	3.85
	8149642	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	15.22	CHEMBL4578	Homo sapiens	Inhibition	%	15.22
	8149740	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	1.41	CHEMBL4578	Homo sapiens	Inhibition	%	1.41
	8149964	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	3.48	CHEMBL4578	Homo sapiens	Inhibition	%	3.48
	8150089	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.54	CHEMBL4578	Homo sapiens	Inhibition	%	0.54
	8150473	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-3.3	CHEMBL4578	Homo sapiens	Inhibition	%	-3.3
	8150593	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-2.88	CHEMBL4578	Homo sapiens	Inhibition	%	-2.88
	8150982	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	11.26	CHEMBL4578	Homo sapiens	Inhibition	%	11.26
	8151145	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-4.14	CHEMBL4578	Homo sapiens	Inhibition	%	-4.14
	8151546	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.14	CHEMBL4578	Homo sapiens	Inhibition	%	2.14
	8151684	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	32.26	CHEMBL4578	Homo sapiens	Inhibition	%	32.26
	8152062	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.64	CHEMBL4578	Homo sapiens	Inhibition	%	1.64
	8152250	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	22.19	CHEMBL4578	Homo sapiens	Inhibition	%	22.19
	8152632	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	9.84	CHEMBL4578	Homo sapiens	Inhibition	%	9.84
	8152746	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	3.25	CHEMBL4578	Homo sapiens	Inhibition	%	3.25
	8152970	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	6.92	CHEMBL4578	Homo sapiens	Inhibition	%	6.92
	8153109	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	4.83	CHEMBL4578	Homo sapiens	Inhibition	%	4.83
	8153470	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	6.1	CHEMBL4578	Homo sapiens	Inhibition	%	6.1
	8153627	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	8.4	CHEMBL4578	Homo sapiens	Inhibition	%	8.4
	8153984	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	61.19	CHEMBL4578	Homo sapiens	Inhibition	%	61.19
	8154305	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	1.29	CHEMBL4578	Homo sapiens	Inhibition	%	1.29
	8154431	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	8.57	CHEMBL4578	Homo sapiens	Inhibition	%	8.57
	8154814	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-0.86	CHEMBL4578	Homo sapiens	Inhibition	%	-0.86
	8154934	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-2.04	CHEMBL4578	Homo sapiens	Inhibition	%	-2.04
	8155158	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-0.08	CHEMBL4578	Homo sapiens	Inhibition	%	-0.08
	8155334	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.66	CHEMBL4578	Homo sapiens	Inhibition	%	0.66
	8155495	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-5.86	CHEMBL4578	Homo sapiens	Inhibition	%	-5.86
	8155719	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	2.86	CHEMBL4578	Homo sapiens	Inhibition	%	2.86
	8155897	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	5.08	CHEMBL4578	Homo sapiens	Inhibition	%	5.08
	8156035	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	1.46	CHEMBL4578	Homo sapiens	Inhibition	%	1.46
	8156259	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	3.63	CHEMBL4578	Homo sapiens	Inhibition	%	3.63
	8156471	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	2.47	CHEMBL4578	Homo sapiens	Inhibition	%	2.47
	8156621	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	7.46	CHEMBL4578	Homo sapiens	Inhibition	%	7.46
	8156845	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	2.36	CHEMBL4578	Homo sapiens	Inhibition	%	2.36
	8156988	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	0.94	CHEMBL4578	Homo sapiens	Inhibition	%	0.94
	8157332	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	17.98	CHEMBL4578	Homo sapiens	Inhibition	%	17.98
	8157473	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	13.05	CHEMBL4578	Homo sapiens	Inhibition	%	13.05
	8157827	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	3.75	CHEMBL4578	Homo sapiens	Inhibition	%	3.75
	8157988	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-1.43	CHEMBL4578	Homo sapiens	Inhibition	%	-1.43
	8158212	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	0.4	CHEMBL4578	Homo sapiens	Inhibition	%	0.4
	8158238	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	9.41	CHEMBL4578	Homo sapiens	Inhibition	%	9.41
	8158462	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	14.78	CHEMBL4578	Homo sapiens	Inhibition	%	14.78
	8158620	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	7.99	CHEMBL4578	Homo sapiens	Inhibition	%	7.99
	8158789	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	2.11	CHEMBL4578	Homo sapiens	Inhibition	%	2.11
	8159013	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	5.13	CHEMBL4578	Homo sapiens	Inhibition	%	5.13
	8159148	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	3.76	CHEMBL4578	Homo sapiens	Inhibition	%	3.76
	8159492	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	4.24	CHEMBL4578	Homo sapiens	Inhibition	%	4.24
	8159623	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	7.45	CHEMBL4578	Homo sapiens	Inhibition	%	7.45
	8159847	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	24.01	CHEMBL4578	Homo sapiens	Inhibition	%	24.01
	8159988	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	4.77	CHEMBL4578	Homo sapiens	Inhibition	%	4.77
	8160349	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.6	CHEMBL4578	Homo sapiens	Inhibition	%	1.6
	8160499	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-3.21	CHEMBL4578	Homo sapiens	Inhibition	%	-3.21
	8160793	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	4.56	CHEMBL4578	Homo sapiens	Inhibition	%	4.56
	8161167	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	7.07	CHEMBL4578	Homo sapiens	Inhibition	%	7.07
	8161310	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	11.57	CHEMBL4578	Homo sapiens	Inhibition	%	11.57
	8161659	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	1.6	CHEMBL4578	Homo sapiens	Inhibition	%	1.6
	8161797	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	63.1	CHEMBL4578	Homo sapiens	Inhibition	%	63.1
	8162021	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	0.82	CHEMBL4578	Homo sapiens	Inhibition	%	0.82
	8162151	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	2.36	CHEMBL4578	Homo sapiens	Inhibition	%	2.36
	8162535	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-0.26	CHEMBL4578	Homo sapiens	Inhibition	%	-0.26
	8162788	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	60.61	CHEMBL4578	Homo sapiens	Inhibition	%	60.61
	8162936	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	62.69	CHEMBL4578	Homo sapiens	Inhibition	%	62.69
	8163329	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	4.2	CHEMBL4578	Homo sapiens	Inhibition	%	4.2
	8163463	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	4.67	CHEMBL4578	Homo sapiens	Inhibition	%	4.67
	8163687	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	1.93	CHEMBL4578	Homo sapiens	Inhibition	%	1.93
	8163810	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	7.4	CHEMBL4578	Homo sapiens	Inhibition	%	7.4
	8164168	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	75.16	CHEMBL4578	Homo sapiens	Inhibition	%	75.16
	8164308	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	2.12	CHEMBL4578	Homo sapiens	Inhibition	%	2.12
	8164687	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	12.5	CHEMBL4578	Homo sapiens	Inhibition	%	12.5
	8164831	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	1.19	CHEMBL4578	Homo sapiens	Inhibition	%	1.19
	8165055	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	2.17	CHEMBL4578	Homo sapiens	Inhibition	%	2.17
	8165125	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	3.77	CHEMBL4578	Homo sapiens	Inhibition	%	3.77
	8165490	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	2.15	CHEMBL4578	Homo sapiens	Inhibition	%	2.15
	8165633	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	51.56	CHEMBL4578	Homo sapiens	Inhibition	%	51.56
	8165857	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	0.21	CHEMBL4578	Homo sapiens	Inhibition	%	0.21
	8165983	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	4.56	CHEMBL4578	Homo sapiens	Inhibition	%	4.56
	8166345	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	4.1	CHEMBL4578	Homo sapiens	Inhibition	%	4.1
	8166475	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	4.46	CHEMBL4578	Homo sapiens	Inhibition	%	4.46
	8166800	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	8.73	CHEMBL4578	Homo sapiens	Inhibition	%	8.73
	8167112	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	10.42	CHEMBL4578	Homo sapiens	Inhibition	%	10.42
	8167253	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	94.4	CHEMBL4578	Homo sapiens	Inhibition	%	94.4
	8167477	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	6.08	CHEMBL4578	Homo sapiens	Inhibition	%	6.08
	8167641	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	7.39	CHEMBL4578	Homo sapiens	Inhibition	%	7.39
	8167998	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	8.51	CHEMBL4578	Homo sapiens	Inhibition	%	8.51
	8168122	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	2.13	CHEMBL4578	Homo sapiens	Inhibition	%	2.13
	8168487	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	6.11	CHEMBL4578	Homo sapiens	Inhibition	%	6.11
	8168623	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	3.51	CHEMBL4578	Homo sapiens	Inhibition	%	3.51
	8168847	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	0.79	CHEMBL4578	Homo sapiens	Inhibition	%	0.79
	8169011	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	55.85	CHEMBL4578	Homo sapiens	Inhibition	%	55.85
	8169377	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	3.47	CHEMBL4578	Homo sapiens	Inhibition	%	3.47
	8169457	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	18.18	CHEMBL4578	Homo sapiens	Inhibition	%	18.18
	8169681	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	81.97	CHEMBL4578	Homo sapiens	Inhibition	%	81.97
	8169815	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	4.51	CHEMBL4578	Homo sapiens	Inhibition	%	4.51
	8170184	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12	Outside typical range	CHEMBL396107	=	Inhibition	%	-11.03	CHEMBL4578	Homo sapiens	Inhibition	%	-11.03
	8170309	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	3.77	CHEMBL4578	Homo sapiens	Inhibition	%	3.77
	8170673	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	6.83	CHEMBL4578	Homo sapiens	Inhibition	%	6.83
	8170808	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	5.5	CHEMBL4578	Homo sapiens	Inhibition	%	5.5
	8171032	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	5.96	CHEMBL4578	Homo sapiens	Inhibition	%	5.96
	8171229	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	3.21	CHEMBL4578	Homo sapiens	Inhibition	%	3.21
	8171446	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	50.46	CHEMBL4578	Homo sapiens	Inhibition	%	50.46
	8171811	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	14.84	CHEMBL4578	Homo sapiens	Inhibition	%	14.84
	8171964	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	4.24	CHEMBL4578	Homo sapiens	Inhibition	%	4.24
	8172320	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	5.79	CHEMBL4578	Homo sapiens	Inhibition	%	5.79
	8172448	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	6.05	CHEMBL4578	Homo sapiens	Inhibition	%	6.05
	8172672	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	2.12	CHEMBL4578	Homo sapiens	Inhibition	%	2.12
	8172814	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	6.85	CHEMBL4578	Homo sapiens	Inhibition	%	6.85
	8173174	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	3.48	CHEMBL4578	Homo sapiens	Inhibition	%	3.48
	8173339	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	2.47	CHEMBL4578	Homo sapiens	Inhibition	%	2.47
	8173704	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	3.77	CHEMBL4578	Homo sapiens	Inhibition	%	3.77
	8174015	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	98.03	CHEMBL4578	Homo sapiens	Inhibition	%	98.03
	8174147	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	2.47	CHEMBL4578	Homo sapiens	Inhibition	%	2.47
	8174519	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.66	CHEMBL4578	Homo sapiens	Inhibition	%	1.66
	8174641	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	2.1	CHEMBL4578	Homo sapiens	Inhibition	%	2.1
	8174865	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	4.18	CHEMBL4578	Homo sapiens	Inhibition	%	4.18
	8175008	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	31.57	CHEMBL4578	Homo sapiens	Inhibition	%	31.57
	8175368	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	26.3	CHEMBL4578	Homo sapiens	Inhibition	%	26.3
	8175624	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	25.83	CHEMBL4578	Homo sapiens	Inhibition	%	25.83
	8175787	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	4.84	CHEMBL4578	Homo sapiens	Inhibition	%	4.84
	8176011	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	5.0	CHEMBL4578	Homo sapiens	Inhibition	%	5.0
	8176164	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	33.89	CHEMBL4578	Homo sapiens	Inhibition	%	33.89
	8176313	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	10.96	CHEMBL4578	Homo sapiens	Inhibition	%	10.96
	8176537	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	3.82	CHEMBL4578	Homo sapiens	Inhibition	%	3.82
	8176669	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	41.37	CHEMBL4578	Homo sapiens	Inhibition	%	41.37
	8177023	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	27.22	CHEMBL4578	Homo sapiens	Inhibition	%	27.22
	8177165	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	4.83	CHEMBL4578	Homo sapiens	Inhibition	%	4.83
	8177527	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	22.29	CHEMBL4578	Homo sapiens	Inhibition	%	22.29
	8177691	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	6.51	CHEMBL4578	Homo sapiens	Inhibition	%	6.51
	8177915	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	4.85	CHEMBL4578	Homo sapiens	Inhibition	%	4.85
	8178055	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	10.43	CHEMBL4578	Homo sapiens	Inhibition	%	10.43
	8178367	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.5	CHEMBL4578	Homo sapiens	Inhibition	%	1.5
	8178494	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	5.13	CHEMBL4578	Homo sapiens	Inhibition	%	5.13
	8178718	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	2.6	CHEMBL4578	Homo sapiens	Inhibition	%	2.6
	8178867	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.83	CHEMBL4578	Homo sapiens	Inhibition	%	0.83
	8179214	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	4.99	CHEMBL4578	Homo sapiens	Inhibition	%	4.99
	8179358	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	49.65	CHEMBL4578	Homo sapiens	Inhibition	%	49.65
	8179582	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	90.56	CHEMBL4578	Homo sapiens	Inhibition	%	90.56
	8179719	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	3.57	CHEMBL4578	Homo sapiens	Inhibition	%	3.57
	8179976	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	3.21	CHEMBL4578	Homo sapiens	Inhibition	%	3.21
	8180354	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	4.24	CHEMBL4578	Homo sapiens	Inhibition	%	4.24
	8180510	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	88.15	CHEMBL4578	Homo sapiens	Inhibition	%	88.15
	8180882	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	20.35	CHEMBL4578	Homo sapiens	Inhibition	%	20.35
	8181015	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	4.23	CHEMBL4578	Homo sapiens	Inhibition	%	4.23
	8181370	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	2.57	CHEMBL4578	Homo sapiens	Inhibition	%	2.57
	8181510	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	8.68	CHEMBL4578	Homo sapiens	Inhibition	%	8.68
	8181734	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	5.64	CHEMBL4578	Homo sapiens	Inhibition	%	5.64
	8181873	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	77.6	CHEMBL4578	Homo sapiens	Inhibition	%	77.6
	8182260	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	22.32	CHEMBL4578	Homo sapiens	Inhibition	%	22.32
	8182400	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.38	CHEMBL4578	Homo sapiens	Inhibition	%	1.38
	8182716	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	4.17	CHEMBL4578	Homo sapiens	Inhibition	%	4.17
	8183062	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	5.51	CHEMBL4578	Homo sapiens	Inhibition	%	5.51
	8183211	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	2.89	CHEMBL4578	Homo sapiens	Inhibition	%	2.89
	8183435	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	11.45	CHEMBL4578	Homo sapiens	Inhibition	%	11.45
	8183564	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	-0.41	CHEMBL4578	Homo sapiens	Inhibition	%	-0.41
	8183930	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	3.75	CHEMBL4578	Homo sapiens	Inhibition	%	3.75
	8184066	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	3.34	CHEMBL4578	Homo sapiens	Inhibition	%	3.34
	8184332	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	5.92	CHEMBL4578	Homo sapiens	Inhibition	%	5.92
	8184703	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	5.38	CHEMBL4578	Homo sapiens	Inhibition	%	5.38
	8184860	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	3.62	CHEMBL4578	Homo sapiens	Inhibition	%	3.62
	8185233	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	0.79	CHEMBL4578	Homo sapiens	Inhibition	%	0.79
	8185364	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	9.23	CHEMBL4578	Homo sapiens	Inhibition	%	9.23
	8185588	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	3.6	CHEMBL4578	Homo sapiens	Inhibition	%	3.6
	8185719	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	41.87	CHEMBL4578	Homo sapiens	Inhibition	%	41.87
	8186082	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	3.69	CHEMBL4578	Homo sapiens	Inhibition	%	3.69
	8186223	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	3.07	CHEMBL4578	Homo sapiens	Inhibition	%	3.07
	8186447	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	4.64	CHEMBL4578	Homo sapiens	Inhibition	%	4.64
	8186611	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	4.31	CHEMBL4578	Homo sapiens	Inhibition	%	4.31
	8186750	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	3.78	CHEMBL4578	Homo sapiens	Inhibition	%	3.78
	8186974	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	4.26	CHEMBL4578	Homo sapiens	Inhibition	%	4.26
	8187072	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	3.07	CHEMBL4578	Homo sapiens	Inhibition	%	3.07
	8187420	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	1.72	CHEMBL4578	Homo sapiens	Inhibition	%	1.72
	8187792	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	1.61	CHEMBL4578	Homo sapiens	Inhibition	%	1.61
	8187921	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	-0.13	CHEMBL4578	Homo sapiens	Inhibition	%	-0.13
	8188288	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	8.5	CHEMBL4578	Homo sapiens	Inhibition	%	8.5
	8188423	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	3.61	CHEMBL4578	Homo sapiens	Inhibition	%	3.61
	8188647	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	4.85	CHEMBL4578	Homo sapiens	Inhibition	%	4.85
	8188697	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.2	CHEMBL4578	Homo sapiens	Inhibition	%	3.2
	8188921	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	9.42	CHEMBL4578	Homo sapiens	Inhibition	%	9.42
	8189069	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	26.68	CHEMBL4578	Homo sapiens	Inhibition	%	26.68
	8189225	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	9.58	CHEMBL4578	Homo sapiens	Inhibition	%	9.58
	8189449	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	5.46	CHEMBL4578	Homo sapiens	Inhibition	%	5.46
	8189598	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	2.93	CHEMBL4578	Homo sapiens	Inhibition	%	2.93
	8189954	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	8.09	CHEMBL4578	Homo sapiens	Inhibition	%	8.09
	8190086	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	4.33	CHEMBL4578	Homo sapiens	Inhibition	%	4.33
	8190310	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	8.21	CHEMBL4578	Homo sapiens	Inhibition	%	8.21
	8190450	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	4.36	CHEMBL4578	Homo sapiens	Inhibition	%	4.36
	8190811	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	2.15	CHEMBL4578	Homo sapiens	Inhibition	%	2.15
	8190975	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	7.73	CHEMBL4578	Homo sapiens	Inhibition	%	7.73
	8191337	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	16.06	CHEMBL4578	Homo sapiens	Inhibition	%	16.06
	8191433	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	3.76	CHEMBL4578	Homo sapiens	Inhibition	%	3.76
	8191657	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	2.15	CHEMBL4578	Homo sapiens	Inhibition	%	2.15
	8191779	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	11.14	CHEMBL4578	Homo sapiens	Inhibition	%	11.14
	8192152	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	3.83	CHEMBL4578	Homo sapiens	Inhibition	%	3.83
	8192281	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	0.76	CHEMBL4578	Homo sapiens	Inhibition	%	0.76
	8192505	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	1.99	CHEMBL4578	Homo sapiens	Inhibition	%	1.99
	8192649	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	1.3	CHEMBL4578	Homo sapiens	Inhibition	%	1.3
	8193009	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	3.83	CHEMBL4578	Homo sapiens	Inhibition	%	3.83
	8193281	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	2.86	CHEMBL4578	Homo sapiens	Inhibition	%	2.86
	8193426	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	80.32	CHEMBL4578	Homo sapiens	Inhibition	%	80.32
	8193807	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	19.03	CHEMBL4578	Homo sapiens	Inhibition	%	19.03
	8193956	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	0.66	CHEMBL4578	Homo sapiens	Inhibition	%	0.66
	8194180	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	6.1	CHEMBL4578	Homo sapiens	Inhibition	%	6.1
	8194311	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	5.67	CHEMBL4578	Homo sapiens	Inhibition	%	5.67
	8194666	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	4.84	CHEMBL4578	Homo sapiens	Inhibition	%	4.84
	8194809	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	7.85	CHEMBL4578	Homo sapiens	Inhibition	%	7.85
	8195166	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	5.49	CHEMBL4578	Homo sapiens	Inhibition	%	5.49
	8195330	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	4.89	CHEMBL4578	Homo sapiens	Inhibition	%	4.89
	8195554	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	17.79	CHEMBL4578	Homo sapiens	Inhibition	%	17.79
	8195693	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	6.02	CHEMBL4578	Homo sapiens	Inhibition	%	6.02
	8196015	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	5.11	CHEMBL4578	Homo sapiens	Inhibition	%	5.11
	8196132	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	0.16	CHEMBL4578	Homo sapiens	Inhibition	%	0.16
	8196356	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	7.57	CHEMBL4578	Homo sapiens	Inhibition	%	7.57
	8196506	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.41	CHEMBL4578	Homo sapiens	Inhibition	%	1.41
	8196858	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	2.35	CHEMBL4578	Homo sapiens	Inhibition	%	2.35
	8196999	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	4.29	CHEMBL4578	Homo sapiens	Inhibition	%	4.29
	8197360	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	10.32	CHEMBL4578	Homo sapiens	Inhibition	%	10.32
	8197635	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	4.94	CHEMBL4578	Homo sapiens	Inhibition	%	4.94
	8197775	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	2.05	CHEMBL4578	Homo sapiens	Inhibition	%	2.05
	8197999	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	8.87	CHEMBL4578	Homo sapiens	Inhibition	%	8.87
	8198156	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	4.86	CHEMBL4578	Homo sapiens	Inhibition	%	4.86
	8198518	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	0.52	CHEMBL4578	Homo sapiens	Inhibition	%	0.52
	8198648	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	8.15	CHEMBL4578	Homo sapiens	Inhibition	%	8.15
	8199003	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	6.67	CHEMBL4578	Homo sapiens	Inhibition	%	6.67
	8199151	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	6.98	CHEMBL4578	Homo sapiens	Inhibition	%	6.98
	8199375	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	11.42	CHEMBL4578	Homo sapiens	Inhibition	%	11.42
	8199509	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	3.34	CHEMBL4578	Homo sapiens	Inhibition	%	3.34
	8199896	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	3.07	CHEMBL4578	Homo sapiens	Inhibition	%	3.07
	8200034	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	4.4	CHEMBL4578	Homo sapiens	Inhibition	%	4.4
	8200362	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	2.47	CHEMBL4578	Homo sapiens	Inhibition	%	2.47
	8200701	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	15.35	CHEMBL4578	Homo sapiens	Inhibition	%	15.35
	8200851	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	5.51	CHEMBL4578	Homo sapiens	Inhibition	%	5.51
	8201205	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	4.91	CHEMBL4578	Homo sapiens	Inhibition	%	4.91
	8201340	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	1.24	CHEMBL4578	Homo sapiens	Inhibition	%	1.24
	8201564	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	3.87	CHEMBL4578	Homo sapiens	Inhibition	%	3.87
	8201697	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	0.29	CHEMBL4578	Homo sapiens	Inhibition	%	0.29
	8201976	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	4.21	CHEMBL4578	Homo sapiens	Inhibition	%	4.21
	8202340	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	0.07	CHEMBL4578	Homo sapiens	Inhibition	%	0.07
	8202507	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	6.72	CHEMBL4578	Homo sapiens	Inhibition	%	6.72
	8202856	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	7.4	CHEMBL4578	Homo sapiens	Inhibition	%	7.4
	8202986	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	4.35	CHEMBL4578	Homo sapiens	Inhibition	%	4.35
	8203210	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	6.7	CHEMBL4578	Homo sapiens	Inhibition	%	6.7
	8203341	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	3.62	CHEMBL4578	Homo sapiens	Inhibition	%	3.62
	8203711	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	4.35	CHEMBL4578	Homo sapiens	Inhibition	%	4.35
	8203845	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	4.69	CHEMBL4578	Homo sapiens	Inhibition	%	4.69
	8204069	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	3.77	CHEMBL4578	Homo sapiens	Inhibition	%	3.77
	8204235	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	5.89	CHEMBL4578	Homo sapiens	Inhibition	%	5.89
	8204372	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	1.72	CHEMBL4578	Homo sapiens	Inhibition	%	1.72
	8204596	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	3.79	CHEMBL4578	Homo sapiens	Inhibition	%	3.79
	8204701	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.1	CHEMBL4578	Homo sapiens	Inhibition	%	1.1
	8205040	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	75.47	CHEMBL4578	Homo sapiens	Inhibition	%	75.47
	8205189	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	8.27	CHEMBL4578	Homo sapiens	Inhibition	%	8.27
	8205413	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	43.85	CHEMBL4578	Homo sapiens	Inhibition	%	43.85
	8205549	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	3.16	CHEMBL4578	Homo sapiens	Inhibition	%	3.16
	8205912	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	4.17	CHEMBL4578	Homo sapiens	Inhibition	%	4.17
	8206044	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	0.51	CHEMBL4578	Homo sapiens	Inhibition	%	0.51
	8206268	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-1.63	CHEMBL4578	Homo sapiens	Inhibition	%	-1.63
	8206320	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	3.14	CHEMBL4578	Homo sapiens	Inhibition	%	3.14
	8206544	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	4.87	CHEMBL4578	Homo sapiens	Inhibition	%	4.87
	8206687	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	5.36	CHEMBL4578	Homo sapiens	Inhibition	%	5.36
	8206867	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	6.89	CHEMBL4578	Homo sapiens	Inhibition	%	6.89
	8207091	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	20.11	CHEMBL4578	Homo sapiens	Inhibition	%	20.11
	8207217	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	4.19	CHEMBL4578	Homo sapiens	Inhibition	%	4.19
	8207571	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	6.28	CHEMBL4578	Homo sapiens	Inhibition	%	6.28
	8207703	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	3.67	CHEMBL4578	Homo sapiens	Inhibition	%	3.67
	8207927	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	4.44	CHEMBL4578	Homo sapiens	Inhibition	%	4.44
	8208072	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	11.89	CHEMBL4578	Homo sapiens	Inhibition	%	11.89
	8208428	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	8.05	CHEMBL4578	Homo sapiens	Inhibition	%	8.05
	8208594	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	3.7	CHEMBL4578	Homo sapiens	Inhibition	%	3.7
	8208951	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	10.21	CHEMBL4578	Homo sapiens	Inhibition	%	10.21
	8209056	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.52	CHEMBL4578	Homo sapiens	Inhibition	%	1.52
	8209280	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	3.29	CHEMBL4578	Homo sapiens	Inhibition	%	3.29
	8209396	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	3.67	CHEMBL4578	Homo sapiens	Inhibition	%	3.67
	8209770	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	0.83	CHEMBL4578	Homo sapiens	Inhibition	%	0.83
	8209906	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	5.63	CHEMBL4578	Homo sapiens	Inhibition	%	5.63
	8210130	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	4.94	CHEMBL4578	Homo sapiens	Inhibition	%	4.94
	8210271	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	2.02	CHEMBL4578	Homo sapiens	Inhibition	%	2.02
	8210631	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	0.98	CHEMBL4578	Homo sapiens	Inhibition	%	0.98
	8210890	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	5.52	CHEMBL4578	Homo sapiens	Inhibition	%	5.52
	8211034	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	4.31	CHEMBL4578	Homo sapiens	Inhibition	%	4.31
	8211428	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	5.51	CHEMBL4578	Homo sapiens	Inhibition	%	5.51
	8211551	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	11.29	CHEMBL4578	Homo sapiens	Inhibition	%	11.29
	8211904	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	13.11	CHEMBL4578	Homo sapiens	Inhibition	%	13.11
	8212260	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	6.24	CHEMBL4578	Homo sapiens	Inhibition	%	6.24
	8212401	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	4.84	CHEMBL4578	Homo sapiens	Inhibition	%	4.84
	8212758	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	0.44	CHEMBL4578	Homo sapiens	Inhibition	%	0.44
	8212928	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	6.22	CHEMBL4578	Homo sapiens	Inhibition	%	6.22
	8213281	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	66.88	CHEMBL4578	Homo sapiens	Inhibition	%	66.88
	8213609	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-3.46	CHEMBL4578	Homo sapiens	Inhibition	%	-3.46
	8213722	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	7.64	CHEMBL4578	Homo sapiens	Inhibition	%	7.64
	8213946	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	1.61	CHEMBL4578	Homo sapiens	Inhibition	%	1.61
	8214093	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.42	CHEMBL4578	Homo sapiens	Inhibition	%	1.42
	8214454	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	23.66	CHEMBL4578	Homo sapiens	Inhibition	%	23.66
	8214588	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	2.96	CHEMBL4578	Homo sapiens	Inhibition	%	2.96
	8214964	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-1.03	CHEMBL4578	Homo sapiens	Inhibition	%	-1.03
	8215215	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	9.7	CHEMBL4578	Homo sapiens	Inhibition	%	9.7
	8215368	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	12.55	CHEMBL4578	Homo sapiens	Inhibition	%	12.55
	8215756	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	5.23	CHEMBL4578	Homo sapiens	Inhibition	%	5.23
	8215875	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	3.61	CHEMBL4578	Homo sapiens	Inhibition	%	3.61
	8216099	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	19.91	CHEMBL4578	Homo sapiens	Inhibition	%	19.91
	8216218	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	2.87	CHEMBL4578	Homo sapiens	Inhibition	%	2.87
	8216578	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	11.08	CHEMBL4578	Homo sapiens	Inhibition	%	11.08
	8216716	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	8.01	CHEMBL4578	Homo sapiens	Inhibition	%	8.01
	8216940	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	12.64	CHEMBL4578	Homo sapiens	Inhibition	%	12.64
	8217074	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	6.34	CHEMBL4578	Homo sapiens	Inhibition	%	6.34
	8217248	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	2.47	CHEMBL4578	Homo sapiens	Inhibition	%	2.47
	8217472	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	2.86	CHEMBL4578	Homo sapiens	Inhibition	%	2.86
	8217603	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	1.64	CHEMBL4578	Homo sapiens	Inhibition	%	1.64
	8217928	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	1.25	CHEMBL4578	Homo sapiens	Inhibition	%	1.25
	8218267	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	3.61	CHEMBL4578	Homo sapiens	Inhibition	%	3.61
	8218394	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	2.38	CHEMBL4578	Homo sapiens	Inhibition	%	2.38
	8218761	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	4.39	CHEMBL4578	Homo sapiens	Inhibition	%	4.39
	8218892	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	7.7	CHEMBL4578	Homo sapiens	Inhibition	%	7.7
	8219116	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	3.83	CHEMBL4578	Homo sapiens	Inhibition	%	3.83
	8219276	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	3.77	CHEMBL4578	Homo sapiens	Inhibition	%	3.77
	8219526	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	2.83	CHEMBL4578	Homo sapiens	Inhibition	%	2.83
	8219687	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	4.21	CHEMBL4578	Homo sapiens	Inhibition	%	4.21
	8219911	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	5.33	CHEMBL4578	Homo sapiens	Inhibition	%	5.33
	8220080	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	6.87	CHEMBL4578	Homo sapiens	Inhibition	%	6.87
	8220433	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	3.23	CHEMBL4578	Homo sapiens	Inhibition	%	3.23
	8220547	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	7.71	CHEMBL4578	Homo sapiens	Inhibition	%	7.71
	8220771	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	5.47	CHEMBL4578	Homo sapiens	Inhibition	%	5.47
	8220909	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	56.78	CHEMBL4578	Homo sapiens	Inhibition	%	56.78
	8221269	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	71.36	CHEMBL4578	Homo sapiens	Inhibition	%	71.36
	8221402	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	2.86	CHEMBL4578	Homo sapiens	Inhibition	%	2.86
	8221791	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-1.76	CHEMBL4578	Homo sapiens	Inhibition	%	-1.76
	8221922	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	8.3	CHEMBL4578	Homo sapiens	Inhibition	%	8.3
	8222244	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	2.17	CHEMBL4578	Homo sapiens	Inhibition	%	2.17
	8222602	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	1.52	CHEMBL4578	Homo sapiens	Inhibition	%	1.52
	8222720	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	11.5	CHEMBL4578	Homo sapiens	Inhibition	%	11.5
	8222944	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	3.65	CHEMBL4578	Homo sapiens	Inhibition	%	3.65
	8223088	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	-9.28	CHEMBL4578	Homo sapiens	Inhibition	%	-9.28
	8223441	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	2.36	CHEMBL4578	Homo sapiens	Inhibition	%	2.36
	8223602	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	0.82	CHEMBL4578	Homo sapiens	Inhibition	%	0.82
	8223852	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	6.13	CHEMBL4578	Homo sapiens	Inhibition	%	6.13
	8224238	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	4.85	CHEMBL4578	Homo sapiens	Inhibition	%	4.85
	8224408	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	10.13	CHEMBL4578	Homo sapiens	Inhibition	%	10.13
	8224767	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	2.88	CHEMBL4578	Homo sapiens	Inhibition	%	2.88
	8225105	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	7.81	CHEMBL4578	Homo sapiens	Inhibition	%	7.81
	8225239	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	4.37	CHEMBL4578	Homo sapiens	Inhibition	%	4.37
	8225601	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	2.58	CHEMBL4578	Homo sapiens	Inhibition	%	2.58
	8225736	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	7.68	CHEMBL4578	Homo sapiens	Inhibition	%	7.68
	8225960	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	3.07	CHEMBL4578	Homo sapiens	Inhibition	%	3.07
	8226118	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.94	CHEMBL4578	Homo sapiens	Inhibition	%	0.94
	8226243	CHEMBL1961978	GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	2.92	CHEMBL4578	Homo sapiens	Inhibition	%	2.92
	8226467	CHEMBL1961979	GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	5.11	CHEMBL4578	Homo sapiens	Inhibition	%	5.11
inactive	9615733	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(-c2[nH]c(-c3ccnc(N)n3)cc2C(N)=O)c1C		CHEMBL1964290	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619291	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncnc2onc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL213505	=	Ki	nM	501.19	CHEMBL4578	Homo sapiens	pKi		6.3
inactive	9619292	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
active	9619293	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1		CHEMBL1987034	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
inactive	9619294	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1993941	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619295	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)c1		CHEMBL1980435	=	Ki	nM	316.23	CHEMBL4578	Homo sapiens	pKi		6.5
inactive	9619296	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619297	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL2005886	=	Ki	nM	125.89	CHEMBL4578	Homo sapiens	pKi		6.9
inactive	9619298	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL481491	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619299	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12		CHEMBL1973142	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619300	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4nc(N)nc(N)c34)cc2)c1		CHEMBL1973145	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619301	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982924	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9619302	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCC(=O)Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL2005936	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619303	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC1CCC(Nc2nccc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1966628	=	Ki	nM	125.89	CHEMBL4578	Homo sapiens	pKi		6.9
inactive	9619304	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc(C(N)=O)c3)cc2)c1		CHEMBL1971141	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619305	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC1CCCCC1Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL1995813	=	Ki	nM	100.0	CHEMBL4578	Homo sapiens	pKi		7.0
inactive	9619306	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1		CHEMBL1993781	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619307	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL244378	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619308	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(OCC(F)(F)F)nccn23)n1		CHEMBL2001957	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619309	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COCCNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1969372	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619310	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1ccccc1		CHEMBL1993413	=	Ki	nM	31.62	CHEMBL4578	Homo sapiens	pKi		7.5
active	9619311	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	5.012	CHEMBL4578	Homo sapiens	pKi		8.3
active	9619312	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C		CHEMBL2006263	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9619313	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	OC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1993584	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619314	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O		CHEMBL1986263	<	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
active	9619315	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CSc1c[nH]c2ncnc(NCCCO)c12		CHEMBL2000114	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619316	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619317	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(CNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)CNS(C)(=O)=O		CHEMBL1971172	=	Ki	nM	15.85	CHEMBL4578	Homo sapiens	pKi		7.8
active	9619318	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12		CHEMBL1975647	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
active	9619319	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1968380	=	Ki	nM	251.19	CHEMBL4578	Homo sapiens	pKi		6.6
inactive	9619320	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1		CHEMBL1964644	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619321	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NCc1ccc(Cl)c(Cl)c1)Nc1ccc2[nH]ncc2c1		CHEMBL1981782	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619322	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNC(=O)c1cc2c(-c3ccccc3F)n[nH]c2s1		CHEMBL1977681	=	Ki	nM	199.53	CHEMBL4578	Homo sapiens	pKi		6.7
inactive	9619323	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNC(=O)C(C)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(C)cc5)cc4)csc23)cn1		CHEMBL1970142	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619324	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
inactive	9619325	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	OCCNc1cc2cc(-c3cccnc3)ccc2cn1		CHEMBL1990912	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619326	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
active	9619327	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(-c4ccccc4)c3n2)c1		CHEMBL1988163	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
inactive	9619328	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1CCCc2oc3cc(C(F)(F)F)ccc3c(=O)c21		CHEMBL2006493	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619329	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1C		CHEMBL1983449	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619330	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1[nH]cnc2c1oc1ccc(Cl)cc12		CHEMBL1992323	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619331	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(Cl)nccn23)n1		CHEMBL1969735	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619332	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2		CHEMBL2002649	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
active	9619333	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1983589	=	Ki	nM	5.012	CHEMBL4578	Homo sapiens	pKi		8.3
active	9619334	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CS(=O)(=O)NCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2005718	=	Ki	nM	1.0	CHEMBL4578	Homo sapiens	pKi		9.0
active	9619335	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCNS(C)(=O)=O)cnc(N)c34)cc2)c1		CHEMBL1994321	=	Ki	nM	794.33	CHEMBL4578	Homo sapiens	pKi		6.1
active	9619336	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21		CHEMBL1997129	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
inactive	9619337	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Fc1ccc(-c2nc3sccn3c2-c2ccncc2)cc1		CHEMBL2000508	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619338	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCCNc1n[s+]([O-])nc1Nc1ccc(F)cc1		CHEMBL1971694	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619339	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2001547	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619340	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619341	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(-n4cccn4)cc3)s2)no1		CHEMBL1986603	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619342	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619343	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CCO)c5)cnc(N)c34)cc2)cc1		CHEMBL1977148	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619344	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(C=C2SC(=O)NC2=O)ccc1O		CHEMBL2003286	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619345	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccn1		CHEMBL1992306	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619346	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL2002165	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9619347	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1989518	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619348	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1998585	=	Ki	nM	251.19	CHEMBL4578	Homo sapiens	pKi		6.6
inactive	9619349	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cn1cncc1C(OCc1c(-c2ccc(OC(F)(F)F)cc2)cc(C#N)c(=O)n1C)c1ccc(C#N)cc1		CHEMBL127898	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619350	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2C		CHEMBL519697	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619351	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(F)c2)c1		CHEMBL2004934	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619352	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
active	9619353	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C(C)C(=O)N(C)C)c5)cnc(N)c34)cc2)cc1		CHEMBL2001485	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
inactive	9619354	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619355	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)CCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1966425	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9619356	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL1984363	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619357	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1		CHEMBL1978099	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619358	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1		CHEMBL1988608	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619359	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)cc1C		CHEMBL184847	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619360	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)c1ccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)cc1		CHEMBL1984367	=	Ki	nM	794.33	CHEMBL4578	Homo sapiens	pKi		6.1
active	9619361	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(CN)CNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1985723	=	Ki	nM	6.31	CHEMBL4578	Homo sapiens	pKi		8.2
active	9619362	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1n[nH]c2cnc(-c3cncc(OCC(N)Cc4cccc(C(F)(F)F)c4)c3)cc12		CHEMBL1998159	=	Ki	nM	15.85	CHEMBL4578	Homo sapiens	pKi		7.8
inactive	9619363	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COCC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(C)nccn23)n1		CHEMBL1982563	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619364	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1CCCN1Cc1ccc2c(c1)[nH]c(=O)c1cccn12		CHEMBL539474	=	Ki	nM	794.33	CHEMBL4578	Homo sapiens	pKi		6.1
inactive	9619365	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1987679	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619366	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(OC(F)F)cc5)cc4)csc23)cn1		CHEMBL1988387	=	Ki	nM	100.0	CHEMBL4578	Homo sapiens	pKi		7.0
active	9619367	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	N#Cc1cccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)c1		CHEMBL1977128	=	Ki	nM	158.49	CHEMBL4578	Homo sapiens	pKi		6.8
inactive	9619368	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619369	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619370	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL1970074	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619371	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1986970	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9619372	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1		CHEMBL1958401	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619373	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1[nH]c2cc(-c3ccccc3)cnc2[nH]1		CHEMBL2003456	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619374	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)cccc12		CHEMBL1966816	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619375	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	=	Ki	nM	251.19	CHEMBL4578	Homo sapiens	pKi		6.6
inactive	9619376	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619377	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1		CHEMBL560813	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619378	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CC(CN2CCCC2)C1		CHEMBL1968791	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
inactive	9619379	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Fc1ccc(-c2nc3occn3c2-c2ccnc(NC3CCNCC3)n2)cc1		CHEMBL1971186	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619380	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2		CHEMBL2003482	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619381	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCCC5)cnc(N)c34)cc2)c1		CHEMBL1973211	=	Ki	nM	794.33	CHEMBL4578	Homo sapiens	pKi		6.1
inactive	9619382	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1984700	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619383	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619384	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	c1ccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)cc1		CHEMBL1998953	=	Ki	nM	63.1	CHEMBL4578	Homo sapiens	pKi		7.2
inactive	9619385	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1		CHEMBL1972125	<	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9619386	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
active	9619387	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	c1cc2cc(-c3ccc4cn[nH]c4c3)cnc2[nH]1		CHEMBL1976134	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619388	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(C(=O)Nc2c(C(N)=O)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL1965131	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619389	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL1972158	=	Ki	nM	501.19	CHEMBL4578	Homo sapiens	pKi		6.3
active	9619390	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
inactive	9619391	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCC#N)c2)n1		CHEMBL1979855	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619392	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619393	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Ki	nM	125.89	CHEMBL4578	Homo sapiens	pKi		6.9
inactive	9619394	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619395	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2006450	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
active	9619396	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21		CHEMBL1975534	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9619397	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(Cc4ccccc4)c3n2)c1		CHEMBL1993424	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619398	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1n[nH]c2c1C(c1ccccc1F)C1=C(CC(C)(C)CC1=O)N2		CHEMBL1966703	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619399	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1969561	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619400	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619401	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)c1cc2sncc2cc1NC(=O)C(=O)O		CHEMBL1997023	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619402	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(C)cc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1964687	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619403	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
inactive	9619404	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCOc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1974254	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619405	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(C(=O)N2c3ccccc3Sc3c(Cl)cncc32)cc1		CHEMBL1988537	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619406	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(C)c2)c1		CHEMBL1969049	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619407	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)cc1		CHEMBL2005828	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619408	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1		CHEMBL363648	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619409	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
inactive	9619410	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1sc2c(Br)ccc(Cl)c2c1N		CHEMBL1998611	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619411	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O		CHEMBL1975900	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619412	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(C=C2SC(=S)NC2=O)ccc1O		CHEMBL1973098	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619413	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1		CHEMBL1972221	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619414	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNC(=O)C=Cc1cnc(N)c2c(-c3cc(F)c4[nH]c(C)cc4c3)csc12		CHEMBL2006778	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619415	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619416	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1c(F)cccc1F		CHEMBL1996979	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
active	9619417	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1cccc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1997025	=	Ki	nM	199.53	CHEMBL4578	Homo sapiens	pKi		6.7
active	9619418	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1968406	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
active	9619419	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1C(=NNc2cccc3c(=O)[nH][nH]c(=O)c23)C(c2ccccc2)=NN1c1ccccc1		CHEMBL1984274	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619420	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1998545	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619421	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1csc(NC(=O)c2sc3nc(-c4ccncc4)ccc3c2N)n1		CHEMBL1986869	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619422	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682558	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619423	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619424	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccc(Cl)cc5o4)cc3)c1)CNC2=O		CHEMBL2002479	=	Ki	nM	79.43	CHEMBL4578	Homo sapiens	pKi		7.1
active	9619425	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NCc1ccc(Cl)cc1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL1967094	=	Ki	nM	199.53	CHEMBL4578	Homo sapiens	pKi		6.7
inactive	9619426	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NC(CO)c1cc(Cl)cc(Cl)c1)c1ccc(-c2ccncc2)cc1		CHEMBL2003341	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619427	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Oc1cccc(Nc2ncnc3scc(Cl)c23)c1		CHEMBL1982992	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619428	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(-c2ccccc2)n(-c2cc(NN=Cc3ccco3)ncn2)n1		CHEMBL1999590	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619429	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1F		CHEMBL1981079	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619430	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
inactive	9619431	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O		CHEMBL1980489	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619432	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)c1		CHEMBL1967116	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
active	9619433	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O		CHEMBL2000832	=	Ki	nM	794.33	CHEMBL4578	Homo sapiens	pKi		6.1
inactive	9619434	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NCc1ccc(Br)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL1970709	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619435	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619436	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(-c2cc3nccn3c(Nc3ccccc3C(N)=O)n2)cc1OC		CHEMBL1998112	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619437	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1972290	=	Ki	nM	1.995	CHEMBL4578	Homo sapiens	pKi		8.7
inactive	9619438	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)cc21		CHEMBL1969126	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619439	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Cc4cccc(Cl)c4)cc3)c12		CHEMBL1980896	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619440	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	501.19	CHEMBL4578	Homo sapiens	pKi		6.3
active	9619441	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1		CHEMBL1991429	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
active	9619442	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1cc2c(Oc3cccc(F)c3)cncc2s1		CHEMBL1964777	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
inactive	9619443	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)C(=O)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1971149	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619444	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc2c(c1)NC(=O)c1ccccc1N2		CHEMBL1999714	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619445	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(O)CNc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1		CHEMBL1994040	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619446	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	0.3162	CHEMBL4578	Homo sapiens	pKi		9.5
active	9619447	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cn1cc(Nc2ncc(Cl)c(Nc3ccccc3C(N)=O)n2)cn1		CHEMBL1984548	=	Ki	nM	1.259	CHEMBL4578	Homo sapiens	pKi		8.9
active	9619448	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL1967302	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
active	9619449	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	=	Ki	nM	79.43	CHEMBL4578	Homo sapiens	pKi		7.1
inactive	9619450	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O		CHEMBL1982506	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619451	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2004716	=	Ki	nM	63.1	CHEMBL4578	Homo sapiens	pKi		7.2
inactive	9619452	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1		CHEMBL1968127	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619453	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1975233	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619454	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12		CHEMBL1985406	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619455	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21		CHEMBL207400	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619456	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(O)ccc1-n1cc(C(=O)NN)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL2000894	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619457	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccccc1NC(=O)Nc1ccc2c(c1)CCc1sc3ncnc(N)c3c1-2		CHEMBL1982135	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619458	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncnc2c1sc1ncnc(N)c12		CHEMBL1976090	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619459	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12		CHEMBL1993243	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619460	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	OCC(CO)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1992922	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
inactive	9619461	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3o2)cc1		CHEMBL2004771	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619462	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1997597	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619463	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4		CHEMBL1969537	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619464	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1976093	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619465	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1		CHEMBL1975256	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619466	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)cnn4c3N)cc2)c1		CHEMBL508928	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
inactive	9619467	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(-c2cc3c(=O)[nH]c4ccccc4n3c2)c1		CHEMBL1991356	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619468	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL2004892	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619469	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1		CHEMBL116070	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619470	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12		CHEMBL1970314	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619471	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL2004871	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619472	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncn3)cc2)c1		CHEMBL2004872	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619473	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC1CCN(C(=O)CO)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL1969879	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619474	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cnccn1)Nc1ccnc2ccccc12		CHEMBL1981720	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619475	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(N)COc1cnc(Cl)c(C=Cc2ccncc2)c1		CHEMBL1993548	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619476	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3nsc4ncnc(N)c34)cc2)c1		CHEMBL262433	=	Ki	nM	316.23	CHEMBL4578	Homo sapiens	pKi		6.5
inactive	9619477	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619478	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1966722	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619479	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(Cl)c1		CHEMBL1983595	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
inactive	9619480	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O		CHEMBL1975500	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619481	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2)c1		CHEMBL394619	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619482	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(O)c1c2c(nc3ccccc13)C(=C1CCCC1)CC2		CHEMBL1996831	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619483	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc1)CCN2		CHEMBL411903	=	Ki	nM	100.0	CHEMBL4578	Homo sapiens	pKi		7.0
active	9619484	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCOCC2)n1		CHEMBL1980253	=	Ki	nM	19.95	CHEMBL4578	Homo sapiens	pKi		7.7
inactive	9619485	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
active	9619486	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN)cnc(N)c34)cc2)c1		CHEMBL1965988	=	Ki	nM	158.49	CHEMBL4578	Homo sapiens	pKi		6.8
inactive	9619487	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
inactive	9619488	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL1989646	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619489	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619490	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1nccn2c(-c3ccnc(NCCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1978200	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619491	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Ki	nM	31.62	CHEMBL4578	Homo sapiens	pKi		7.5
inactive	9619492	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O		CHEMBL1970522	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619493	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21		CHEMBL1964692	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
inactive	9619494	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NC(CO)Cc1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL1996931	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619495	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	FC(F)(F)c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C(F)(F)F)c1		CHEMBL1964413	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619496	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL1973483	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619497	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1998470	=	Ki	nM	125.89	CHEMBL4578	Homo sapiens	pKi		6.9
inactive	9619498	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1		CHEMBL1997340	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619499	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cn1cc(Nc2ncc(Br)c(Nc3ccccc3C(N)=O)n2)cn1		CHEMBL1994669	=	Ki	nM	1.585	CHEMBL4578	Homo sapiens	pKi		8.8
inactive	9619500	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619501	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619502	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cn1cc(-c2ccncn2)c(-c2ccc(F)cc2)n1		CHEMBL1989474	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619503	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619504	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1nc2ccccc2n1CCCO)c1cccc([N+](=O)[O-])c1		CHEMBL210887	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619505	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	Ki	nM	316.23	CHEMBL4578	Homo sapiens	pKi		6.5
inactive	9619506	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C(F)(F)F)c2)c1		CHEMBL1971021	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619507	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(OC(F)(F)F)c4)c3)cc12		CHEMBL1965836	=	Ki	nM	251.19	CHEMBL4578	Homo sapiens	pKi		6.6
inactive	9619508	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12		CHEMBL583144	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619509	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1		CHEMBL1974310	=	Ki	nM	794.33	CHEMBL4578	Homo sapiens	pKi		6.1
inactive	9619510	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619511	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncnc2sc3c(c12)-c1ccc(NC(=O)Nc2ccccc2)cc1CC3		CHEMBL1994693	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
active	9619512	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1cccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982957	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
active	9619513	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
active	9619514	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1975138	=	Ki	nM	199.53	CHEMBL4578	Homo sapiens	pKi		6.7
inactive	9619515	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
inactive	9619516	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619517	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
inactive	9619518	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc2nnc(SCc3cn4ccccc4n3)n2c2ccccc12		CHEMBL1980704	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619519	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1sc2ccc(Cl)c(Cl)c2c1NC(=O)c1ccc(Cl)cc1		CHEMBL2003271	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619520	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccncc4)nn12)CCCC3		CHEMBL1966808	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619521	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2		CHEMBL2004447	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619522	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(O)c1ccccc1Nc1ncnc(Nc2ccc(F)cc2)n1		CHEMBL1992231	=	Ki	nM	79.43	CHEMBL4578	Homo sapiens	pKi		7.1
active	9619523	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Ki	nM	199.53	CHEMBL4578	Homo sapiens	pKi		6.7
inactive	9619524	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	OCCNc1cc2cc(-c3ccsc3)ccc2cn1		CHEMBL1973860	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619525	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL260135	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619526	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9619527	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=S(=O)(O)c1ccc(NCc2ccc3c(c2)OCO3)c2c(O)cccc12		CHEMBL2004544	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619528	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12		CHEMBL1982610	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9619529	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(C2(c3cccc(C)c3)CC2C(=O)Nc2ccncc2)c1		CHEMBL1999496	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623085	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ccc(-c2csc3c(C=Cc4nc5ccccc5[nH]4)cnc(N)c23)cc1		CHEMBL1988300	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623086	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
active	9623087	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
inactive	9623088	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCCNc1ccc2c3c(cccc13)C(=O)N(CCNCCO)C2=O		CHEMBL1987359	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623089	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623090	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC1CCCCC1Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL1994438	=	Ki	nM	1.585	CHEMBL4578	Homo sapiens	pKi		8.8
inactive	9623091	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623092	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23		CHEMBL1969502	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623093	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682553	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623094	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)c1		CHEMBL1983963	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623095	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)cc1		CHEMBL1997764	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623096	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Oc1ccc(-c2n[nH]c(Nc3cccc(Cl)c3)c2-c2ccc(O)cc2)cc1		CHEMBL1985092	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
active	9623097	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL1981410	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
inactive	9623098	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1		CHEMBL1996234	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623099	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(C=C2C(=O)ON=C2c2ccc(Br)cc2)cc1OC		CHEMBL1991434	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623100	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)c1cccc2c(S(=O)(=O)N(CCN)c3cncc(-c4ccc5cnccc5c4)c3)cccc12		CHEMBL1967544	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
active	9623101	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	=	Ki	nM	251.19	CHEMBL4578	Homo sapiens	pKi		6.6
active	9623102	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL340384	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
active	9623103	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)C1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1969151	=	Ki	nM	3.162	CHEMBL4578	Homo sapiens	pKi		8.5
inactive	9623104	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1996587	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623105	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1		CHEMBL1964804	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623106	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(-c2cnc3c(Br)cnn3c2)cc1		CHEMBL443962	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623107	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O		CHEMBL2000354	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
active	9623108	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1965507	=	Ki	nM	79.43	CHEMBL4578	Homo sapiens	pKi		7.1
active	9623109	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Ki	nM	794.33	CHEMBL4578	Homo sapiens	pKi		6.1
inactive	9623110	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12		CHEMBL1967564	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623111	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	=	Ki	nM	251.19	CHEMBL4578	Homo sapiens	pKi		6.6
active	9623112	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL2000071	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9623113	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc2c(NC(=O)Nc3cc(C(F)(F)F)ccn3)ccnc2c1		CHEMBL1979176	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623114	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(OC)cc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)c1		CHEMBL2002613	=	Ki	nM	794.33	CHEMBL4578	Homo sapiens	pKi		6.1
inactive	9623115	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc2c(C)n1		CHEMBL2000408	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623116	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	=	Ki	nM	199.53	CHEMBL4578	Homo sapiens	pKi		6.7
inactive	9623117	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1		CHEMBL1978014	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623118	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cnccn1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1994538	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623119	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1975490	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
inactive	9623120	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1964444	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623121	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Clc1csc2ncnc(Nc3ccccc3)c12		CHEMBL1986139	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623122	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)cccc12		CHEMBL1980540	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623123	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
active	9623124	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN(C)C)cnc(N)c34)cc2)c1		CHEMBL1979883	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
active	9623125	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1984162	=	Ki	nM	3.981	CHEMBL4578	Homo sapiens	pKi		8.4
active	9623126	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1998432	=	Ki	nM	1.259	CHEMBL4578	Homo sapiens	pKi		8.9
inactive	9623127	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1		CHEMBL491758	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623128	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C		CHEMBL1986186	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623129	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2		CHEMBL1970189	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623130	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncnc2c1c(I)nn2C1CCC(O)CC1		CHEMBL1996791	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623131	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C)sc4ncnc(N)c34)cc2)c1		CHEMBL371206	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623132	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC		CHEMBL1974664	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623133	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
active	9623134	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	501.19	CHEMBL4578	Homo sapiens	pKi		6.3
inactive	9623135	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NC(CO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1974288	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623136	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1		CHEMBL196363	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
inactive	9623137	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC		CHEMBL1190711	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623138	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623139	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL404367	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623140	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1		CHEMBL1966343	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623141	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1n[nH]c2ccc(-c3cncc(OCCN)c3)cc12		CHEMBL1967887	=	Ki	nM	501.19	CHEMBL4578	Homo sapiens	pKi		6.3
inactive	9623142	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623143	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)cc1C		CHEMBL2000335	=	Ki	nM	125.89	CHEMBL4578	Homo sapiens	pKi		6.9
active	9623144	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Ki	nM	79.43	CHEMBL4578	Homo sapiens	pKi		7.1
inactive	9623145	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cn1cc(-c2cnn3c(N)c(-c4ccc(NC(=O)Nc5cccc(C(F)(F)F)c5)cc4)cnc23)cn1		CHEMBL1988717	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623146	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	<	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
active	9623147	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Ki	nM	158.49	CHEMBL4578	Homo sapiens	pKi		6.8
active	9623148	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(F)c2)n1		CHEMBL243298	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9623149	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1		CHEMBL1973808	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623150	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2000429	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623151	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)cc1		CHEMBL1972576	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623152	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623153	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1992342	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623154	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(Cl)ccc1NC(=S)NNC(=O)C(O)(c1ccccc1)c1ccccc1		CHEMBL1988173	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623155	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccc(F)cc1		CHEMBL1966204	=	Ki	nM	50.12	CHEMBL4578	Homo sapiens	pKi		7.3
active	9623156	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	N#CC1=C(N)n2c(sc(=Cc3ccco3)c2=O)=C(C(N)=O)C1c1ccco1		CHEMBL1989805	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
inactive	9623157	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL1965423	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623158	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCC(N)(C#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12)CC		CHEMBL1983025	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
inactive	9623159	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623160	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623161	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21		CHEMBL2001920	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
active	9623162	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC		CHEMBL1241473	=	Ki	nM	39.81	CHEMBL4578	Homo sapiens	pKi		7.4
active	9623163	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	=	Ki	nM	199.53	CHEMBL4578	Homo sapiens	pKi		6.7
inactive	9623164	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCN(CC)CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2001257	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623165	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1		CHEMBL1992536	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623166	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1		CHEMBL1992740	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623167	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1cccc(Cl)c1		CHEMBL1973348	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623168	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCN)c1		CHEMBL2006188	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623169	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1967531	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623170	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1		CHEMBL1973893	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623171	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12		CHEMBL1970913	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623172	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
inactive	9623173	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(C)NC(=O)c2cc(C)c(-c3ccc4[nH]nc(C)c4c3)s2)c1		CHEMBL1997534	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623174	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623175	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)Cn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL1985095	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623176	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623177	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1		CHEMBL1682540	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623178	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623179	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1		CHEMBL1994864	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623180	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOCC5CC5)c4)n[nH]c2-3)CC1		CHEMBL2002446	=	Ki	nM	63.1	CHEMBL4578	Homo sapiens	pKi		7.2
active	9623181	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1		CHEMBL497151	=	Ki	nM	501.19	CHEMBL4578	Homo sapiens	pKi		6.3
inactive	9623182	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1		CHEMBL246970	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623183	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL340921	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
inactive	9623184	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	N#Cc1ccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)nc1		CHEMBL1999718	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623185	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccc(Cl)cc1		CHEMBL1987073	=	Ki	nM	50.12	CHEMBL4578	Homo sapiens	pKi		7.3
active	9623186	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL1973540	=	Ki	nM	6.31	CHEMBL4578	Homo sapiens	pKi		8.2
inactive	9623187	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1Nc2ccccc2Nc2nnc(I)cc21		CHEMBL1977346	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623188	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL1971649	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623189	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Ki	nM	39.81	CHEMBL4578	Homo sapiens	pKi		7.4
active	9623190	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	=	Ki	nM	316.23	CHEMBL4578	Homo sapiens	pKi		6.5
inactive	9623191	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(-c2ccc(NC(=O)Nc3cc(F)cc(F)c3)cc2)c2c(N)noc12		CHEMBL1969190	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623192	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)n[nH]c12		CHEMBL1973937	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623193	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	<	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
active	9623194	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	=	Ki	nM	199.53	CHEMBL4578	Homo sapiens	pKi		6.7
active	9623195	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	=	Ki	nM	794.33	CHEMBL4578	Homo sapiens	pKi		6.1
active	9623196	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCN(CC)CC#Cc1ccc2c(c1)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL2007044	=	Ki	nM	50.12	CHEMBL4578	Homo sapiens	pKi		7.3
active	9623197	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(C=C(C#N)c2nc3ccccc3[nH]2)c(Br)cc1O		CHEMBL1994241	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623198	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	=	Ki	nM	501.19	CHEMBL4578	Homo sapiens	pKi		6.3
inactive	9623199	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1ccc(Cl)cc1		CHEMBL1998829	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623200	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623201	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1		CHEMBL1988838	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9623202	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(C(=O)Nc6ccccc6F)c5)nc5ccccn45)n3)cc2)CC1		CHEMBL1981725	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623203	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1ccc(NC2CCCCC2N)nc1Nc1cccc(Cl)c1		CHEMBL1982753	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
active	9623204	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Oc1cc(O)cc(C=Cc2ccc(O)c(O)c2)c1		CHEMBL1972346	=	Ki	nM	79.43	CHEMBL4578	Homo sapiens	pKi		7.1
inactive	9623205	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1		CHEMBL1982866	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623206	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(O)c1ccccc1Nc1ncnc(Nc2cccc(F)c2)n1		CHEMBL1979933	=	Ki	nM	794.33	CHEMBL4578	Homo sapiens	pKi		6.1
inactive	9623207	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c12		CHEMBL1965570	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623208	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3		CHEMBL2007592	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623209	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	OC1CCCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1976936	=	Ki	nM	25.12	CHEMBL4578	Homo sapiens	pKi		7.6
inactive	9623210	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623211	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12		CHEMBL1082440	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623212	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1		CHEMBL1614705	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623213	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)s2)c1		CHEMBL1984633	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623214	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623215	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(C)NC(=O)N2CC=C(c3c[nH]c4ncccc34)CC2)c1		CHEMBL1965845	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623216	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1)c1c(F)cccc1F		CHEMBL2006715	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9623217	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1cccc2[nH]c(-c3ccc(NC(=O)c4cccc(S(=O)(=O)N5CCOCC5)c4)cc3)nc12		CHEMBL1986597	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623218	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1cccc2[nH]c(-c3ccncc3)nc12		CHEMBL1990482	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623219	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Fc1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1		CHEMBL1990904	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623220	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1987448	=	Ki	nM	5.012	CHEMBL4578	Homo sapiens	pKi		8.3
active	9623221	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NCC1CCCCC1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL2005475	=	Ki	nM	79.43	CHEMBL4578	Homo sapiens	pKi		7.1
inactive	9623222	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623223	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2C)c1		CHEMBL183844	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623224	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC1=NN(c2ccc(Cl)c(Cl)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1997349	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
inactive	9623225	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL220057	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623226	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682545	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623227	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1974935	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623228	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(OC2CCCC2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL2001224	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623229	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
inactive	9623230	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(O)Cc1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1976732	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623231	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CS(=O)(=O)NC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL2005216	=	Ki	nM	25.12	CHEMBL4578	Homo sapiens	pKi		7.6
active	9623232	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1964937	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623233	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21		CHEMBL1969506	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623234	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1		CHEMBL1980163	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623235	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(=O)N(c1ccncc1)c1c(NC(C)C(C)(C)C)c(=O)c1=O		CHEMBL2005899	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623236	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1		CHEMBL1682552	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623237	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	=	Ki	nM	79.43	CHEMBL4578	Homo sapiens	pKi		7.1
inactive	9623238	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1		CHEMBL2002702	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623239	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL1970903	=	Ki	nM	316.23	CHEMBL4578	Homo sapiens	pKi		6.5
active	9623240	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	3.162	CHEMBL4578	Homo sapiens	pKi		8.5
active	9623241	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)c1		CHEMBL1969523	=	Ki	nM	50.12	CHEMBL4578	Homo sapiens	pKi		7.3
inactive	9623242	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(=O)N1CCC(Nc2nccc(-c3c(-c4ccc(F)cc4)nc4occn34)n2)CC1		CHEMBL1986781	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623243	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccccc2)[nH]1		CHEMBL526133	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623244	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21		CHEMBL1230122	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623245	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	Ki	nM	158.49	CHEMBL4578	Homo sapiens	pKi		6.8
active	9623246	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1		CHEMBL387971	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
active	9623247	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3[nH]2)cc1		CHEMBL1979057	=	Ki	nM	251.19	CHEMBL4578	Homo sapiens	pKi		6.6
inactive	9623248	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
inactive	9623249	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1999428	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623250	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCN1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1967560	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623251	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3noc4ncnc(N)c34)cc2)c1		CHEMBL211378	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623252	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623253	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1982465	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
active	9623254	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL2001751	=	Ki	nM	5.012	CHEMBL4578	Homo sapiens	pKi		8.3
inactive	9623255	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1		CHEMBL2003420	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623256	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccccc1NC(=O)Nc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL1984586	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623257	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12		CHEMBL1972659	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623258	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)cc1Cl		CHEMBL272453	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623259	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3C)cc2)c1		CHEMBL1970217	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623260	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	3.162	CHEMBL4578	Homo sapiens	pKi		8.5
inactive	9623261	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O		CHEMBL2005528	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623262	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)c1		CHEMBL185569	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9623263	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1		CHEMBL1969843	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623264	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(-c2ccc3[nH]nc(C(=O)Nc4ccccc4)c3c2)ccc1O		CHEMBL2007002	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623265	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623266	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1		CHEMBL1987007	=	Ki	nM	316.23	CHEMBL4578	Homo sapiens	pKi		6.5
active	9623267	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Clc1cc(-c2c[nH]c3ncccc23)cc(NCc2ccccc2)n1		CHEMBL1969588	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
active	9623268	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	=	Ki	nM	79.43	CHEMBL4578	Homo sapiens	pKi		7.1
inactive	9623269	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(Nc2nccc(Nc3cc(C4CCCCC4)no3)n2)cc(OC)c1OC		CHEMBL1984711	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623270	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623271	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL484390	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623272	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O		CHEMBL1979252	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623273	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623274	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12		CHEMBL1986499	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
inactive	9623275	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1		CHEMBL1972937	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623276	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21		CHEMBL2000393	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9623277	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C)c2)c1		CHEMBL2004311	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623278	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Brc1cnc2[nH]cc(-c3ccccc3)c2c1		CHEMBL1992634	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623279	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1242373	=	Ki	nM	794.33	CHEMBL4578	Homo sapiens	pKi		6.1
inactive	9623280	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1988075	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623281	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Fc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL316264	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623282	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623283	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1		CHEMBL2001239	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
active	9623284	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncnc2scc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1988594	=	Ki	nM	316.23	CHEMBL4578	Homo sapiens	pKi		6.5
active	9623285	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O		CHEMBL2001288	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
active	9623286	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)c1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1		CHEMBL1992363	=	Ki	nM	39.81	CHEMBL4578	Homo sapiens	pKi		7.4
inactive	9623287	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623288	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12		CHEMBL1999811	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623289	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O		CHEMBL1985074	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623290	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc2n1CC1CC1		CHEMBL1982874	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623291	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL2000481	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623292	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1991725	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623293	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4sncc34)cc2)c1		CHEMBL1992242	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623294	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2007296	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623295	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1		CHEMBL396523	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623296	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1970203	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623297	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(c1cc(Cc2n[nH]c(=O)c3c2CCCC3)ccc1F)N1CCN(c2ncccn2)CC1		CHEMBL1986530	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623298	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1c(NCCc2ccc(Oc3ccccc3)cc2)c(Nc2ccncc2)c1=O		CHEMBL1999321	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623299	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4sc(C)nc4c3)csc12		CHEMBL1968590	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623300	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCCCC4)cc3OC)nc2N1C1CCCC1		CHEMBL2005375	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623301	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Clc1ccc(-c2n[nH]cc2-c2ccncn2)cc1Cl		CHEMBL1984191	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623302	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br		CHEMBL1971029	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623303	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL394790	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623304	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21		CHEMBL226471	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623305	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1996111	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9623306	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1		CHEMBL1974702	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623307	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1965589	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623308	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NCCCCCCNC(=O)Nc1cccnc1)Nc1cccnc1		CHEMBL1998193	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623309	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)O)s3)c2cc1OC		CHEMBL474432	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623310	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1nnc(-c2cc3c(Oc4ccc(C(F)(F)F)cc4)cncc3s2)o1		CHEMBL1988153	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623311	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(O)c1ccccc1Nc1ncnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL1986666	=	Ki	nM	158.49	CHEMBL4578	Homo sapiens	pKi		6.8
active	9623312	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	=	Ki	nM	251.19	CHEMBL4578	Homo sapiens	pKi		6.6
inactive	9623313	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623314	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623315	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NCCC(C(=O)Nc1ccc2[nH]ncc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL1998121	=	Ki	nM	199.53	CHEMBL4578	Homo sapiens	pKi		6.7
active	9623316	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)N)cnc(N)c34)cc2)c1		CHEMBL1979577	=	Ki	nM	125.89	CHEMBL4578	Homo sapiens	pKi		6.9
inactive	9623317	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CC4CC4)nccn23)n1		CHEMBL1991800	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623318	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1nn(-c2ccccc2)c2c1c(=O)c1cc(Cl)ccc1n2O		CHEMBL379835	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623319	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cn1cc(C(CN)c2cncc(C=Cc3ccncc3)c2)c2ccccc21		CHEMBL1979357	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9623320	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCCOc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1996817	=	Ki	nM	501.19	CHEMBL4578	Homo sapiens	pKi		6.3
inactive	9623321	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623322	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL468280	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9623323	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(C)c2oc(Nc3ccc(-c4cccc(C(N)=O)c4N)cc3F)nc2c1		CHEMBL1990884	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626868	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	<	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9626869	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL256835	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626870	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1980142	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626871	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL41783	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626872	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc2c1Nc1cc(Nc3ccncc3)ccc1C(=O)N2		CHEMBL2006276	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626873	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
inactive	9626874	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)noc12		CHEMBL271381	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626875	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(C(=O)Nc2c(C#N)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL2006785	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626876	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1982466	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626877	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O		CHEMBL1995740	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626878	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	N#Cc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1		CHEMBL1990162	=	Ki	nM	125.89	CHEMBL4578	Homo sapiens	pKi		6.9
active	9626879	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	5.012	CHEMBL4578	Homo sapiens	pKi		8.3
inactive	9626880	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
inactive	9626881	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1995832	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626882	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Oc1ccc(Nc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1		CHEMBL1969042	=	Ki	nM	1000.0	CHEMBL4578	Homo sapiens	pKi		6.0
active	9626883	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(C=C(C#N)c2nc3cc(C)ccc3[nH]2)c(Br)cc1O		CHEMBL2000345	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
active	9626884	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1		CHEMBL1999931	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
inactive	9626885	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL2007064	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626886	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	=	Ki	nM	794.33	CHEMBL4578	Homo sapiens	pKi		6.1
active	9626887	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccc(Cl)c(Cl)c4)c3)cc12		CHEMBL1991063	=	Ki	nM	199.53	CHEMBL4578	Homo sapiens	pKi		6.7
inactive	9626888	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1976240	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626889	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C)c3)cc2)c2c(N)noc12		CHEMBL1979093	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626890	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1[nH]c2sccc2c2nc(-c3ccncc3)nn12		CHEMBL1968151	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626891	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)c1		CHEMBL1987009	=	Ki	nM	100.0	CHEMBL4578	Homo sapiens	pKi		7.0
active	9626892	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12		CHEMBL2002726	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
inactive	9626893	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cnccn1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL2003817	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626894	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1nnc(-c2cc3c(Oc4ccc(Cl)cc4)cncc3s2)o1		CHEMBL1994830	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626895	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21		CHEMBL226403	<	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
active	9626896	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cc(C)ccc4F)cc3)csc12		CHEMBL2005631	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626897	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncc(C=CC(=O)NCCCn2ccnc2)c2scc(-c3ccc(Br)cc3)c12		CHEMBL1994938	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626898	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1977223	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9626899	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626900	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(C)C(=O)Oc1ccc2c(c1)nc(NC(=O)c1cccc([N+](=O)[O-])c1)n2CCCO		CHEMBL1236126	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626901	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NCCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL1966279	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626902	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	=	Ki	nM	316.23	CHEMBL4578	Homo sapiens	pKi		6.5
inactive	9626903	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)Cn1c(N)nc2c(F)cc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2004419	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626904	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cc(F)ccc1F		CHEMBL1995811	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
inactive	9626905	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1ccc2cn[nH]c2c1)c1ccc(Cl)cc1		CHEMBL1972489	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626906	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Brc1ccc2[nH]nc(-c3ccccc3)c2c1		CHEMBL1994074	=	Ki	nM	501.19	CHEMBL4578	Homo sapiens	pKi		6.3
active	9626907	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	=	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626908	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cccc(N2CCOCC2)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1972119	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626909	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL1090356	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626910	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626911	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1986328	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626912	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(C(F)(F)F)cc12		CHEMBL1976455	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626913	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626914	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	c1ccc(CNc2nc3ccc(-c4ccncc4)cc3s2)cc1		CHEMBL1983534	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626915	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O		CHEMBL1982361	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626916	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	OCCC(Nc1nc2ccc(-c3ccncc3)cc2s1)c1ccccc1		CHEMBL1982122	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626917	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1ccc(-c2cccc3sncc23)cc1)Nc1ccc(F)c(C(F)(F)F)c1		CHEMBL2000801	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626918	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1		CHEMBL1999112	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626919	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682546	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626920	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1991395	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626921	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN1CCN(c2cccc(Nc3nccc(-c4c(C(N)=O)nc5ccccn45)n3)c2)CC1		CHEMBL1971245	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626922	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL1972142	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626923	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1966514	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626924	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(F)c1		CHEMBL2003638	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626925	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	N#Cc1ccc2nc(N)n(-c3nc(-c4ccccc4)cs3)c2c1		CHEMBL1996066	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626926	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(C(=O)O)ccc4F)cc3)c12		CHEMBL1993722	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626927	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL1979970	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626928	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1nc(COc2ccccc2Cl)sc1-c1ccnc(N)n1		CHEMBL1375640	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626929	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)cn1		CHEMBL249282	=	Ki	nM	630.96	CHEMBL4578	Homo sapiens	pKi		6.2
inactive	9626930	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1		CHEMBL2006237	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626931	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1967720	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626932	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12		CHEMBL1624529	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626933	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1F		CHEMBL1969755	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626934	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1979516	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626935	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1nccn2c(C3CC(CN4CCCC4)C3)nc(-c3cccc(OCc4ccccc4)c3)c12		CHEMBL1991138	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626936	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626937	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12		CHEMBL1989029	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626938	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1		CHEMBL392642	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626939	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Ki	nM	158.49	CHEMBL4578	Homo sapiens	pKi		6.8
inactive	9626940	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1965631	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626941	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccccc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1		CHEMBL1980144	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626942	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2OC)c1		CHEMBL1991188	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626943	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1972849	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626944	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	=	Ki	nM	158.49	CHEMBL4578	Homo sapiens	pKi		6.8
inactive	9626945	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL231209	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626946	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12		CHEMBL1976220	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626947	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CN1CCN(C2CCC(n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1997617	=	Ki	nM	398.11	CHEMBL4578	Homo sapiens	pKi		6.4
inactive	9626948	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL259922	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626949	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CCN)nccn23)n1		CHEMBL1982383	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626950	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CCCCn1c(NC(=O)c2cccc(C#N)c2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL1969301	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626951	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17370	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626952	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)c12		CHEMBL1987910	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626953	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1ccc2c(NC(=O)Nc3cccc(Br)n3)ccnc2c1		CHEMBL1983932	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626954	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	Ki	nM	251.19	CHEMBL4578	Homo sapiens	pKi		6.6
inactive	9626955	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626956	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc2cc(-c3csc4c(-c5cccc(S(C)(=O)=O)c5)cnc(N)c34)ccc2[nH]1		CHEMBL1997822	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626957	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	Cc1cc(OCC2CCC(C(=O)O)C2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL1991285	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
inactive	9626958	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	1995.26	CHEMBL4578	Homo sapiens	pKi		5.7
inactive	9626959	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1		CHEMBL243088	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
active	9626960	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	100.0	CHEMBL4578	Homo sapiens	pKi		7.0
active	9626961	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1cccc(F)c1F		CHEMBL1974416	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
active	9626962	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	=	Ki	nM	1258.93	CHEMBL4578	Homo sapiens	pKi		5.9
inactive	9626963	CHEMBL1963804	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MELK	F	O=C(c1cccc(-c2cnc3[nH]ccc3c2)c1)N1CCOCC1		CHEMBL1997872	<	Ki	nM	1584.89	CHEMBL4578	Homo sapiens	pKi		5.8
	10839400	CHEMBL2014966	Inhibition of MELK at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	78.0	CHEMBL4578	Homo sapiens	INH	%	78.0
	10839592	CHEMBL2016288	Inhibition of MELK assessed as residual activity at 1 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	71.0	CHEMBL4578	Homo sapiens	Activity	%	71.0
	10839646	CHEMBL2015156	Inhibition of MELK assessed as residual activity at 10 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	21.0	CHEMBL4578	Homo sapiens	Activity	%	21.0
	12046360	CHEMBL2157287	Inhibition of MELK at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	-0.5	CHEMBL4578	Homo sapiens	INH	%	-0.5
	12170782	CHEMBL2209910	Inhibition of MELK assessed as residual activity at 1 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	102.0	CHEMBL4578	Homo sapiens	Activity	%	102.0
	12170913	CHEMBL2213909	Inhibition of MELK assessed as residual activity at 10 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	93.0	CHEMBL4578	Homo sapiens	Activity	%	93.0
	12172349	CHEMBL2210614	Inhibition of MELK assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	85.0	CHEMBL4578	Homo sapiens	Activity	%	85.0
	12183846	CHEMBL2211542	Inhibition of MELK	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	pIC50		5.0
	12212988	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12212989	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	80.0	CHEMBL4578	Homo sapiens	Residual Activity	%	80.0
	12212990	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12212991	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	88.0	CHEMBL4578	Homo sapiens	Residual Activity	%	88.0
	12212992	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	109.0	CHEMBL4578	Homo sapiens	Residual Activity	%	109.0
	12212993	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	95.0	CHEMBL4578	Homo sapiens	Residual Activity	%	95.0
	12212994	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	42.0	CHEMBL4578	Homo sapiens	Residual Activity	%	42.0
	12212995	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12212996	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12212997	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	92.0	CHEMBL4578	Homo sapiens	Residual Activity	%	92.0
	12212998	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	76.0	CHEMBL4578	Homo sapiens	Residual Activity	%	76.0
	12212999	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	65.0	CHEMBL4578	Homo sapiens	Residual Activity	%	65.0
	12213000	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	90.0	CHEMBL4578	Homo sapiens	Residual Activity	%	90.0
	12213001	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	72.0	CHEMBL4578	Homo sapiens	Residual Activity	%	72.0
	12213002	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	83.0	CHEMBL4578	Homo sapiens	Residual Activity	%	83.0
	12213003	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	77.0	CHEMBL4578	Homo sapiens	Residual Activity	%	77.0
	12213004	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12213005	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	84.0	CHEMBL4578	Homo sapiens	Residual Activity	%	84.0
	12213006	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	78.0	CHEMBL4578	Homo sapiens	Residual Activity	%	78.0
	12213007	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	2.0	CHEMBL4578	Homo sapiens	Residual Activity	%	2.0
	12213008	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	88.0	CHEMBL4578	Homo sapiens	Residual Activity	%	88.0
	12213009	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12213010	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	78.0	CHEMBL4578	Homo sapiens	Residual Activity	%	78.0
	12213011	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	75.0	CHEMBL4578	Homo sapiens	Residual Activity	%	75.0
	12213012	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12213013	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12213014	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	27.0	CHEMBL4578	Homo sapiens	Residual Activity	%	27.0
	12213015	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	73.0	CHEMBL4578	Homo sapiens	Residual Activity	%	73.0
	12213016	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	81.0	CHEMBL4578	Homo sapiens	Residual Activity	%	81.0
	12213017	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12213018	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	97.0	CHEMBL4578	Homo sapiens	Residual Activity	%	97.0
	12213019	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12213020	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	94.0	CHEMBL4578	Homo sapiens	Residual Activity	%	94.0
	12213021	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	92.0	CHEMBL4578	Homo sapiens	Residual Activity	%	92.0
	12213022	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12213023	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	75.0	CHEMBL4578	Homo sapiens	Residual Activity	%	75.0
	12213024	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	47.0	CHEMBL4578	Homo sapiens	Residual Activity	%	47.0
	12213025	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	88.0	CHEMBL4578	Homo sapiens	Residual Activity	%	88.0
	12213026	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	75.0	CHEMBL4578	Homo sapiens	Residual Activity	%	75.0
	12213027	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	78.0	CHEMBL4578	Homo sapiens	Residual Activity	%	78.0
	12213028	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	96.0	CHEMBL4578	Homo sapiens	Residual Activity	%	96.0
	12213029	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	90.0	CHEMBL4578	Homo sapiens	Residual Activity	%	90.0
	12213030	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	9.0	CHEMBL4578	Homo sapiens	Residual Activity	%	9.0
	12213031	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	4.0	CHEMBL4578	Homo sapiens	Residual Activity	%	4.0
	12213032	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	98.0	CHEMBL4578	Homo sapiens	Residual Activity	%	98.0
	12213033	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12213034	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	98.0	CHEMBL4578	Homo sapiens	Residual Activity	%	98.0
	12213035	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	56.0	CHEMBL4578	Homo sapiens	Residual Activity	%	56.0
	12213036	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	67.0	CHEMBL4578	Homo sapiens	Residual Activity	%	67.0
	12213037	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	74.0	CHEMBL4578	Homo sapiens	Residual Activity	%	74.0
	12213038	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	54.0	CHEMBL4578	Homo sapiens	Residual Activity	%	54.0
	12213039	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	72.0	CHEMBL4578	Homo sapiens	Residual Activity	%	72.0
	12213040	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	6.0	CHEMBL4578	Homo sapiens	Residual Activity	%	6.0
	12213041	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	74.0	CHEMBL4578	Homo sapiens	Residual Activity	%	74.0
	12213042	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	80.0	CHEMBL4578	Homo sapiens	Residual Activity	%	80.0
	12213043	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	80.0	CHEMBL4578	Homo sapiens	Residual Activity	%	80.0
	12213044	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	77.0	CHEMBL4578	Homo sapiens	Residual Activity	%	77.0
	12213045	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	86.0	CHEMBL4578	Homo sapiens	Residual Activity	%	86.0
	12213046	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	43.0	CHEMBL4578	Homo sapiens	Residual Activity	%	43.0
	12213047	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12213048	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	60.0	CHEMBL4578	Homo sapiens	Residual Activity	%	60.0
	12213049	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	5.0	CHEMBL4578	Homo sapiens	Residual Activity	%	5.0
	12213050	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	70.0	CHEMBL4578	Homo sapiens	Residual Activity	%	70.0
	12213051	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	85.0	CHEMBL4578	Homo sapiens	Residual Activity	%	85.0
	12213052	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	74.0	CHEMBL4578	Homo sapiens	Residual Activity	%	74.0
	12213053	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	49.0	CHEMBL4578	Homo sapiens	Residual Activity	%	49.0
	12213054	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	60.0	CHEMBL4578	Homo sapiens	Residual Activity	%	60.0
	12213055	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	80.0	CHEMBL4578	Homo sapiens	Residual Activity	%	80.0
	12213056	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	64.0	CHEMBL4578	Homo sapiens	Residual Activity	%	64.0
	12213057	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	76.0	CHEMBL4578	Homo sapiens	Residual Activity	%	76.0
	12213058	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	72.0	CHEMBL4578	Homo sapiens	Residual Activity	%	72.0
	12213059	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	61.0	CHEMBL4578	Homo sapiens	Residual Activity	%	61.0
	12213060	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	41.0	CHEMBL4578	Homo sapiens	Residual Activity	%	41.0
	12213061	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	79.0	CHEMBL4578	Homo sapiens	Residual Activity	%	79.0
	12213062	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	64.0	CHEMBL4578	Homo sapiens	Residual Activity	%	64.0
	12213063	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	71.0	CHEMBL4578	Homo sapiens	Residual Activity	%	71.0
	12213064	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	114.0	CHEMBL4578	Homo sapiens	Residual Activity	%	114.0
	12213065	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	8.0	CHEMBL4578	Homo sapiens	Residual Activity	%	8.0
	12213066	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	69.0	CHEMBL4578	Homo sapiens	Residual Activity	%	69.0
	12213067	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	2.0	CHEMBL4578	Homo sapiens	Residual Activity	%	2.0
	12213068	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	94.0	CHEMBL4578	Homo sapiens	Residual Activity	%	94.0
	12213069	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	83.0	CHEMBL4578	Homo sapiens	Residual Activity	%	83.0
	12213070	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	87.0	CHEMBL4578	Homo sapiens	Residual Activity	%	87.0
	12213071	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	105.0	CHEMBL4578	Homo sapiens	Residual Activity	%	105.0
	12213072	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	105.0	CHEMBL4578	Homo sapiens	Residual Activity	%	105.0
	12213073	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	100.0	CHEMBL4578	Homo sapiens	Residual Activity	%	100.0
	12213074	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	88.0	CHEMBL4578	Homo sapiens	Residual Activity	%	88.0
	12213075	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	107.0	CHEMBL4578	Homo sapiens	Residual Activity	%	107.0
	12213076	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	93.0	CHEMBL4578	Homo sapiens	Residual Activity	%	93.0
	12213077	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	15.0	CHEMBL4578	Homo sapiens	Residual Activity	%	15.0
	12213078	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	102.0	CHEMBL4578	Homo sapiens	Residual Activity	%	102.0
	12213079	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12213080	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	46.0	CHEMBL4578	Homo sapiens	Residual Activity	%	46.0
	12213081	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	96.0	CHEMBL4578	Homo sapiens	Residual Activity	%	96.0
	12213082	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	104.0	CHEMBL4578	Homo sapiens	Residual Activity	%	104.0
	12213083	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	75.0	CHEMBL4578	Homo sapiens	Residual Activity	%	75.0
	12213084	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	76.0	CHEMBL4578	Homo sapiens	Residual Activity	%	76.0
	12213085	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	96.0	CHEMBL4578	Homo sapiens	Residual Activity	%	96.0
	12213086	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	95.0	CHEMBL4578	Homo sapiens	Residual Activity	%	95.0
	12213087	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	53.0	CHEMBL4578	Homo sapiens	Residual Activity	%	53.0
	12213088	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	27.0	CHEMBL4578	Homo sapiens	Residual Activity	%	27.0
	12213089	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	1.0	CHEMBL4578	Homo sapiens	Residual Activity	%	1.0
	12213090	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	109.0	CHEMBL4578	Homo sapiens	Residual Activity	%	109.0
	12213091	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	55.0	CHEMBL4578	Homo sapiens	Residual Activity	%	55.0
	12213092	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	81.0	CHEMBL4578	Homo sapiens	Residual Activity	%	81.0
	12213093	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	86.0	CHEMBL4578	Homo sapiens	Residual Activity	%	86.0
	12215925	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	84.0	CHEMBL4578	Homo sapiens	Residual Activity	%	84.0
	12215926	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	85.0	CHEMBL4578	Homo sapiens	Residual Activity	%	85.0
	12215927	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	104.0	CHEMBL4578	Homo sapiens	Residual Activity	%	104.0
	12215928	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12215929	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	97.0	CHEMBL4578	Homo sapiens	Residual Activity	%	97.0
	12215930	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	104.0	CHEMBL4578	Homo sapiens	Residual Activity	%	104.0
	12215931	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	69.0	CHEMBL4578	Homo sapiens	Residual Activity	%	69.0
	12215932	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	77.0	CHEMBL4578	Homo sapiens	Residual Activity	%	77.0
	12215933	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12215934	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	88.0	CHEMBL4578	Homo sapiens	Residual Activity	%	88.0
	12215935	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	72.0	CHEMBL4578	Homo sapiens	Residual Activity	%	72.0
	12215936	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	90.0	CHEMBL4578	Homo sapiens	Residual Activity	%	90.0
	12215937	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	71.0	CHEMBL4578	Homo sapiens	Residual Activity	%	71.0
	12215938	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12215939	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	76.0	CHEMBL4578	Homo sapiens	Residual Activity	%	76.0
	12215940	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	59.0	CHEMBL4578	Homo sapiens	Residual Activity	%	59.0
	12215941	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	56.0	CHEMBL4578	Homo sapiens	Residual Activity	%	56.0
	12215942	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	24.0	CHEMBL4578	Homo sapiens	Residual Activity	%	24.0
	12215943	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	7.0	CHEMBL4578	Homo sapiens	Residual Activity	%	7.0
	12215944	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	94.0	CHEMBL4578	Homo sapiens	Residual Activity	%	94.0
	12215945	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	66.0	CHEMBL4578	Homo sapiens	Residual Activity	%	66.0
	12215946	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	114.0	CHEMBL4578	Homo sapiens	Residual Activity	%	114.0
	12215947	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	74.0	CHEMBL4578	Homo sapiens	Residual Activity	%	74.0
	12215948	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	17.0	CHEMBL4578	Homo sapiens	Residual Activity	%	17.0
	12215949	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	77.0	CHEMBL4578	Homo sapiens	Residual Activity	%	77.0
	12215950	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	99.0	CHEMBL4578	Homo sapiens	Residual Activity	%	99.0
	12215951	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	13.0	CHEMBL4578	Homo sapiens	Residual Activity	%	13.0
	12215952	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	104.0	CHEMBL4578	Homo sapiens	Residual Activity	%	104.0
	12215953	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	73.0	CHEMBL4578	Homo sapiens	Residual Activity	%	73.0
	12215954	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	67.0	CHEMBL4578	Homo sapiens	Residual Activity	%	67.0
	12215955	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	97.0	CHEMBL4578	Homo sapiens	Residual Activity	%	97.0
	12215956	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	40.0	CHEMBL4578	Homo sapiens	Residual Activity	%	40.0
	12215957	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	34.0	CHEMBL4578	Homo sapiens	Residual Activity	%	34.0
	12215958	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	67.0	CHEMBL4578	Homo sapiens	Residual Activity	%	67.0
	12215959	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	67.0	CHEMBL4578	Homo sapiens	Residual Activity	%	67.0
	12215960	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	45.0	CHEMBL4578	Homo sapiens	Residual Activity	%	45.0
	12215961	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12215962	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	5.0	CHEMBL4578	Homo sapiens	Residual Activity	%	5.0
	12215963	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	73.0	CHEMBL4578	Homo sapiens	Residual Activity	%	73.0
	12215964	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	65.0	CHEMBL4578	Homo sapiens	Residual Activity	%	65.0
	12215965	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	69.0	CHEMBL4578	Homo sapiens	Residual Activity	%	69.0
	12215966	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	74.0	CHEMBL4578	Homo sapiens	Residual Activity	%	74.0
	12215967	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12215968	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	85.0	CHEMBL4578	Homo sapiens	Residual Activity	%	85.0
	12215969	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	24.0	CHEMBL4578	Homo sapiens	Residual Activity	%	24.0
	12215970	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	82.0	CHEMBL4578	Homo sapiens	Residual Activity	%	82.0
	12215971	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	92.0	CHEMBL4578	Homo sapiens	Residual Activity	%	92.0
	12215972	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	78.0	CHEMBL4578	Homo sapiens	Residual Activity	%	78.0
	12215973	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	87.0	CHEMBL4578	Homo sapiens	Residual Activity	%	87.0
	12215974	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	63.0	CHEMBL4578	Homo sapiens	Residual Activity	%	63.0
	12215975	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	92.0	CHEMBL4578	Homo sapiens	Residual Activity	%	92.0
	12215976	CHEMBL2219263	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	2.0	CHEMBL4578	Homo sapiens	Residual Activity	%	2.0
	12215977	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12215978	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	27.0	CHEMBL4578	Homo sapiens	Residual Activity	%	27.0
	12215979	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12215980	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12215981	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	112.0	CHEMBL4578	Homo sapiens	Residual Activity	%	112.0
	12215982	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	73.0	CHEMBL4578	Homo sapiens	Residual Activity	%	73.0
	12215983	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	51.0	CHEMBL4578	Homo sapiens	Residual Activity	%	51.0
	12215984	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	59.0	CHEMBL4578	Homo sapiens	Residual Activity	%	59.0
	12215985	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	67.0	CHEMBL4578	Homo sapiens	Residual Activity	%	67.0
	12215986	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	103.0	CHEMBL4578	Homo sapiens	Residual Activity	%	103.0
	12215987	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	99.0	CHEMBL4578	Homo sapiens	Residual Activity	%	99.0
	12215988	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	45.0	CHEMBL4578	Homo sapiens	Residual Activity	%	45.0
	12215989	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	96.0	CHEMBL4578	Homo sapiens	Residual Activity	%	96.0
	12215990	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	30.0	CHEMBL4578	Homo sapiens	Residual Activity	%	30.0
	12215991	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	49.0	CHEMBL4578	Homo sapiens	Residual Activity	%	49.0
	12215992	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	97.0	CHEMBL4578	Homo sapiens	Residual Activity	%	97.0
	12215993	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	46.0	CHEMBL4578	Homo sapiens	Residual Activity	%	46.0
	12215994	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	31.0	CHEMBL4578	Homo sapiens	Residual Activity	%	31.0
	12215995	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	78.0	CHEMBL4578	Homo sapiens	Residual Activity	%	78.0
	12215996	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	2.0	CHEMBL4578	Homo sapiens	Residual Activity	%	2.0
	12215997	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	87.0	CHEMBL4578	Homo sapiens	Residual Activity	%	87.0
	12215998	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	76.0	CHEMBL4578	Homo sapiens	Residual Activity	%	76.0
	12215999	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	84.0	CHEMBL4578	Homo sapiens	Residual Activity	%	84.0
	12216000	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	86.0	CHEMBL4578	Homo sapiens	Residual Activity	%	86.0
	12216001	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	95.0	CHEMBL4578	Homo sapiens	Residual Activity	%	95.0
	12216002	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	62.0	CHEMBL4578	Homo sapiens	Residual Activity	%	62.0
	12216003	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	3.0	CHEMBL4578	Homo sapiens	Residual Activity	%	3.0
	12216004	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	28.0	CHEMBL4578	Homo sapiens	Residual Activity	%	28.0
	12216005	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	101.0	CHEMBL4578	Homo sapiens	Residual Activity	%	101.0
	12216006	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	75.0	CHEMBL4578	Homo sapiens	Residual Activity	%	75.0
	12216007	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	82.0	CHEMBL4578	Homo sapiens	Residual Activity	%	82.0
	12216008	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	80.0	CHEMBL4578	Homo sapiens	Residual Activity	%	80.0
	12216009	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	65.0	CHEMBL4578	Homo sapiens	Residual Activity	%	65.0
	12216010	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12216011	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	80.0	CHEMBL4578	Homo sapiens	Residual Activity	%	80.0
	12216012	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	87.0	CHEMBL4578	Homo sapiens	Residual Activity	%	87.0
	12216013	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	11.0	CHEMBL4578	Homo sapiens	Residual Activity	%	11.0
	12216014	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	97.0	CHEMBL4578	Homo sapiens	Residual Activity	%	97.0
	12216015	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	103.0	CHEMBL4578	Homo sapiens	Residual Activity	%	103.0
	12216016	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	92.0	CHEMBL4578	Homo sapiens	Residual Activity	%	92.0
	12216017	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	105.0	CHEMBL4578	Homo sapiens	Residual Activity	%	105.0
	12216018	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	100.0	CHEMBL4578	Homo sapiens	Residual Activity	%	100.0
	12216019	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	4.0	CHEMBL4578	Homo sapiens	Residual Activity	%	4.0
	12216020	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	1.0	CHEMBL4578	Homo sapiens	Residual Activity	%	1.0
	12216021	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	84.0	CHEMBL4578	Homo sapiens	Residual Activity	%	84.0
	12216022	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	76.0	CHEMBL4578	Homo sapiens	Residual Activity	%	76.0
	12216023	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	86.0	CHEMBL4578	Homo sapiens	Residual Activity	%	86.0
	12216024	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	34.0	CHEMBL4578	Homo sapiens	Residual Activity	%	34.0
	12216025	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	33.0	CHEMBL4578	Homo sapiens	Residual Activity	%	33.0
	12216026	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	88.0	CHEMBL4578	Homo sapiens	Residual Activity	%	88.0
	12216027	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	26.0	CHEMBL4578	Homo sapiens	Residual Activity	%	26.0
	12216028	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	31.0	CHEMBL4578	Homo sapiens	Residual Activity	%	31.0
	12216029	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	1.0	CHEMBL4578	Homo sapiens	Residual Activity	%	1.0
	12216030	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	24.0	CHEMBL4578	Homo sapiens	Residual Activity	%	24.0
	12216031	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	72.0	CHEMBL4578	Homo sapiens	Residual Activity	%	72.0
	12216032	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	87.0	CHEMBL4578	Homo sapiens	Residual Activity	%	87.0
	12216033	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	50.0	CHEMBL4578	Homo sapiens	Residual Activity	%	50.0
	12216034	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	86.0	CHEMBL4578	Homo sapiens	Residual Activity	%	86.0
	12216035	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	7.0	CHEMBL4578	Homo sapiens	Residual Activity	%	7.0
	12216036	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	72.0	CHEMBL4578	Homo sapiens	Residual Activity	%	72.0
	12216037	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	46.0	CHEMBL4578	Homo sapiens	Residual Activity	%	46.0
	12216038	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	2.0	CHEMBL4578	Homo sapiens	Residual Activity	%	2.0
	12216039	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	78.0	CHEMBL4578	Homo sapiens	Residual Activity	%	78.0
	12216040	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	65.0	CHEMBL4578	Homo sapiens	Residual Activity	%	65.0
	12216041	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	75.0	CHEMBL4578	Homo sapiens	Residual Activity	%	75.0
	12216042	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	26.0	CHEMBL4578	Homo sapiens	Residual Activity	%	26.0
	12216043	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	63.0	CHEMBL4578	Homo sapiens	Residual Activity	%	63.0
	12216044	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	78.0	CHEMBL4578	Homo sapiens	Residual Activity	%	78.0
	12216045	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	31.0	CHEMBL4578	Homo sapiens	Residual Activity	%	31.0
	12216046	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	129.0	CHEMBL4578	Homo sapiens	Residual Activity	%	129.0
	12216047	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	77.0	CHEMBL4578	Homo sapiens	Residual Activity	%	77.0
	12216048	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	63.0	CHEMBL4578	Homo sapiens	Residual Activity	%	63.0
	12216049	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	13.0	CHEMBL4578	Homo sapiens	Residual Activity	%	13.0
	12216050	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	77.0	CHEMBL4578	Homo sapiens	Residual Activity	%	77.0
	12216051	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	20.0	CHEMBL4578	Homo sapiens	Residual Activity	%	20.0
	12216052	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	59.0	CHEMBL4578	Homo sapiens	Residual Activity	%	59.0
	12216053	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	82.0	CHEMBL4578	Homo sapiens	Residual Activity	%	82.0
	12216054	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	3.0	CHEMBL4578	Homo sapiens	Residual Activity	%	3.0
	12216055	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	60.0	CHEMBL4578	Homo sapiens	Residual Activity	%	60.0
	12216056	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	-2.0	CHEMBL4578	Homo sapiens	Residual Activity	%	-2.0
	12216057	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12216058	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	24.0	CHEMBL4578	Homo sapiens	Residual Activity	%	24.0
	12216059	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	82.0	CHEMBL4578	Homo sapiens	Residual Activity	%	82.0
	12216060	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	87.0	CHEMBL4578	Homo sapiens	Residual Activity	%	87.0
	12216061	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	95.0	CHEMBL4578	Homo sapiens	Residual Activity	%	95.0
	12216062	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	77.0	CHEMBL4578	Homo sapiens	Residual Activity	%	77.0
	12216063	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	61.0	CHEMBL4578	Homo sapiens	Residual Activity	%	61.0
	12216064	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	84.0	CHEMBL4578	Homo sapiens	Residual Activity	%	84.0
	12216065	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	90.0	CHEMBL4578	Homo sapiens	Residual Activity	%	90.0
	12216066	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	7.0	CHEMBL4578	Homo sapiens	Residual Activity	%	7.0
	12216067	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	84.0	CHEMBL4578	Homo sapiens	Residual Activity	%	84.0
	12216068	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	97.0	CHEMBL4578	Homo sapiens	Residual Activity	%	97.0
	12216069	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	7.0	CHEMBL4578	Homo sapiens	Residual Activity	%	7.0
	12216070	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	101.0	CHEMBL4578	Homo sapiens	Residual Activity	%	101.0
	12216071	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	92.0	CHEMBL4578	Homo sapiens	Residual Activity	%	92.0
	12216072	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	16.0	CHEMBL4578	Homo sapiens	Residual Activity	%	16.0
	12216073	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	76.0	CHEMBL4578	Homo sapiens	Residual Activity	%	76.0
	12216074	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	100.0	CHEMBL4578	Homo sapiens	Residual Activity	%	100.0
	12216075	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	85.0	CHEMBL4578	Homo sapiens	Residual Activity	%	85.0
	12216076	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	36.0	CHEMBL4578	Homo sapiens	Residual Activity	%	36.0
	12216077	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	10.0	CHEMBL4578	Homo sapiens	Residual Activity	%	10.0
	12216078	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	-1.0	CHEMBL4578	Homo sapiens	Residual Activity	%	-1.0
	12216079	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	113.0	CHEMBL4578	Homo sapiens	Residual Activity	%	113.0
	12216080	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	72.0	CHEMBL4578	Homo sapiens	Residual Activity	%	72.0
	12216081	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	64.0	CHEMBL4578	Homo sapiens	Residual Activity	%	64.0
	12216082	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	77.0	CHEMBL4578	Homo sapiens	Residual Activity	%	77.0
	12216083	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	48.0	CHEMBL4578	Homo sapiens	Residual Activity	%	48.0
	12216084	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	67.0	CHEMBL4578	Homo sapiens	Residual Activity	%	67.0
	12216085	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	77.0	CHEMBL4578	Homo sapiens	Residual Activity	%	77.0
	12216086	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	68.0	CHEMBL4578	Homo sapiens	Residual Activity	%	68.0
	12216087	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	87.0	CHEMBL4578	Homo sapiens	Residual Activity	%	87.0
	12216088	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	89.0	CHEMBL4578	Homo sapiens	Residual Activity	%	89.0
	12216089	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	52.0	CHEMBL4578	Homo sapiens	Residual Activity	%	52.0
	12216090	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	30.0	CHEMBL4578	Homo sapiens	Residual Activity	%	30.0
	12216091	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	83.0	CHEMBL4578	Homo sapiens	Residual Activity	%	83.0
	12216092	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	65.0	CHEMBL4578	Homo sapiens	Residual Activity	%	65.0
	12216093	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	24.0	CHEMBL4578	Homo sapiens	Residual Activity	%	24.0
	12216094	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	63.0	CHEMBL4578	Homo sapiens	Residual Activity	%	63.0
	12216095	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	27.0	CHEMBL4578	Homo sapiens	Residual Activity	%	27.0
	12216096	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	82.0	CHEMBL4578	Homo sapiens	Residual Activity	%	82.0
	12216097	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	72.0	CHEMBL4578	Homo sapiens	Residual Activity	%	72.0
	12216098	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	18.0	CHEMBL4578	Homo sapiens	Residual Activity	%	18.0
	12216099	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	16.0	CHEMBL4578	Homo sapiens	Residual Activity	%	16.0
	12216100	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	13.0	CHEMBL4578	Homo sapiens	Residual Activity	%	13.0
	12216101	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	5.0	CHEMBL4578	Homo sapiens	Residual Activity	%	5.0
	12216102	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	83.0	CHEMBL4578	Homo sapiens	Residual Activity	%	83.0
	12216103	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	18.0	CHEMBL4578	Homo sapiens	Residual Activity	%	18.0
	12216104	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	100.0	CHEMBL4578	Homo sapiens	Residual Activity	%	100.0
	12216105	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	75.0	CHEMBL4578	Homo sapiens	Residual Activity	%	75.0
	12216106	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	24.0	CHEMBL4578	Homo sapiens	Residual Activity	%	24.0
	12216107	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	38.0	CHEMBL4578	Homo sapiens	Residual Activity	%	38.0
	12216108	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	93.0	CHEMBL4578	Homo sapiens	Residual Activity	%	93.0
	12216109	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	0.0	CHEMBL4578	Homo sapiens	Residual Activity	%	0.0
	12216110	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	70.0	CHEMBL4578	Homo sapiens	Residual Activity	%	70.0
	12216111	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	29.0	CHEMBL4578	Homo sapiens	Residual Activity	%	29.0
	12216112	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	16.0	CHEMBL4578	Homo sapiens	Residual Activity	%	16.0
	12216113	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	70.0	CHEMBL4578	Homo sapiens	Residual Activity	%	70.0
	12216114	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	3.0	CHEMBL4578	Homo sapiens	Residual Activity	%	3.0
	12216115	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	48.0	CHEMBL4578	Homo sapiens	Residual Activity	%	48.0
	12216116	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	59.0	CHEMBL4578	Homo sapiens	Residual Activity	%	59.0
	12216117	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	62.0	CHEMBL4578	Homo sapiens	Residual Activity	%	62.0
	12216118	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	9.0	CHEMBL4578	Homo sapiens	Residual Activity	%	9.0
	12216119	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	53.0	CHEMBL4578	Homo sapiens	Residual Activity	%	53.0
	12216120	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	-1.0	CHEMBL4578	Homo sapiens	Residual Activity	%	-1.0
	12216121	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	70.0	CHEMBL4578	Homo sapiens	Residual Activity	%	70.0
	12216122	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	67.0	CHEMBL4578	Homo sapiens	Residual Activity	%	67.0
	12216123	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	52.0	CHEMBL4578	Homo sapiens	Residual Activity	%	52.0
	12216124	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	50.0	CHEMBL4578	Homo sapiens	Residual Activity	%	50.0
	12216125	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	51.0	CHEMBL4578	Homo sapiens	Residual Activity	%	51.0
	12216126	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	65.0	CHEMBL4578	Homo sapiens	Residual Activity	%	65.0
	12216127	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	3.0	CHEMBL4578	Homo sapiens	Residual Activity	%	3.0
	12216128	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	80.0	CHEMBL4578	Homo sapiens	Residual Activity	%	80.0
	12216129	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	85.0	CHEMBL4578	Homo sapiens	Residual Activity	%	85.0
	12216130	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	68.0	CHEMBL4578	Homo sapiens	Residual Activity	%	68.0
	12216131	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	91.0	CHEMBL4578	Homo sapiens	Residual Activity	%	91.0
	12216132	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	40.0	CHEMBL4578	Homo sapiens	Residual Activity	%	40.0
	12216133	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	46.0	CHEMBL4578	Homo sapiens	Residual Activity	%	46.0
	12216134	CHEMBL2219264	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	0.0	CHEMBL4578	Homo sapiens	Residual Activity	%	0.0
	12672985	CHEMBL2339720	Inhibition of recombinant MELK (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336379	=	Activity	%	19.0	CHEMBL4578	Homo sapiens	Activity	%	19.0
	12672986	CHEMBL2339720	Inhibition of recombinant MELK (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336377	=	Activity	%	27.0	CHEMBL4578	Homo sapiens	Activity	%	27.0
	12727731	CHEMBL2351165	Inhibition of MELK (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	76.0	CHEMBL4578	Homo sapiens	Activity	%	76.0
	12729019	CHEMBL2350443	Inhibition of MELK (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	92.0	CHEMBL4578	Homo sapiens	Activity	%	92.0
	12729905	CHEMBL2349809	Inhibition of MELK (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	76.0	CHEMBL4578	Homo sapiens	Activity	%	76.0
	12730162	CHEMBL2351165	Inhibition of MELK (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	88.0	CHEMBL4578	Homo sapiens	Activity	%	88.0
	13301912	CHEMBL2383372	Inhibition of human MELK at 1 uM relative to control	B	CC(=O)Nc1cccc(-c2n[nH]c3cc(-c4cnn(C)c4)c(NC4CCCCC4)cc23)c1		CHEMBL2380587	>	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
Not Active	13324727	CHEMBL2390474	Activity at MELK (unknown origin)	B	O=C(O)c1cccc(CN2C(=O)/C(=C(\c3ccccc3)c3ccc(Cl)cc3)c3ccccc32)c1		CHEMBL2386114		Activity			CHEMBL4578	Homo sapiens	Activity		
	13375780	CHEMBL2404175	Inhibition of MELK (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	52.0	CHEMBL4578	Homo sapiens	INH	%	52.0
	13406740	CHEMBL2415766	Inhibition of MELK (unknown origin) at 10 uM	B	CC(C)c1nc2ccccc2n1-c1nc(N2CCOCC2)c2nc(CN3CCC(C(C)(C)O)CC3)n(C)c2n1		CHEMBL2171952	=	Inhibition	%	63.0	CHEMBL4578	Homo sapiens	INH	%	63.0
	13439717	CHEMBL2426957	Competitive binding affinity to MELK (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	=	Inhibition	%	94.0	CHEMBL4578	Homo sapiens	INH	%	94.0
	13439812	CHEMBL2426957	Competitive binding affinity to MELK (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	13443074	CHEMBL2427502	Inhibition of MELK (unknown origin) at 1 uM relative to control	B	COc1ccc(NC(=O)/C=C/CN(C)C)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1		CHEMBL2426288	>	Inhibition	%	75.0	CHEMBL4578	Homo sapiens	INH	%	75.0
	13445645	CHEMBL2426957	Competitive binding affinity to MELK (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	=	Inhibition	%	74.0	CHEMBL4578	Homo sapiens	INH	%	74.0
	13451632	CHEMBL2426957	Competitive binding affinity to MELK (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	=	Inhibition	%	94.0	CHEMBL4578	Homo sapiens	INH	%	94.0
	13465467	CHEMBL2434216	Inhibition of human MELK assessed as residual activity at 1 uM relative to control	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Activity	%	115.0	CHEMBL4578	Homo sapiens	Activity	%	115.0
	13465493	CHEMBL2434607	Inhibition of human MELK assessed as residual activity at 10 uM relative to control	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Activity	%	64.0	CHEMBL4578	Homo sapiens	Activity	%	64.0
	13465518	CHEMBL2434191	Inhibition of human MELK assessed as residual activity at 25 uM relative to control	B	COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1		CHEMBL576349	=	Activity	%	75.0	CHEMBL4578	Homo sapiens	Activity	%	75.0
	13465541	CHEMBL2434607	Inhibition of human MELK assessed as residual activity at 10 uM relative to control	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Activity	%	83.0	CHEMBL4578	Homo sapiens	Activity	%	83.0
	13466467	CHEMBL2434216	Inhibition of human MELK assessed as residual activity at 1 uM relative to control	B	CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1		CHEMBL2430324	=	Activity	%	103.14	CHEMBL4578	Homo sapiens	Activity	%	103.14
	13466494	CHEMBL2434607	Inhibition of human MELK assessed as residual activity at 10 uM relative to control	B	CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1		CHEMBL2430324	=	Activity	%	105.87	CHEMBL4578	Homo sapiens	Activity	%	105.87
	13466521	CHEMBL2434216	Inhibition of human MELK assessed as residual activity at 1 uM relative to control	B	CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL2430323	=	Activity	%	76.11	CHEMBL4578	Homo sapiens	Activity	%	76.11
	13466548	CHEMBL2434607	Inhibition of human MELK assessed as residual activity at 10 uM relative to control	B	CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL2430323	=	Activity	%	38.93	CHEMBL4578	Homo sapiens	Activity	%	38.93
	13476408	CHEMBL2439132	Inhibition of human wild type MELK at 1 uM by qPCR analysis relative to control	B	CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1		CHEMBL2436978	>	Inhibition	%	90.0	CHEMBL4578	Homo sapiens	INH	%	90.0
Active	13488406	CHEMBL2439419	Inhibition of human MELK at 1 uM	B	Clc1ccc2ncc(Br)n2n1		CHEMBL2436439		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
Active	13488407	CHEMBL2439419	Inhibition of human MELK at 1 uM	B	CN1CCC(Nc2ccc3ncc(-c4cnn(-c5ccc(C#N)cc5)c4)n3n2)CC1		CHEMBL2436446		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
	13507559	CHEMBL2443995	Inhibition of MELK (unknown origin)	B	CN(C)c1ccc(Oc2cc(O)cc(O)c2-c2cc(C(=O)NC3CCN(C4CCC5(CC4)OCCO5)CC3)no2)cc1		CHEMBL2443026	>	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
	13507560	CHEMBL2443995	Inhibition of MELK (unknown origin)	B	CC(C)Nc1ccc(Oc2cc(O)cc(O)c2-c2cc(C(=O)NC3CCN(C)CC3)no2)cc1		CHEMBL2443139	>	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
	13507561	CHEMBL2443995	Inhibition of MELK (unknown origin)	B	CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc(N(C)C)cc3)on2)CC1		CHEMBL2443138	>	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
	13507562	CHEMBL2443995	Inhibition of MELK (unknown origin)	B	CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc([N+](=O)[O-])cc3)on2)CC1		CHEMBL2443044	>	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
	13872101	CHEMBL3101409	Inhibition of human MELK assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	87.0	CHEMBL4578	Homo sapiens	Activity	%	87.0
	14582549	CHEMBL3242550	Inhibition of human MELK assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	109.0	CHEMBL4578	Homo sapiens	Activity	%	109.0
	14648114	CHEMBL3267014	Inhibition of human MELK at 1 uM relative to control	B	CC(C)CCNc1ccc(-c2cnc3ccc(NC4CCN(C)CC4)nn23)cn1		CHEMBL2380687	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	14648115	CHEMBL3267014	Inhibition of human MELK at 1 uM relative to control	B	N[C@H]1CC[C@H](Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1		CHEMBL3264059	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	14751785	CHEMBL3300955	Inhibition of MELK (unknown origin)	B	CC(C)(C)CNC(=O)CC1CNC(=O)c2cc(-c3ccsc3)cn21		CHEMBL3298400	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	14751786	CHEMBL3300955	Inhibition of MELK (unknown origin)	B	CN1CCN(C[C@@H](NC(=O)C[C@H]2CNC(=O)c3cc(-c4cccc(Cl)c4)cn32)C2CCCCC2)CC1		CHEMBL3297762	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	14979208	CHEMBL3379057	Inhibition of MELK kinase (unknown origin) using KKLNRTLSFAEPG/gamma[33P]ATP by Millipore kinase/scintillation counting analysis	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)Nc1ccc2c(c1)CCNCC2		CHEMBL3355059	=	IC50	nM	23000.0	CHEMBL4578	Homo sapiens	IC50	uM	23.0
	14979209	CHEMBL3379056	Inhibition of MELK kinase (unknown origin) using KKLNRTLSFAEPG/gamma[33P]ATP at 1 uM by Millipore kinase/scintillation counting analysis	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)Nc1ccc2c(c1)CCNCC2		CHEMBL3355059	=	Inhibition	%	97.0	CHEMBL4578	Homo sapiens	INH	%	97.0
	14979210	CHEMBL3379055	Inhibition of MELK kinase (unknown origin) using biotinylated ZIP-tide peptide/gamma[33P]ATP by scintillation counting analysis	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)Nc1ccc2c(c1)CCNCC2		CHEMBL3355059	=	IC50	nM	37.0	CHEMBL4578	Homo sapiens	IC50	uM	0.037
	14979211	CHEMBL3379055	Inhibition of MELK kinase (unknown origin) using biotinylated ZIP-tide peptide/gamma[33P]ATP by scintillation counting analysis	B	O=C(Nc1ccc2c(c1)CCNCC2)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3355058	=	IC50	nM	410.0	CHEMBL4578	Homo sapiens	IC50	uM	0.41
	14979212	CHEMBL3379055	Inhibition of MELK kinase (unknown origin) using biotinylated ZIP-tide peptide/gamma[33P]ATP by scintillation counting analysis	B	O=C(Nc1ccc2c(c1)CCNCC2)c1ccc(Br)cc1		CHEMBL3355057	=	IC50	nM	31000.0	CHEMBL4578	Homo sapiens	IC50	uM	31.0
	14979213	CHEMBL3379055	Inhibition of MELK kinase (unknown origin) using biotinylated ZIP-tide peptide/gamma[33P]ATP by scintillation counting analysis	B	NCCCOc1cc(-c2cn[nH]c2)ccc1C(=O)Nc1ccccc1		CHEMBL3355056	=	IC50	nM	1000.0	CHEMBL4578	Homo sapiens	IC50	uM	1.0
	14979214	CHEMBL3379055	Inhibition of MELK kinase (unknown origin) using biotinylated ZIP-tide peptide/gamma[33P]ATP by scintillation counting analysis	B	COc1cc(O)cc(Nc2ccc(C(=O)Nc3ccccc3)c(OCCCN)c2)c1		CHEMBL3355055	=	IC50	nM	4200.0	CHEMBL4578	Homo sapiens	IC50	uM	4.2
	14979215	CHEMBL3379055	Inhibition of MELK kinase (unknown origin) using biotinylated ZIP-tide peptide/gamma[33P]ATP by scintillation counting analysis	B	COc1cc(O)cc(Nc2ccc(C(=O)Nc3ccc4c(c3)CNCC4)cc2)c1		CHEMBL3355054	=	IC50	nM	2100.0	CHEMBL4578	Homo sapiens	IC50	uM	2.1
	14979216	CHEMBL3379055	Inhibition of MELK kinase (unknown origin) using biotinylated ZIP-tide peptide/gamma[33P]ATP by scintillation counting analysis	B	O=C(Nc1ccc2c(c1)CNCC2)c1ccc(F)cc1		CHEMBL3355053	=	IC50	nM	160000.0	CHEMBL4578	Homo sapiens	IC50	uM	160.0
	14979222	CHEMBL3379605	Inhibition of MELK (unknown origin) using Biotin-KKLNRTLSFAEPG substrate by Astex/scintillation counting analysis	B	COc1cc(OCC#Cc2ccc3ccncc3c2)ccc1CN1CCNCC1		CHEMBL3355063	=	IC50	nM	720.0	CHEMBL4578	Homo sapiens	IC50	uM	0.72
	14979223	CHEMBL3379605	Inhibition of MELK (unknown origin) using Biotin-KKLNRTLSFAEPG substrate by Astex/scintillation counting analysis	B	CCOc1cc(OCC#Cc2ccc3ccncc3c2)ccc1CN		CHEMBL3355062	=	IC50	nM	650.0	CHEMBL4578	Homo sapiens	IC50	uM	0.65
	14979224	CHEMBL3379605	Inhibition of MELK (unknown origin) using Biotin-KKLNRTLSFAEPG substrate by Astex/scintillation counting analysis	B	COc1cc(OCC#Cc2ccc3ccncc3c2)ccc1CN		CHEMBL3355061	=	IC50	nM	5100.0	CHEMBL4578	Homo sapiens	IC50	uM	5.1
	14979225	CHEMBL3379605	Inhibition of MELK (unknown origin) using Biotin-KKLNRTLSFAEPG substrate by Astex/scintillation counting analysis	B	NCc1ccc(OCC#Cc2ccc3ccncc3c2)cc1		CHEMBL3355060	=	IC50	nM	24000.0	CHEMBL4578	Homo sapiens	IC50	uM	24.0
	14979226	CHEMBL3379608	Inhibition of MELK (unknown origin)	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)Nc1ccc2c(c1)CCNCC2		CHEMBL3355059	=	IC50	nM	37.0	CHEMBL4578	Homo sapiens	IC50	nM	37.0
	14979227	CHEMBL3379605	Inhibition of MELK (unknown origin) using Biotin-KKLNRTLSFAEPG substrate by Astex/scintillation counting analysis	B	FC(F)(F)c1cc(OCC#Cc2ccc3ccncc3c2)ccc1CN1CCNCC1		CHEMBL3355064	=	IC50	nM	300.0	CHEMBL4578	Homo sapiens	IC50	uM	0.3
Not Determined	14979228	CHEMBL3379605	Inhibition of MELK (unknown origin) using Biotin-KKLNRTLSFAEPG substrate by Astex/scintillation counting analysis	B	CNc1cc2ccc(C#CCOc3ccc(CN4CCNCC4)c(C(F)(F)F)c3)cc2cn1		CHEMBL3355065		IC50			CHEMBL4578	Homo sapiens	IC50		
	14979229	CHEMBL3379605	Inhibition of MELK (unknown origin) using Biotin-KKLNRTLSFAEPG substrate by Astex/scintillation counting analysis	B	OCC#Cc1ccc2ccncc2c1		CHEMBL3355067	=	IC50	nM	3100.0	CHEMBL4578	Homo sapiens	IC50	uM	3.1
Not Determined	14979230	CHEMBL3379606	Inhibition of MELK (unknown origin) using KKLNRTLSFAEPG substrate by Millipore/scintillation counting analysis	B	NCc1ccc(OCC#Cc2ccc3ccncc3c2)cc1		CHEMBL3355060		IC50			CHEMBL4578	Homo sapiens	IC50		
Not Determined	14979231	CHEMBL3379606	Inhibition of MELK (unknown origin) using KKLNRTLSFAEPG substrate by Millipore/scintillation counting analysis	B	COc1cc(OCC#Cc2ccc3ccncc3c2)ccc1CN		CHEMBL3355061		IC50			CHEMBL4578	Homo sapiens	IC50		
Not Determined	14979232	CHEMBL3379606	Inhibition of MELK (unknown origin) using KKLNRTLSFAEPG substrate by Millipore/scintillation counting analysis	B	CCOc1cc(OCC#Cc2ccc3ccncc3c2)ccc1CN		CHEMBL3355062		IC50			CHEMBL4578	Homo sapiens	IC50		
	14979233	CHEMBL3379606	Inhibition of MELK (unknown origin) using KKLNRTLSFAEPG substrate by Millipore/scintillation counting analysis	B	COc1cc(OCC#Cc2ccc3ccncc3c2)ccc1CN1CCNCC1		CHEMBL3355063	=	IC50	nM	520.0	CHEMBL4578	Homo sapiens	IC50	uM	0.52
	14979234	CHEMBL3379606	Inhibition of MELK (unknown origin) using KKLNRTLSFAEPG substrate by Millipore/scintillation counting analysis	B	FC(F)(F)c1cc(OCC#Cc2ccc3ccncc3c2)ccc1CN1CCNCC1		CHEMBL3355064	=	IC50	nM	7.6	CHEMBL4578	Homo sapiens	IC50	uM	0.0076
	14979235	CHEMBL3379606	Inhibition of MELK (unknown origin) using KKLNRTLSFAEPG substrate by Millipore/scintillation counting analysis	B	CNc1cc2ccc(C#CCOc3ccc(CN4CCNCC4)c(C(F)(F)F)c3)cc2cn1		CHEMBL3355065	=	IC50	nM	19.0	CHEMBL4578	Homo sapiens	IC50	uM	0.019
Not Determined	14979236	CHEMBL3379606	Inhibition of MELK (unknown origin) using KKLNRTLSFAEPG substrate by Millipore/scintillation counting analysis	B	C(#Cc1ccc2ccncc2c1)COc1ccccc1		CHEMBL3355066		IC50			CHEMBL4578	Homo sapiens	IC50		
Not Determined	14979237	CHEMBL3379606	Inhibition of MELK (unknown origin) using KKLNRTLSFAEPG substrate by Millipore/scintillation counting analysis	B	OCC#Cc1ccc2ccncc2c1		CHEMBL3355067		IC50			CHEMBL4578	Homo sapiens	IC50		
	14979238	CHEMBL3379607	Inhibition of MELK (unknown origin) at 1 uM	B	CNc1cc2ccc(C#CCOc3ccc(CN4CCNCC4)c(C(F)(F)F)c3)cc2cn1		CHEMBL3355065	=	Inhibition	%	100.0	CHEMBL4578	Homo sapiens	INH	%	100.0
	14979239	CHEMBL3379608	Inhibition of MELK (unknown origin)	B	CNc1cc2ccc(C#CCOc3ccc(CN4CCNCC4)c(C(F)(F)F)c3)cc2cn1		CHEMBL3355065	=	IC50	nM	20.0	CHEMBL4578	Homo sapiens	IC50	nM	20.0
	14979258	CHEMBL3379627	Inhibition of MELK (unknown origin) using Biotin-KKLNRTLSFAEPG substrate at 300 uM by Astex/scintillation counting analysis	B	C(#Cc1ccc2ccncc2c1)COc1ccccc1		CHEMBL3355066	=	Inhibition	%	52.0	CHEMBL4578	Homo sapiens	INH	%	52.0
	15019153	CHEMBL3364355	Inhibition of MELK (unknown origin) at 1 uM in presence of 100 uM ATP	B	C=CC(=O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C		CHEMBL3298512	=	Inhibition	%	62.0	CHEMBL4578	Homo sapiens	INH	%	62.0
	15036858	CHEMBL3381087	Inhibition of MELK (unknown origin)	B	Nc1nc2c3c(F)cccc3nc(Cc3ccc4c(c3)OCO4)n2n1		CHEMBL3309990	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	15036859	CHEMBL3381087	Inhibition of MELK (unknown origin)	B	Nc1ccc2c(c1)nc(Cc1ccc3c(c1)OCO3)n1nc(N)nc21		CHEMBL3309995	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	15036860	CHEMBL3381087	Inhibition of MELK (unknown origin)	B	OCCCNc1ccc2c(c1)nc(-c1ccc3c(c1)OCO3)n1ncnc21		CHEMBL3309997	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	15036861	CHEMBL3381087	Inhibition of MELK (unknown origin)	B	Nc1nc2c3ccc(NCCO)cc3nc(Cc3ccc4c(c3)OCO4)n2n1		CHEMBL3309998	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	15036862	CHEMBL3381087	Inhibition of MELK (unknown origin)	B	CN1CCN(c2cc(F)c3c(c2)nc(Cc2ccc4c(c2)OCO4)n2nc(N)nc32)CC1		CHEMBL3310151	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	15055361	CHEMBL3380493	Inhibition of MELK (unknown origin) assessed as residual activity at 1 uM by radiometric protein kinase assay	B	COc1cc(-c2c[nH]c(=O)c(-c3cc(OC)c(OC)c(OC)c3)n2)ccc1O		CHEMBL3358999	=	Activity	%	15.0	CHEMBL4578	Homo sapiens	Activity	%	15.0
	15072440	CHEMBL3388053	Inhibition of MELK (unknown origin) assessed as remaining enzyme activity at 10 uM by radioactive [33P]-ATP filter binding assay	B	Cc1ccc(-c2cc(C(=O)Nc3ccnc(Cl)c3)nn2-c2ccc3ccccc3n2)cc1		CHEMBL3338802	=	Activity	%	98.0	CHEMBL4578	Homo sapiens	Activity	%	98.0
	15109396	CHEMBL3373406	Inhibition of MELK (unknown origin) assessed as residual enzyme activity at 10 uM	B	COc1cccc(C(=O)Nc2nc3cc4c(cc3[nH]2)OC(F)(F)O4)c1		CHEMBL3337846	=	Activity	%	21.0	CHEMBL4578	Homo sapiens	Activity	%	21.0
	15135680	CHEMBL3375820	Inhibition of MELK (unknown origin) at 1 uM	B	COC1CCN(c2nccc(Nc3cc4c(cn3)ncn4C(C)C)n2)CC1		CHEMBL3354190	>	Inhibition	%	80.0	CHEMBL4578	Homo sapiens	INH	%	80.0
	15137731	CHEMBL3385164	Inhibition of MELK (unknown origin) assessed as residual enzyme activity at 10 uM	B	CO[C@H]1CC[C@H](NC(=O)c2n[nH]cc2NC(=O)c2ccccc2)CC1		CHEMBL3335124	=	Activity	%	32.0	CHEMBL4578	Homo sapiens	Activity	%	32.0
	15137732	CHEMBL3385164	Inhibition of MELK (unknown origin) assessed as residual enzyme activity at 10 uM	B	COc1cccc(OC)c1C(=O)Nc1c[nH]nc1C(=O)N[C@H]1CC[C@H](OC)CC1		CHEMBL3335141	=	Activity	%	100.0	CHEMBL4578	Homo sapiens	Activity	%	100.0
	15137733	CHEMBL3385164	Inhibition of MELK (unknown origin) assessed as residual enzyme activity at 10 uM	B	CO[C@H]1CC[C@H](NC(=O)c2n[nH]cc2NC(=O)c2ccc(-c3ccccc3)o2)CC1		CHEMBL3335153	=	Activity	%	13.0	CHEMBL4578	Homo sapiens	Activity	%	13.0
	15137734	CHEMBL3385164	Inhibition of MELK (unknown origin) assessed as residual enzyme activity at 10 uM	B	COc1cccc(OC)c1C(=O)Nc1c[nH]nc1C(=O)NCc1ccccc1		CHEMBL3335161	=	Activity	%	96.0	CHEMBL4578	Homo sapiens	Activity	%	96.0
	15237688	CHEMBL3423971	Inhibition of human MELK by millipore radiometric assay	B	O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1		CHEMBL3422092	=	IC50	nM	160.0	CHEMBL4578	Homo sapiens	IC50	nM	160.0
	15251873	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL443738	=	Activity	%	49.0	CHEMBL4578	Homo sapiens	Activity	%	49.0
	15251924	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427170	=	Activity	%	26.0	CHEMBL4578	Homo sapiens	Activity	%	26.0
	15252026	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427171	=	Activity	%	60.0	CHEMBL4578	Homo sapiens	Activity	%	60.0
	15252671	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427172	=	Activity	%	72.0	CHEMBL4578	Homo sapiens	Activity	%	72.0
	15252773	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)CS3)sc2c1		CHEMBL3427173	=	Activity	%	65.0	CHEMBL4578	Homo sapiens	Activity	%	65.0
	15252875	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)CS3)sc2c1		CHEMBL3427174	=	Activity	%	83.0	CHEMBL4578	Homo sapiens	Activity	%	83.0
	15253549	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427175	=	Activity	%	68.0	CHEMBL4578	Homo sapiens	Activity	%	68.0
	15253651	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427176	=	Activity	%	71.0	CHEMBL4578	Homo sapiens	Activity	%	71.0
	15253753	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427177	=	Activity	%	66.0	CHEMBL4578	Homo sapiens	Activity	%	66.0
	15254419	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427178	=	Activity	%	49.0	CHEMBL4578	Homo sapiens	Activity	%	49.0
	15254521	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@H]1C(=O)O		CHEMBL3427179	=	Activity	%	52.0	CHEMBL4578	Homo sapiens	Activity	%	52.0
	15254623	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@@H]1C(=O)O		CHEMBL3427180	=	Activity	%	32.0	CHEMBL4578	Homo sapiens	Activity	%	32.0
	15255314	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427181	=	Activity	%	40.0	CHEMBL4578	Homo sapiens	Activity	%	40.0
	15255416	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427182	=	Activity	%	44.0	CHEMBL4578	Homo sapiens	Activity	%	44.0
	15255519	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427183	=	Activity	%	105.0	CHEMBL4578	Homo sapiens	Activity	%	105.0
	15256250	CHEMBL3427829	Inhibition of MELK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427184	=	Activity	%	89.0	CHEMBL4578	Homo sapiens	Activity	%	89.0
	15685899	CHEMBL3607975	Inhibition of human MELK	B	NC(=O)c1cc(F)cc2c1C(=O)N(C1CCN(C3CCC(F)(F)CC3)CC1)C2		CHEMBL3606021	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	15756916	CHEMBL3631294	Inhibition of MELK (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	-0.03	CHEMBL4578	Homo sapiens	INH	%	-0.03
	15757807	CHEMBL3631294	Inhibition of MELK (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	69.33	CHEMBL4578	Homo sapiens	INH	%	69.33
	15758786	CHEMBL3631294	Inhibition of MELK (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	8.47	CHEMBL4578	Homo sapiens	INH	%	8.47
	16413475	CHEMBL3742705	Inhibition of MELK (unknown origin)	B	O=C(O)C1CN(Cc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2)C1		CHEMBL3741589	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	16425430	CHEMBL3749829	Inhibition of MELK (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	16426148	CHEMBL3750475	Inhibition of MELK (unknown origin)	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	nM	10000.0
	16431902	CHEMBL3747995	Inhibition of human MELK using [KKLNRTLSFAEPG] as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	16451512	CHEMBL3760635	Inhibition of MELK (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	12.3	CHEMBL4578	Homo sapiens	INH	%	12.3
	16495126	CHEMBL3777489	Inhibition of N-terminal His6-tagged recombinant human MELK expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	-2.0	CHEMBL4578	Homo sapiens	Activity	%	-2.0
	16496045	CHEMBL3777489	Inhibition of N-terminal His6-tagged recombinant human MELK expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	6.0	CHEMBL4578	Homo sapiens	Activity	%	6.0
	16508232	CHEMBL3777489	Inhibition of N-terminal His6-tagged recombinant human MELK expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	-21.0	CHEMBL4578	Homo sapiens	Activity	%	-21.0
	16562726	CHEMBL3802281	Inhibition of MELK (unknown origin) using peptide substrate incubated for 30 mins by europium donor dye-based plate reader analysis	B	CC(C)(C)C(=O)Nc1ccc2c(c1)/C(=C1/Nc3ccccc3/C1=N\O)C(=O)N2		CHEMBL513703	=	IC50	nM	2800.0	CHEMBL4578	Homo sapiens	IC50	uM	2.8
	16562727	CHEMBL3802281	Inhibition of MELK (unknown origin) using peptide substrate incubated for 30 mins by europium donor dye-based plate reader analysis	B	CCCCC(=O)Nc1ccc2c(c1)/C(=C1/Nc3ccccc3/C1=N\O)C(=O)N2		CHEMBL3797480	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	16562728	CHEMBL3802281	Inhibition of MELK (unknown origin) using peptide substrate incubated for 30 mins by europium donor dye-based plate reader analysis	B	CCCC(=O)Nc1ccc2c(c1)/C(=C1/Nc3ccccc3/C1=N\O)C(=O)N2		CHEMBL3799585	=	IC50	nM	1000.0	CHEMBL4578	Homo sapiens	IC50	uM	1.0
	16587030	CHEMBL3807442	Inhibition of MELK (unknown origin) in presence of gamma33-ATP	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	16611983	CHEMBL3815477	Inhibition of human MELK (2 to 651 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL405665	=	Activity	%	-64.0	CHEMBL4578	Homo sapiens	Activity	%	-64.0
	16611984	CHEMBL3815477	Inhibition of human MELK (2 to 651 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCCCc1cc(-c2c[nH]c3ncccc23)nc(N)n1		CHEMBL3814340	=	Activity	%	-89.0	CHEMBL4578	Homo sapiens	Activity	%	-89.0
	16611985	CHEMBL3815477	Inhibition of human MELK (2 to 651 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1		CHEMBL3814140	=	Activity	%	-81.0	CHEMBL4578	Homo sapiens	Activity	%	-81.0
	16611986	CHEMBL3815477	Inhibition of human MELK (2 to 651 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCCCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1		CHEMBL3815046	=	Activity	%	-85.0	CHEMBL4578	Homo sapiens	Activity	%	-85.0
	16614537	CHEMBL3817568	Inhibition of human MELK at 1 uM using [KKLNRTLSFAEPG] as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	1.0	CHEMBL4578	Homo sapiens	INH	%	1.0
	16618163	CHEMBL3817268	Inhibition of recombinant human GST-tagged MELK catalytic domain (1 to 340 residues) expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	16628489	CHEMBL3820301	Inhibition of human recombinant full-length MELK expressed in Escherichia coli at 1 uM using KKLNRTLSFAEPG as substrate after 30 mins	B	O=C(Nc1cc(Nc2c(Cl)cnc3c2OCO3)ccn1)C1CC1		CHEMBL3818173	<	Inhibition	%	80.0	CHEMBL4578	Homo sapiens	INH	%	80.0
	16640387	CHEMBL3824966	Binding affinity to MELK (unknown origin) expressed in Escherichia coli by SPR analysis	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OCC4CCNCC4)cn3)cc2)CC1		CHEMBL3824068	=	IC50	nM	2.0	CHEMBL4578	Homo sapiens	IC50	uM	0.002
	16640388	CHEMBL3824965	Inhibition of full-length MELK (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OCC4CCNCC4)cn3)cc2)CC1		CHEMBL3824068	=	IC50	nM	5.0	CHEMBL4578	Homo sapiens	IC50	uM	0.005
Not Determined	16640389	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	Fc1cc(N2CCOCC2)ccc1-n1cc(-c2ccncc2OCC2CCNCC2)cn1		CHEMBL3824328		IC50			CHEMBL4578	Homo sapiens	IC50		
	16640390	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	c1cc(-c2cnn(-c3ccc(N4CCOCC4)cc3)c2)c(OCC2CCNCC2)cn1		CHEMBL3823302	=	IC50	nM	210.0	CHEMBL4578	Homo sapiens	IC50	uM	0.21
Not Determined	16640391	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	Fc1ccccc1-n1cc(-c2ccncc2OCC2CCNCC2)cn1		CHEMBL3822876		IC50			CHEMBL4578	Homo sapiens	IC50		
Not Determined	16640392	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	c1ccc(-n2cc(-c3ccncc3OCC3CCNCC3)cn2)cc1		CHEMBL3824074		IC50			CHEMBL4578	Homo sapiens	IC50		
	16640393	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	CC(C)COc1cnccc1-c1cnn(-c2ccc(N3CCN(C)CC3)cc2)c1		CHEMBL3823918	=	IC50	nM	410.0	CHEMBL4578	Homo sapiens	IC50	uM	0.41
	16640394	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OC4CCCCC4)cn3)cc2)CC1		CHEMBL3823874	=	IC50	nM	150.0	CHEMBL4578	Homo sapiens	IC50	uM	0.15
	16640395	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OC4CCNCC4)cn3)cc2)CC1		CHEMBL3822465	=	IC50	nM	260.0	CHEMBL4578	Homo sapiens	IC50	uM	0.26
	16640396	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OCc4ccncc4)cn3)cc2)CC1		CHEMBL3824157	=	IC50	nM	1440.0	CHEMBL4578	Homo sapiens	IC50	uM	1.44
	16640397	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OC[C@H]4CC[C@H](N)CC4)cn3)cc2)CC1		CHEMBL3823975	=	IC50	nM	57.0	CHEMBL4578	Homo sapiens	IC50	uM	0.057
	16640398	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OCC4CCNCC4)cn3)cc2)CC1		CHEMBL3824068	=	IC50	nM	140.0	CHEMBL4578	Homo sapiens	IC50	uM	0.14
	16640399	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4)cn3)cc2)CC1		CHEMBL3823597	=	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
Not Determined	16640400	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	COc1cnccc1-c1cnn(-c2ccc(N3CCN(C)CC3)cc2)c1		CHEMBL3823633		IC50			CHEMBL4578	Homo sapiens	IC50		
	16640401	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4F)cn3)cc2)CC1		CHEMBL3824174	=	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
Not Determined	16640402	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	CS(=O)(=O)c1ccc(-n2cc(-c3ccc(O)cc3)cn2)cc1		CHEMBL3824280		IC50			CHEMBL4578	Homo sapiens	IC50		
Not Determined	16640403	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	CS(=O)(=O)c1ccc(-n2cc(-c3ccccc3)cn2)cc1		CHEMBL3822777		IC50			CHEMBL4578	Homo sapiens	IC50		
Not Determined	16640404	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	CS(=O)(=O)c1ccc(-n2cc(-c3ccncc3)cn2)cc1		CHEMBL3823920		IC50			CHEMBL4578	Homo sapiens	IC50		
	16640405	CHEMBL3824964	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 2 mM ATP measured after 20 mins by time-resolved fluorescence assay	B	O=C(NCc1ccccn1)c1ccc(-n2cc(-c3ccncc3)cn2)cc1		CHEMBL3823306	=	IC50	nM	18800.0	CHEMBL4578	Homo sapiens	IC50	uM	18.8
	16640406	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	Fc1cc(N2CCOCC2)ccc1-n1cc(-c2ccncc2OCC2CCNCC2)cn1		CHEMBL3824328	=	IC50	nM	0.3	CHEMBL4578	Homo sapiens	IC50	uM	0.0003
	16640407	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	c1cc(-c2cnn(-c3ccc(N4CCOCC4)cc3)c2)c(OCC2CCNCC2)cn1		CHEMBL3823302	=	IC50	nM	6.0	CHEMBL4578	Homo sapiens	IC50	uM	0.006
	16640408	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	Fc1ccccc1-n1cc(-c2ccncc2OCC2CCNCC2)cn1		CHEMBL3822876	=	IC50	nM	13.0	CHEMBL4578	Homo sapiens	IC50	uM	0.013
	16640409	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	c1ccc(-n2cc(-c3ccncc3OCC3CCNCC3)cn2)cc1		CHEMBL3824074	=	IC50	nM	36.0	CHEMBL4578	Homo sapiens	IC50	uM	0.036
	16640410	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CC(C)COc1cnccc1-c1cnn(-c2ccc(N3CCN(C)CC3)cc2)c1		CHEMBL3823918	=	IC50	nM	9.0	CHEMBL4578	Homo sapiens	IC50	uM	0.009
	16640411	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OC4CCCCC4)cn3)cc2)CC1		CHEMBL3823874	=	IC50	nM	4.0	CHEMBL4578	Homo sapiens	IC50	uM	0.004
	16640412	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OC4CCNCC4)cn3)cc2)CC1		CHEMBL3822465	=	IC50	nM	6.0	CHEMBL4578	Homo sapiens	IC50	uM	0.006
	16640413	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OCc4ccncc4)cn3)cc2)CC1		CHEMBL3824157	=	IC50	nM	25.0	CHEMBL4578	Homo sapiens	IC50	uM	0.025
	16640414	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OC[C@H]4CC[C@H](N)CC4)cn3)cc2)CC1		CHEMBL3823975	=	IC50	nM	1.0	CHEMBL4578	Homo sapiens	IC50	uM	0.001
	16640415	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OCC4CCNCC4)cn3)cc2)CC1		CHEMBL3824068	=	IC50	nM	2.0	CHEMBL4578	Homo sapiens	IC50	uM	0.002
	16640416	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4)cn3)cc2)CC1		CHEMBL3823597	=	IC50	nM	80.0	CHEMBL4578	Homo sapiens	IC50	uM	0.08
	16640417	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	COc1cnccc1-c1cnn(-c2ccc(N3CCN(C)CC3)cc2)c1		CHEMBL3823633	=	IC50	nM	64.0	CHEMBL4578	Homo sapiens	IC50	uM	0.064
	16640418	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4F)cn3)cc2)CC1		CHEMBL3824174	=	IC50	nM	70.0	CHEMBL4578	Homo sapiens	IC50	uM	0.07
	16640419	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CS(=O)(=O)c1ccc(-n2cc(-c3ccc(O)cc3)cn2)cc1		CHEMBL3824280	=	IC50	nM	520.0	CHEMBL4578	Homo sapiens	IC50	uM	0.52
	16640420	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CS(=O)(=O)c1ccc(-n2cc(-c3ccccc3)cn2)cc1		CHEMBL3822777	>	IC50	nM	20000.0	CHEMBL4578	Homo sapiens	IC50	uM	20.0
	16640421	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CS(=O)(=O)c1ccc(-n2cc(-c3ccncc3)cn2)cc1		CHEMBL3823920	=	IC50	nM	400.0	CHEMBL4578	Homo sapiens	IC50	uM	0.4
	16640422	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-c3cc(-c4ccccc4)n[nH]3)cc2)CC1		CHEMBL3824282	=	IC50	nM	670.0	CHEMBL4578	Homo sapiens	IC50	uM	0.67
	16640423	CHEMBL3824963	Inhibition of MELK catalytic domain (unknown origin) preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	O=C(NCc1ccccn1)c1ccc(-n2cc(-c3ccncc3)cn2)cc1		CHEMBL3823306	=	IC50	nM	180.0	CHEMBL4578	Homo sapiens	IC50	uM	0.18
	16640437	CHEMBL3824977	Inhibition of MELK catalytic domain (unknown origin) at 1 uM preincubated for 20 mins followed by addition of KinEASE STK S1 peptide as substrate in presence of 20 uM ATP measured after 20 mins by time-resolved fluorescence assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OCC4CCNCC4)cn3)cc2)CC1		CHEMBL3824068	=	Inhibition	%	86.0	CHEMBL4578	Homo sapiens	INH	%	86.0
	16654134	CHEMBL3829188	Inhibition of human MELK (2 to 651 residues) assessed as remaining enzyme activity at 50 uM after 30 mins by 33P-ATP filter-binding assay	B	Cc1cc(=O)c2c(O)cc(O)c([C@H]3CCN(C)C[C@H]3O)c2o1		CHEMBL1077604	=	Activity	%	80.0	CHEMBL4578	Homo sapiens	Activity	%	80.0
217571	17606223	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	IC50	nM	0.4	CHEMBL4578	Homo sapiens	IC50	nM	0.4
235371	17623334	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3674238	=	IC50	nM	1.1	CHEMBL4578	Homo sapiens	IC50	nM	1.1
309621	17690257	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(Cl)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688334	=	IC50	nM	310.0	CHEMBL4578	Homo sapiens	IC50	nM	310.0
309622	17690258	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](N(C)C)CC1		CHEMBL3688335	=	IC50	nM	0.3	CHEMBL4578	Homo sapiens	IC50	nM	0.3
309623	17690259	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](N(C)C)CC1		CHEMBL3688336	=	IC50	nM	1.2	CHEMBL4578	Homo sapiens	IC50	nM	1.2
309624	17690260	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)nc23)CC1		CHEMBL3688337	=	IC50	nM	0.5	CHEMBL4578	Homo sapiens	IC50	nM	0.5
309625	17690261	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)nc23)CC1		CHEMBL3688338	=	IC50	nM	0.8	CHEMBL4578	Homo sapiens	IC50	nM	0.8
309626	17690262	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	IC50	nM	1.1	CHEMBL4578	Homo sapiens	IC50	nM	1.1
309627	17690263	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688340	=	IC50	nM	1.3	CHEMBL4578	Homo sapiens	IC50	nM	1.3
309628	17690264	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CN(C)C)CC4)c3n2)cc(Cl)c1O		CHEMBL3688341	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
309629	17690265	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CCN(C)C)CC1		CHEMBL3688342	=	IC50	nM	0.7	CHEMBL4578	Homo sapiens	IC50	nM	0.7
309630	17690266	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CCN(C)C)CC1		CHEMBL3688343	=	IC50	nM	1.4	CHEMBL4578	Homo sapiens	IC50	nM	1.4
309631	17690267	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc(O)c(OC(F)(F)F)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688344	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
309632	17690268	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)nc23)CC1		CHEMBL3688345	=	IC50	nM	1.0	CHEMBL4578	Homo sapiens	IC50	nM	1.0
309633	17690269	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)nc23)CC1		CHEMBL3688346	=	IC50	nM	1.4	CHEMBL4578	Homo sapiens	IC50	nM	1.4
309634	17690270	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(S(C)(=O)=O)c(N[C@H]4CC[C@H](CN(C)C)CC4)c3n2)cc(Cl)c1O		CHEMBL3688347	=	IC50	nM	0.9	CHEMBL4578	Homo sapiens	IC50	nM	0.9
309635	17690271	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)nc23)CC1		CHEMBL3688348	=	IC50	nM	0.5	CHEMBL4578	Homo sapiens	IC50	nM	0.5
309636	17690272	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)nc23)cc1		CHEMBL3688349	=	IC50	nM	2.8	CHEMBL4578	Homo sapiens	IC50	nM	2.8
309637	17690273	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)nc23)cc1		CHEMBL3688350	=	IC50	nM	8.1	CHEMBL4578	Homo sapiens	IC50	nM	8.1
309638	17690274	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(S(C)(=O)=O)c(Nc4ccc(CN(C)C)cc4)c3n2)cc(Cl)c1O		CHEMBL3688351	=	IC50	nM	5.0	CHEMBL4578	Homo sapiens	IC50	nM	5.0
309639	17690275	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1cccc(CCN2CCCC2)c1		CHEMBL3688352	=	IC50	nM	32.0	CHEMBL4578	Homo sapiens	IC50	nM	32.0
309640	17690276	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1Nc1cccc(CCN2CCCC2)c1		CHEMBL3688353	=	IC50	nM	140.0	CHEMBL4578	Homo sapiens	IC50	nM	140.0
309641	17690277	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(OCCN(C)C)nc1		CHEMBL3688354	=	IC50	nM	4.6	CHEMBL4578	Homo sapiens	IC50	nM	4.6
309642	17690278	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1Nc1ccc(OCCN(C)C)nc1		CHEMBL3688355	=	IC50	nM	15.0	CHEMBL4578	Homo sapiens	IC50	nM	15.0
309643	17690279	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4ccc(OCCN(C)C)nc4)c3n2)cc(Cl)c1O		CHEMBL3688356	=	IC50	nM	8.9	CHEMBL4578	Homo sapiens	IC50	nM	8.9
309644	17690280	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCOc1ccc(Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)nc23)cn1		CHEMBL3688357	=	IC50	nM	5.3	CHEMBL4578	Homo sapiens	IC50	nM	5.3
309645	17690281	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCOc1ccc(Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)nc23)cn1		CHEMBL3688358	=	IC50	nM	19.0	CHEMBL4578	Homo sapiens	IC50	nM	19.0
309646	17690282	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(S(C)(=O)=O)c(Nc4ccc(OCCN(C)C)nc4)c3n2)cc(Cl)c1O		CHEMBL3688359	=	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
309647	17690283	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1NCC1CCN(C)CC1		CHEMBL3688360	=	IC50	nM	0.7	CHEMBL4578	Homo sapiens	IC50	nM	0.7
309648	17690284	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(CCN(C)C)cc1		CHEMBL3688361	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
309649	17690285	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1Nc1ccc(CCN(C)C)cc1		CHEMBL3688362	=	IC50	nM	5.9	CHEMBL4578	Homo sapiens	IC50	nM	5.9
309650	17690286	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4ccc(CCN(C)C)cc4)c3n2)cc(Cl)c1O		CHEMBL3688363	=	IC50	nM	3.7	CHEMBL4578	Homo sapiens	IC50	nM	3.7
309651	17690287	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)nc23)CC1		CHEMBL3688364	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
309652	17690288	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1cnn(C2CCN(C)CC2)c1		CHEMBL3688365	=	IC50	nM	7.8	CHEMBL4578	Homo sapiens	IC50	nM	7.8
309653	17690289	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(CN2CCN(C)CC2)cc1		CHEMBL3688366	=	IC50	nM	6.1	CHEMBL4578	Homo sapiens	IC50	nM	6.1
309654	17690290	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1Nc1ccc(CN2CCN(C)CC2)cc1		CHEMBL3688367	=	IC50	nM	37.0	CHEMBL4578	Homo sapiens	IC50	nM	37.0
309655	17690291	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N1CCC(CCN2CCCC2)CC1		CHEMBL3688368	=	IC50	nM	2.1	CHEMBL4578	Homo sapiens	IC50	nM	2.1
309656	17690292	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N1CCC(CCN2CCCC2)CC1		CHEMBL3688369	=	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
309657	17690293	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(NCCN(C)C)nc1		CHEMBL3688370	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
309658	17690294	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1Nc1ccc(NCCN(C)C)nc1		CHEMBL3688371	=	IC50	nM	30.0	CHEMBL4578	Homo sapiens	IC50	nM	30.0
309659	17690295	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)nc34)cn2)C1		CHEMBL3688372	=	IC50	nM	1.2	CHEMBL4578	Homo sapiens	IC50	nM	1.2
309660	17690296	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1cnc(N2CCC(N)C2)nc1		CHEMBL3688373	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
309661	17690297	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cn[nH]c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688374	=	IC50	nM	17.0	CHEMBL4578	Homo sapiens	IC50	nM	17.0
309662	17690298	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CO)CC1		CHEMBL3688375	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
309663	17690299	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)CO)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)nc23)CC1		CHEMBL3688376	=	IC50	nM	0.3	CHEMBL4578	Homo sapiens	IC50	nM	0.3
309664	17690300	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1NC1CCN(C)CC1		CHEMBL3688377	=	IC50	nM	5.8	CHEMBL4578	Homo sapiens	IC50	nM	5.8
309665	17690301	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1NC1CCN(C)CC1		CHEMBL3688378	=	IC50	nM	6.1	CHEMBL4578	Homo sapiens	IC50	nM	6.1
309666	17690302	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN2CCOCC2)CC1		CHEMBL3688379	=	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
309667	17690303	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)CCO)CC1		CHEMBL3688380	=	IC50	nM	0.6	CHEMBL4578	Homo sapiens	IC50	nM	0.6
309668	17690304	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)CCO)CC1		CHEMBL3688381	=	IC50	nM	1.0	CHEMBL4578	Homo sapiens	IC50	nM	1.0
309669	17690305	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(F)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688382	=	IC50	nM	1.9	CHEMBL4578	Homo sapiens	IC50	nM	1.9
309670	17690306	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCC(N(C)C)C2)nc1		CHEMBL3688383	=	IC50	nM	8.2	CHEMBL4578	Homo sapiens	IC50	nM	8.2
309671	17690307	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCC(N(C)C)C2)nc1		CHEMBL3688384	=	IC50	nM	27.0	CHEMBL4578	Homo sapiens	IC50	nM	27.0
309672	17690308	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC1CCN(c2ccc(Nc3c(C(C)=O)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)nc34)cn2)C1		CHEMBL3688385	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
309673	17690309	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC1CCN(c2ccc(Nc3c(C(C)=O)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)nc34)cn2)C1		CHEMBL3688386	=	IC50	nM	12.0	CHEMBL4578	Homo sapiens	IC50	nM	12.0
309674	17690310	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc4[nH]cnc4c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688387	=	IC50	nM	17.0	CHEMBL4578	Homo sapiens	IC50	nM	17.0
309675	17690311	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccncc3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3692782	=	IC50	nM	16.0	CHEMBL4578	Homo sapiens	IC50	nM	16.0
309676	17690312	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cnc(C#N)nc3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3692783	=	IC50	nM	1.2	CHEMBL4578	Homo sapiens	IC50	nM	1.2
309677	17690313	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3c(C)n[nH]c3C)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3692784	=	IC50	nM	1000.0	CHEMBL4578	Homo sapiens	IC50	nM	1000.0
309678	17690314	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(C)c(O)c(C)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3692785	=	IC50	nM	4.7	CHEMBL4578	Homo sapiens	IC50	nM	4.7
309679	17690315	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(CN2CCCC2)cc1		CHEMBL3692786	=	IC50	nM	4.3	CHEMBL4578	Homo sapiens	IC50	nM	4.3
309680	17690316	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1		CHEMBL3692787	=	IC50	nM	0.4	CHEMBL4578	Homo sapiens	IC50	nM	0.4
309681	17690317	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1		CHEMBL3692788	=	IC50	nM	0.9	CHEMBL4578	Homo sapiens	IC50	nM	0.9
309682	17690318	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN2CCN(C)CC2)CC1		CHEMBL3692789	=	IC50	nM	0.8	CHEMBL4578	Homo sapiens	IC50	nM	0.8
309683	17690319	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCCC(N)C2)nc1		CHEMBL3692790	=	IC50	nM	1.2	CHEMBL4578	Homo sapiens	IC50	nM	1.2
309684	17690320	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCCC(N)C2)nc1		CHEMBL3692791	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
309685	17690321	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3692792	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
309686	17690322	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3692793	=	IC50	nM	1.2	CHEMBL4578	Homo sapiens	IC50	nM	1.2
309687	17690323	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN2CCN(C)CC2)CC1		CHEMBL3692794	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
309688	17690324	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](NC(=O)C(N)C(C)C)CC1		CHEMBL3692795	=	IC50	nM	1.2	CHEMBL4578	Homo sapiens	IC50	nM	1.2
309689	17690325	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN2CCNCC2)CC1		CHEMBL3692796	=	IC50	nM	0.6	CHEMBL4578	Homo sapiens	IC50	nM	0.6
309690	17690326	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCC[C@H](N)C2)nc1		CHEMBL3692797	=	IC50	nM	0.5	CHEMBL4578	Homo sapiens	IC50	nM	0.5
309691	17690327	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCC[C@H](N)C2)nc1		CHEMBL3692798	=	IC50	nM	4.3	CHEMBL4578	Homo sapiens	IC50	nM	4.3
309692	17690328	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](NC(=O)C(C)N)CC1		CHEMBL3692799	=	IC50	nM	7.5	CHEMBL4578	Homo sapiens	IC50	nM	7.5
309693	17690329	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](NC(=O)C(C)N)CC1		CHEMBL3692800	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
309694	17690330	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](NC(=O)[C@@H]2CCCN2)CC1		CHEMBL3692801	=	IC50	nM	1.0	CHEMBL4578	Homo sapiens	IC50	nM	1.0
309695	17690331	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](NC(=O)[C@@H]2CCCN2)CC1		CHEMBL3692802	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
309696	17690332	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(N3CCC(O)C3)nc2c1N[C@H]1CC[C@H](CN2CCC(O)C2)CC1		CHEMBL3692803	=	IC50	nM	740.0	CHEMBL4578	Homo sapiens	IC50	nM	740.0
309697	17690333	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(N3CCCC3)nc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1		CHEMBL3692804	=	IC50	nM	2000.0	CHEMBL4578	Homo sapiens	IC50	nM	2000.0
309698	17690334	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](NC(=O)C(N)C(C)C)CC1		CHEMBL3692805	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
309699	17690335	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)nc23)CC1		CHEMBL3692806	=	IC50	nM	0.6	CHEMBL4578	Homo sapiens	IC50	nM	0.6
309700	17690336	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)nc23)CC1		CHEMBL3692807	=	IC50	nM	0.5	CHEMBL4578	Homo sapiens	IC50	nM	0.5
309701	17690337	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cnc4[nH]ccc4c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3692808	=	IC50	nM	13.0	CHEMBL4578	Homo sapiens	IC50	nM	13.0
309702	17690338	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)nc34)cn2)C1		CHEMBL3692809	=	IC50	nM	1.0	CHEMBL4578	Homo sapiens	IC50	nM	1.0
309703	17690339	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CN(C)C)CC4)c3n2)cc1		CHEMBL3692810	=	IC50	nM	31.0	CHEMBL4578	Homo sapiens	IC50	nM	31.0
309704	17690340	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1c(Cl)cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CN(C)C)CC4)c3n2)cc1Cl		CHEMBL3692811	=	IC50	nM	120.0	CHEMBL4578	Homo sapiens	IC50	nM	120.0
309705	17690341	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc(O)nc3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3692812	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
309706	17690342	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc(C#N)nc3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3692813	=	IC50	nM	4.5	CHEMBL4578	Homo sapiens	IC50	nM	4.5
309707	17690343	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc(O)cc3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3692814	=	IC50	nM	4.5	CHEMBL4578	Homo sapiens	IC50	nM	4.5
309708	17690344	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1NC[C@H]1CC[C@H](N(C)C)CC1		CHEMBL3692815	=	IC50	nM	0.6	CHEMBL4578	Homo sapiens	IC50	nM	0.6
309709	17690345	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1NC[C@H]1CC[C@H](N(C)C)CC1		CHEMBL3692816	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
309710	17690346	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](O)CC1		CHEMBL3692817	=	IC50	nM	15.0	CHEMBL4578	Homo sapiens	IC50	nM	15.0
309711	17690347	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](O)CC1		CHEMBL3692818	=	IC50	nM	12.0	CHEMBL4578	Homo sapiens	IC50	nM	12.0
309712	17690348	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@@H](CN(C)C)CC1		CHEMBL3692819	=	IC50	nM	1.1	CHEMBL4578	Homo sapiens	IC50	nM	1.1
309713	17690349	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@@H](CN(C)C)CC1		CHEMBL3692820	=	IC50	nM	0.6	CHEMBL4578	Homo sapiens	IC50	nM	0.6
309714	17690350	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCC[C@@H](N)C2)nc1		CHEMBL3692821	=	IC50	nM	2.0	CHEMBL4578	Homo sapiens	IC50	nM	2.0
309715	17690351	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCC[C@@H](N)C2)nc1		CHEMBL3692822	=	IC50	nM	3.6	CHEMBL4578	Homo sapiens	IC50	nM	3.6
309716	17690352	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@@H]1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)nc34)cn2)C1		CHEMBL3692823	=	IC50	nM	0.93	CHEMBL4578	Homo sapiens	IC50	nM	0.93
309717	17690353	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@@H]1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)nc34)cn2)C1		CHEMBL3692824	=	IC50	nM	0.46	CHEMBL4578	Homo sapiens	IC50	nM	0.46
309718	17690354	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](Nc2c(C(=O)CO)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)nc23)CC1		CHEMBL3692825	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
309719	17690355	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)CO)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)nc23)CC1		CHEMBL3692826	=	IC50	nM	1.3	CHEMBL4578	Homo sapiens	IC50	nM	1.3
309720	17690356	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3692827	=	IC50	nM	2.8	CHEMBL4578	Homo sapiens	IC50	nM	2.8
309721	17690357	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3692828	=	IC50	nM	1.3	CHEMBL4578	Homo sapiens	IC50	nM	1.3
309722	17690358	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCC[C@H](N)C2)nc1		CHEMBL3692829	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
309723	17690359	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCC[C@H](N)C2)nc1		CHEMBL3692830	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
309724	17690360	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN2CC[C@@H](F)C2)CC1		CHEMBL3692831	=	IC50	nM	2.0	CHEMBL4578	Homo sapiens	IC50	nM	2.0
309725	17690361	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CCCN(c2ccc(Nc3c(C(=O)C4CCC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)nc34)cn2)C1		CHEMBL3692832	=	IC50	nM	1.4	CHEMBL4578	Homo sapiens	IC50	nM	1.4
309726	17690362	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)C3CCC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)nc23)CC1		CHEMBL3692833	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
309727	17690363	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)C3CCC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)nc23)CC1		CHEMBL3692834	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
309728	17690364	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCC[C@@H](N)C2)nc1		CHEMBL3692835	=	IC50	nM	1.1	CHEMBL4578	Homo sapiens	IC50	nM	1.1
309729	17690365	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCC[C@@H](N)C2)nc1		CHEMBL3692836	=	IC50	nM	1.3	CHEMBL4578	Homo sapiens	IC50	nM	1.3
309730	17690366	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(N2CCC[C@@H](N)C2)nc1		CHEMBL3692837	=	IC50	nM	6.5	CHEMBL4578	Homo sapiens	IC50	nM	6.5
309731	17690367	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3692838	=	IC50	nM	1.9	CHEMBL4578	Homo sapiens	IC50	nM	1.9
309732	17690368	CHEMBL3706362	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3692839	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
322629	17701666	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4ccc(O)cc4)cc23)CC1		CHEMBL3674154	=	IC50	nM	21.0	CHEMBL4578	Homo sapiens	IC50	nM	21.0
322630	17701667	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](N)CC4)c3c2)ccc1O		CHEMBL3674155	=	IC50	nM	7.0	CHEMBL4578	Homo sapiens	IC50	nM	7.0
322631	17701668	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N#Cc1ncc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](N)CC4)c3c2)cn1		CHEMBL3674156	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
322632	17701669	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3ccc(C#N)nc3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674157	=	IC50	nM	30.0	CHEMBL4578	Homo sapiens	IC50	nM	30.0
322633	17701670	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4ccc5[nH]cnc5c4)cc23)CC1		CHEMBL3674158	=	IC50	nM	18.0	CHEMBL4578	Homo sapiens	IC50	nM	18.0
322634	17701671	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N#Cc1ccc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](N)CC4)c3c2)s1		CHEMBL3674159	=	IC50	nM	46.0	CHEMBL4578	Homo sapiens	IC50	nM	46.0
322635	17701672	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC(CN(C)C)CC4)c3c2)ccc1O		CHEMBL3674160	=	IC50	nM	3.6	CHEMBL4578	Homo sapiens	IC50	nM	3.6
322636	17701673	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC5(CCNC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3674161	=	IC50	nM	4.0	CHEMBL4578	Homo sapiens	IC50	nM	4.0
322637	17701674	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(F)c4)cc23)CC1		CHEMBL3639730	=	IC50	nM	23.0	CHEMBL4578	Homo sapiens	IC50	nM	23.0
322638	17701675	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674162	=	IC50	nM	7.6	CHEMBL4578	Homo sapiens	IC50	nM	7.6
322639	17701676	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674162	=	IC50	nM	3.0	CHEMBL4578	Homo sapiens	IC50	nM	3.0
322640	17701677	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)cc4Cl)cc23)CC1		CHEMBL3674163	=	IC50	nM	72.0	CHEMBL4578	Homo sapiens	IC50	nM	72.0
322641	17701678	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@@H](N)CC4)c3c2)ccc1O		CHEMBL3674164	=	IC50	nM	1.9	CHEMBL4578	Homo sapiens	IC50	nM	1.9
322642	17701679	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NC4CCN(C)CC4)c3c2)ccc1O		CHEMBL3674165	=	IC50	nM	26.0	CHEMBL4578	Homo sapiens	IC50	nM	26.0
322643	17701680	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674166	=	IC50	nM	6.5	CHEMBL4578	Homo sapiens	IC50	nM	6.5
322644	17701681	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(F)c4)cc23)CC1		CHEMBL3674167	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
322645	17701682	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(F)c4)cc23)CC1)N(C)C		CHEMBL3674168	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
322646	17701683	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C1CCC(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(OC)c4)cc23)CC1		CHEMBL3674169	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
322647	17701684	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C1CCC(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(OC)c4)cc23)CC1		CHEMBL3674169	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
322648	17701685	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC(C(C)N(C)C)CC4)c3c2)ccc1O		CHEMBL3674170	=	IC50	nM	3.4	CHEMBL4578	Homo sapiens	IC50	nM	3.4
322649	17701686	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C1CCC(Nc2c(C(=O)C3CC3)cnc3ccc(-c4ccc(O)c(Cl)c4)cc23)CC1		CHEMBL3674171	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
322650	17701687	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C1CCC(Nc2c(C(=O)C3CC3)cnc3ccc(-c4ccc(O)c(OC)c4)cc23)CC1		CHEMBL3674172	=	IC50	nM	7.0	CHEMBL4578	Homo sapiens	IC50	nM	7.0
322651	17701688	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NCC4CCN(C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674173	=	IC50	nM	3.4	CHEMBL4578	Homo sapiens	IC50	nM	3.4
322652	17701689	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674174	=	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
322653	17701690	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4ccncc4)cc23)CC1		CHEMBL3674175	=	IC50	nM	54.0	CHEMBL4578	Homo sapiens	IC50	nM	54.0
322654	17701691	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cn[nH]c4)cc23)CC1		CHEMBL3674176	=	IC50	nM	67.0	CHEMBL4578	Homo sapiens	IC50	nM	67.0
322655	17701692	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(F)c(O)c(F)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674177	=	IC50	nM	43.0	CHEMBL4578	Homo sapiens	IC50	nM	43.0
322656	17701693	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3ccc(O)c(Cl)c3)cc2c1NCCN1CCNCC1)C1CC1		CHEMBL3674178	=	IC50	nM	17.0	CHEMBL4578	Homo sapiens	IC50	nM	17.0
322657	17701694	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3ccc(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674179	=	IC50	nM	23.0	CHEMBL4578	Homo sapiens	IC50	nM	23.0
322658	17701695	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674180	=	IC50	nM	2.5	CHEMBL4578	Homo sapiens	IC50	nM	2.5
322659	17701696	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674180	=	IC50	nM	2.8	CHEMBL4578	Homo sapiens	IC50	nM	2.8
322660	17701697	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C1CCC(Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(Cl)c(O)c(OC)c4)cc23)CC1		CHEMBL3674181	=	IC50	nM	5.3	CHEMBL4578	Homo sapiens	IC50	nM	5.3
322661	17701698	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NCC4CCNCC4)c3c2)cc(Cl)c1O		CHEMBL3674182	=	IC50	nM	4.4	CHEMBL4578	Homo sapiens	IC50	nM	4.4
322662	17701699	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(S(C)(=O)=O)c(N4CCC(C(C)N(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674183	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
322663	17701700	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C1CCN(c2c(S(C)(=O)=O)cnc3ccc(-c4ccc(O)c(Cl)c4)cc23)CC1)N(C)C		CHEMBL3674184	=	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
322664	17701701	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NC4CCN(C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674185	=	IC50	nM	7.9	CHEMBL4578	Homo sapiens	IC50	nM	7.9
322665	17701702	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC(C(C)N(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674186	=	IC50	nM	1.3	CHEMBL4578	Homo sapiens	IC50	nM	1.3
322666	17701703	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](N(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674187	=	IC50	nM	1.9	CHEMBL4578	Homo sapiens	IC50	nM	1.9
322667	17701704	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674188	=	IC50	nM	4.1	CHEMBL4578	Homo sapiens	IC50	nM	4.1
322668	17701705	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(F)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674189	=	IC50	nM	40.0	CHEMBL4578	Homo sapiens	IC50	nM	40.0
322669	17701706	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](N)CC4)c3c2)cc(Cl)c1O		CHEMBL3674190	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
322670	17701707	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)CC(C)C)c(N[C@H]4CC[C@H](N)CC4)c3c2)cc(Cl)c1O		CHEMBL3674191	=	IC50	nM	5.0	CHEMBL4578	Homo sapiens	IC50	nM	5.0
322671	17701708	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674192	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
322672	17701709	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](N(C)C)CC4)c3c2)ccc1O		CHEMBL3674194	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
322673	17701710	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674195	=	IC50	nM	2.2	CHEMBL4578	Homo sapiens	IC50	nM	2.2
322674	17701711	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1)N(C)C		CHEMBL3674196	=	IC50	nM	3.7	CHEMBL4578	Homo sapiens	IC50	nM	3.7
322675	17701712	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCC(CNc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674197	=	IC50	nM	21.0	CHEMBL4578	Homo sapiens	IC50	nM	21.0
322676	17701713	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC(CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674198	=	IC50	nM	0.8	CHEMBL4578	Homo sapiens	IC50	nM	0.8
322677	17701714	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4ccc(O)c(Cl)c4)cc23)CC1		CHEMBL3674199	=	IC50	nM	4.6	CHEMBL4578	Homo sapiens	IC50	nM	4.6
322678	17701715	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC(CN5CCCC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3674200	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
322679	17701716	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N1CCC(CN2CCCC2)CC1)C1CC1		CHEMBL3674201	=	IC50	nM	2.9	CHEMBL4578	Homo sapiens	IC50	nM	2.9
322680	17701717	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2cc3c(N[C@H]4CC[C@H](N)CC4)c(C(=O)C4CC4)cnc3cc2F)cc(Cl)c1O		CHEMBL3674202	=	IC50	nM	13.0	CHEMBL4578	Homo sapiens	IC50	nM	13.0
322681	17701718	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3cc(F)c(-c4cc(F)c(O)c(F)c4)cc23)CC1		CHEMBL3674203	=	IC50	nM	42.0	CHEMBL4578	Homo sapiens	IC50	nM	42.0
322682	17701719	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3cc(F)c(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674204	=	IC50	nM	27.0	CHEMBL4578	Homo sapiens	IC50	nM	27.0
322683	17701720	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C1CCC(Nc2c(C(C)=O)cnc3ccc(-c4cc(Cl)c(O)c(OC)c4)cc23)CC1		CHEMBL3674205	=	IC50	nM	6.1	CHEMBL4578	Homo sapiens	IC50	nM	6.1
322684	17701721	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N4CCC(CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674206	=	IC50	nM	2.2	CHEMBL4578	Homo sapiens	IC50	nM	2.2
322685	17701722	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC(CN5CCCC5)CC4)c3c2)cc(F)c1O		CHEMBL3674207	=	IC50	nM	4.1	CHEMBL4578	Homo sapiens	IC50	nM	4.1
322686	17701723	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NC45CC6CC(CC(N)(C6)C4)C5)c3c2)cc(Cl)c1O		CHEMBL3674208	=	IC50	nM	8.7	CHEMBL4578	Homo sapiens	IC50	nM	8.7
322687	17701724	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)[C@H]1CC[C@@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(OC)c4)cc23)CC1		CHEMBL3674209	=	IC50	nM	3.2	CHEMBL4578	Homo sapiens	IC50	nM	3.2
322688	17701725	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3ccc(O)c(OC(F)(F)F)c3)cc2c1N1CCC(CN2CCCC2)CC1)C1CC1		CHEMBL3674210	=	IC50	nM	12.0	CHEMBL4578	Homo sapiens	IC50	nM	12.0
322689	17701726	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(OC)c4)cc23)CC1		CHEMBL3674211	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
322690	17701727	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NC[C@H]4CC[C@H](N(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674212	=	IC50	nM	4.3	CHEMBL4578	Homo sapiens	IC50	nM	4.3
322691	17701728	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674213	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
322692	17701729	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3ccc(O)c(Cl)c3)cc2c1N1CCC(CN2CCCC2)CC1		CHEMBL3674214	=	IC50	nM	20.0	CHEMBL4578	Homo sapiens	IC50	nM	20.0
322693	17701730	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N4CCC(CN5CCCC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3674215	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
322694	17701731	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N1CCC(CN2CCCC2)CC1		CHEMBL3674216	=	IC50	nM	13.0	CHEMBL4578	Homo sapiens	IC50	nM	13.0
322695	17701732	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](CNc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674218	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
322696	17701733	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](CNc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674219	=	IC50	nM	5.5	CHEMBL4578	Homo sapiens	IC50	nM	5.5
322697	17701734	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3ccc(O)c(Cl)c3)cc2c1N1CCC(CN2CCOCC2)CC1)C1CC1		CHEMBL3674220	=	IC50	nM	35.0	CHEMBL4578	Homo sapiens	IC50	nM	35.0
322698	17701735	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC(CN5CCOCC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3674221	=	IC50	nM	8.1	CHEMBL4578	Homo sapiens	IC50	nM	8.1
322699	17701736	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C1CCC(Nc2c(C(C)=O)cnc3ccc(-c4ccc(O)c(Cl)c4)cc23)CC1		CHEMBL3674222	=	IC50	nM	21.0	CHEMBL4578	Homo sapiens	IC50	nM	21.0
322700	17701737	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N1CCC(CN2CCCC2)CC1		CHEMBL3674223	=	IC50	nM	6.9	CHEMBL4578	Homo sapiens	IC50	nM	6.9
322701	17701738	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(CN(C)C)cc4)c3c2)cc(Cl)c1O		CHEMBL3674224	=	IC50	nM	4.0	CHEMBL4578	Homo sapiens	IC50	nM	4.0
322702	17701739	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3ccc(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N2CCCC2)CC1)C1CC1		CHEMBL3674225	=	IC50	nM	4.6	CHEMBL4578	Homo sapiens	IC50	nM	4.6
322703	17701740	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](N5CCCC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3674226	=	IC50	nM	2.1	CHEMBL4578	Homo sapiens	IC50	nM	2.1
322704	17701741	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674227	=	IC50	nM	3.2	CHEMBL4578	Homo sapiens	IC50	nM	3.2
322705	17701742	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674228	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
322706	17701743	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)CC(C)C)c(N[C@H]4CC[C@H](N(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674229	=	IC50	nM	4.3	CHEMBL4578	Homo sapiens	IC50	nM	4.3
322707	17701744	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(C2CCN(c3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)CC2)CC1		CHEMBL3674230	=	IC50	nM	4.6	CHEMBL4578	Homo sapiens	IC50	nM	4.6
322708	17701745	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(C2CCN(c3c(C(=O)C4CC4)cnc4ccc(-c5ccc(O)c(Cl)c5)cc34)CC2)CC1		CHEMBL3674231	=	IC50	nM	5.0	CHEMBL4578	Homo sapiens	IC50	nM	5.0
322709	17701746	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC(N5CCN(C)CC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3674232	=	IC50	nM	2.2	CHEMBL4578	Homo sapiens	IC50	nM	2.2
322710	17701747	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCOc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC(CN(C)C)CC4)c3c2)ccc1O		CHEMBL3674233	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
322711	17701748	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(-c4ccc(CN(C)C)cc4)c3c2)cc(Cl)c1O		CHEMBL3674234	=	IC50	nM	4.2	CHEMBL4578	Homo sapiens	IC50	nM	4.2
322712	17701749	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c(C(=O)C3CCCC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674239	=	IC50	nM	4.6	CHEMBL4578	Homo sapiens	IC50	nM	4.6
322713	17701750	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C1CCC(Nc2c(C(=O)C3CCCC3)cnc3ccc(-c4ccc(O)c(Cl)c4)cc23)CC1		CHEMBL3674240	=	IC50	nM	19.0	CHEMBL4578	Homo sapiens	IC50	nM	19.0
322714	17701751	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C1CCC(Nc2c(C(=O)C3CCCC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674241	=	IC50	nM	9.2	CHEMBL4578	Homo sapiens	IC50	nM	9.2
322715	17701752	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(C(=O)C3CCCC3)cnc3ccc(-c4ccc(O)c(Cl)c4)cc23)cc1		CHEMBL3674242	=	IC50	nM	89.0	CHEMBL4578	Homo sapiens	IC50	nM	89.0
322716	17701753	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(C(=O)C3CCCC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674243	=	IC50	nM	14.0	CHEMBL4578	Homo sapiens	IC50	nM	14.0
322717	17701754	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c(C(=O)C3CCCC3)cnc3ccc(-c4ccc(O)c(Cl)c4)cc23)CC1		CHEMBL3674244	=	IC50	nM	31.0	CHEMBL4578	Homo sapiens	IC50	nM	31.0
322718	17701755	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(C(=O)CNc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674245	=	IC50	nM	25.0	CHEMBL4578	Homo sapiens	IC50	nM	25.0
322719	17701756	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4ccc(CN(C)C)cc4)c3c2)cc(Cl)c1O		CHEMBL3674246	=	IC50	nM	3.7	CHEMBL4578	Homo sapiens	IC50	nM	3.7
322720	17701757	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674247	=	IC50	nM	3.4	CHEMBL4578	Homo sapiens	IC50	nM	3.4
322721	17701758	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(C(=O)CNc2c(C(=O)C3CC3)cnc3ccc(-c4ccc(O)c(Cl)c4)cc23)CC1		CHEMBL3674248	=	IC50	nM	95.0	CHEMBL4578	Homo sapiens	IC50	nM	95.0
322722	17701759	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCN(CCN5CCCC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3674249	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
322723	17701760	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NCC(=O)N4CCN(C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674250	=	IC50	nM	1000.0	CHEMBL4578	Homo sapiens	IC50	nM	1000.0
322724	17701761	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(CN2CCCC2)cc1)C1CC1		CHEMBL3674251	=	IC50	nM	8.8	CHEMBL4578	Homo sapiens	IC50	nM	8.8
322725	17701762	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(Cc2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cc2)CC1		CHEMBL3674252	=	IC50	nM	7.6	CHEMBL4578	Homo sapiens	IC50	nM	7.6
322726	17701763	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(CN5CCN(C)CC5)cc4)c3c2)cc(Cl)c1O		CHEMBL3674253	=	IC50	nM	8.4	CHEMBL4578	Homo sapiens	IC50	nM	8.4
322727	17701764	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674254	=	IC50	nM	16.0	CHEMBL4578	Homo sapiens	IC50	nM	16.0
322728	17701765	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674255	=	IC50	nM	3.4	CHEMBL4578	Homo sapiens	IC50	nM	3.4
322729	17701766	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674255	=	IC50	nM	5.5	CHEMBL4578	Homo sapiens	IC50	nM	5.5
322730	17701767	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N1CCN(CCN2CCCC2)CC1)C1CC1		CHEMBL3674256	=	IC50	nM	5.8	CHEMBL4578	Homo sapiens	IC50	nM	5.8
322731	17701768	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3ccc(O)c(Cl)c3)cc2c1N1CCN(CCN2CCCC2)CC1)C1CC1		CHEMBL3674257	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
322732	17701769	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(N5CCNCC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3674258	=	IC50	nM	3.8	CHEMBL4578	Homo sapiens	IC50	nM	3.8
322733	17701770	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(CN5CCN(C)CC5)cc4)c3c2)ccc1O		CHEMBL3674259	=	IC50	nM	17.0	CHEMBL4578	Homo sapiens	IC50	nM	17.0
322734	17701771	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(Cc2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5ccc(O)c(Cl)c5)cc34)cc2)CC1		CHEMBL3674260	=	IC50	nM	19.0	CHEMBL4578	Homo sapiens	IC50	nM	19.0
322735	17701772	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CS(=O)(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N1CCC(CN2CCCC2)CC1		CHEMBL3639731	=	IC50	nM	5.1	CHEMBL4578	Homo sapiens	IC50	nM	5.1
322736	17701773	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CS(=O)(=O)c1cnc2ccc(-c3ccc(O)c(Cl)c3)cc2c1N1CCC(CN2CCCC2)CC1		CHEMBL3674261	=	IC50	nM	9.0	CHEMBL4578	Homo sapiens	IC50	nM	9.0
322737	17701774	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCNCC2)nc1)C1CC1		CHEMBL3674262	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
322738	17701775	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(S(C)(=O)=O)c(Nc4ccc(CN(C)C)cc4)c3c2)cc(Cl)c1O		CHEMBL3674263	=	IC50	nM	6.8	CHEMBL4578	Homo sapiens	IC50	nM	6.8
322739	17701776	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(S(C)(=O)=O)cnc3ccc(-c4ccc(O)c(Cl)c4)cc23)cc1		CHEMBL3674264	=	IC50	nM	9.1	CHEMBL4578	Homo sapiens	IC50	nM	9.1
322740	17701777	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(S(C)(=O)=O)c(N4CCC(CN5CCCC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3674265	=	IC50	nM	2.0	CHEMBL4578	Homo sapiens	IC50	nM	2.0
322741	17701778	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cnc(C#N)nc3)cc2c1Nc1ccc(CN2CCCC2)cc1		CHEMBL3674266	=	IC50	nM	2.9	CHEMBL4578	Homo sapiens	IC50	nM	2.9
322742	17701779	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cnc(C#N)nc3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3674267	=	IC50	nM	2.2	CHEMBL4578	Homo sapiens	IC50	nM	2.2
322743	17701780	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN2CCCC2)cc1		CHEMBL3674268	=	IC50	nM	35.0	CHEMBL4578	Homo sapiens	IC50	nM	35.0
322744	17701781	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN2CCCC2)cc1		CHEMBL3674268	=	IC50	nM	3.2	CHEMBL4578	Homo sapiens	IC50	nM	3.2
322745	17701782	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)nc1		CHEMBL3674269	=	IC50	nM	9.9	CHEMBL4578	Homo sapiens	IC50	nM	9.9
322746	17701783	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cnc(C#N)nc3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3674270	=	IC50	nM	7.3	CHEMBL4578	Homo sapiens	IC50	nM	7.3
322747	17701784	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4ccc(CN5CCCC5)cc4)c3c2)cc(Cl)c1O		CHEMBL3674271	=	IC50	nM	5.9	CHEMBL4578	Homo sapiens	IC50	nM	5.9
322748	17701785	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674272	=	IC50	nM	2.3	CHEMBL4578	Homo sapiens	IC50	nM	2.3
322749	17701786	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674272	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
322750	17701787	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(S(C)(=O)=O)c(N[C@H]4CC[C@H](CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674273	=	IC50	nM	4.1	CHEMBL4578	Homo sapiens	IC50	nM	4.1
322751	17701788	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674274	=	IC50	nM	6.3	CHEMBL4578	Homo sapiens	IC50	nM	6.3
322752	17701789	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(S(C)(=O)=O)cnc3ccc(-c4ccc(O)c(Cl)c4)cc23)CC1		CHEMBL3674275	=	IC50	nM	13.0	CHEMBL4578	Homo sapiens	IC50	nM	13.0
322753	17701790	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCNCC2)nc1)C1CC1		CHEMBL3674276	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
322754	17701791	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cnc(C#N)nc4)cc23)CC1		CHEMBL3674277	=	IC50	nM	2.5	CHEMBL4578	Homo sapiens	IC50	nM	2.5
322755	17701792	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3ccc(O)c(Cl)c3)cc2c1Nc1ccc(N2CCNCC2)nc1)C1CC1		CHEMBL3674278	=	IC50	nM	6.2	CHEMBL4578	Homo sapiens	IC50	nM	6.2
322756	17701793	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C#N)c(N4CCC(CN5CCCC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3674279	=	IC50	nM	3.7	CHEMBL4578	Homo sapiens	IC50	nM	3.7
322757	17701794	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(CN(C)C)cn4)c3c2)cc(Cl)c1O		CHEMBL3674280	=	IC50	nM	19.0	CHEMBL4578	Homo sapiens	IC50	nM	19.0
322758	17701795	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(c2ccc(-c3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cc2)CC1		CHEMBL3674281	=	IC50	nM	33.0	CHEMBL4578	Homo sapiens	IC50	nM	33.0
322759	17701796	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(-c2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674282	=	IC50	nM	3.9	CHEMBL4578	Homo sapiens	IC50	nM	3.9
322760	17701797	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(C#N)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674283	=	IC50	nM	56.0	CHEMBL4578	Homo sapiens	IC50	nM	56.0
322761	17701798	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N#Cc1cnc2ccc(-c3ccc(O)c(Cl)c3)cc2c1N1CCC(CN2CCCC2)CC1		CHEMBL3674284	=	IC50	nM	43.0	CHEMBL4578	Homo sapiens	IC50	nM	43.0
322762	17701799	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N#Cc1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N1CCC(CN2CCCC2)CC1		CHEMBL3674285	=	IC50	nM	35.0	CHEMBL4578	Homo sapiens	IC50	nM	35.0
322763	17701800	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)nc1		CHEMBL3674286	=	IC50	nM	49.0	CHEMBL4578	Homo sapiens	IC50	nM	49.0
322764	17701801	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(-c4ccc(CN5CCCC5)cc4)c3c2)cc(Cl)c1O		CHEMBL3674287	=	IC50	nM	14.0	CHEMBL4578	Homo sapiens	IC50	nM	14.0
322765	17701802	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCN(C(=O)CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674288	=	IC50	nM	1.1	CHEMBL4578	Homo sapiens	IC50	nM	1.1
322766	17701803	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(-c4ccc(N5CCN(C)CC5)cc4)c3c2)cc(Cl)c1O		CHEMBL3674289	=	IC50	nM	18.0	CHEMBL4578	Homo sapiens	IC50	nM	18.0
322767	17701804	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cnc(C#N)nc4)cc23)nc1		CHEMBL3674290	=	IC50	nM	58.0	CHEMBL4578	Homo sapiens	IC50	nM	58.0
322768	17701805	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N1CCN(CCN2CCCC2)C(=O)C1)C1CC1		CHEMBL3674291	=	IC50	nM	4.4	CHEMBL4578	Homo sapiens	IC50	nM	4.4
322769	17701806	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC(=O)N1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4ccc(O)c(Cl)c4)cc23)CC1		CHEMBL3674292	=	IC50	nM	4.0	CHEMBL4578	Homo sapiens	IC50	nM	4.0
322770	17701807	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC(=O)N1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674293	=	IC50	nM	3.5	CHEMBL4578	Homo sapiens	IC50	nM	3.5
322771	17701808	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCCC1c1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)nc1		CHEMBL3674294	=	IC50	nM	43.0	CHEMBL4578	Homo sapiens	IC50	nM	43.0
322772	17701809	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(C5CCCN5C)cn4)c3c2)cc(Cl)c1O		CHEMBL3674295	=	IC50	nM	36.0	CHEMBL4578	Homo sapiens	IC50	nM	36.0
322773	17701810	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCCC1c1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)nc1		CHEMBL3674296	=	IC50	nM	22.0	CHEMBL4578	Homo sapiens	IC50	nM	22.0
322774	17701811	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](Nc2c(C#N)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674297	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
322775	17701812	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C#N)c(N[C@H]4CC[C@H](N(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674298	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
322776	17701813	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(Cl)cc1-c1ccc2ncc(C(=O)C3CC3)c(N3CCC(CN(C)C)CC3)c2c1		CHEMBL3674299	=	IC50	nM	60.0	CHEMBL4578	Homo sapiens	IC50	nM	60.0
322777	17701814	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4ccc5cc(O)ccc5c4)cc23)CC1		CHEMBL3674300	=	IC50	nM	14.0	CHEMBL4578	Homo sapiens	IC50	nM	14.0
322778	17701815	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1-c1ccc(NCCN2CCOCC2)nc1)C1CC1		CHEMBL3674301	=	IC50	nM	18.0	CHEMBL4578	Homo sapiens	IC50	nM	18.0
322779	17701816	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCNC(=O)c1ccc(-c2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674302	=	IC50	nM	2.5	CHEMBL4578	Homo sapiens	IC50	nM	2.5
322780	17701817	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1-c1ccc(CN2CCCC2)cc1)C1CC1		CHEMBL3674303	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
322781	17701818	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4ccc5[nH]ccc5c4)cc23)CC1		CHEMBL3674304	=	IC50	nM	94.0	CHEMBL4578	Homo sapiens	IC50	nM	94.0
322782	17701819	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4ccc(O)c(C(F)(F)F)c4)cc23)CC1		CHEMBL3674305	=	IC50	nM	14.0	CHEMBL4578	Homo sapiens	IC50	nM	14.0
322783	17701820	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC(=O)N1CC2CC1CN2c1c(C(=O)C2CC2)cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc12		CHEMBL3674306	=	IC50	nM	69.0	CHEMBL4578	Homo sapiens	IC50	nM	69.0
322784	17701821	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CC5CC4CN5C(=O)CN(C)C)c3c2)cc(F)c1O		CHEMBL3674307	=	IC50	nM	7.8	CHEMBL4578	Homo sapiens	IC50	nM	7.8
322785	17701822	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCOc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC(CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674308	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
322786	17701823	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4ccc(OC(F)F)cc4)cc23)CC1		CHEMBL3674309	=	IC50	nM	630.0	CHEMBL4578	Homo sapiens	IC50	nM	630.0
322787	17701824	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1-c1ccc(N2CCNCC2)nc1)C1CC1		CHEMBL3674310	=	IC50	nM	9.1	CHEMBL4578	Homo sapiens	IC50	nM	9.1
322788	17701825	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(CN2CCOCC2)cc1)C1CC1		CHEMBL3674311	=	IC50	nM	83.0	CHEMBL4578	Homo sapiens	IC50	nM	83.0
322789	17701826	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N#Cc1ncc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(CN5CCOCC5)cc4)c3c2)cn1		CHEMBL3674312	=	IC50	nM	15.0	CHEMBL4578	Homo sapiens	IC50	nM	15.0
322790	17701827	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(CN5CCOCC5)cc4)c3c2)cc(Cl)c1O		CHEMBL3674313	=	IC50	nM	66.0	CHEMBL4578	Homo sapiens	IC50	nM	66.0
322791	17701828	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN2CCOCC2)cc1)C1CC1		CHEMBL3674314	=	IC50	nM	20.0	CHEMBL4578	Homo sapiens	IC50	nM	20.0
322792	17701829	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC(=O)N1CC2CC1CN2c1c(C(=O)C2CC2)cnc2ccc(-c3ccc(O)c(Cl)c3)cc12		CHEMBL3674315	=	IC50	nM	51.0	CHEMBL4578	Homo sapiens	IC50	nM	51.0
322793	17701830	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4ccc(C(F)F)cc4)cc23)CC1		CHEMBL3674316	=	IC50	nM	910.0	CHEMBL4578	Homo sapiens	IC50	nM	910.0
322794	17701831	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c([S+](C)[O-])cnc3ccc(-c4ccc(O)c(Cl)c4)cc23)CC1		CHEMBL3674317	=	IC50	nM	16.0	CHEMBL4578	Homo sapiens	IC50	nM	16.0
322795	17701832	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c([S+](C)[O-])cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674318	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
322796	17701833	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc([S+](C)[O-])c(N4CCC(CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674319	=	IC50	nM	5.1	CHEMBL4578	Homo sapiens	IC50	nM	5.1
322797	17701834	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cnc(C#N)nc5)cc34)cn2)CC1		CHEMBL3674320	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
322798	17701835	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(N5CCN(C)CC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3674321	=	IC50	nM	15.0	CHEMBL4578	Homo sapiens	IC50	nM	15.0
322799	17701836	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3674322	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
322800	17701837	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3674323	=	IC50	nM	23.0	CHEMBL4578	Homo sapiens	IC50	nM	23.0
322801	17701838	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c([S+](C)[O-])cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674324	=	IC50	nM	8.2	CHEMBL4578	Homo sapiens	IC50	nM	8.2
322802	17701839	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4ccc5c(c4)CC(=O)N5)cc23)CC1		CHEMBL3674325	=	IC50	nM	660.0	CHEMBL4578	Homo sapiens	IC50	nM	660.0
322803	17701840	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(-c4cnc(N5CCN(C)CC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3674326	=	IC50	nM	72.0	CHEMBL4578	Homo sapiens	IC50	nM	72.0
322804	17701841	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(-c4ccc(C(=O)N5CCN(C)CC5)cc4)c3c2)cc(Cl)c1O		CHEMBL3674327	=	IC50	nM	8.1	CHEMBL4578	Homo sapiens	IC50	nM	8.1
322805	17701842	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N4CCN(C(=O)CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3674328	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
322806	17701843	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(Cc2cccc(-c3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)c2)CC1		CHEMBL3674329	=	IC50	nM	7.8	CHEMBL4578	Homo sapiens	IC50	nM	7.8
322807	17701844	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(c2ncc(-c3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3674330	=	IC50	nM	40.0	CHEMBL4578	Homo sapiens	IC50	nM	40.0
322808	17701845	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc4cc(O)ccc4[nH]3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674331	=	IC50	nM	54.0	CHEMBL4578	Homo sapiens	IC50	nM	54.0
322809	17701846	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COC(=O)c1ccc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC(CN(C)C)CC4)c3c2)cc1		CHEMBL3674332	=	IC50	nM	1400.0	CHEMBL4578	Homo sapiens	IC50	nM	1400.0
322810	17701847	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(Cc2ccc(-c3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cc2)CC1		CHEMBL3674333	=	IC50	nM	6.1	CHEMBL4578	Homo sapiens	IC50	nM	6.1
322811	17701848	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4ccc(N5CCN(C)CC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3674334	=	IC50	nM	16.0	CHEMBL4578	Homo sapiens	IC50	nM	16.0
322812	17701849	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N1CCN(C(=O)CN(C)C)CC1		CHEMBL3674335	=	IC50	nM	6.9	CHEMBL4578	Homo sapiens	IC50	nM	6.9
322813	17701850	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1-c1ccc(OCCN2CCCC2)cc1)C1CC1		CHEMBL3674336	=	IC50	nM	5.6	CHEMBL4578	Homo sapiens	IC50	nM	5.6
322814	17701851	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCOc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](N)CC4)c3c2)cc(Cl)c1O		CHEMBL3674337	=	IC50	nM	2.1	CHEMBL4578	Homo sapiens	IC50	nM	2.1
322815	17701852	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCN(C)CC2)nc1		CHEMBL3674338	=	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
322816	17701853	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCN(C)CC2)nc1		CHEMBL3674338	=	IC50	nM	4.1	CHEMBL4578	Homo sapiens	IC50	nM	4.1
322817	17701854	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(Cn2ccnc2)cc1)C1CC1		CHEMBL3674339	=	IC50	nM	19.0	CHEMBL4578	Homo sapiens	IC50	nM	19.0
322818	17701855	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(Cn5ccnc5)cc4)c3c2)cc(Cl)c1O		CHEMBL3674340	=	IC50	nM	14.0	CHEMBL4578	Homo sapiens	IC50	nM	14.0
322819	17701856	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[S+]([O-])c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674341	=	IC50	nM	7.5	CHEMBL4578	Homo sapiens	IC50	nM	7.5
322820	17701857	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4ccc(C(=O)O)cc4)cc23)CC1		CHEMBL3674342	=	IC50	nM	1400.0	CHEMBL4578	Homo sapiens	IC50	nM	1400.0
322821	17701858	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](CN)CC4)c3c2)cc(Cl)c1O		CHEMBL3674343	=	IC50	nM	3.0	CHEMBL4578	Homo sapiens	IC50	nM	3.0
322822	17701859	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](CN)CC4)c3c2)cc(Cl)c1O		CHEMBL3674343	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
322823	17701860	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674344	=	IC50	nM	2.9	CHEMBL4578	Homo sapiens	IC50	nM	2.9
322824	17701861	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cnc(N2CCNCC2)nc1)C1CC1		CHEMBL3674345	=	IC50	nM	4.8	CHEMBL4578	Homo sapiens	IC50	nM	4.8
322825	17701862	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cnc(N2CCNCC2)nc1)C1CC1		CHEMBL3674346	=	IC50	nM	2.1	CHEMBL4578	Homo sapiens	IC50	nM	2.1
322826	17701863	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[S+]([O-])c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674347	=	IC50	nM	46.0	CHEMBL4578	Homo sapiens	IC50	nM	46.0
322827	17701864	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[S+]([O-])c1cnc2ccc(-c3ccc(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674348	=	IC50	nM	36.0	CHEMBL4578	Homo sapiens	IC50	nM	36.0
322828	17701865	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc([S+](C)[O-])c(N[C@H]4CC[C@H](N)CC4)c3c2)cc(Cl)c1O		CHEMBL3674349	=	IC50	nM	4.9	CHEMBL4578	Homo sapiens	IC50	nM	4.9
322829	17701866	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674350	=	IC50	nM	46.0	CHEMBL4578	Homo sapiens	IC50	nM	46.0
322830	17701867	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C(C)C)c(N[C@H]4CC[C@H](N)CC4)c3c2)cc(Cl)c1O		CHEMBL3674351	=	IC50	nM	7.0	CHEMBL4578	Homo sapiens	IC50	nM	7.0
322831	17701868	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4cnc(N5CCNCC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3674352	=	IC50	nM	4.7	CHEMBL4578	Homo sapiens	IC50	nM	4.7
322832	17701869	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674353	=	IC50	nM	8.9	CHEMBL4578	Homo sapiens	IC50	nM	8.9
322833	17701870	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674353	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
322834	17701871	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(CN)cc4)c3c2)cc(Cl)c1O		CHEMBL3674354	=	IC50	nM	3.2	CHEMBL4578	Homo sapiens	IC50	nM	3.2
322835	17701872	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674355	=	IC50	nM	3.8	CHEMBL4578	Homo sapiens	IC50	nM	3.8
322836	17701873	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3674355	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
322837	17701874	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N#Cc1ncc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(CN)cc4)c3c2)cn1		CHEMBL3674356	=	IC50	nM	1.3	CHEMBL4578	Homo sapiens	IC50	nM	1.3
322838	17701875	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674357	=	IC50	nM	1.9	CHEMBL4578	Homo sapiens	IC50	nM	1.9
322839	17701876	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cnn(C2CCNCC2)c1)C1CC1		CHEMBL3674358	=	IC50	nM	17.0	CHEMBL4578	Homo sapiens	IC50	nM	17.0
322840	17701877	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4cnn(C5CCNCC5)c4)c3c2)cc(Cl)c1O		CHEMBL3674359	=	IC50	nM	2.2	CHEMBL4578	Homo sapiens	IC50	nM	2.2
322841	17701878	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@@H](CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3639732	=	IC50	nM	2.0	CHEMBL4578	Homo sapiens	IC50	nM	2.0
322842	17701879	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674360	=	IC50	nM	2.8	CHEMBL4578	Homo sapiens	IC50	nM	2.8
322843	17701880	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC[C@H]1CC[C@@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674361	=	IC50	nM	3.4	CHEMBL4578	Homo sapiens	IC50	nM	3.4
322844	17701881	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(C4=CCNCC4)c3c2)cc(Cl)c1O		CHEMBL3674362	=	IC50	nM	4.4	CHEMBL4578	Homo sapiens	IC50	nM	4.4
322845	17701882	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(OC)c4)cc23)CC1		CHEMBL3674363	=	IC50	nM	1.4	CHEMBL4578	Homo sapiens	IC50	nM	1.4
322846	17701883	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@@H](CN(C)CC#N)CC4)c3c2)cc(Cl)c1O		CHEMBL3674364	=	IC50	nM	13.0	CHEMBL4578	Homo sapiens	IC50	nM	13.0
322847	17701884	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3ccc(O)c(Cl)c3)cc2c1Nc1cnn(C2CCNCC2)c1)C1CC1		CHEMBL3674365	=	IC50	nM	3.0	CHEMBL4578	Homo sapiens	IC50	nM	3.0
322848	17701885	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cnn(C2CCNCC2)c1)C1CC1		CHEMBL3674366	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
322849	17701886	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(C4=CCN(C(=O)CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3679161	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
322850	17701887	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cnc(C#N)nc4)cc23)CC1		CHEMBL3679162	=	IC50	nM	1.4	CHEMBL4578	Homo sapiens	IC50	nM	1.4
322851	17701888	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679163	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
322852	17701889	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(CC#N)C[C@H]1CC[C@@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679164	=	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
322853	17701890	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCNCC2)cn1)C1CC1		CHEMBL3679165	=	IC50	nM	4.8	CHEMBL4578	Homo sapiens	IC50	nM	4.8
322854	17701891	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679166	=	IC50	nM	2.1	CHEMBL4578	Homo sapiens	IC50	nM	2.1
322855	17701892	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3679167	=	IC50	nM	15.0	CHEMBL4578	Homo sapiens	IC50	nM	15.0
322856	17701893	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(N5CCNCC5)cn4)c3c2)cc(Cl)c1O		CHEMBL3679168	=	IC50	nM	4.4	CHEMBL4578	Homo sapiens	IC50	nM	4.4
322857	17701894	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(OC)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3679169	=	IC50	nM	3.8	CHEMBL4578	Homo sapiens	IC50	nM	3.8
322858	17701895	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3679170	=	IC50	nM	4.5	CHEMBL4578	Homo sapiens	IC50	nM	4.5
322859	17701896	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3679170	=	IC50	nM	5.2	CHEMBL4578	Homo sapiens	IC50	nM	5.2
322860	17701897	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3679171	=	IC50	nM	17.0	CHEMBL4578	Homo sapiens	IC50	nM	17.0
322861	17701898	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCN(C)CC4)c3c2)cc(Cl)c1O		CHEMBL3679172	=	IC50	nM	8.8	CHEMBL4578	Homo sapiens	IC50	nM	8.8
322862	17701899	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(c2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679173	=	IC50	nM	25.0	CHEMBL4578	Homo sapiens	IC50	nM	25.0
322863	17701900	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3679174	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
322864	17701901	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(-c4cn[nH]c4)c3c2)cc(Cl)c1O		CHEMBL3679175	=	IC50	nM	110.0	CHEMBL4578	Homo sapiens	IC50	nM	110.0
322865	17701902	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3679176	=	IC50	nM	16.0	CHEMBL4578	Homo sapiens	IC50	nM	16.0
322866	17701903	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(OC)c3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3679177	=	IC50	nM	20.0	CHEMBL4578	Homo sapiens	IC50	nM	20.0
322867	17701904	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cnc(C#N)nc3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3679178	=	IC50	nM	3.8	CHEMBL4578	Homo sapiens	IC50	nM	3.8
322868	17701905	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2cc3c(Nc4ccc(CN(C)C)cc4)c(C(=O)C4CC4)cnc3cc2F)cc(Cl)c1O		CHEMBL3679179	=	IC50	nM	64.0	CHEMBL4578	Homo sapiens	IC50	nM	64.0
322869	17701906	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(C(=O)C3CC3)cnc3cc(F)c(-c4cc(F)c(O)c(Cl)c4)cc23)cc1		CHEMBL3679180	=	IC50	nM	77.0	CHEMBL4578	Homo sapiens	IC50	nM	77.0
322870	17701907	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H]1CC[C@H](Nc2c(C(C)=O)cnc3ccc(-c4cc(Cl)c(O)c(OC)c4)cc23)CC1		CHEMBL3679181	=	IC50	nM	4.3	CHEMBL4578	Homo sapiens	IC50	nM	4.3
322871	17701908	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H]1CC[C@H](Nc2c(C(C)=O)cnc3ccc(-c4cc(Cl)c(O)c(OC)c4)cc23)CC1		CHEMBL3679181	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
322872	17701909	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4ccc(C(N)=O)cc4)c3c2)cc(Cl)c1O		CHEMBL3679182	=	IC50	nM	18.0	CHEMBL4578	Homo sapiens	IC50	nM	18.0
322873	17701910	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(C(N)=O)cc1		CHEMBL3679183	=	IC50	nM	19.0	CHEMBL4578	Homo sapiens	IC50	nM	19.0
322874	17701911	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(C(N)=O)cc4)c3c2)cc(Cl)c1O		CHEMBL3679184	=	IC50	nM	40.0	CHEMBL4578	Homo sapiens	IC50	nM	40.0
322875	17701912	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(C(=O)C3CC3)cnc3cc(F)c(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3679185	=	IC50	nM	20.0	CHEMBL4578	Homo sapiens	IC50	nM	20.0
322876	17701913	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3679186	=	IC50	nM	2.0	CHEMBL4578	Homo sapiens	IC50	nM	2.0
322877	17701914	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3679186	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
322878	17701915	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(N5CCC(N)CC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679187	=	IC50	nM	5.7	CHEMBL4578	Homo sapiens	IC50	nM	5.7
322879	17701916	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2cc(F)c3ncc(C(=O)C4CC4)c(Nc4ccc(CN(C)C)cc4)c3c2)cc(Cl)c1O		CHEMBL3679188	=	IC50	nM	1100.0	CHEMBL4578	Homo sapiens	IC50	nM	1100.0
322880	17701917	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(C(=O)C3CC3)cnc3c(F)cc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3679189	=	IC50	nM	580.0	CHEMBL4578	Homo sapiens	IC50	nM	580.0
322881	17701918	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4cnc(N5CCC(N)CC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679190	=	IC50	nM	5.6	CHEMBL4578	Homo sapiens	IC50	nM	5.6
322882	17701919	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(N5CCCC(N)C5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679191	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
322883	17701920	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3c(F)cc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679192	=	IC50	nM	5100.0	CHEMBL4578	Homo sapiens	IC50	nM	5100.0
322884	17701921	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679193	=	IC50	nM	4.4	CHEMBL4578	Homo sapiens	IC50	nM	4.4
322885	17701922	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3679186	=	IC50	nM	5.6	CHEMBL4578	Homo sapiens	IC50	nM	5.6
322886	17701923	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H]1CC[C@H](Nc2c(C(C)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679194	=	IC50	nM	2.5	CHEMBL4578	Homo sapiens	IC50	nM	2.5
322887	17701924	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2cc(F)c(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCNCC2)nc1)C1CC1		CHEMBL3679195	=	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
322888	17701925	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H]1CC[C@H](Nc2c(C(C)=O)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679196	=	IC50	nM	110.0	CHEMBL4578	Homo sapiens	IC50	nM	110.0
322889	17701926	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679197	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
322890	17701927	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679197	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
322891	17701928	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(C(=O)C3CC3)cnc3c(F)cc(-c4cc(F)c(O)c(Cl)c4)cc23)cc1		CHEMBL3679198	=	IC50	nM	1800.0	CHEMBL4578	Homo sapiens	IC50	nM	1800.0
322892	17701929	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2cc(F)c3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](N)CC4)c3c2)cc(Cl)c1O		CHEMBL3679199	=	IC50	nM	260.0	CHEMBL4578	Homo sapiens	IC50	nM	260.0
322893	17701930	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3c(F)cc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679200	=	IC50	nM	2100.0	CHEMBL4578	Homo sapiens	IC50	nM	2100.0
322894	17701931	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCN(c2ncc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3679201	=	IC50	nM	3.0	CHEMBL4578	Homo sapiens	IC50	nM	3.0
322895	17701932	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCN(c2ncc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3679202	=	IC50	nM	8.3	CHEMBL4578	Homo sapiens	IC50	nM	8.3
322896	17701933	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(N5CCC(N)C5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679203	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
322897	17701934	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](CN5CC[C@@H](F)C5)CC4)c3c2)cc(Cl)c1O		CHEMBL3679204	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
322898	17701935	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CC[C@@H](F)C2)CC1)C1CC1		CHEMBL3679205	=	IC50	nM	16.0	CHEMBL4578	Homo sapiens	IC50	nM	16.0
322899	17701936	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CC[C@@H](F)C2)CC1)C1CC1		CHEMBL3679206	=	IC50	nM	4.3	CHEMBL4578	Homo sapiens	IC50	nM	4.3
322900	17701937	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCN(c2ncc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679207	=	IC50	nM	3.0	CHEMBL4578	Homo sapiens	IC50	nM	3.0
322901	17701938	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCN(c2ncc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679207	=	IC50	nM	4.0	CHEMBL4578	Homo sapiens	IC50	nM	4.0
322902	17701939	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCN(c2ncc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679208	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
322903	17701940	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679209	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
322904	17701941	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679210	=	IC50	nM	1.9	CHEMBL4578	Homo sapiens	IC50	nM	1.9
322905	17701942	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679210	=	IC50	nM	3.7	CHEMBL4578	Homo sapiens	IC50	nM	3.7
322906	17701943	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2cc3c(Nc4ccc(N5CCNCC5)nc4)c(C(=O)C4CC4)cnc3cc2F)cc(Cl)c1O		CHEMBL3639780	=	IC50	nM	21.0	CHEMBL4578	Homo sapiens	IC50	nM	21.0
322907	17701944	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NC4C[C@@H]5CC[C@H](C4)N5)c3c2)cc(Cl)c1O		CHEMBL3679211	=	IC50	nM	4.2	CHEMBL4578	Homo sapiens	IC50	nM	4.2
322908	17701945	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@@H]1C[C@@H]2CC[C@H](C1)N2)C1CC1		CHEMBL3679212	=	IC50	nM	4.5	CHEMBL4578	Homo sapiens	IC50	nM	4.5
322909	17701946	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN2CCC(F)(F)C2)cc1)C1CC1		CHEMBL3679213	=	IC50	nM	630.0	CHEMBL4578	Homo sapiens	IC50	nM	630.0
322910	17701947	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4cnc(N5CCC(N)C5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679214	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
322911	17701948	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C=CCN(CC=C)C1(C)CCC(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679215	=	IC50	nM	89.0	CHEMBL4578	Homo sapiens	IC50	nM	89.0
322912	17701949	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1)C1CC1		CHEMBL3679216	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
322913	17701950	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1)C1CC1		CHEMBL3679216	=	IC50	nM	1.4	CHEMBL4578	Homo sapiens	IC50	nM	1.4
322914	17701951	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](CN5CCCC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3679217	=	IC50	nM	2.8	CHEMBL4578	Homo sapiens	IC50	nM	2.8
322915	17701952	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1)C1CC1		CHEMBL3679218	=	IC50	nM	3.2	CHEMBL4578	Homo sapiens	IC50	nM	3.2
322916	17701953	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1)C1CC1		CHEMBL3679218	=	IC50	nM	3.7	CHEMBL4578	Homo sapiens	IC50	nM	3.7
322917	17701954	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(N)nc4)c3c2)cc(Cl)c1O		CHEMBL3679219	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
322918	17701955	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Nc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cn1		CHEMBL3679220	=	IC50	nM	14.0	CHEMBL4578	Homo sapiens	IC50	nM	14.0
322919	17701956	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Nc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cn1		CHEMBL3679221	=	IC50	nM	32.0	CHEMBL4578	Homo sapiens	IC50	nM	32.0
322920	17701957	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCC(n2cc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3679222	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
322921	17701958	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCC(n2cc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3679223	=	IC50	nM	1.3	CHEMBL4578	Homo sapiens	IC50	nM	1.3
322922	17701959	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cnc(N2CCNCC2)nc1		CHEMBL3679224	=	IC50	nM	4.8	CHEMBL4578	Homo sapiens	IC50	nM	4.8
322923	17701960	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N4CCC(C5CCNCC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3679225	=	IC50	nM	4.2	CHEMBL4578	Homo sapiens	IC50	nM	4.2
322924	17701961	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N1CCC(C2CCNCC2)CC1)C1CC1		CHEMBL3679226	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
322925	17701962	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3679227	=	IC50	nM	7.3	CHEMBL4578	Homo sapiens	IC50	nM	7.3
322926	17701963	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COC1CCN(C[C@H]2CC[C@H](Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)CC2)C1		CHEMBL3679228	=	IC50	nM	2.3	CHEMBL4578	Homo sapiens	IC50	nM	2.3
322927	17701964	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](CN5CCC(OC)C5)CC4)c3c2)cc(Cl)c1O		CHEMBL3679229	=	IC50	nM	5.0	CHEMBL4578	Homo sapiens	IC50	nM	5.0
322928	17701965	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCC(O)C2)CC1)C1CC1		CHEMBL3679230	=	IC50	nM	0.73	CHEMBL4578	Homo sapiens	IC50	nM	0.73
322929	17701966	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)(N)c1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3679231	=	IC50	nM	1.4	CHEMBL4578	Homo sapiens	IC50	nM	1.4
322930	17701967	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)(N)c1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3679231	=	IC50	nM	1.1	CHEMBL4578	Homo sapiens	IC50	nM	1.1
322931	17701968	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(C(C)(C)N)cc4)c3c2)cc(Cl)c1O		CHEMBL3679232	=	IC50	nM	3.6	CHEMBL4578	Homo sapiens	IC50	nM	3.6
322932	17701969	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)(N)c1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cc1		CHEMBL3679233	=	IC50	nM	2.8	CHEMBL4578	Homo sapiens	IC50	nM	2.8
322933	17701970	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3679234	=	IC50	nM	2.0	CHEMBL4578	Homo sapiens	IC50	nM	2.0
322934	17701971	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C(C)C)c(N[C@H]4CC[C@H](CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3679235	=	IC50	nM	6.3	CHEMBL4578	Homo sapiens	IC50	nM	6.3
322935	17701972	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(OC)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3679236	=	IC50	nM	5.1	CHEMBL4578	Homo sapiens	IC50	nM	5.1
322936	17701973	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3679237	=	IC50	nM	2.2	CHEMBL4578	Homo sapiens	IC50	nM	2.2
322937	17701974	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(NC5CCCNC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679238	=	IC50	nM	2.5	CHEMBL4578	Homo sapiens	IC50	nM	2.5
322938	17701975	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(NC2CCCNC2)nc1)C1CC1		CHEMBL3679239	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
322939	17701976	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(NC2CCCNC2)nc1)C1CC1		CHEMBL3679240	=	IC50	nM	2.3	CHEMBL4578	Homo sapiens	IC50	nM	2.3
322940	17701977	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(CCN(C)C)cc4)c3c2)cc(Cl)c1O		CHEMBL3679241	=	IC50	nM	5.5	CHEMBL4578	Homo sapiens	IC50	nM	5.5
322941	17701978	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3679242	=	IC50	nM	2.2	CHEMBL4578	Homo sapiens	IC50	nM	2.2
322942	17701979	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3679242	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
322943	17701980	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cc1		CHEMBL3679243	=	IC50	nM	8.2	CHEMBL4578	Homo sapiens	IC50	nM	8.2
322944	17701981	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4cnc(N5CCNCC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679244	=	IC50	nM	4.4	CHEMBL4578	Homo sapiens	IC50	nM	4.4
322945	17701982	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(OC)c3)cc2c1Nc1ccc(N2CCNCC2)nc1		CHEMBL3679245	=	IC50	nM	4.2	CHEMBL4578	Homo sapiens	IC50	nM	4.2
322946	17701983	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(C[C@H]2CC[C@H](Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)CC2)CC1		CHEMBL3679246	=	IC50	nM	4.2	CHEMBL4578	Homo sapiens	IC50	nM	4.2
322947	17701984	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(C[C@H]2CC[C@H](Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)CC2)CC1		CHEMBL3679246	=	IC50	nM	2.8	CHEMBL4578	Homo sapiens	IC50	nM	2.8
322948	17701985	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3679247	=	IC50	nM	6.6	CHEMBL4578	Homo sapiens	IC50	nM	6.6
322949	17701986	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@@H]1C[C@@H]2CC[C@H](C1)N2)C1CC1		CHEMBL3679248	=	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
322950	17701987	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4cccc(CN(C)C)c4)c3c2)cc(Cl)c1O		CHEMBL3679249	=	IC50	nM	3.7	CHEMBL4578	Homo sapiens	IC50	nM	3.7
322951	17701988	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCNCC2)nc1		CHEMBL3679250	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
322952	17701989	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1cccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)c1		CHEMBL3679251	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
322953	17701990	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCNCC2)nc1		CHEMBL3679252	=	IC50	nM	150.0	CHEMBL4578	Homo sapiens	IC50	nM	150.0
322954	17701991	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCCN(c2ncc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679253	=	IC50	nM	1.1	CHEMBL4578	Homo sapiens	IC50	nM	1.1
322955	17701992	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COC1CCN(C[C@H]2CC[C@H](Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)CC2)C1		CHEMBL3679254	=	IC50	nM	24.0	CHEMBL4578	Homo sapiens	IC50	nM	24.0
322956	17701993	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCCN(c2ncc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679255	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
322957	17701994	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1cccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)c1		CHEMBL3679256	=	IC50	nM	5.1	CHEMBL4578	Homo sapiens	IC50	nM	5.1
322958	17701995	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](CN5CCC(O)C5)CC4)c3c2)cc(Cl)c1O		CHEMBL3679257	=	IC50	nM	2.3	CHEMBL4578	Homo sapiens	IC50	nM	2.3
322959	17701996	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCC(O)C2)CC1)C1CC1		CHEMBL3679258	=	IC50	nM	2.1	CHEMBL4578	Homo sapiens	IC50	nM	2.1
322960	17701997	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(CCO)C[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679259	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
322961	17701998	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](CN(C)CCO)CC4)c3c2)cc(Cl)c1O		CHEMBL3679260	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
322962	17701999	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(CCO)C[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679261	=	IC50	nM	0.8	CHEMBL4578	Homo sapiens	IC50	nM	0.8
322963	17702000	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(CCO)C[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679261	=	IC50	nM	0.74	CHEMBL4578	Homo sapiens	IC50	nM	0.74
322964	17702001	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(C[C@H]2CC[C@H](Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)CC2)CC1		CHEMBL3679262	=	IC50	nM	9.8	CHEMBL4578	Homo sapiens	IC50	nM	9.8
322965	17702002	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](CN5CCN(C)CC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3679263	=	IC50	nM	3.5	CHEMBL4578	Homo sapiens	IC50	nM	3.5
322966	17702003	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC1(N)CCC(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679264	=	IC50	nM	3.4	CHEMBL4578	Homo sapiens	IC50	nM	3.4
322967	17702004	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NC4CCC(C)(N)CC4)c3c2)cc(Cl)c1O		CHEMBL3679265	=	IC50	nM	1.2	CHEMBL4578	Homo sapiens	IC50	nM	1.2
322968	17702005	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C(C)C)c(Nc4ccc(CN(C)C)cc4)c3c2)cc(Cl)c1O		CHEMBL3679266	=	IC50	nM	27.0	CHEMBL4578	Homo sapiens	IC50	nM	27.0
322969	17702006	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3679267	=	IC50	nM	7.6	CHEMBL4578	Homo sapiens	IC50	nM	7.6
322970	17702007	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1NC1CCC(N2CC[C@@H](F)C2)CC1)C1CC1		CHEMBL3679268	=	IC50	nM	7.5	CHEMBL4578	Homo sapiens	IC50	nM	7.5
322971	17702008	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1NC1CCC(N2CC[C@@H](F)C2)CC1)C1CC1		CHEMBL3679269	=	IC50	nM	4.0	CHEMBL4578	Homo sapiens	IC50	nM	4.0
322972	17702009	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4cnc(N5CCCC(N)C5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679270	=	IC50	nM	2.8	CHEMBL4578	Homo sapiens	IC50	nM	2.8
322973	17702010	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NC4CCC(N5CC[C@@H](F)C5)CC4)c3c2)cc(Cl)c1O		CHEMBL3679271	=	IC50	nM	6.2	CHEMBL4578	Homo sapiens	IC50	nM	6.2
322974	17702011	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679272	=	IC50	nM	1.1	CHEMBL4578	Homo sapiens	IC50	nM	1.1
322975	17702012	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679272	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
322976	17702013	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679273	=	IC50	nM	1.9	CHEMBL4578	Homo sapiens	IC50	nM	1.9
322977	17702014	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(N5CCC[C@@H](N)C5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679274	=	IC50	nM	2.1	CHEMBL4578	Homo sapiens	IC50	nM	2.1
322978	17702015	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@@H]1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679275	=	IC50	nM	1.0	CHEMBL4578	Homo sapiens	IC50	nM	1.0
322979	17702016	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@@H]1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679276	=	IC50	nM	0.76	CHEMBL4578	Homo sapiens	IC50	nM	0.76
322980	17702017	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@]1(O)CC[C@@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679277	=	IC50	nM	1.1	CHEMBL4578	Homo sapiens	IC50	nM	1.1
322981	17702018	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4ccc(CN5CCN(C)CC5)cc4)c3c2)cc(Cl)c1O		CHEMBL3679278	=	IC50	nM	9.8	CHEMBL4578	Homo sapiens	IC50	nM	9.8
322982	17702019	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN2CCN(C)CC2)cc1		CHEMBL3679279	=	IC50	nM	8.2	CHEMBL4578	Homo sapiens	IC50	nM	8.2
322983	17702020	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN2CCN(C)CC2)cc1		CHEMBL3679279	=	IC50	nM	2.9	CHEMBL4578	Homo sapiens	IC50	nM	2.9
322984	17702021	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(CN2CCN(C)CC2)cc1		CHEMBL3679280	=	IC50	nM	33.0	CHEMBL4578	Homo sapiens	IC50	nM	33.0
322985	17702022	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cn1		CHEMBL3679281	=	IC50	nM	8.9	CHEMBL4578	Homo sapiens	IC50	nM	8.9
322986	17702023	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN2CCCC2)nc1)C1CC1		CHEMBL3679282	=	IC50	nM	7.8	CHEMBL4578	Homo sapiens	IC50	nM	7.8
322987	17702024	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(CN5CCCC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679283	=	IC50	nM	13.0	CHEMBL4578	Homo sapiens	IC50	nM	13.0
322988	17702025	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(N5CCC[C@H](N)C5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679284	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
322989	17702026	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COC1CCN(C2CCC(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)CC2)C1		CHEMBL3679285	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
322990	17702027	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C1CCN(C[C@H]2CC[C@H](Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)CC2)C1		CHEMBL3679286	=	IC50	nM	4.0	CHEMBL4578	Homo sapiens	IC50	nM	4.0
322991	17702028	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C1CCN(C[C@H]2CC[C@H](Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)CC2)C1		CHEMBL3679287	=	IC50	nM	3.0	CHEMBL4578	Homo sapiens	IC50	nM	3.0
322992	17702029	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1NC1CCC(N2CCC(F)(F)C2)CC1)C1CC1		CHEMBL3679288	=	IC50	nM	140.0	CHEMBL4578	Homo sapiens	IC50	nM	140.0
322993	17702030	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(NC5CCNC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679289	=	IC50	nM	3.3	CHEMBL4578	Homo sapiens	IC50	nM	3.3
322994	17702031	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(NC2CCNC2)nc1)C1CC1		CHEMBL3679290	=	IC50	nM	24.0	CHEMBL4578	Homo sapiens	IC50	nM	24.0
322995	17702032	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(NC2CCNC2)nc1)C1CC1		CHEMBL3679291	=	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
322996	17702033	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(N[C@H]4CC[C@H](CN5CCC(N(C)C)C5)CC4)c3c2)cc(Cl)c1O		CHEMBL3679292	=	IC50	nM	3.9	CHEMBL4578	Homo sapiens	IC50	nM	3.9
322997	17702034	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(N5CCC(O)C5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679293	=	IC50	nM	12.0	CHEMBL4578	Homo sapiens	IC50	nM	12.0
322998	17702035	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCC(O)C2)nc1)C1CC1		CHEMBL3679294	=	IC50	nM	6.9	CHEMBL4578	Homo sapiens	IC50	nM	6.9
322999	17702036	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCC(O)C2)nc1)C1CC1		CHEMBL3679295	=	IC50	nM	25.0	CHEMBL4578	Homo sapiens	IC50	nM	25.0
323000	17702037	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(CN2CCCC2)nc1)C1CC1		CHEMBL3679296	=	IC50	nM	14.0	CHEMBL4578	Homo sapiens	IC50	nM	14.0
323001	17702038	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@]1(O)CC[C@@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679297	=	IC50	nM	4.2	CHEMBL4578	Homo sapiens	IC50	nM	4.2
323002	17702039	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCNCC2)nc1		CHEMBL3679298	=	IC50	nM	6.9	CHEMBL4578	Homo sapiens	IC50	nM	6.9
323003	17702040	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1NC1CCC(N2CCC(F)(F)C2)CC1)C1CC1		CHEMBL3679299	=	IC50	nM	830.0	CHEMBL4578	Homo sapiens	IC50	nM	830.0
323004	17702041	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NC4CCC(N5CCC(F)(F)C5)CC4)c3c2)cc(Cl)c1O		CHEMBL3679300	=	IC50	nM	290.0	CHEMBL4578	Homo sapiens	IC50	nM	290.0
323005	17702042	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(NCCO)nc4)c3c2)cc(Cl)c1O		CHEMBL3679301	=	IC50	nM	14.0	CHEMBL4578	Homo sapiens	IC50	nM	14.0
323006	17702043	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(NCCO)nc1)C1CC1		CHEMBL3679302	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
323007	17702044	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(NCCO)nc1)C1CC1		CHEMBL3679303	=	IC50	nM	30.0	CHEMBL4578	Homo sapiens	IC50	nM	30.0
323008	17702045	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C(C)C)c(Nc4ccc(N5CCNCC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679304	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
323009	17702046	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCCC(N)C2)nc1		CHEMBL3679305	=	IC50	nM	0.86	CHEMBL4578	Homo sapiens	IC50	nM	0.86
323010	17702047	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(Cc2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3679306	=	IC50	nM	18.0	CHEMBL4578	Homo sapiens	IC50	nM	18.0
323011	17702048	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(CN5CCN(C)CC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679307	=	IC50	nM	16.0	CHEMBL4578	Homo sapiens	IC50	nM	16.0
323012	17702049	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(Cc2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3679308	=	IC50	nM	50.0	CHEMBL4578	Homo sapiens	IC50	nM	50.0
323013	17702050	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3679309	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
323014	17702051	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COC1CCN(C2CCC(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)CC2)C1		CHEMBL3639781	=	IC50	nM	3.5	CHEMBL4578	Homo sapiens	IC50	nM	3.5
323015	17702052	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NC4CCC(N5CCC(OC)C5)CC4)c3c2)cc(Cl)c1O		CHEMBL3679310	=	IC50	nM	3.3	CHEMBL4578	Homo sapiens	IC50	nM	3.3
323016	17702053	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4ccc(N5CCCC(N)C5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679311	=	IC50	nM	3.2	CHEMBL4578	Homo sapiens	IC50	nM	3.2
323017	17702054	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(N5CCC(N(C)C)C5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679312	=	IC50	nM	13.0	CHEMBL4578	Homo sapiens	IC50	nM	13.0
323018	17702055	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679313	=	IC50	nM	4.7	CHEMBL4578	Homo sapiens	IC50	nM	4.7
323019	17702056	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679314	=	IC50	nM	12.0	CHEMBL4578	Homo sapiens	IC50	nM	12.0
323020	17702057	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4cccc(CCN(C)C)c4)c3c2)cc(Cl)c1O		CHEMBL3679315	=	IC50	nM	5.6	CHEMBL4578	Homo sapiens	IC50	nM	5.6
323021	17702058	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCc1cccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)c1		CHEMBL3679316	=	IC50	nM	8.3	CHEMBL4578	Homo sapiens	IC50	nM	8.3
323022	17702059	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C1CCN(Cc2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cc2)C1		CHEMBL3679317	=	IC50	nM	7.2	CHEMBL4578	Homo sapiens	IC50	nM	7.2
323023	17702060	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C1CCN(Cc2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cc2)C1		CHEMBL3679317	=	IC50	nM	5.6	CHEMBL4578	Homo sapiens	IC50	nM	5.6
323024	17702061	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C1CCN(Cc2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cc2)C1		CHEMBL3679318	=	IC50	nM	12.0	CHEMBL4578	Homo sapiens	IC50	nM	12.0
323025	17702062	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(CN5CCC(N(C)C)C5)cc4)c3c2)cc(Cl)c1O		CHEMBL3679319	=	IC50	nM	8.4	CHEMBL4578	Homo sapiens	IC50	nM	8.4
323026	17702063	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCc1cccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)c1		CHEMBL3679320	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
323027	17702064	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCCC(n2cc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679321	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
323028	17702065	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CNCCF)CC1)C1CC1		CHEMBL3679322	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
323029	17702066	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CNCCF)CC1)C1CC1		CHEMBL3679323	=	IC50	nM	3.0	CHEMBL4578	Homo sapiens	IC50	nM	3.0
323030	17702067	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCNCC2)nc1		CHEMBL3679324	=	IC50	nM	1.4	CHEMBL4578	Homo sapiens	IC50	nM	1.4
323031	17702068	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCCC(n2cc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3679325	=	IC50	nM	1.3	CHEMBL4578	Homo sapiens	IC50	nM	1.3
323032	17702069	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4ccc(N5CCNCC5)nc4)c3c2)cc(Cl)c1O		CHEMBL3679326	=	IC50	nM	2.3	CHEMBL4578	Homo sapiens	IC50	nM	2.3
323033	17702070	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H]1CC[C@H](n2cc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3679327	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
323034	17702071	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](n2cc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3679328	=	IC50	nM	1.1	CHEMBL4578	Homo sapiens	IC50	nM	1.1
323035	17702072	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC(O)c1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cc1		CHEMBL3679329	=	IC50	nM	5.9	CHEMBL4578	Homo sapiens	IC50	nM	5.9
323036	17702073	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(C(O)CN(C)C)cc4)c3c2)cc(Cl)c1O		CHEMBL3679330	=	IC50	nM	6.5	CHEMBL4578	Homo sapiens	IC50	nM	6.5
323037	17702074	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC(O)c1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cc1		CHEMBL3679331	=	IC50	nM	3.5	CHEMBL4578	Homo sapiens	IC50	nM	3.5
323038	17702075	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCOc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cn1		CHEMBL3679332	=	IC50	nM	6.9	CHEMBL4578	Homo sapiens	IC50	nM	6.9
323039	17702076	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCOc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cn1		CHEMBL3679333	=	IC50	nM	3.2	CHEMBL4578	Homo sapiens	IC50	nM	3.2
323040	17702077	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(OCCN(C)C)nc4)c3c2)cc(Cl)c1O		CHEMBL3679334	=	IC50	nM	3.6	CHEMBL4578	Homo sapiens	IC50	nM	3.6
323041	17702078	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(OC)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3679335	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
323042	17702079	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3679336	=	IC50	nM	4.0	CHEMBL4578	Homo sapiens	IC50	nM	4.0
323043	17702080	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3679337	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
323044	17702081	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3679337	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
323045	17702082	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@@H]1CC[C@@H](CN(C)C)C1		CHEMBL3679338	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
323046	17702083	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@@H]1CC[C@@H](CN(C)C)C1		CHEMBL3679339	=	IC50	nM	5.5	CHEMBL4578	Homo sapiens	IC50	nM	5.5
323047	17702084	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1NC1CCNCC1)C1CC1		CHEMBL3679340	=	IC50	nM	9.2	CHEMBL4578	Homo sapiens	IC50	nM	9.2
323048	17702085	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc2c(c1)CCC2N(C)C		CHEMBL3679341	=	IC50	nM	3.3	CHEMBL4578	Homo sapiens	IC50	nM	3.3
323049	17702086	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(F)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3679342	=	IC50	nM	35.0	CHEMBL4578	Homo sapiens	IC50	nM	35.0
323050	17702087	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(OCCN)nc4)c3c2)cc(Cl)c1O		CHEMBL3679343	=	IC50	nM	4.3	CHEMBL4578	Homo sapiens	IC50	nM	4.3
323051	17702088	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCOc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cn1		CHEMBL3679344	=	IC50	nM	1.9	CHEMBL4578	Homo sapiens	IC50	nM	1.9
323052	17702089	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCOc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cn1		CHEMBL3679345	=	IC50	nM	5.5	CHEMBL4578	Homo sapiens	IC50	nM	5.5
323053	17702090	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(F)c5)cc34)cn2)C1		CHEMBL3679346	=	IC50	nM	3.0	CHEMBL4578	Homo sapiens	IC50	nM	3.0
323054	17702091	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1NC1CCNCC1)C1CC1		CHEMBL3679347	=	IC50	nM	5.7	CHEMBL4578	Homo sapiens	IC50	nM	5.7
323055	17702092	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NC4CCNCC4)c3c2)cc(Cl)c1O		CHEMBL3679348	=	IC50	nM	3.4	CHEMBL4578	Homo sapiens	IC50	nM	3.4
323056	17702093	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@@H]1CC[C@@H](CN2CCN(C)CC2)C1		CHEMBL3679349	=	IC50	nM	5.7	CHEMBL4578	Homo sapiens	IC50	nM	5.7
323057	17702094	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN(C)C)c1		CHEMBL3679350	=	IC50	nM	2.2	CHEMBL4578	Homo sapiens	IC50	nM	2.2
323058	17702095	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4cccc(CCN(C)C)c4)c3c2)cc(Cl)c1O		CHEMBL3679351	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
323059	17702096	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1		CHEMBL3679352	=	IC50	nM	4.7	CHEMBL4578	Homo sapiens	IC50	nM	4.7
323060	17702097	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCCC(N)C2)nc1		CHEMBL3679353	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
323061	17702098	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCCC(N)C2)nc1		CHEMBL3679353	=	IC50	nM	0.99	CHEMBL4578	Homo sapiens	IC50	nM	0.99
323062	17702099	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CN5CCCC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3679354	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
323063	17702100	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1CCN(c2cc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)ccn2)CC1		CHEMBL3679355	=	IC50	nM	4.1	CHEMBL4578	Homo sapiens	IC50	nM	4.1
323064	17702101	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCN(C)CC2)nc1		CHEMBL3679356	=	IC50	nM	36.0	CHEMBL4578	Homo sapiens	IC50	nM	36.0
323065	17702102	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCN(C)CC2)nc1		CHEMBL3679357	=	IC50	nM	55.0	CHEMBL4578	Homo sapiens	IC50	nM	55.0
323066	17702103	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CCN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3679358	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
323067	17702104	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CCN(C)C)CC1		CHEMBL3679359	=	IC50	nM	3.2	CHEMBL4578	Homo sapiens	IC50	nM	3.2
323068	17702105	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CCN(C)C)CC1		CHEMBL3679359	=	IC50	nM	1.3	CHEMBL4578	Homo sapiens	IC50	nM	1.3
323069	17702106	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CCN(C)C)CC1		CHEMBL3679360	=	IC50	nM	4.8	CHEMBL4578	Homo sapiens	IC50	nM	4.8
323070	17702107	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CCN(C)C)CC1		CHEMBL3679360	=	IC50	nM	4.4	CHEMBL4578	Homo sapiens	IC50	nM	4.4
323071	17702108	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4ccc(CCN(C)C)cc4)c3c2)cc(Cl)c1O		CHEMBL3679361	=	IC50	nM	4.2	CHEMBL4578	Homo sapiens	IC50	nM	4.2
323072	17702109	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CCN(C)C)cc1		CHEMBL3679362	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
323073	17702110	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(CCN(C)C)cc1		CHEMBL3679363	=	IC50	nM	8.3	CHEMBL4578	Homo sapiens	IC50	nM	8.3
323074	17702111	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(Nc4ccc(NCCN(C)C)nc4)c3c2)cc(Cl)c1O		CHEMBL3679364	=	IC50	nM	2.9	CHEMBL4578	Homo sapiens	IC50	nM	2.9
323075	17702112	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCNc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cn1		CHEMBL3679365	=	IC50	nM	4.3	CHEMBL4578	Homo sapiens	IC50	nM	4.3
323076	17702113	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCNc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cn1		CHEMBL3679365	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
323077	17702114	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CN5CCC(O)C5)CC4)c3c2)cc(Cl)c1O		CHEMBL3679366	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
323078	17702115	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@@H]1CCC[C@@H](CN(C)C)C1		CHEMBL3679367	=	IC50	nM	2.3	CHEMBL4578	Homo sapiens	IC50	nM	2.3
323079	17702116	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@@H]1CCC[C@@H](CN(C)C)C1		CHEMBL3679368	=	IC50	nM	6.7	CHEMBL4578	Homo sapiens	IC50	nM	6.7
323080	17702117	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@@H]4CCC[C@@H](CN(C)C)C4)c3c2)cc(Cl)c1O		CHEMBL3679369	=	IC50	nM	1.0	CHEMBL4578	Homo sapiens	IC50	nM	1.0
323081	17702118	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCC(O)C2)CC1		CHEMBL3679370	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
323082	17702119	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N(C)C)CC1		CHEMBL3679371	=	IC50	nM	20.0	CHEMBL4578	Homo sapiens	IC50	nM	20.0
323083	17702120	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(OC)c3)cc2c1N[C@H]1CC[C@H](N(C)C)CC1		CHEMBL3679372	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
323084	17702121	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N1CCC(CCN2CCCC2)CC1)C1CC1		CHEMBL3679373	=	IC50	nM	2.3	CHEMBL4578	Homo sapiens	IC50	nM	2.3
323085	17702122	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N(C)C)CC1		CHEMBL3679374	=	IC50	nM	6.2	CHEMBL4578	Homo sapiens	IC50	nM	6.2
323086	17702123	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(NCCN(C)C)nc1		CHEMBL3679375	=	IC50	nM	5.3	CHEMBL4578	Homo sapiens	IC50	nM	5.3
323087	17702124	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN(C)C)c1		CHEMBL3684125	=	IC50	nM	13.0	CHEMBL4578	Homo sapiens	IC50	nM	13.0
323088	17702125	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCC(N)C2)nc1		CHEMBL3684126	=	IC50	nM	3.4	CHEMBL4578	Homo sapiens	IC50	nM	3.4
323089	17702126	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCC(N)C2)nc1		CHEMBL3684127	=	IC50	nM	2.6	CHEMBL4578	Homo sapiens	IC50	nM	2.6
323090	17702127	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(NCCN(C)C)nc1		CHEMBL3684128	=	IC50	nM	14.0	CHEMBL4578	Homo sapiens	IC50	nM	14.0
323091	17702128	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N(C)C)CC1		CHEMBL3684129	=	IC50	nM	8.7	CHEMBL4578	Homo sapiens	IC50	nM	8.7
323092	17702129	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CC4)c(NC4CCN(C5CCNC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3684130	=	IC50	nM	2.9	CHEMBL4578	Homo sapiens	IC50	nM	2.9
323093	17702130	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N(C)C)CC1		CHEMBL3684131	=	IC50	nM	2.2	CHEMBL4578	Homo sapiens	IC50	nM	2.2
323094	17702131	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N(C)C)CC1		CHEMBL3684131	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
323095	17702132	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1		CHEMBL3684132	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
323096	17702133	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1		CHEMBL3684132	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
323097	17702134	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(OC)c3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3684133	=	IC50	nM	4.9	CHEMBL4578	Homo sapiens	IC50	nM	4.9
323098	17702135	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3684134	=	IC50	nM	15.0	CHEMBL4578	Homo sapiens	IC50	nM	15.0
323099	17702136	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3684135	=	IC50	nM	5.4	CHEMBL4578	Homo sapiens	IC50	nM	5.4
323100	17702137	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCNCC2)CC1		CHEMBL3684136	=	IC50	nM	2.1	CHEMBL4578	Homo sapiens	IC50	nM	2.1
323101	17702138	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCC(N)C2)nc1		CHEMBL3684137	=	IC50	nM	6.0	CHEMBL4578	Homo sapiens	IC50	nM	6.0
323102	17702139	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(Nc4ccc(N5CCC(N)C5)nc4)c3c2)cc(Cl)c1O		CHEMBL3684138	=	IC50	nM	1.9	CHEMBL4578	Homo sapiens	IC50	nM	1.9
323103	17702140	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(OC)c3)cc2c1Nc1ccc(N2CCC(N)C2)nc1		CHEMBL3684139	=	IC50	nM	3.4	CHEMBL4578	Homo sapiens	IC50	nM	3.4
323104	17702141	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCNc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cn1		CHEMBL3684140	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
323105	17702142	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCNc1ccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cn1		CHEMBL3684140	=	IC50	nM	3.4	CHEMBL4578	Homo sapiens	IC50	nM	3.4
323106	17702143	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(F)c5)cc34)cn2)CC1		CHEMBL3684141	=	IC50	nM	21.0	CHEMBL4578	Homo sapiens	IC50	nM	21.0
323107	17702144	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCC(N)C2)CC1		CHEMBL3684142	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
323108	17702145	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CN5CCC(N)C5)CC4)c3c2)cc(Cl)c1O		CHEMBL3684143	=	IC50	nM	2.0	CHEMBL4578	Homo sapiens	IC50	nM	2.0
323109	17702146	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCN(C)CC2)CC1		CHEMBL3684144	=	IC50	nM	13.0	CHEMBL4578	Homo sapiens	IC50	nM	13.0
323110	17702147	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCN(C)CC2)CC1		CHEMBL3684145	=	IC50	nM	5.5	CHEMBL4578	Homo sapiens	IC50	nM	5.5
323111	17702148	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCNCC2)CC1		CHEMBL3684146	=	IC50	nM	8.8	CHEMBL4578	Homo sapiens	IC50	nM	8.8
323112	17702149	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1C[C@H](CN(C)C)C1		CHEMBL3684147	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
323113	17702150	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC1CCN(c2ccc(Nc3c(C(C)=O)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3684148	=	IC50	nM	5.6	CHEMBL4578	Homo sapiens	IC50	nM	5.6
323114	17702151	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCC(N)C2)CC1		CHEMBL3684149	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
323115	17702152	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CN5CCN(C)CC5)CC4)c3c2)cc(Cl)c1O		CHEMBL3684150	=	IC50	nM	5.8	CHEMBL4578	Homo sapiens	IC50	nM	5.8
323116	17702153	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC1CCN(c2ccc(Nc3c(C(C)=O)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3684151	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
323117	17702154	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3684152	=	IC50	nM	2.8	CHEMBL4578	Homo sapiens	IC50	nM	2.8
323118	17702155	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C[C@H]1CC[C@H](Nc2c(C(C)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684153	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
323119	17702156	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C[C@H]1CC[C@H](Nc2c(C(C)=O)cnc3ccc(-c4cc(Cl)c(O)c(OC)c4)cc23)CC1		CHEMBL3684154	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
323120	17702157	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCC[C@H]2CO)CC1		CHEMBL3684155	=	IC50	nM	1.1	CHEMBL4578	Homo sapiens	IC50	nM	1.1
323121	17702158	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CN5CCC[C@H]5CO)CC4)c3c2)cc(Cl)c1O		CHEMBL3684156	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
323122	17702159	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C[C@H]1CC[C@H](Nc2c(C(C)=O)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684157	=	IC50	nM	5.6	CHEMBL4578	Homo sapiens	IC50	nM	5.6
323123	17702160	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(F)c3)cc2c1Nc1ccc(CN2CCCC2)nc1)C1CC1		CHEMBL3684158	=	IC50	nM	35.0	CHEMBL4578	Homo sapiens	IC50	nM	35.0
323124	17702161	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCc1cccc(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(F)c4)cc23)c1		CHEMBL3684159	=	IC50	nM	26.0	CHEMBL4578	Homo sapiens	IC50	nM	26.0
323125	17702162	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN2CCCC2)c1)C1CC1		CHEMBL3684160	=	IC50	nM	5.6	CHEMBL4578	Homo sapiens	IC50	nM	5.6
323126	17702163	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN2CCCC2)c1)C1CC1		CHEMBL3684160	=	IC50	nM	2.9	CHEMBL4578	Homo sapiens	IC50	nM	2.9
323127	17702164	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN2CCCC2)c1)C1CC1		CHEMBL3639830	=	IC50	nM	4.7	CHEMBL4578	Homo sapiens	IC50	nM	4.7
323128	17702165	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN2CCCC2)c1)C1CC1		CHEMBL3639830	=	IC50	nM	12.0	CHEMBL4578	Homo sapiens	IC50	nM	12.0
323129	17702166	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN2CCCC2)c1		CHEMBL3684161	=	IC50	nM	4.0	CHEMBL4578	Homo sapiens	IC50	nM	4.0
323130	17702167	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN2CCCC2)c1		CHEMBL3684161	=	IC50	nM	2.1	CHEMBL4578	Homo sapiens	IC50	nM	2.1
323131	17702168	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN2CCCC2)c1		CHEMBL3684162	=	IC50	nM	16.0	CHEMBL4578	Homo sapiens	IC50	nM	16.0
323132	17702169	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3684163	=	IC50	nM	2.0	CHEMBL4578	Homo sapiens	IC50	nM	2.0
323133	17702170	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cnn(C2CCN(C)CC2)c1		CHEMBL3684164	=	IC50	nM	2.8	CHEMBL4578	Homo sapiens	IC50	nM	2.8
323134	17702171	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC1CCCN(c2ccc(Nc3c(C(C)=O)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3684165	=	IC50	nM	1.2	CHEMBL4578	Homo sapiens	IC50	nM	1.2
323135	17702172	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC1CCCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3684166	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
323136	17702173	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCC[C@@H]2CO)CC1		CHEMBL3684167	=	IC50	nM	6.5	CHEMBL4578	Homo sapiens	IC50	nM	6.5
323137	17702174	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CN5CCCC(N)C5)CC4)c3c2)cc(Cl)c1O		CHEMBL3684168	=	IC50	nM	16.0	CHEMBL4578	Homo sapiens	IC50	nM	16.0
323138	17702175	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC(N)C2)CC1		CHEMBL3684169	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
323139	17702176	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CN5CCC[C@@H]5CO)CC4)c3c2)cc(Cl)c1O		CHEMBL3684170	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
323140	17702177	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCC[C@@H]2CO)CC1		CHEMBL3684171	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
323141	17702178	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cnn(C2CCN(C)C2)c1		CHEMBL3684172	=	IC50	nM	2.1	CHEMBL4578	Homo sapiens	IC50	nM	2.1
323142	17702179	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cnn(C2CCN(C)C2)c1		CHEMBL3684173	=	IC50	nM	0.9	CHEMBL4578	Homo sapiens	IC50	nM	0.9
323143	17702180	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC1CCCN(c2ccc(Nc3c(C(C)=O)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3684165	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
323144	17702181	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(C)C[C@H]1CC[C@H](Nc2c(C(C)=O)cnc3ccc(-c4cc(Cl)c(O)c(OC)c4)cc23)CC1		CHEMBL3684174	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
323145	17702182	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(C)C[C@H]1CC[C@H](Nc2c(C(C)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684175	=	IC50	nM	1.4	CHEMBL4578	Homo sapiens	IC50	nM	1.4
323146	17702183	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC(N)C2)CC1		CHEMBL3684176	=	IC50	nM	4.3	CHEMBL4578	Homo sapiens	IC50	nM	4.3
323147	17702184	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCN1CCC(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684177	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
323148	17702185	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCN1CCC(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684177	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
323149	17702186	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1NC1CCN(CCN(C)C)CC1		CHEMBL3684178	=	IC50	nM	5.3	CHEMBL4578	Homo sapiens	IC50	nM	5.3
323150	17702187	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCN1CCC(Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684179	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
323151	17702188	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1NC1CCN(CCN(C)C)CC1		CHEMBL3684180	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
323152	17702189	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCCC(N)C2)nc1		CHEMBL3684181	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
323153	17702190	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCCC(N)C2)nc1		CHEMBL3684182	=	IC50	nM	1.8	CHEMBL4578	Homo sapiens	IC50	nM	1.8
323154	17702191	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CCC[C@@H](CN(C)C)C1		CHEMBL3684183	=	IC50	nM	8.3	CHEMBL4578	Homo sapiens	IC50	nM	8.3
323155	17702192	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CCC[C@@H](CN(C)C)C1		CHEMBL3684184	=	IC50	nM	3.3	CHEMBL4578	Homo sapiens	IC50	nM	3.3
323156	17702193	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(CCc2cccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)c2)CC1		CHEMBL3684185	=	IC50	nM	17.0	CHEMBL4578	Homo sapiens	IC50	nM	17.0
323157	17702194	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(CCc2cccc(Nc3c(C(=O)C4CC4)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)c2)CC1		CHEMBL3684186	=	IC50	nM	5.1	CHEMBL4578	Homo sapiens	IC50	nM	5.1
323158	17702195	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN2CCN(C)CC2)c1		CHEMBL3684187	=	IC50	nM	19.0	CHEMBL4578	Homo sapiens	IC50	nM	19.0
323159	17702196	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN2CCN(C)CC2)c1		CHEMBL3684188	=	IC50	nM	5.4	CHEMBL4578	Homo sapiens	IC50	nM	5.4
323160	17702197	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CCC[C@@H](CN2CCN(C)CC2)C1		CHEMBL3684189	=	IC50	nM	9.0	CHEMBL4578	Homo sapiens	IC50	nM	9.0
323161	17702198	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1c(C)nc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3684190	=	IC50	nM	170.0	CHEMBL4578	Homo sapiens	IC50	nM	170.0
323162	17702199	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1c(C)nc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3684191	=	IC50	nM	820.0	CHEMBL4578	Homo sapiens	IC50	nM	820.0
323163	17702200	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CCC[C@@H](CN2CCN(C)CC2)C1		CHEMBL3684192	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
323164	17702201	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cnn(C2CCN(C)CC2)c1		CHEMBL3684193	=	IC50	nM	1.4	CHEMBL4578	Homo sapiens	IC50	nM	1.4
323165	17702202	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1c(C)nc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCN(C)CC2)nc1		CHEMBL3684194	=	IC50	nM	540.0	CHEMBL4578	Homo sapiens	IC50	nM	540.0
323166	17702203	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1c(C)nc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCN(C)CC2)nc1		CHEMBL3684195	=	IC50	nM	97.0	CHEMBL4578	Homo sapiens	IC50	nM	97.0
323167	17702204	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4cc(C(F)(F)F)c(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3684196	=	IC50	nM	4200.0	CHEMBL4578	Homo sapiens	IC50	nM	4200.0
323168	17702205	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCN(c2ccc(Nc3c(C(=O)C4CC4)cnc4cc(C(F)(F)F)c(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3684197	=	IC50	nM	3100.0	CHEMBL4578	Homo sapiens	IC50	nM	3100.0
323169	17702206	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3cc(C(F)(F)F)c(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684198	=	IC50	nM	770.0	CHEMBL4578	Homo sapiens	IC50	nM	770.0
323170	17702207	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3cc(C(F)(F)F)c(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684199	=	IC50	nM	930.0	CHEMBL4578	Homo sapiens	IC50	nM	930.0
323171	17702208	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1		CHEMBL3684200	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
323172	17702209	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCC[C@H]2CO)CC1		CHEMBL3684201	=	IC50	nM	4.6	CHEMBL4578	Homo sapiens	IC50	nM	4.6
323173	17702210	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(C)C[C@H]1CC[C@H](Nc2c(C(C)=O)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684202	=	IC50	nM	2.045	CHEMBL4578	Homo sapiens	IC50	nM	2.045
323174	17702211	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1		CHEMBL3684203	=	IC50	nM	2.3	CHEMBL4578	Homo sapiens	IC50	nM	2.3
323175	17702212	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2cc(C)c(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3684204	=	IC50	nM	550.0	CHEMBL4578	Homo sapiens	IC50	nM	550.0
323176	17702213	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(OCCN(C)C)nc1		CHEMBL3684205	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
323177	17702214	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1NC1CCC(C(=O)N2CCN(C)CC2)CC1		CHEMBL3684206	=	IC50	nM	18.0	CHEMBL4578	Homo sapiens	IC50	nM	18.0
323178	17702215	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1NC1CCCN(CCN(C)C)C1		CHEMBL3684207	=	IC50	nM	1.9	CHEMBL4578	Homo sapiens	IC50	nM	1.9
323179	17702216	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1NC1CCCN(CCN(C)C)C1		CHEMBL3684208	=	IC50	nM	40.0	CHEMBL4578	Homo sapiens	IC50	nM	40.0
323180	17702217	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(OCCN(C)C)nc1		CHEMBL3684209	=	IC50	nM	2.8	CHEMBL4578	Homo sapiens	IC50	nM	2.8
323181	17702218	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCC(N(C)C)C2)nc1		CHEMBL3684210	=	IC50	nM	18.0	CHEMBL4578	Homo sapiens	IC50	nM	18.0
323182	17702219	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCC(N(C)C)C2)nc1		CHEMBL3684211	=	IC50	nM	3.2	CHEMBL4578	Homo sapiens	IC50	nM	3.2
323183	17702220	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCC(N(C)C)C2)nc1		CHEMBL3684211	=	IC50	nM	2.1	CHEMBL4578	Homo sapiens	IC50	nM	2.1
323184	17702221	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2cc(C)c(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCN(C)CC2)nc1		CHEMBL3684212	=	IC50	nM	460.0	CHEMBL4578	Homo sapiens	IC50	nM	460.0
323185	17702222	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2cc(C)c(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3684213	=	IC50	nM	3400.0	CHEMBL4578	Homo sapiens	IC50	nM	3400.0
323186	17702223	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2cc(C)c(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3684214	=	IC50	nM	200.0	CHEMBL4578	Homo sapiens	IC50	nM	200.0
323187	17702224	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2cc(C)c(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3684215	=	IC50	nM	840.0	CHEMBL4578	Homo sapiens	IC50	nM	840.0
323188	17702225	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCC(N(C)C)C2)nc1		CHEMBL3684216	=	IC50	nM	6.2	CHEMBL4578	Homo sapiens	IC50	nM	6.2
323189	17702226	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CCC[C@H](CCN(C)C)C1		CHEMBL3684217	=	IC50	nM	3.2	CHEMBL4578	Homo sapiens	IC50	nM	3.2
323190	17702227	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CCC[C@H](CCN(C)C)C1		CHEMBL3684218	=	IC50	nM	6.7	CHEMBL4578	Homo sapiens	IC50	nM	6.7
323191	17702228	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCC(N(C)C)C2)nc1		CHEMBL3684219	=	IC50	nM	3.9	CHEMBL4578	Homo sapiens	IC50	nM	3.9
323192	17702229	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](C(=O)N(C)C)CC1		CHEMBL3684220	=	IC50	nM	9.3	CHEMBL4578	Homo sapiens	IC50	nM	9.3
323193	17702230	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2cc(C)c(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCN(C)CC2)nc1		CHEMBL3684221	=	IC50	nM	340.0	CHEMBL4578	Homo sapiens	IC50	nM	340.0
323194	17702231	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cnc(C)c(CCN2CCCC2)c1		CHEMBL3684222	=	IC50	nM	14.0	CHEMBL4578	Homo sapiens	IC50	nM	14.0
323195	17702232	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)CCO[C@H]1CC[C@H](Nc2c(C(C)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684223	=	IC50	nM	2.9	CHEMBL4578	Homo sapiens	IC50	nM	2.9
323196	17702233	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)CCO[C@H]1CC[C@H](Nc2c(C(C)=O)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684224	=	IC50	nM	10.0	CHEMBL4578	Homo sapiens	IC50	nM	10.0
323197	17702234	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](C(=O)N(C)C)CC1		CHEMBL3684225	=	IC50	nM	35.0	CHEMBL4578	Homo sapiens	IC50	nM	35.0
323198	17702235	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cnc(C)c(CCN2CCCC2)c1		CHEMBL3684226	=	IC50	nM	2.8	CHEMBL4578	Homo sapiens	IC50	nM	2.8
323199	17702236	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2cc(C)c(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCC(N)C2)CC1		CHEMBL3684227	=	IC50	nM	55.0	CHEMBL4578	Homo sapiens	IC50	nM	55.0
323200	17702237	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cncc(CCN2CCCC2)c1		CHEMBL3684228	=	IC50	nM	6.7	CHEMBL4578	Homo sapiens	IC50	nM	6.7
323201	17702238	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](NC(=O)C2CCCN2C)CC1		CHEMBL3684229	=	IC50	nM	16.0	CHEMBL4578	Homo sapiens	IC50	nM	16.0
323202	17702239	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](NC(=O)C2CCCN2C)CC1		CHEMBL3684230	=	IC50	nM	3.5	CHEMBL4578	Homo sapiens	IC50	nM	3.5
323203	17702240	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](NC(=O)CN(C)C)CC1		CHEMBL3684231	=	IC50	nM	8.8	CHEMBL4578	Homo sapiens	IC50	nM	8.8
323204	17702241	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](NC(=O)CN(C)C)CC1		CHEMBL3684232	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
323205	17702242	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](NC(=O)[C@H](C)N)CC1		CHEMBL3684233	=	IC50	nM	7.9	CHEMBL4578	Homo sapiens	IC50	nM	7.9
323206	17702243	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CS(=O)(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN2CCCC2)c1		CHEMBL3684234	=	IC50	nM	11.0	CHEMBL4578	Homo sapiens	IC50	nM	11.0
323207	17702244	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cncc(CCN2CCCC2)c1		CHEMBL3684235	=	IC50	nM	40.0	CHEMBL4578	Homo sapiens	IC50	nM	40.0
323208	17702245	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cncc(CCN2CCCC2)c1)C1CC1		CHEMBL3684236	=	IC50	nM	6.4	CHEMBL4578	Homo sapiens	IC50	nM	6.4
323209	17702246	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1cncc(CCN2CCCC2)c1)C1CC1		CHEMBL3684237	=	IC50	nM	19.0	CHEMBL4578	Homo sapiens	IC50	nM	19.0
323210	17702247	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CS(=O)(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN2CCCC2)c1		CHEMBL3684238	=	IC50	nM	2.0	CHEMBL4578	Homo sapiens	IC50	nM	2.0
323211	17702248	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCOc1ccc(Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)cn1		CHEMBL3684239	=	IC50	nM	3.5	CHEMBL4578	Homo sapiens	IC50	nM	3.5
323212	17702249	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCOc1ccc(Nc2c(S(C)(=O)=O)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)cn1		CHEMBL3684240	=	IC50	nM	8.3	CHEMBL4578	Homo sapiens	IC50	nM	8.3
323213	17702250	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](NC(=O)[C@H](C)N)CC1		CHEMBL3684241	=	IC50	nM	0.66	CHEMBL4578	Homo sapiens	IC50	nM	0.66
323214	17702251	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(S(=O)(=O)N2CCN(C)CC2)cc1		CHEMBL3684242	=	IC50	nM	36.0	CHEMBL4578	Homo sapiens	IC50	nM	36.0
323215	17702252	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc(-c4ccc(O)cc4)cc3)cc2c1Nc1cccc(CCN2CCCC2)c1		CHEMBL3684243	=	IC50	nM	3400.0	CHEMBL4578	Homo sapiens	IC50	nM	3400.0
323216	17702253	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C1CCN(c2ccc(Nc3c(S(C)(=O)=O)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3684244	=	IC50	nM	9.2	CHEMBL4578	Homo sapiens	IC50	nM	9.2
323217	17702254	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CS(=O)(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1		CHEMBL3684245	=	IC50	nM	2.7	CHEMBL4578	Homo sapiens	IC50	nM	2.7
323218	17702255	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CS(=O)(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1		CHEMBL3684246	=	IC50	nM	9.5	CHEMBL4578	Homo sapiens	IC50	nM	9.5
323219	17702256	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](C(=O)NCCN(C)C)CC1		CHEMBL3684247	=	IC50	nM	2.3	CHEMBL4578	Homo sapiens	IC50	nM	2.3
323220	17702257	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](C(=O)NCCN(C)C)CC1		CHEMBL3684248	=	IC50	nM	5.2	CHEMBL4578	Homo sapiens	IC50	nM	5.2
323221	17702258	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(S(=O)(=O)N2CCN(C)CC2)cc1		CHEMBL3684249	=	IC50	nM	39.0	CHEMBL4578	Homo sapiens	IC50	nM	39.0
323222	17702259	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc4nc[nH]c4c3)cc2c1Nc1cnn(C2CCN(C)CC2)c1		CHEMBL3684250	=	IC50	nM	65.0	CHEMBL4578	Homo sapiens	IC50	nM	65.0
323223	17702260	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc4nc[nH]c4c3)cc2c1Nc1cccc(CCN2CCCC2)c1		CHEMBL3684251	=	IC50	nM	220.0	CHEMBL4578	Homo sapiens	IC50	nM	220.0
323224	17702261	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cc(CCN2CCCC2)cnc1C		CHEMBL3684252	=	IC50	nM	21.0	CHEMBL4578	Homo sapiens	IC50	nM	21.0
323225	17702262	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](C(=O)N2CCN(C)CC2)CC1		CHEMBL3684253	=	IC50	nM	4.4	CHEMBL4578	Homo sapiens	IC50	nM	4.4
323226	17702263	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCC(n2cc(Nc3c(S(C)(=O)=O)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3684254	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
323227	17702264	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCC(n2cc(Nc3c(S(C)(=O)=O)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3684255	=	IC50	nM	3.2	CHEMBL4578	Homo sapiens	IC50	nM	3.2
323228	17702265	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc4nc[nH]c4c3)cc2c1Nc1ccc(N2CCN(C)CC2)nc1		CHEMBL3684256	=	IC50	nM	100.0	CHEMBL4578	Homo sapiens	IC50	nM	100.0
323229	17702266	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc4nc[nH]c4c3)cc2c1Nc1ccc(OCCN(C)C)nc1		CHEMBL3684257	=	IC50	nM	42.0	CHEMBL4578	Homo sapiens	IC50	nM	42.0
323230	17702267	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2cc(F)c(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3684258	=	IC50	nM	1.7	CHEMBL4578	Homo sapiens	IC50	nM	1.7
323231	17702268	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2cc(F)c(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3684259	=	IC50	nM	17.0	CHEMBL4578	Homo sapiens	IC50	nM	17.0
323232	17702269	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc4nc[nH]c4c3)cc2c1Nc1ccc(N2CCC(N(C)C)C2)nc1		CHEMBL3639831	=	IC50	nM	110.0	CHEMBL4578	Homo sapiens	IC50	nM	110.0
323233	17702270	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C1CCN(c2ccc(Nc3c(S(C)(=O)=O)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)C1		CHEMBL3684260	=	IC50	nM	2.4	CHEMBL4578	Homo sapiens	IC50	nM	2.4
323234	17702271	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](NC(=O)C(N)C(C)C)CC1		CHEMBL3684261	=	IC50	nM	4.7	CHEMBL4578	Homo sapiens	IC50	nM	4.7
323235	17702272	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccncc3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3684262	=	IC50	nM	230.0	CHEMBL4578	Homo sapiens	IC50	nM	230.0
323236	17702273	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CS(=O)(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCCC(N)C2)nc1		CHEMBL3684263	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
323237	17702274	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc4[nH]ncc4c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3684264	=	IC50	nM	100.0	CHEMBL4578	Homo sapiens	IC50	nM	100.0
323238	17702275	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc4nc[nH]c4c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3684265	=	IC50	nM	130.0	CHEMBL4578	Homo sapiens	IC50	nM	130.0
323239	17702276	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cn[nH]c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3684266	=	IC50	nM	74.0	CHEMBL4578	Homo sapiens	IC50	nM	74.0
323240	17702277	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CS(=O)(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCCC(N)C2)nc1		CHEMBL3684267	=	IC50	nM	0.94	CHEMBL4578	Homo sapiens	IC50	nM	0.94
323241	17702278	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](NC(=O)[C@@H](N)C(C)(C)C)CC1		CHEMBL3684268	=	IC50	nM	28.0	CHEMBL4578	Homo sapiens	IC50	nM	28.0
323242	17702279	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](NC(=O)C(N)C(C)C)CC1		CHEMBL3684269	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
323243	17702280	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CCCC4)c(N[C@H]4CC[C@H](CN(C)C)CC4)c3c2)cc(Cl)c1O		CHEMBL3684270	=	IC50	nM	4.8	CHEMBL4578	Homo sapiens	IC50	nM	4.8
323244	17702281	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)C3CCCC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684271	=	IC50	nM	3.0	CHEMBL4578	Homo sapiens	IC50	nM	3.0
323245	17702282	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)C(C)(C)C)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684272	=	IC50	nM	22.0	CHEMBL4578	Homo sapiens	IC50	nM	22.0
323246	17702283	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)C(C)(C)C)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684273	=	IC50	nM	34.0	CHEMBL4578	Homo sapiens	IC50	nM	34.0
323247	17702284	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](NC(=O)[C@@H]2CCCN2)CC1		CHEMBL3684274	=	IC50	nM	1.9	CHEMBL4578	Homo sapiens	IC50	nM	1.9
323248	17702285	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](NC(=O)[C@@H]2CCCN2)CC1		CHEMBL3684275	=	IC50	nM	12.0	CHEMBL4578	Homo sapiens	IC50	nM	12.0
323249	17702286	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](NC(=O)[C@@H](N)C(C)(C)C)CC1		CHEMBL3684276	=	IC50	nM	4.2	CHEMBL4578	Homo sapiens	IC50	nM	4.2
323250	17702287	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2cc(F)c(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1		CHEMBL3684277	=	IC50	nM	7.0	CHEMBL4578	Homo sapiens	IC50	nM	7.0
323251	17702288	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(=O)C4CCCC4)c(Nc4cccc(CCN5CCCC5)c4)c3c2)cc(Cl)c1O		CHEMBL3684278	=	IC50	nM	18.0	CHEMBL4578	Homo sapiens	IC50	nM	18.0
323252	17702289	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2cc(F)c(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN2CCCC2)CC1		CHEMBL3684279	=	IC50	nM	19.0	CHEMBL4578	Homo sapiens	IC50	nM	19.0
323253	17702290	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2cc3c(N[C@H]4CC[C@H](CN5CCCC5)CC4)c(C(C)=O)cnc3cc2F)cc(Cl)c1O		CHEMBL3684280	=	IC50	nM	7.9	CHEMBL4578	Homo sapiens	IC50	nM	7.9
323254	17702291	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1cccc(CCN2CCCC2)c1)C1CCCC1		CHEMBL3684281	=	IC50	nM	9.6	CHEMBL4578	Homo sapiens	IC50	nM	9.6
323255	17702292	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(N)C(=O)N[C@H]1CC[C@H](Nc2c(C(=O)C(C)(C)C)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684282	=	IC50	nM	15.0	CHEMBL4578	Homo sapiens	IC50	nM	15.0
323256	17702293	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc4cc(O)ccc4c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3684283	=	IC50	nM	64.0	CHEMBL4578	Homo sapiens	IC50	nM	64.0
323257	17702294	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCC(n2cc(Nc3c(C(=O)C(C)(C)C)cnc4ccc(-c5cc(F)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3684284	=	IC50	nM	17.0	CHEMBL4578	Homo sapiens	IC50	nM	17.0
323258	17702295	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN1CCC(n2cc(Nc3c(C(=O)C(C)(C)C)cnc4ccc(-c5cc(Cl)c(O)c(Cl)c5)cc34)cn2)CC1		CHEMBL3684285	=	IC50	nM	6.2	CHEMBL4578	Homo sapiens	IC50	nM	6.2
323259	17702296	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(N)C(=O)N[C@H]1CC[C@H](Nc2c(C(=O)C(C)(C)C)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3684286	=	IC50	nM	47.0	CHEMBL4578	Homo sapiens	IC50	nM	47.0
323260	17702297	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2c(c1)CN(c1ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](CN(C)C)CC4)c3c1)C2=O		CHEMBL3684287	=	IC50	nM	1200.0	CHEMBL4578	Homo sapiens	IC50	nM	1200.0
323261	17702298	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(N2CCC[C@H](N)C2)nc1		CHEMBL3684288	=	IC50	nM	1.2	CHEMBL4578	Homo sapiens	IC50	nM	1.2
323262	17702299	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3ccc(O)cc3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3684289	=	IC50	nM	80.0	CHEMBL4578	Homo sapiens	IC50	nM	80.0
323263	17702300	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674166	=	IC50	nM	1.9	CHEMBL4578	Homo sapiens	IC50	nM	1.9
323264	17702301	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674174	=	IC50	nM	5.4	CHEMBL4578	Homo sapiens	IC50	nM	5.4
323265	17702302	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(=O)c1cnc2ccc(-c3cc(F)c(O)c(F)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674177	=	IC50	nM	17.0	CHEMBL4578	Homo sapiens	IC50	nM	17.0
323266	17702303	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](N)CC1		CHEMBL3674188	=	IC50	nM	3.4	CHEMBL4578	Homo sapiens	IC50	nM	3.4
323267	17702304	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(-c2ccc3ncc(C(C)=O)c(N[C@H]4CC[C@H](N)CC4)c3c2)cc(Cl)c1O		CHEMBL3674190	=	IC50	nM	1.2	CHEMBL4578	Homo sapiens	IC50	nM	1.2
323268	17702305	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674192	=	IC50	nM	1.6	CHEMBL4578	Homo sapiens	IC50	nM	1.6
323269	17702306	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(F)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674193	=	IC50	nM	2.9	CHEMBL4578	Homo sapiens	IC50	nM	2.9
323270	17702307	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C[C@H]1CC[C@H](Nc2c(C(=O)C3CC3)cnc3ccc(-c4cc(Cl)c(O)c(Cl)c4)cc23)CC1		CHEMBL3674217	=	IC50	nM	0.85	CHEMBL4578	Homo sapiens	IC50	nM	0.85
323271	17702308	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=C(c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN2CCCC2)cc1)C1CC1		CHEMBL3674235	=	IC50	nM	150.0	CHEMBL4578	Homo sapiens	IC50	nM	150.0
323272	17702309	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3674236	=	IC50	nM	6.6	CHEMBL4578	Homo sapiens	IC50	nM	6.6
323273	17702310	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1Nc1ccc(CN(C)C)cc1		CHEMBL3674236	=	IC50	nM	2.2	CHEMBL4578	Homo sapiens	IC50	nM	2.2
323274	17702311	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3674237	=	IC50	nM	6.1	CHEMBL4578	Homo sapiens	IC50	nM	6.1
323275	17702312	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(F)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3674237	=	IC50	nM	4.0	CHEMBL4578	Homo sapiens	IC50	nM	4.0
323276	17702313	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3674238	=	IC50	nM	3.1	CHEMBL4578	Homo sapiens	IC50	nM	3.1
323277	17702314	CHEMBL3705873	Kinase Assay: MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)cc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3674238	=	IC50	nM	0.94	CHEMBL4578	Homo sapiens	IC50	nM	0.94
Inactive	17918598	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918599	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918600	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918601	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	=	Kd	nM	57.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	57.0
Uncertain	17918602	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	1379.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	1379.0
Inactive	17918603	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918604	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918605	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918606	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918607	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918608	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918609	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918610	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918611	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918612	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	=	Kd	nM	8215.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	8215.0
Inactive	17918613	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918614	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918615	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Kd	nM	1706.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	1706.0
Inactive	17918616	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918617	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	=	Kd	nM	2805.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	2805.0
Inactive	17918618	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918619	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918620	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918621	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918622	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918623	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918624	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918625	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918626	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918627	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918628	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	=	Kd	nM	4227.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	4227.0
Inactive	17918629	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918630	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918631	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918632	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918633	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918634	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918635	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	=	Kd	nM	1458.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	1458.0
Inactive	17918636	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918637	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918638	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918639	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Kd	nM	83.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	83.0
Inactive	17918640	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918641	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918642	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918643	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918644	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918645	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918646	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918647	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918648	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918649	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918650	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918651	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918652	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918653	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918654	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918655	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	=	Kd	nM	1816.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	1816.0
Inactive	17918656	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918657	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918658	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918659	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918660	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918661	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918662	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918663	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918664	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918665	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918666	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918667	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918668	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918669	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918670	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918671	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918672	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918673	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918674	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918675	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	=	Kd	nM	4533.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	4533.0
Inactive	17918676	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918677	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918678	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918679	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918680	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918681	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	2928.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	2928.0
Inactive	17918682	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918683	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918684	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918685	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918686	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	1645.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	1645.0
Inactive	17918687	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918688	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	53.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	53.0
Active	17918689	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	185.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	185.0
Inactive	17918690	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918691	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918692	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918693	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918694	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918695	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918696	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918697	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918698	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918699	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918700	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918701	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918702	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918703	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918704	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918705	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918706	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918707	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918708	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918709	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918710	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918711	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17918712	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	Kd	nM	240.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	240.0
Inactive	17918713	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918714	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918715	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918716	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	=	Kd	nM	1795.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	1795.0
Inactive	17918717	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918718	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918719	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Kd	nM	23232.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	23232.0
Active	17918720	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	=	Kd	nM	217.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	217.0
Inactive	17918721	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918722	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918723	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918724	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918725	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	=	Kd	nM	4695.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	4695.0
Uncertain	17918726	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Kd	nM	320.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	320.0
Inactive	17918727	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918728	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918729	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918730	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918731	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918732	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918733	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918734	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918735	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918736	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918737	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918738	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918739	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918740	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918741	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918742	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918743	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918744	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918745	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918746	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918747	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918748	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	1353.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	1353.0
Inactive	17918749	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918750	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918751	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918752	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918753	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918754	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918755	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918756	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918757	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918758	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	=	Kd	nM	29933.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	29933.0
Inactive	17918759	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918760	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918761	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17918762	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	=	Kd	nM	2300.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	2300.0
Inactive	17918763	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918764	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918765	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918766	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918767	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918768	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918769	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918770	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918771	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918772	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918773	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918774	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918775	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918776	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918777	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918778	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918779	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918780	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918781	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918782	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918783	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918784	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918785	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918786	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918787	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918788	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918789	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918790	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918791	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918792	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918793	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918794	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918795	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918796	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918797	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918798	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918799	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	=	Kd	nM	5166.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	5166.0
Inactive	17918800	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918801	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918802	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918803	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918804	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918805	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918806	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918807	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918808	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918809	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918810	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918811	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918812	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918813	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	Kd	nM	29.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	29.0
Inactive	17918814	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918815	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918816	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918817	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918818	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918819	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918820	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918821	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918822	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918823	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918824	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918825	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918826	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918827	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	=	Kd	nM	897.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	897.0
Active	17918828	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Kd	nM	1922.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	1922.0
Active	17918829	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	=	Kd	nM	4081.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	4081.0
Inactive	17918830	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918831	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918832	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918833	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17918834	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	=	Kd	nM	2987.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	2987.0
Active	17918835	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	=	Kd	nM	45694.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	45694.0
Inactive	17918836	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918837	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918838	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17918839	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	30000.0
Active	17918840	CHEMBL3991787	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	=	Kd	nM	918.0	CHEMBL4578	Homo sapiens	Kd apparent	nM	918.0
	18024573	CHEMBL4006633	Inhibition of MELK (unknown origin) containing kinase domain and UBA domain using STK S1 as substrate after 20 mins by HTRF assay	B	COc1ccc2nc(CNC(=O)c3ccc(-c4cnccc4OCC4CCNCC4)cc3)[nH]c2c1		CHEMBL4071823	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
	18024574	CHEMBL4006633	Inhibition of MELK (unknown origin) containing kinase domain and UBA domain using STK S1 as substrate after 20 mins by HTRF assay	B	CNc1ncc(-c2ccc(C(=O)NCc3nc4ccc(OC)cc4[nH]3)cc2)c(OCC2CCNCC2)n1		CHEMBL4092605	=	IC50	nM	1.5	CHEMBL4578	Homo sapiens	IC50	nM	1.5
	18024575	CHEMBL4006633	Inhibition of MELK (unknown origin) containing kinase domain and UBA domain using STK S1 as substrate after 20 mins by HTRF assay	B	COc1ccc2nc(CNC(=O)c3ccc(-c4cnc(Nc5ccccc5)nc4OCC4CCNCC4)cc3)[nH]c2c1		CHEMBL4077934	=	IC50	nM	0.15	CHEMBL4578	Homo sapiens	IC50	nM	0.15
	18024576	CHEMBL4006633	Inhibition of MELK (unknown origin) containing kinase domain and UBA domain using STK S1 as substrate after 20 mins by HTRF assay	B	O=C(NCc1nc2ccccc2[nH]1)c1ccc(-c2cnccc2OCC2CCNCC2)cc1		CHEMBL4095977	=	IC50	nM	12.0	CHEMBL4578	Homo sapiens	IC50	nM	12.0
	18024577	CHEMBL4006633	Inhibition of MELK (unknown origin) containing kinase domain and UBA domain using STK S1 as substrate after 20 mins by HTRF assay	B	CNc1ncc(-c2ccc(C(=O)NCc3nc4ccccc4[nH]3)cc2)c(OCC2CCNCC2)n1		CHEMBL4066968	=	IC50	nM	9.2	CHEMBL4578	Homo sapiens	IC50	nM	9.2
	18024578	CHEMBL4006633	Inhibition of MELK (unknown origin) containing kinase domain and UBA domain using STK S1 as substrate after 20 mins by HTRF assay	B	O=C(NCc1nc2ccccc2[nH]1)c1ccc(-c2cnc(Nc3ccccc3)nc2OCC2CCNCC2)cc1		CHEMBL4088246	=	IC50	nM	1.1	CHEMBL4578	Homo sapiens	IC50	nM	1.1
	18024579	CHEMBL4006633	Inhibition of MELK (unknown origin) containing kinase domain and UBA domain using STK S1 as substrate after 20 mins by HTRF assay	B	O=C(CNC(=O)c1ccc(-c2cnccc2OCC2CCNCC2)cc1)Nc1ccccc1		CHEMBL4093545	=	IC50	nM	740.0	CHEMBL4578	Homo sapiens	IC50	nM	740.0
	18024580	CHEMBL4006633	Inhibition of MELK (unknown origin) containing kinase domain and UBA domain using STK S1 as substrate after 20 mins by HTRF assay	B	CNc1ncc(-c2ccc(C(=O)NCC(=O)Nc3ccccc3)cc2)c(OCC2CCNCC2)n1		CHEMBL4065944	=	IC50	nM	120.0	CHEMBL4578	Homo sapiens	IC50	nM	120.0
	18024581	CHEMBL4006633	Inhibition of MELK (unknown origin) containing kinase domain and UBA domain using STK S1 as substrate after 20 mins by HTRF assay	B	O=C(CNC(=O)c1ccc(-c2cnc(Nc3ccccc3)nc2OCC2CCNCC2)cc1)Nc1ccccc1		CHEMBL4085799	=	IC50	nM	8.8	CHEMBL4578	Homo sapiens	IC50	nM	8.8
Not Determined	18066731	CHEMBL4014539	Inhibition of human MELK	B	COc1ccc(-c2cnc3scc(NC(=O)C4CCCCC4)c3c2)cc1OC		CHEMBL3334979		IC50			CHEMBL4578	Homo sapiens	IC50		
	18066732	CHEMBL4014540	Inhibition of human MELK at 10 uM relative to control	B	CCOc1cc(/C=C2\Oc3ccc(OC)cc3C2=O)ccc1O		CHEMBL4105195	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	18066733	CHEMBL4014540	Inhibition of human MELK at 10 uM relative to control	B	COc1ccc2c(c1)C(=O)/C(=C/c1ccc(O)c(O)c1)O2		CHEMBL4087337	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	18066734	CHEMBL4014540	Inhibition of human MELK at 10 uM relative to control	B	O=C1/C(=C/c2ccc(O)c(O)c2)Oc2cc(O)ccc21		CHEMBL490355	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	18114255	CHEMBL4025239	Inhibition of wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	98.0	CHEMBL4578	Homo sapiens	Activity	%	98.0
	18135866	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/C1=CC=C2C=CC(Br)=CC21.Cl		CHEMBL4064740	=	IC50	nM	400.0	CHEMBL4578	Homo sapiens	IC50	nM	400.0
	18135867	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409	=	IC50	nM	225.0	CHEMBL4578	Homo sapiens	IC50	nM	225.0
	18135868	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	Cl.Cl.N=C(N)NCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL4080669	=	IC50	nM	440.0	CHEMBL4578	Homo sapiens	IC50	nM	440.0
	18135869	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	=	IC50	nM	340.0	CHEMBL4578	Homo sapiens	IC50	nM	340.0
	18135870	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	Cl.NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@@H]1CCCNC1		CHEMBL4061324	=	IC50	nM	900.0	CHEMBL4578	Homo sapiens	IC50	nM	900.0
	18135871	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	=	IC50	nM	685.0	CHEMBL4578	Homo sapiens	IC50	nM	685.0
	18135872	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	IC50	nM	43.0	CHEMBL4578	Homo sapiens	IC50	nM	43.0
	18135873	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	IC50	nM	760.0	CHEMBL4578	Homo sapiens	IC50	nM	760.0
	18135874	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	O=C1Nc2ccc3scnc3c2/C1=C/c1cnc[nH]1		CHEMBL4088537	=	IC50	nM	720.0	CHEMBL4578	Homo sapiens	IC50	nM	720.0
	18135875	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	IC50	nM	330.0	CHEMBL4578	Homo sapiens	IC50	nM	330.0
	18135876	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4ccc(C(=O)N(C)C)cc43)c3ccccc3)cc2)CC1		CHEMBL4070814	=	IC50	nM	67.0	CHEMBL4578	Homo sapiens	IC50	nM	67.0
	18135877	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CNC(=O)c1ccc2c(c1)/C(=C(/Nc1ccc(N(C)C(=O)CN3CCN(C)CC3)cc1)c1ccccc1)C(=O)N2		CHEMBL4083922	=	IC50	nM	18.0	CHEMBL4578	Homo sapiens	IC50	nM	18.0
	18135878	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4cc(C(=O)NCCCN)ccc43)c3ccccc3)cc2)CC1		CHEMBL4062202	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	nM	5000.0
	18135879	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN(C)CCCNC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL4061117	=	IC50	nM	2700.0	CHEMBL4578	Homo sapiens	IC50	nM	2700.0
	18135880	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4ccc(C(=O)O)cc43)c3ccccc3)cc2)CC1		CHEMBL4089284	=	IC50	nM	5.2	CHEMBL4578	Homo sapiens	IC50	nM	5.2
	18135881	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4cc(C(=O)O)ccc43)c3ccccc3)cc2)CC1		CHEMBL4099431	=	IC50	nM	1145.0	CHEMBL4578	Homo sapiens	IC50	nM	1145.0
	18135882	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4ccc(F)cc43)c3ccccc3)cc2)CC1		CHEMBL4081410	=	IC50	nM	24.0	CHEMBL4578	Homo sapiens	IC50	nM	24.0
	18135883	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CC(=O)c1ccc2c(c1)/C(=C(/Nc1ccc(N(C)C(=O)CN3CCN(C)CC3)cc1)c1ccccc1)C(=O)N2		CHEMBL4075402	=	IC50	nM	354.0	CHEMBL4578	Homo sapiens	IC50	nM	354.0
	18135884	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	COC(=O)c1ccc2c(c1)/C(=C(/Nc1ccc(N(C)C(=O)CN3CCN(C)CC3)cc1)c1ccccc1)C(=O)N2		CHEMBL4062168	=	IC50	nM	3.0	CHEMBL4578	Homo sapiens	IC50	nM	3.0
	18135885	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4ccccc43)c3ccccc3)cc2)CC1		CHEMBL1908392	=	IC50	nM	3.6	CHEMBL4578	Homo sapiens	IC50	nM	3.6
Active	18135900	CHEMBL4029831	Inhibition of MELK in human HCC70 cells assessed as reduction in Mcl-1 expression up to 2.5 uM after 18 hrs under serum free condition by Western blot method	B	COC(=O)c1ccc2c(c1)/C(=C(/Nc1ccc(N(C)C(=O)CN3CCN(C)CC3)cc1)c1ccccc1)C(=O)N2		CHEMBL4062168		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
	18135905	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Ki	nM	5.6	CHEMBL4578	Homo sapiens	Ki	nM	5.6
	18135906	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4ccccc43)c3ccccc3)cc2)CC1		CHEMBL1908392	=	Ki	nM	0.47	CHEMBL4578	Homo sapiens	Ki	nM	0.47
	18135907	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	COC(=O)c1ccc2c(c1)/C(=C(/Nc1ccc(N(C)C(=O)CN3CCN(C)CC3)cc1)c1ccccc1)C(=O)N2		CHEMBL4062168	=	Ki	nM	0.39	CHEMBL4578	Homo sapiens	Ki	nM	0.39
	18135908	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CC(=O)c1ccc2c(c1)/C(=C(/Nc1ccc(N(C)C(=O)CN3CCN(C)CC3)cc1)c1ccccc1)C(=O)N2		CHEMBL4075402	=	Ki	nM	46.0	CHEMBL4578	Homo sapiens	Ki	nM	46.0
	18135909	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4ccc(F)cc43)c3ccccc3)cc2)CC1		CHEMBL4081410	=	Ki	nM	3.1	CHEMBL4578	Homo sapiens	Ki	nM	3.1
	18135910	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4cc(C(=O)O)ccc43)c3ccccc3)cc2)CC1		CHEMBL4099431	=	Ki	nM	149.0	CHEMBL4578	Homo sapiens	Ki	nM	149.0
	18135911	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4ccc(C(=O)O)cc43)c3ccccc3)cc2)CC1		CHEMBL4089284	=	Ki	nM	0.68	CHEMBL4578	Homo sapiens	Ki	nM	0.68
	18135912	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN(C)CCCNC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL4061117	=	Ki	nM	358.0	CHEMBL4578	Homo sapiens	Ki	nM	358.0
	18135913	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4cc(C(=O)NCCCN)ccc43)c3ccccc3)cc2)CC1		CHEMBL4062202	>	Ki	nM	650.0	CHEMBL4578	Homo sapiens	Ki	nM	650.0
	18135914	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CNC(=O)c1ccc2c(c1)/C(=C(/Nc1ccc(N(C)C(=O)CN3CCN(C)CC3)cc1)c1ccccc1)C(=O)N2		CHEMBL4083922	=	Ki	nM	2.3	CHEMBL4578	Homo sapiens	Ki	nM	2.3
	18135915	CHEMBL4029820	Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method	B	CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4ccc(C(=O)N(C)C)cc43)c3ccccc3)cc2)CC1		CHEMBL4070814	=	Ki	nM	8.8	CHEMBL4578	Homo sapiens	Ki	nM	8.8
	18147993	CHEMBL4032836	Inhibition of MELK (unknown origin) at 10 uM after 60 mins in presence of [gamma-33P]-ATP by microplate scintillation counting	B	N#Cc1ccc2c(c1)[nH]c(=O)n2[C@H]1C[C@H](c2nnc(-c3ccncn3)n2-c2ccccc2Cl)C1		CHEMBL4095003	=	Inhibition	%	70.0	CHEMBL4578	Homo sapiens	INH	%	70.0
	18153274	CHEMBL4034401	Inhibition of MELK Lysine 2 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	>	Inhibition	%	35.0	CHEMBL4578	Homo sapiens	INH	%	35.0
	18156521	CHEMBL4035087	Inhibition of MELK (unknown origin)	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(OC)cc12		CHEMBL4075551	=	IC50	nM	6100.0	CHEMBL4578	Homo sapiens	IC50	uM	6.1
	18156522	CHEMBL4035087	Inhibition of MELK (unknown origin)	B	CCN(CC)CC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4068776	=	IC50	nM	3700.0	CHEMBL4578	Homo sapiens	IC50	uM	3.7
	18156523	CHEMBL4035087	Inhibition of MELK (unknown origin)	B	CCN(CC)CCCCNc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4076106	=	IC50	nM	2100.0	CHEMBL4578	Homo sapiens	IC50	uM	2.1
Tde	18156527	CHEMBL4035102	Inhibition of MELK in human MDA-MB-231 cells assessed as upregulation of p53-dependent p21WAF1/CIP1 expression at 5 uM by Western blot method	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2ccccc2)nc2cc(Cl)ccc12		CHEMBL4094697		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
Tde	18156528	CHEMBL4035102	Inhibition of MELK in human MDA-MB-231 cells assessed as upregulation of p53-dependent p21WAF1/CIP1 expression at 5 uM by Western blot method	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4090364		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
Tde	18156529	CHEMBL4035103	Inhibition of MELK in human MDA-MB-468 cells assessed as upregulation of p53-dependent p21WAF1/CIP1 expression at 5 uM by Western blot method	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2ccccc2)nc2cc(Cl)ccc12		CHEMBL4094697		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
Tde	18156530	CHEMBL4035103	Inhibition of MELK in human MDA-MB-468 cells assessed as upregulation of p53-dependent p21WAF1/CIP1 expression at 5 uM by Western blot method	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4090364		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
Active	18156531	CHEMBL4035104	Inhibition of MELK in human MDA-MB-468 cells assessed as decrease in cyclin A2 level at 5 uM measured over 48 hrs by Western blot method	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2ccccc2)nc2cc(Cl)ccc12		CHEMBL4094697		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
Active	18156532	CHEMBL4035104	Inhibition of MELK in human MDA-MB-468 cells assessed as decrease in cyclin A2 level at 5 uM measured over 48 hrs by Western blot method	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4090364		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
Active	18156533	CHEMBL4035105	Inhibition of MELK in human MDA-MB-231 cells assessed as decrease in cyclin A2 level at 5 uM measured over 48 hrs by Western blot method	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2ccccc2)nc2cc(Cl)ccc12		CHEMBL4094697		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
Active	18156534	CHEMBL4035105	Inhibition of MELK in human MDA-MB-231 cells assessed as decrease in cyclin A2 level at 5 uM measured over 48 hrs by Western blot method	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4090364		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
	18156558	CHEMBL4035087	Inhibition of MELK (unknown origin)	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4090364	=	IC50	nM	1400.0	CHEMBL4578	Homo sapiens	IC50	uM	1.4
	18156561	CHEMBL4035092	Inhibition of MELK (unknown origin) at 20 uM relative to control	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4090364	>	Inhibition	%	98.0	CHEMBL4578	Homo sapiens	INH	%	98.0
Tde	18156562	CHEMBL4035106	Inhibition of MELK in human MDA-MB-468 cells assessed as decrease in p53 phosphorylation at Ser15 residue at 5 uM by Western blot method	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2ccccc2)nc2cc(Cl)ccc12		CHEMBL4094697		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
Tde	18156563	CHEMBL4035106	Inhibition of MELK in human MDA-MB-468 cells assessed as decrease in p53 phosphorylation at Ser15 residue at 5 uM by Western blot method	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4090364		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
	18156570	CHEMBL4035087	Inhibition of MELK (unknown origin)	B	CCN(CC)CCC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4090438	=	IC50	nM	2600.0	CHEMBL4578	Homo sapiens	IC50	uM	2.6
	18156571	CHEMBL4035087	Inhibition of MELK (unknown origin)	B	Nc1ccc2nc(/C=C/c3ccc(C(F)(F)F)cc3)nc(NCCCN3CCOCC3)c2c1		CHEMBL4069405	=	IC50	nM	3500.0	CHEMBL4578	Homo sapiens	IC50	uM	3.5
	18156572	CHEMBL4035087	Inhibition of MELK (unknown origin)	B	CCN(CC)CCCC(C)Nc1nc(CCc2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4098153	=	IC50	nM	7700.0	CHEMBL4578	Homo sapiens	IC50	uM	7.7
	18156573	CHEMBL4035087	Inhibition of MELK (unknown origin)	B	CCN(CC)CCCC(C)Nc1nc(CCc2ccc(C(F)(F)F)cc2)nc2ccc(N)cc12		CHEMBL4080127	=	IC50	nM	1300.0	CHEMBL4578	Homo sapiens	IC50	uM	1.3
	18156574	CHEMBL4035087	Inhibition of MELK (unknown origin)	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2cccc(C(F)(F)F)c2)nc2ccc(N)cc12		CHEMBL4059705	=	IC50	nM	6800.0	CHEMBL4578	Homo sapiens	IC50	uM	6.8
	18156575	CHEMBL4035087	Inhibition of MELK (unknown origin)	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2ccccc2C(F)(F)F)nc2ccc(N)cc12		CHEMBL4087997	=	IC50	nM	8900.0	CHEMBL4578	Homo sapiens	IC50	uM	8.9
	18203763	CHEMBL4044050	Inhibition of wild-type human full length MELK (M1 to V651 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	100.0	CHEMBL4578	Homo sapiens	Activity	%	100.0
	18232119	CHEMBL4050383	Inhibition of human MELK assessed as residual activity at 1 uM in presence of [33P]ATP by filter binding assay relative to control	B	NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4077554	=	Activity	%	93.0	CHEMBL4578	Homo sapiens	Activity	%	93.0
	18253453	CHEMBL4055010	Inhibition of wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	79.0	CHEMBL4578	Homo sapiens	Activity	%	79.0
	18253454	CHEMBL4055010	Inhibition of wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	79.0	CHEMBL4578	Homo sapiens	Activity	%	79.0
	18265900	CHEMBL4057350	Inhibition of MELK (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	38.0	CHEMBL4578	Homo sapiens	INH	%	38.0
	18266094	CHEMBL4057544	Inhibition of MELK (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1		CHEMBL4088455	=	Inhibition	%	4.0	CHEMBL4578	Homo sapiens	INH	%	4.0
	18282158	CHEMBL4120113	Inhibition of recombinant GST-tagged human MELK expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	30.4	CHEMBL4578	Homo sapiens	INH	%	30.4
	18282477	CHEMBL4120113	Inhibition of recombinant GST-tagged human MELK expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	12.6	CHEMBL4578	Homo sapiens	INH	%	12.6
	18282769	CHEMBL4120354	Inhibition of MELK (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	38.0	CHEMBL4578	Homo sapiens	INH	%	38.0
	18282938	CHEMBL4120523	Inhibition of MELK (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	51.0	CHEMBL4578	Homo sapiens	INH	%	51.0
	18283162	CHEMBL4120747	Inhibition of MELK (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	10.7	CHEMBL4578	Homo sapiens	INH	%	10.7
	18431070	CHEMBL4155751	Inhibition of recombinant GST-tagged human MELK expressed in baculovirus expression system at 1 uM by Z'-Lyte assay relative to control	B	O=C1Nc2ccc(C(=O)N[C@H](CO)c3ccccc3)cc2/C1=C(\c1ccccc1)c1ncc[nH]1		CHEMBL4160587	=	Inhibition	%	101.0	CHEMBL4578	Homo sapiens	INH	%	101.0
	18440305	CHEMBL4157129	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	100.0	CHEMBL4578	Homo sapiens	Activity	%	100.0
	18449913	CHEMBL4178149	Inhibition of human MELK (2 to 651 residues) assessed as residual activity at 500 nM in presence of 33P-ATP by filter binding assay relative to control	B	Cc1cccc(-c2nc(N)sc2-c2ccc3ncccc3n2)c1		CHEMBL4209540	=	Activity	%	91.0	CHEMBL4578	Homo sapiens	Activity	%	91.0
	18484261	CHEMBL4185908	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	97.0	CHEMBL4578	Homo sapiens	Activity	%	97.0
	18484745	CHEMBL4185908	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	78.0	CHEMBL4578	Homo sapiens	Activity	%	78.0
	18507714	CHEMBL4191048	Inhibition of recombinant human MELK (1 to 340 residues) at 1 uM using KKLNRTLSFAEPG as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	28.0	CHEMBL4578	Homo sapiens	INH	%	28.0
	18653523	CHEMBL4230142	Inhibition of MELK (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	-3.0	CHEMBL4578	Homo sapiens	INH	%	-3.0
	18653524	CHEMBL4230142	Inhibition of MELK (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	2.0	CHEMBL4578	Homo sapiens	INH	%	2.0
	18655427	CHEMBL4230808	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	84.0	CHEMBL4578	Homo sapiens	Activity	%	84.0
	18725395	CHEMBL4259092	Inhibition of MELK (unknown origin)	B	CC(=O)n1nc(C)c(-c2ccc(Cl)c(Cl)c2)c1N		CHEMBL4276946	>	IC50	nM	100000.0	CHEMBL4578	Homo sapiens	IC50	uM	100.0
	18738157	CHEMBL4261670	Inhibition of recombinant C-terminal His6-tagged human MELK expressed in Escherichia coli BL21 (DE3) RIL using FAM-GS-derived peptide as substrate after 3 hrs by IMAP method	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	IC50	nM	0.41	CHEMBL4578	Homo sapiens	IC50	nM	0.41
	18751042	CHEMBL4263860	Inhibition of MELK (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	24.0	CHEMBL4578	Homo sapiens	INH	%	24.0
	18752000	CHEMBL4264397	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	75.0	CHEMBL4578	Homo sapiens	Activity	%	75.0
	18764542	CHEMBL4267083	Inhibition of human MELK at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)cc3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4288103	=	Inhibition	%	70.0	CHEMBL4578	Homo sapiens	INH	%	70.0
	18764543	CHEMBL4267083	Inhibition of human MELK at 100 nM	B	CN1CCC(c2nc(-c3cccc(S(C)(=O)=O)c3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4286880	<	Inhibition	%	70.0	CHEMBL4578	Homo sapiens	INH	%	70.0
	18764544	CHEMBL4267083	Inhibition of human MELK at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)c(NS(C)(=O)=O)c3)c(-c3ccnc(NCC4CC4)n3)s2)CC1		CHEMBL4286841	<	Inhibition	%	70.0	CHEMBL4578	Homo sapiens	INH	%	70.0
	18858061	CHEMBL4307907	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	100.0	CHEMBL4578	Homo sapiens	Activity	%	100.0
	18892653	CHEMBL4314596	Inhibition of recombinant human MELK (1 to 340 residues) assessed as residual activity at 10 uM using KKLNRTLSFAEPG as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	113.5	CHEMBL4578	Homo sapiens	Activity	%	113.5
	18919509	CHEMBL4322866	Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged MELK (unknown origin) (1 to 493 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	50.0	CHEMBL4578	Homo sapiens	Kd	nM	50.0
	18919697	CHEMBL4322866	Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged MELK (unknown origin) (1 to 493 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	41.0	CHEMBL4578	Homo sapiens	Kd	nM	41.0
	18938081	CHEMBL4327767	Inhibition of human MELK assessed as residual activity at 1 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	93.82	CHEMBL4578	Homo sapiens	Activity	%	93.82
	18938082	CHEMBL4327767	Inhibition of human MELK assessed as residual activity at 1 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	101.76	CHEMBL4578	Homo sapiens	Activity	%	101.76
	18938612	CHEMBL4328131	Inhibition of human MELK assessed as residual activity at 100 uM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL4578	Homo sapiens	Activity	%	65.0
	18938992	CHEMBL4328495	Inhibition of human MELK using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.542	CHEMBL4578	Homo sapiens	IC50	10'-10M	5.42
	18950438	CHEMBL4331203	Inhibition of MELK (unknown origin) at 1 uM relative to control	B	c1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cc(N2CCOCC2)n1		CHEMBL4460272	=	Inhibition	%	60.0	CHEMBL4578	Homo sapiens	INH	%	60.0
	18953686	CHEMBL4331931	Inhibition of MELK (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(NC3CCCCC3)c12		CHEMBL4440433	=	Inhibition	%	91.0	CHEMBL4578	Homo sapiens	INH	%	91.0
	18953752	CHEMBL4331931	Inhibition of MELK (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(Nc3ccccc3F)c12		CHEMBL4449552	=	Inhibition	%	83.0	CHEMBL4578	Homo sapiens	INH	%	83.0
	18953845	CHEMBL4331931	Inhibition of MELK (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(OC3CCCCC3)c12		CHEMBL4524629	=	Inhibition	%	95.0	CHEMBL4578	Homo sapiens	INH	%	95.0
	18953937	CHEMBL4331990	Inhibition of MELK (unknown origin) at 1 uM relative to control	B	CC(C)n1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cn1		CHEMBL4589022	=	Inhibition	%	84.0	CHEMBL4578	Homo sapiens	INH	%	84.0
	18954001	CHEMBL4331990	Inhibition of MELK (unknown origin) at 1 uM relative to control	B	c1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cc(N2CCOCC2)n1		CHEMBL4460272	=	Inhibition	%	79.0	CHEMBL4578	Homo sapiens	INH	%	79.0
	18954068	CHEMBL4331931	Inhibition of MELK (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(Nc3ccc4ncsc4c3)c12		CHEMBL4588446	=	Inhibition	%	86.0	CHEMBL4578	Homo sapiens	INH	%	86.0
	18958716	CHEMBL4333247	Inhibition of recombinant human MELK expressed in Escherichia coli at 5 uM using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay relative to control	B	CC(C)Nc1nc(N)c(C(=O)c2ccc(Cl)s2)s1		CHEMBL4460795	=	Inhibition	%	46.0	CHEMBL4578	Homo sapiens	INH	%	46.0
	18958717	CHEMBL4333247	Inhibition of recombinant human MELK expressed in Escherichia coli at 5 uM using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay relative to control	B	CC(C)Nc1sc(C(=O)c2ccccc2)c(N)c1C#N		CHEMBL4464876	=	Inhibition	%	47.0	CHEMBL4578	Homo sapiens	INH	%	47.0
	18958718	CHEMBL4333247	Inhibition of recombinant human MELK expressed in Escherichia coli at 5 uM using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay relative to control	B	Cc1ccc(C(=O)c2sc(NC(C)C)c(C#N)c2N)cc1		CHEMBL4550638	=	Inhibition	%	49.0	CHEMBL4578	Homo sapiens	INH	%	49.0
	18958719	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	N#Cc1c(NCCN2CCNCC2)sc(C(=O)c2ccc(Br)s2)c1N		CHEMBL4550810	=	IC50	nM	98.0	CHEMBL4578	Homo sapiens	IC50	uM	0.098
	18958720	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	N#Cc1c(NCCCN)sc(C(=O)c2ccc(Br)s2)c1N		CHEMBL4543318	=	IC50	nM	141.0	CHEMBL4578	Homo sapiens	IC50	uM	0.141
	18958721	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	N#Cc1c(NCC(N)=O)sc(C(=O)c2ccc(Br)s2)c1N		CHEMBL4476804	=	IC50	nM	540.0	CHEMBL4578	Homo sapiens	IC50	uM	0.54
	18958722	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	N#Cc1c(NCCO)sc(C(=O)c2ccc(Br)s2)c1N		CHEMBL4561737	=	IC50	nM	313.0	CHEMBL4578	Homo sapiens	IC50	uM	0.313
	18958723	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	N#Cc1ccccc1Nc1sc(C(=O)c2ccc(Br)s2)c(N)c1C#N		CHEMBL4544167	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
	18958724	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	N#Cc1c(Nc2ccccc2F)sc(C(=O)c2ccc(Cl)s2)c1N		CHEMBL4517341	=	IC50	nM	707.0	CHEMBL4578	Homo sapiens	IC50	uM	0.707
	18958725	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	N#Cc1c(NCc2ccccc2)sc(C(=O)c2ccc(Cl)s2)c1N		CHEMBL4471795	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
	18958726	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	C=CCNc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4466246	=	IC50	nM	638.0	CHEMBL4578	Homo sapiens	IC50	uM	0.638
	18958727	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CCNc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4451160	=	IC50	nM	222.0	CHEMBL4578	Homo sapiens	IC50	uM	0.222
	18958728	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)N(C)c1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4577252	=	IC50	nM	1417.0	CHEMBL4578	Homo sapiens	IC50	uM	1.417
	18958729	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	COc1ccc(C(=O)c2sc3nc(C)ccc3c2N)cc1OC		CHEMBL4585980	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
	18958730	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	Cc1ccc(C(=O)c2sc3nc(C)ccc3c2N)cc1		CHEMBL3975306	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
	18958731	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1nc(N)c(C(=O)c2ccc(Cl)s2)s1		CHEMBL4460795	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
	18958732	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C(N)=O		CHEMBL4525206	=	IC50	nM	388.0	CHEMBL4578	Homo sapiens	IC50	uM	0.388
	18958733	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)cc1C#N		CHEMBL4468259	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
	18958734	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccc(-c3cccc(O)c3)s2)c(N)c1C#N		CHEMBL4535071	=	IC50	nM	350.0	CHEMBL4578	Homo sapiens	IC50	uM	0.35
	18958735	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccc(-c3ccc(O)cc3)s2)c(N)c1C#N		CHEMBL4471276	=	IC50	nM	241.0	CHEMBL4578	Homo sapiens	IC50	uM	0.241
	18958736	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccc(-c3ccncc3)s2)c(N)c1C#N		CHEMBL4525991	=	IC50	nM	269.0	CHEMBL4578	Homo sapiens	IC50	uM	0.269
	18958737	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2cc(Br)cs2)c(N)c1C#N		CHEMBL4454199	=	IC50	nM	599.0	CHEMBL4578	Homo sapiens	IC50	uM	0.599
	18958738	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2cc(Cl)cs2)c(N)c1C#N		CHEMBL4538177	=	IC50	nM	575.0	CHEMBL4578	Homo sapiens	IC50	uM	0.575
	18958739	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	Cc1ccc(C(=O)c2sc(NC(C)C)c(C#N)c2N)s1		CHEMBL4584382	=	IC50	nM	494.0	CHEMBL4578	Homo sapiens	IC50	uM	0.494
	18958740	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccc(I)s2)c(N)c1C#N		CHEMBL4450084	=	IC50	nM	112.0	CHEMBL4578	Homo sapiens	IC50	uM	0.112
	18958741	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccc(Br)s2)c(N)c1C#N		CHEMBL4452507	=	IC50	nM	122.0	CHEMBL4578	Homo sapiens	IC50	uM	0.122
	18958742	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	IC50	nM	192.0	CHEMBL4578	Homo sapiens	IC50	uM	0.192
	18958743	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CCNc1sc(C(=O)c2cccs2)c(N)c1C#N		CHEMBL1419805	=	IC50	nM	1185.0	CHEMBL4578	Homo sapiens	IC50	uM	1.185
	18958744	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccco2)c(N)c1C#N		CHEMBL4564918	=	IC50	nM	1353.0	CHEMBL4578	Homo sapiens	IC50	uM	1.353
	18958745	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccn[nH]2)c(N)c1C#N		CHEMBL4467842	=	IC50	nM	1701.0	CHEMBL4578	Homo sapiens	IC50	uM	1.701
	18958746	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2cccnc2)c(N)c1C#N		CHEMBL4560455	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
	18958747	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccncc2)c(N)c1C#N		CHEMBL4446294	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
	18958748	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccc(C#N)cc2)c(N)c1C#N		CHEMBL4549181	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
	18958749	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2cccc(C#N)c2)c(N)c1C#N		CHEMBL4563640	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
	18958750	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	COc1ccc(C(=O)c2sc(NC(C)C)c(C#N)c2N)cc1		CHEMBL4445131	=	IC50	nM	4126.0	CHEMBL4578	Homo sapiens	IC50	uM	4.126
	18958751	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(C)Nc1sc(C(=O)c2ccc3c(c2)OCO3)c(N)c1C#N		CHEMBL4579783	=	IC50	nM	1116.0	CHEMBL4578	Homo sapiens	IC50	uM	1.116
	18958752	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	COc1ccc(C(=O)c2sc(NC(C)C)c(C#N)c2N)cc1OC		CHEMBL4461952	=	IC50	nM	1774.0	CHEMBL4578	Homo sapiens	IC50	uM	1.774
	18958753	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	C=CCNc1sc(C(=O)C(C)(C)C)c(N)c1C#N		CHEMBL1493492	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
	18958754	CHEMBL4333246	Inhibition of recombinant human MELK expressed in Escherichia coli using ZIPtide as substrate measured after 0.5 hrs by ADP-Glo assay	B	CC(=O)c1sc(NC(C)C)c(C#N)c1N		CHEMBL4466827	>	IC50	nM	5000.0	CHEMBL4578	Homo sapiens	IC50	uM	5.0
	18958972	CHEMBL4333494	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	14.0	CHEMBL4578	Homo sapiens	Activity	%	14.0
	18964445	CHEMBL4335161	Inhibition of recombinant human MELK (1 to 340 residues) assessed as residual activity at 1 uM using KKLNRTLSFAEPG as substrate incubated for 40 mins in presence of [gamma-33ATP by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	89.0	CHEMBL4578	Homo sapiens	Activity	%	89.0
	18964446	CHEMBL4335161	Inhibition of recombinant human MELK (1 to 340 residues) assessed as residual activity at 1 uM using KKLNRTLSFAEPG as substrate incubated for 40 mins in presence of [gamma-33ATP by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	105.0	CHEMBL4578	Homo sapiens	Activity	%	105.0
	18971978	CHEMBL4336988	Inhibition of recombinant human MELK (1 to 340 residues) assessed as residual activity at 10 uM using KKLNRTLSFAEPG as substrate incubated for 40 mins in presence of [gamma-33ATP by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	25.0	CHEMBL4578	Homo sapiens	Activity	%	25.0
Not Active	19039703	CHEMBL4351939	Inhibition of recombinant human MELK (1 to 340 residues) at 10 uM using KKLNRTLSFAEPG as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
Active	19041180	CHEMBL4352441	Inhibition of human MELK at 10 uM using KKLNRTLSFAEPG as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
	19059685	CHEMBL4357986	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL4578	Homo sapiens	Activity	%	100.0
	19090250	CHEMBL4365824	Inhibition of wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	96.0	CHEMBL4578	Homo sapiens	Activity	%	96.0
	19092005	CHEMBL4366479	Inhibition of human MELK at 100 nM using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	9.78	CHEMBL4578	Homo sapiens	INH	%	9.78
	19118514	CHEMBL4372358	Inhibition of recombinant human N-terminal GST-tagged MELK (1 to 340 residues) expressed in baculovirus infected Sf21 insect cells using KKLNRTLSFAEPG as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	Cc1cccc(Cn2nc(C)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1		CHEMBL4483816	=	IC50	nM	258.0	CHEMBL4578	Homo sapiens	IC50	nM	258.0
	19118540	CHEMBL4372384	Inhibition of recombinant human N-terminal GST-tagged MELK (1 to 340 residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using KKLNRTLSFAEPG as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	Cc1cccc(Cn2nc(C)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1		CHEMBL4483816	>	Inhibition	%	60.0	CHEMBL4578	Homo sapiens	INH	%	60.0
	19144640	CHEMBL4377656	Inhibition of recombinant human MELK (1 to 340 residues) at 1 uM using KKLNRTLSFAEPG as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	88.0	CHEMBL4578	Homo sapiens	INH	%	88.0
	19147926	CHEMBL4379400	Inhibition of recombinant human MELK (1 to 340 residues) using KKLNRTLSFAEPG as substrate incubated for 40 mins in presence of [gamma-33ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL4578	Homo sapiens	IC50	uM	10.0
	19159513	CHEMBL4382617	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	54.0	CHEMBL4578	Homo sapiens	Activity	%	54.0
	19181080	CHEMBL4387291	Inhibition of recombinant human GST-tagged MELK catalytic domain (1 to 340 residues) expressed in baculovirus expression system at 0.1 uM using serine/threonine-17 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	12.5	CHEMBL4578	Homo sapiens	INH	%	12.5
	19181305	CHEMBL4387291	Inhibition of recombinant human GST-tagged MELK catalytic domain (1 to 340 residues) expressed in baculovirus expression system at 0.1 uM using serine/threonine-17 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	44.0	CHEMBL4578	Homo sapiens	INH	%	44.0
	19191494	CHEMBL4389336	Inhibition of wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	36.0	CHEMBL4578	Homo sapiens	INH	%	36.0
	19191999	CHEMBL4389813	Inhibition of wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	23.0	CHEMBL4578	Homo sapiens	INH	%	23.0
	19200255	CHEMBL4391439	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	14.0	CHEMBL4578	Homo sapiens	Activity	%	14.0
	19243678	CHEMBL4400270	Inhibition of human MELK at 1 uM relative to control	B	CN(C)Cc1ccn2c(-c3ccnc(N)n3)c(-c3ccc(F)cc3)nc2c1		CHEMBL425949	>	Inhibition	%	90.0	CHEMBL4578	Homo sapiens	INH	%	90.0
	19243679	CHEMBL4400270	Inhibition of human MELK at 1 uM relative to control	B	CN(C)Cc1ccn2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c(C3CC3)nc2c1		CHEMBL4437958	>	Inhibition	%	90.0	CHEMBL4578	Homo sapiens	INH	%	90.0
	19243680	CHEMBL4400270	Inhibition of human MELK at 1 uM relative to control	B	CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cc(NCCN(C)C)ccn23)n1		CHEMBL4474940	=	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	19266501	CHEMBL4405451	Inhibition of wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	19276036	CHEMBL4408039	Inhibition of recombinant human MELK (1 to 340 end residues) at 1 uM using KKLNRTLSFAEPG as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	53.0	CHEMBL4578	Homo sapiens	INH	%	53.0
	19294839	CHEMBL4412210	Inhibition of human MELK using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4090364	=	IC50	nM	1400.0	CHEMBL4578	Homo sapiens	IC50	uM	1.4
Active	19317094	CHEMBL4417288	Inhibition of MELK (unknown origin) at 1000 nM relative to control	B	Cc1c(C(=O)Nc2ccc3ccccc3n2)cnn1-c1ccccc1Br		CHEMBL4555217		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
	20600592	CHEMBL4603544	Inhibition of recombinant human GST-tagged MELK catalytic domain expressed in baculovirus expression system using serine/threonine-17 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL4578	Homo sapiens	IC50	uM	100.0
	20604092	CHEMBL4604473	Inhibition of GST tagged human MELK expressed in baculovirus expression system at 10 uM after 1 hr by Z'-LYTE assay relative to control	B	O=C(OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]cnc32)[C@H](O)[C@@H]1O)c1cc[nH]c1		CHEMBL4637966	=	Inhibition	%	97.0	CHEMBL4578	Homo sapiens	INH	%	97.0
	20604093	CHEMBL4604473	Inhibition of GST tagged human MELK expressed in baculovirus expression system at 10 uM after 1 hr by Z'-LYTE assay relative to control	B	Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)c3ccc[nH]3)[C@@H](O)[C@H]2O)c(=O)[nH]1		CHEMBL4642516	=	Inhibition	%	96.0	CHEMBL4578	Homo sapiens	INH	%	96.0
	20604094	CHEMBL4604473	Inhibition of GST tagged human MELK expressed in baculovirus expression system at 10 uM after 1 hr by Z'-LYTE assay relative to control	B	Nc1ncnc2c1ncn2[C@@H]1O[C@H](COC(=O)c2ccc[nH]2)[C@@H](O)[C@H]1O		CHEMBL4633057	=	Inhibition	%	95.0	CHEMBL4578	Homo sapiens	INH	%	95.0
	20604105	CHEMBL4604473	Inhibition of GST tagged human MELK expressed in baculovirus expression system at 10 uM after 1 hr by Z'-LYTE assay relative to control	B	Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)c3cc[nH]c3)[C@@H](O)[C@H]2O)c(=O)[nH]1		CHEMBL4634615	=	Inhibition	%	87.0	CHEMBL4578	Homo sapiens	INH	%	87.0
	20604106	CHEMBL4604473	Inhibition of GST tagged human MELK expressed in baculovirus expression system at 10 uM after 1 hr by Z'-LYTE assay relative to control	B	Nc1ncnc2c1ncn2[C@@H]1O[C@H](COC(=O)c2cc[nH]c2)[C@@H](O)[C@H]1O		CHEMBL4647499	=	Inhibition	%	98.0	CHEMBL4578	Homo sapiens	INH	%	98.0
	20604107	CHEMBL4604473	Inhibition of GST tagged human MELK expressed in baculovirus expression system at 10 uM after 1 hr by Z'-LYTE assay relative to control	B	O=C(OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]cnc32)[C@H](O)[C@@H]1O)c1ccc[nH]1		CHEMBL4636133	=	Inhibition	%	97.0	CHEMBL4578	Homo sapiens	INH	%	97.0
	20629078	CHEMBL4610392	Inhibition of wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual activity at 500 nM by Kinomescan method relative to control	B	CCOC(=O)c1cnc2ccc(-c3ccncc3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL4646793	=	Activity	%	4.7	CHEMBL4578	Homo sapiens	Activity	%	4.7
	20629086	CHEMBL4610400	Inhibition of wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual activity at 100 nM by Kinomescan method relative to control	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	Activity	%	6.2	CHEMBL4578	Homo sapiens	Activity	%	6.2
	20629108	CHEMBL4610418	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system by Kinomescan method	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	Kd	nM	15.0	CHEMBL4578	Homo sapiens	Kd	nM	15.0
	20629109	CHEMBL4610418	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system by Kinomescan method	B	CCOC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL4647416	=	Kd	nM	11.0	CHEMBL4578	Homo sapiens	Kd	nM	11.0
	20629110	CHEMBL4610418	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system by Kinomescan method	B	CCCCNC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL4644916	=	Kd	nM	12.0	CHEMBL4578	Homo sapiens	Kd	nM	12.0
	20629111	CHEMBL4610418	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system by Kinomescan method	B	CCOC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN)CC1		CHEMBL4645393	=	Kd	nM	9.0	CHEMBL4578	Homo sapiens	Kd	nM	9.0
	20629112	CHEMBL4610418	Binding affinity to wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system by Kinomescan method	B	CCOC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](C(=O)N(C)C)CC1		CHEMBL4648260	=	Kd	nM	13.0	CHEMBL4578	Homo sapiens	Kd	nM	13.0
	20712368	CHEMBL4629321	Inhibition of MELK (unknown origin)	B	O=C(NO)c1ccc(Cn2c(=O)n(CCc3ccccc3)c(=O)c3ccccc32)cc1		CHEMBL4550214	=	IC50	nM	200.0	CHEMBL4578	Homo sapiens	IC50	uM	0.2
	20712371	CHEMBL4629321	Inhibition of MELK (unknown origin)	B	N=C(N)N/N=C/c1cccc(Cl)c1Cl		CHEMBL2369159	=	IC50	nM	200.0	CHEMBL4578	Homo sapiens	IC50	uM	0.2
	20712372	CHEMBL4629321	Inhibition of MELK (unknown origin)	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)Nc1ccc2c(c1)CCNCC2		CHEMBL3355059	=	IC50	nM	200.0	CHEMBL4578	Homo sapiens	IC50	uM	0.2
	20712373	CHEMBL4629321	Inhibition of MELK (unknown origin)	B	COc1ccc(/C=C2\SC(=S)NC2=O)cc1C#C[Si](C)(C)C		CHEMBL4288096	=	IC50	nM	200.0	CHEMBL4578	Homo sapiens	IC50	uM	0.2
	20712374	CHEMBL4629321	Inhibition of MELK (unknown origin)	B	CNC(=O)COc1cc2cc(Nc3nc(N4C[C@@H](C)C[C@@H](C)C4)ncc3Cl)ccc2n(C)c1=O		CHEMBL4640049	=	IC50	nM	200.0	CHEMBL4578	Homo sapiens	IC50	uM	0.2
	22392099	CHEMBL4667194	Inhibition of recombinant human GST-tagged MELK (1 to 340 residues) expressed in baculovirus expression system using Ser/Thr 17 as substrate at 10 uM incubated for 60 mins by Z'-lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	-6.0	CHEMBL4578	Homo sapiens	INH	%	-6.0
	22423463	CHEMBL4674307	Inhibition of human MELK using KKLNRTLSFAEPG as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	80.45	CHEMBL4578	Homo sapiens	Activity	%	80.45
	22423464	CHEMBL4674307	Inhibition of human MELK using KKLNRTLSFAEPG as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	6.15	CHEMBL4578	Homo sapiens	Activity	%	6.15
	22429684	CHEMBL4676001	Inhibition of MELK (unknown origin) at 10 uM in presence of substrate and [gamma-33P]-ATP by scintillation counting method relative to control	B	O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2		CHEMBL3716365	=	Inhibition	%	57.0	CHEMBL4578	Homo sapiens	INH	%	57.0
	22751203	CHEMBL4699845	Inhibition of MELK (unknown origin) using FRET-peptide as substrate incubated for 1 hr by Z-lyte assay	B	Nc1cccc2cc[nH]c(=O)c12		CHEMBL4784866	=	IC50	nM	9480.0	CHEMBL4578	Homo sapiens	IC50	uM	9.48
Active	22751206	CHEMBL4699848	Binding affinity to human N-terminal His-tagged MELK (1 to 337 residues) expressed in Escherichia coli BL21 pLysS at 50 uM by STD-NMR analysis	B	Nc1cccc2cc[nH]c(=O)c12		CHEMBL4784866		Activity			CHEMBL4578	Homo sapiens	Activity		
	22751207	CHEMBL4699849	Displacement of kinase tracer 236 from human N-terminal His-tagged MELK (1 to 337 residues) expressed in Escherichia coli BL21 pLysS by microscale thermophoresis assay	B	Nc1cccc2cc[nH]c(=O)c12		CHEMBL4784866	=	Ki	nM	5470.0	CHEMBL4578	Homo sapiens	Ki	uM	5.47
	22751208	CHEMBL4699849	Displacement of kinase tracer 236 from human N-terminal His-tagged MELK (1 to 337 residues) expressed in Escherichia coli BL21 pLysS by microscale thermophoresis assay	B	Nc1cccc2cc[nH]c(=O)c12		CHEMBL4784866	=	EC50	nM	21100.0	CHEMBL4578	Homo sapiens	EC50	uM	21.1
	22843672	CHEMBL4720658	Inhibition of human MELK using KKLNRTLSFAEPG as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.687	CHEMBL4578	Homo sapiens	IC50	10^-10M	6.87
	22844020	CHEMBL4721006	Inhibition of human MELK assessed as residual activity using KKLNRTLSFAEPG as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	96.46	CHEMBL4578	Homo sapiens	Activity	%	96.46
	22844790	CHEMBL4721465	Inhibition of wild-type human full length MELK (M1 to V651 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	97.91	CHEMBL4578	Homo sapiens	Activity	%	97.91
Not Active	22909949	CHEMBL4734077	Inhibition of recombinant human full length GST-tagged MELK expressed in baculovirus expression system using serine/threonine-21 peptide as substrate at 10 uM by Z'-LYTE assay	B	c1ccc(CSc2ncnc3[nH]cnc23)cc1		CHEMBL397434		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
Not Active	22909950	CHEMBL4734077	Inhibition of recombinant human full length GST-tagged MELK expressed in baculovirus expression system using serine/threonine-21 peptide as substrate at 10 uM by Z'-LYTE assay	B	Clc1cccc(CSc2ncnc3[nH]cnc23)c1		CHEMBL4754930		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
Not Active	22909951	CHEMBL4734077	Inhibition of recombinant human full length GST-tagged MELK expressed in baculovirus expression system using serine/threonine-21 peptide as substrate at 10 uM by Z'-LYTE assay	B	Brc1ccccc1CSc1ncnc2[nH]cnc12		CHEMBL4776788		Inhibition	%		CHEMBL4578	Homo sapiens	INH		
	22952901	CHEMBL4766838	Inhibition of recombinant human MELK (1 to 340 residues) assessed as residual activity at 10 uM using KKLNRTLSFAEPG as substrate incubated for 40 mins in presence of [gamma-33ATP by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	39.0	CHEMBL4578	Homo sapiens	Activity	%	39.0
	22960890	CHEMBL4768805	Inhibition of human MELK at 100 nM in presence of ATP relative to control	B	Cl.O=C1Nc2ccc(F)cc2/C1=C1/Nc2ccccc2/C1=N\OCCN1CCNCC1		CHEMBL4791998	=	Inhibition	%	86.0	CHEMBL4578	Homo sapiens	INH	%	86.0
	22960891	CHEMBL4768806	Inhibition of human MELK in presence of ATP	B	Cl.O=C1Nc2ccc(F)cc2/C1=C1/Nc2ccccc2/C1=N\OCCN1CCNCC1		CHEMBL4791998	=	IC50	nM	5.54	CHEMBL4578	Homo sapiens	IC50	nM	5.54
	23122342	CHEMBL4804741	Inhibition of MELK in human NCI-H929 cells by mass spectroscopic analysis	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	IC50	nM	45900.0	CHEMBL4578	Homo sapiens	IC50	uM	45.9
	23122343	CHEMBL4804741	Inhibition of MELK in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	IC50	nM	49500.0	CHEMBL4578	Homo sapiens	IC50	uM	49.5
	23122344	CHEMBL4804741	Inhibition of MELK in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	IC50	nM	56500.0	CHEMBL4578	Homo sapiens	IC50	uM	56.5
	23122345	CHEMBL4804742	Inhibition of MELK in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	Inhibition	%	35.0	CHEMBL4578	Homo sapiens	INH	%	35.0
	23122346	CHEMBL4804742	Inhibition of MELK in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	Inhibition	%	35.0	CHEMBL4578	Homo sapiens	INH	%	35.0
	23122347	CHEMBL4804742	Inhibition of MELK in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	Inhibition	%	50.0	CHEMBL4578	Homo sapiens	INH	%	50.0
	23122671	CHEMBL4805022	Inhibition of human MELK assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	97.0	CHEMBL4578	Homo sapiens	Activity	%	97.0
	23123366	CHEMBL4805610	Inhibition of human MELK assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	85.0	CHEMBL4578	Homo sapiens	Activity	%	85.0
	23123825	CHEMBL4806069	Inhibition of DNA-tagged human MELK assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	83.0	CHEMBL4578	Homo sapiens	Activity	%	83.0
	23124822	CHEMBL4806627	Inhibition of human MELK assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	75.0	CHEMBL4578	Homo sapiens	Activity	%	75.0
	23124823	CHEMBL4806627	Inhibition of human MELK assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	84.0	CHEMBL4578	Homo sapiens	Activity	%	84.0
	23128302	CHEMBL4807909	Inhibition of MELK (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL4578	Homo sapiens	Activity	%	75.0
	23128303	CHEMBL4807909	Inhibition of MELK (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL4578	Homo sapiens	Activity	%	75.0
	23128304	CHEMBL4807909	Inhibition of MELK (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL4578	Homo sapiens	Activity	%	75.0
	23195916	CHEMBL4819731	Inhibition of human recombinant MELK (1 to 340 residues) using KKLNRTLSFAEPG peptide as substrate at 100 nM by direct-filter Binding radiometric assay relative to control	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(C)cc(=O)n([C@H]3CC[C@@H](NC(=O)C4CCCCC4)CC3)c2n1		CHEMBL4875028	=	Inhibition	%	77.0	CHEMBL4578	Homo sapiens	INH	%	77.0
	23279623	CHEMBL4836789	Inhibition of MELK (unknown origin) assessed as residual activity at 500 nM	B	FC(F)(F)c1n[nH]cc1-c1nc2ccc3[nH]ncc3c2c2c1CCCC2		CHEMBL4593398	=	Activity	%	4.0	CHEMBL4578	Homo sapiens	Activity	%	4.0
	23279624	CHEMBL4836789	Inhibition of MELK (unknown origin) assessed as residual activity at 500 nM	B	Cc1n[nH]c2ccc3nc(-c4c[nH]nc4C(F)(F)F)c4c(c3c12)CCCC4		CHEMBL4856135	=	Activity	%	4.0	CHEMBL4578	Homo sapiens	Activity	%	4.0
	23287853	CHEMBL4838728	Inhibition of N-terminal GST-tagged MELK (1 to 493 residues) (unknown origin) expressed in Escherichia coli	B	CCC[C@H](C)Nc1ncc2c(C3CCN(C(=O)c4cc(C)nc(C)c4)CC3)cn([C@H]3CC[C@H](O)CC3)c2n1		CHEMBL4877347	=	IC50	nM	95.7	CHEMBL4578	Homo sapiens	IC50	nM	95.7
	23287854	CHEMBL4838728	Inhibition of N-terminal GST-tagged MELK (1 to 493 residues) (unknown origin) expressed in Escherichia coli	B	CCC[C@H](C)Nc1ncc2c(-c3ccc(CN4CCCN(C)CC4)cc3)cn([C@H]3CC[C@H](O)CC3)c2n1		CHEMBL4283353	=	IC50	nM	2.3	CHEMBL4578	Homo sapiens	IC50	nM	2.3
	23289602	CHEMBL4839133	Inhibition of human MELK assessed as residual kinase activity at 1 uM relative to control	B	CN1CCN(c2ccc(-c3cc4c(N5CCN(C(=O)Nc6ccc(Cl)c(C(F)(F)F)c6)CC5)ncnc4s3)cc2)CC1		CHEMBL4874448	=	Activity	%	17.0	CHEMBL4578	Homo sapiens	Activity	%	17.0
	23289608	CHEMBL4839139	Inhibition of human MELK	B	CN1CCN(c2ccc(-c3cc4c(N5CCN(C(=O)Nc6ccc(Cl)c(C(F)(F)F)c6)CC5)ncnc4s3)cc2)CC1		CHEMBL4874448	=	IC50	nM	699.7	CHEMBL4578	Homo sapiens	IC50	nM	699.7
	23295510	CHEMBL4840522	Inhibition of recombinant GST-tagged human MELK expressed in baculovirus expression system at 1 uM measured by select screen assay relative to control	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4c3CN(Cc3cc(F)cc(F)c3)C4(C)C)cc2)CC1		CHEMBL4849505	=	Inhibition	%	22.0	CHEMBL4578	Homo sapiens	INH	%	22.0
	23299258	CHEMBL4841729	Inhibition of MELK (unknown origin) at 1000 nM relative to control	B	Nc1c(-c2nc3cc(N4CCN(C(=O)CCCCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)ccc3[nH]2)c(=O)[nH]c2cccc(F)c12		CHEMBL4860038	=	Inhibition	%	11.0	CHEMBL4578	Homo sapiens	INH	%	11.0
	23299259	CHEMBL4841729	Inhibition of MELK (unknown origin) at 1000 nM relative to control	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Inhibition	%	70.0	CHEMBL4578	Homo sapiens	INH	%	70.0
Not Active	23317506	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	96.0	CHEMBL4578	Homo sapiens	% Control	%	96.0
Not Active	23317974	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23318641	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	74.0	CHEMBL4578	Homo sapiens	% Control	%	74.0
Not Active	23319124	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	79.0	CHEMBL4578	Homo sapiens	% Control	%	79.0
Not Active	23319761	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23320236	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23320914	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Slightly Active	23321382	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	46.0	CHEMBL4578	Homo sapiens	% Control	%	46.0
Not Active	23322012	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	65.0	CHEMBL4578	Homo sapiens	% Control	%	65.0
Not Active	23322480	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	84.0	CHEMBL4578	Homo sapiens	% Control	%	84.0
Not Active	23323169	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	65.0	CHEMBL4578	Homo sapiens	% Control	%	65.0
Not Active	23323637	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	78.0	CHEMBL4578	Homo sapiens	% Control	%	78.0
Not Active	23324055	CHEMBL4880674	MELK (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	26.0	CHEMBL4578	Homo sapiens	% inhibition	%	26.0
Not Active	23324491	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23325126	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	96.0	CHEMBL4578	Homo sapiens	% Control	%	96.0
Not Active	23325594	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	85.0	CHEMBL4578	Homo sapiens	% Control	%	85.0
Not Active	23326241	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	59.0	CHEMBL4578	Homo sapiens	% Control	%	59.0
Not Active	23326709	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	96.0	CHEMBL4578	Homo sapiens	% Control	%	96.0
Not Active	23327409	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	54.0	CHEMBL4578	Homo sapiens	% Control	%	54.0
Not Active	23327877	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23328464	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	90.0	CHEMBL4578	Homo sapiens	% Control	%	90.0
Not Active	23328932	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23329416	CHEMBL4881123	MELK(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	105.0	CHEMBL4578	Homo sapiens	% residual kinase activity	%	105.0
Not Active	23329878	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	85.0	CHEMBL4578	Homo sapiens	% Control	%	85.0
Not Active	23330346	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	93.0	CHEMBL4578	Homo sapiens	% Control	%	93.0
Not Active	23331102	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23331570	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23332157	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23332623	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23333341	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	88.2	CHEMBL4578	Homo sapiens	% Control	%	88.2
Not Active	23333980	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	53.0	CHEMBL4578	Homo sapiens	% Control	%	53.0
Not Active	23334448	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	74.0	CHEMBL4578	Homo sapiens	% Control	%	74.0
Not Active	23335427	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	57.0	CHEMBL4578	Homo sapiens	% Control	%	57.0
Not Active	23335895	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	89.0	CHEMBL4578	Homo sapiens	% Control	%	89.0
Not Active	23336522	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	97.0	CHEMBL4578	Homo sapiens	% Control	%	97.0
Not Active	23336990	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23337679	CHEMBL4882050	MELK Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	94.0	CHEMBL4578	Homo sapiens	% Ctrl	%	94.0
Not Active	23338071	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	87.0	CHEMBL4578	Homo sapiens	% Control	%	87.0
Not Active	23338539	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	92.0	CHEMBL4578	Homo sapiens	% Control	%	92.0
Not Active	23339151	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23339619	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23340256	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23340724	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	99.0	CHEMBL4578	Homo sapiens	% Control	%	99.0
Not Active	23341381	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23341849	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23342465	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	94.0	CHEMBL4578	Homo sapiens	% Control	%	94.0
Not Active	23342933	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23343563	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23344031	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	86.0	CHEMBL4578	Homo sapiens	% Control	%	86.0
Not Active	23344669	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	93.0	CHEMBL4578	Homo sapiens	% Control	%	93.0
Slightly Active	23345242	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	44.0	CHEMBL4578	Homo sapiens	% Control	%	44.0
Not Active	23345710	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	84.0	CHEMBL4578	Homo sapiens	% Control	%	84.0
Not Active	23346287	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	88.0	CHEMBL4578	Homo sapiens	% Control	%	88.0
Not Active	23346755	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23347357	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	58.7	CHEMBL4578	Homo sapiens	% Control	%	58.7
Not Active	23347847	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23348426	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23348894	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23349481	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	69.0	CHEMBL4578	Homo sapiens	% Control	%	69.0
Not Active	23350099	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23350567	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	96.0	CHEMBL4578	Homo sapiens	% Control	%	96.0
Not Active	23351172	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	93.0	CHEMBL4578	Homo sapiens	% Control	%	93.0
Not Active	23351640	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	84.0	CHEMBL4578	Homo sapiens	% Control	%	84.0
Not Active	23352132	CHEMBL4882821	MELK Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	5.436	CHEMBL4578	Homo sapiens	% Inhibition	%	5.4358
Not Active	23352664	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	88.0	CHEMBL4578	Homo sapiens	% Control	%	88.0
Not Active	23353132	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	55.0	CHEMBL4578	Homo sapiens	% Control	%	55.0
Not Active	23354014	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	98.0	CHEMBL4578	Homo sapiens	% Control	%	98.0
Not Active	23354482	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23355214	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	65.0	CHEMBL4578	Homo sapiens	% Control	%	65.0
Not Active	23355682	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	67.0	CHEMBL4578	Homo sapiens	% Control	%	67.0
Not Active	23356318	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23356786	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	94.0	CHEMBL4578	Homo sapiens	% Control	%	94.0
Not Active	23357395	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23358042	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23358510	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23359096	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23359694	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	74.0	CHEMBL4578	Homo sapiens	% Control	%	74.0
Not Active	23360162	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	78.0	CHEMBL4578	Homo sapiens	% Control	%	78.0
Not Active	23360747	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23361215	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	90.0	CHEMBL4578	Homo sapiens	% Control	%	90.0
Not Active	23361788	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23362324	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23362792	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23364434	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	67.0	CHEMBL4578	Homo sapiens	% Control	%	67.0
Not Active	23364902	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	73.0	CHEMBL4578	Homo sapiens	% Control	%	73.0
Not Active	23365641	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	78.0	CHEMBL4578	Homo sapiens	% Control	%	78.0
Not Active	23366184	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23366774	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	92.0	CHEMBL4578	Homo sapiens	% Control	%	92.0
Not Active	23367242	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	80.0	CHEMBL4578	Homo sapiens	% Control	%	80.0
Not Active	23367642	CHEMBL4883995	MELK ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	81.0	CHEMBL4578	Homo sapiens	% Residual activity with Skepinone-L	%	81.0
Not Active	23368120	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	66.0	CHEMBL4578	Homo sapiens	% Control	%	66.0
Not Active	23368588	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	78.0	CHEMBL4578	Homo sapiens	% Control	%	78.0
Not Active	23369187	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23369655	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	95.0	CHEMBL4578	Homo sapiens	% Control	%	95.0
Not Active	23370136	CHEMBL4884380	MELK(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	39.0	CHEMBL4578	Homo sapiens	% residual kinase activity	%	39.0
Slightly Active	23370623	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	43.0	CHEMBL4578	Homo sapiens	% Control	%	43.0
Not Active	23371091	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	81.0	CHEMBL4578	Homo sapiens	% Control	%	81.0
Not Active	23371900	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23372368	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
	23372815	CHEMBL4884780	MELK(MELKLGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL4578	Homo sapiens	pIC50		6.0
	23373224	CHEMBL4885071	MELK(MELKLGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL4578	Homo sapiens	pIC50		6.0
	23373582	CHEMBL4885359	MELK(MELKLGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL4578	Homo sapiens	pIC50		6.0
Not Active	23375033	CHEMBL4886022	MELK Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	12.5	CHEMBL4578	Homo sapiens	% Inhibition	%	12.5
Not Active	23375795	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	77.0	CHEMBL4578	Homo sapiens	% Control	%	77.0
Not Active	23376263	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	95.0	CHEMBL4578	Homo sapiens	% Control	%	95.0
Not Active	23376840	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	82.0	CHEMBL4578	Homo sapiens	% Control	%	82.0
Not Active	23377308	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	81.0	CHEMBL4578	Homo sapiens	% Control	%	81.0
Not Active	23378168	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	91.0	CHEMBL4578	Homo sapiens	% Control	%	91.0
Not Active	23378636	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	100.0	CHEMBL4578	Homo sapiens	% Control	%	100.0
Not Active	23379803	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	55.0	CHEMBL4578	Homo sapiens	% Control	%	55.0
Not Active	23380271	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	78.0	CHEMBL4578	Homo sapiens	% Control	%	78.0
Not Active	23380965	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	86.0	CHEMBL4578	Homo sapiens	% Control	%	86.0
Not Active	23381613	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	86.0	CHEMBL4578	Homo sapiens	% Control	%	86.0
Not Active	23382081	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	89.0	CHEMBL4578	Homo sapiens	% Control	%	89.0
Slightly Active	23382705	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	23.0	CHEMBL4578	Homo sapiens	% Control	%	23.0
Slightly Active	23383173	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	40.0	CHEMBL4578	Homo sapiens	% Control	%	40.0
Not Active	23383886	CHEMBL4887504	MELK Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	103.0	CHEMBL4578	Homo sapiens	% Ctrl	%	103.0
Not Active	23384345	CHEMBL4887940	MELK(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O	Outside typical range	CHEMBL4802045		Inhibition	%	-11.67	CHEMBL4578	Homo sapiens	% inhibition	%	-11.67
Not Active	23384674	CHEMBL4888200	MELK SelectScreen Kinase panel (LifeTechnologies)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		Inhibition	%	30.0	CHEMBL4578	Homo sapiens	% Inhibition	%	30.0
Not Active	23385088	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	59.0	CHEMBL4578	Homo sapiens	% Control	%	59.0
Not Active	23385555	CHEMBL4879812	KinomeScan assay: inhibition of MELK	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	52.0	CHEMBL4578	Homo sapiens	% Control	%	52.0
